{"PMC7368157": [["Telemedicine screening and scheduling ::: Materials and MethodsThe study period corresponded with the implementation of a postoperative telemedicine program within the Hand Surgery Division at our institution.", [["Methods", "TREATMENT", 56, 63], ["The study", "TEST", 63, 72], ["a postoperative telemedicine program", "TREATMENT", 120, 156]]], ["All patients from the senior author\u2019s (L.C.G.) outpatient clinic who were indicated for surgery during a 3-month period from February 2019 to April 2019 were screened for eligibility for this investigation.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["surgery", "TREATMENT", 88, 95], ["this investigation", "TEST", 187, 205]]], ["The first patient enrolled in this investigation was the first telemedical visit performed in our division.", [["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17]]], ["When a patient was indicated for surgical intervention, technological and clinical inclusion criteria were reviewed, and those patients meeting the criteria were offered the option of scheduling their first postoperative visit (7\u201314 days after surgery) as a telemedicine visit.", [["patient", "ORGANISM", 7, 14], ["patients", "ORGANISM", 127, 135], ["patient", "SPECIES", 7, 14], ["patients", "SPECIES", 127, 135], ["surgical intervention", "TREATMENT", 33, 54], ["surgery", "TREATMENT", 244, 251]]], ["The second postoperative visit (4\u20136 weeks after surgery) was a conventional in-clinic appointment in the outpatient clinic for all patients.Telemedicine screening and scheduling ::: Materials and MethodsPatients electing for a telemedicine postoperative visit were given a 1-page FAQ (frequently asked questions) and trouble-shooting guide (Appendix A; available on the Journal\u2019s Web site at www.jhandsurg.org).", [["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["surgery", "TREATMENT", 48, 55], ["Appendix", "ANATOMY", 341, 349]]], ["Patients were sent automated appointment reminders 24 hours prior and 1 hour prior to their appointment.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Patients could log into the telemedicine platform prior to the visit in order to familiarize themselves with the software.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["The type of device utilized by the patient was recorded.", [["patient", "ORGANISM", 35, 42], ["patient", "SPECIES", 35, 42], ["The type of device", "TREATMENT", 0, 18]]], ["The senior author (L.C G.) performed all of the postoperative telemedicine visits on a tablet device.Telemedicine visit ::: Materials and MethodsBoth the patient and the surgeon logged into the telemedicine platform at the scheduled visit time.", [["patient", "ORGANISM", 154, 161], ["patient", "SPECIES", 154, 161], ["a tablet device", "TREATMENT", 85, 100]]], ["Prior to initiating the visit, the patient signed an electronic informed consent.", [["patient", "ORGANISM", 35, 42], ["patient", "SPECIES", 35, 42]]], ["Information relating to HIPAA (Health Insurance Portability and Accountability Act) compliance and protected health information relative to the software can be found on the InTouch Web site (https://intouchhealth.com/privacy-policy/).", [["InTouch Web site", "DNA", 173, 189]]], ["To further safeguard protected health information, the patient was informed whether any other people were present in the room, which included medical students, residents, and therapists.", [["patient", "ORGANISM", 55, 62], ["people", "ORGANISM", 94, 100], ["patient", "SPECIES", 55, 62], ["people", "SPECIES", 94, 100]]], ["All visits were conducted with the office door closed.Telemedicine visit ::: Materials and MethodsFor the physical examination, patients were asked to remove their dressing and the wound was inspected.", [["wound", "ANATOMY", 181, 186], ["patients", "ORGANISM", 128, 136], ["wound", "PATHOLOGICAL_FORMATION", 181, 186], ["patients", "SPECIES", 128, 136], ["the physical examination", "TEST", 102, 126], ["their dressing", "TREATMENT", 158, 172], ["the wound", "PROBLEM", 177, 186], ["wound", "OBSERVATION", 181, 186]]], ["All wounds were closed with absorbable suture.", [["wounds", "ANATOMY", 4, 10], ["wounds", "PATHOLOGICAL_FORMATION", 4, 10], ["All wounds", "PROBLEM", 0, 10], ["absorbable suture", "TREATMENT", 28, 45], ["wounds", "OBSERVATION", 4, 10], ["absorbable suture", "OBSERVATION", 28, 45]]], ["A remote physical examination was then performed on all patients.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["A remote physical examination", "TEST", 0, 29]]], ["We asked the patient to perform passive and active range of motion.", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20]]], ["Sensation was assessed by having the patient compare sensation to light touch on regions of the surgical extremity to the nonsurgical side.Telemedicine visit ::: Materials and MethodsIf radiographs were obtained prior to the visit, they were viewed within the electronic medical record system.", [["extremity", "ANATOMY", 105, 114], ["patient", "ORGANISM", 37, 44], ["extremity", "ORGANISM_SUBDIVISION", 105, 114], ["patient", "SPECIES", 37, 44], ["light touch", "TEST", 66, 77], ["Methods", "TREATMENT", 176, 183], ["radiographs", "TEST", 186, 197], ["surgical extremity", "ANATOMY", 96, 114], ["nonsurgical", "OBSERVATION", 122, 133]]], ["For patients who lived near a facility within our health system that had the ability to obtain radiographs, these images were immediately available within our Picture Archiving and Communication Systems (PACS).", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["radiographs", "TEST", 95, 106], ["these images", "TEST", 108, 120]]], ["Radiographs obtained at outside facilities were uploaded into LifeImage (Newton, MA) and could be viewed during the encounter.", [["Radiographs", "TEST", 0, 11]]], ["Orders for any medications were placed electronically.", [["any medications", "TREATMENT", 11, 26]]], ["This was the same process utilized for conventional in-clinic visits.Data collection ::: Materials and MethodsBaseline demographics were recorded for each patient.", [["patient", "ORGANISM", 155, 162], ["patient", "SPECIES", 155, 162]]], ["At the time of the initial consultation prior to surgery, patients were asked to complete a Numeric Pain Rating Scale (NPRS) and Patient-Reported Outcomes Measurement Information System (PROMIS) instruments, which included the PROMIS Self-Efficacy for Managing Symptoms Short-Form 4a, PROMIS Pain Interference Short-Form 4a, and the PROMIS Upper Extremity Short-Form 7a.Data collection ::: Materials and MethodsPatients completed an NPRS during the first postoperative telemedicine visit.", [["Pain", "DISEASE", 100, 104], ["Pain", "DISEASE", 292, 296], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["Patient", "SPECIES", 129, 136], ["surgery", "TREATMENT", 49, 56], ["a Numeric Pain Rating Scale", "TREATMENT", 90, 117], ["Managing Symptoms", "PROBLEM", 252, 269], ["PROMIS Pain Interference", "PROBLEM", 285, 309], ["Upper Extremity", "ANATOMY", 340, 355]]], ["Both the patient and the surgeon were asked to rate the audio and video quality of the call on a 3-point scale with 1 indicating no audio or visual availability, 2 indicating reduced audio or visual feed quality, and 3 indicating a well-functioning, clear audio or visual feed.", [["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16], ["reduced audio or visual feed quality", "PROBLEM", 175, 211]]], ["The length of the telemedicine call was also recorded.Data collection ::: Materials and MethodsDuring the second in-clinic postoperative visit, patients were asked to complete an NPRS and the PROMIS Upper Extremity questionnaire.", [["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["an NPRS", "TEST", 176, 183], ["length", "OBSERVATION_MODIFIER", 4, 10], ["Upper Extremity", "ANATOMY", 199, 214]]], ["In addition, we recorded visit time, travel time, travel distance, and patient satisfaction information.", [["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78]]], ["Mileage and travel times were recorded using Google Maps (https://www.google.com/maps), utilizing the patient\u2019s home address and the address of our outpatient clinic.", [["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109]]], ["Travel times were determined at the time of the clinic visit in order to account for traffic fluctuations.", [["traffic fluctuations", "PROBLEM", 85, 105]]], ["Visit times were recorded using the appointment \u201ccheck-in\u201d and \u201ccheck-out\u201d times within our electronic medical records system.Data collection ::: Materials and MethodsAt the conclusion of the in-clinic visit, patients were asked to rate the telemedicine program with respect to ease of use on an 11-point Likert scale, with 0 indicating very difficult and 10 indicating very easy.", [["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 209, 217], ["Methods", "TREATMENT", 160, 167], ["Likert scale", "TEST", 305, 317]]], ["Patients also completed an 11-point Likert scale to rate their satisfaction with both the telemedicine and the in-clinic postoperative visits, with 0 indicating very unsatisfied and 10 indicating very satisfied.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Patients were asked whether they would choose a telemedicine or an in-clinic postoperative visit in the future.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Utilizing a similar written questionnaire distributed by Abel et al4 for a telemedicine program, patients were asked to select their reasons for choosing telemedicine.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105]]], ["The time required to complete outcome measures and questionnaires was included in the visit times for both the telemedicine and the in-clinic visit.Statistics ::: Materials and MethodsDescriptive statistics were used for baseline demographics.", [["MethodsDescriptive statistics", "TREATMENT", 177, 206]]], ["We used Student t testing and chi-square testing to compare the means or proportions between the 2 visits.", [["Student t testing", "TEST", 8, 25], ["chi-square testing", "TEST", 30, 48]]], ["Differences of P less than .05 were considered statistically significant.ResultsDuring the 3-month study period, the senior author (L.C.G.) preformed a total of 147 surgical procedures.", [["surgical procedures", "TREATMENT", 165, 184]]], ["Twenty-four patients did not meet the inclusion criteria.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["An additional 36 patients had clinical exclusion criteria and were not eligible to participate.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["Fifty-seven of the 87 patients who met inclusion criteria, and were eligible for the study, elected to participate (66%).", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["the study", "TEST", 81, 90]]], ["All of the 57 included patients completed both postoperative visits.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31]]], ["Baseline demographics for all patients included in this investigation are presented in Table 1.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]], ["Demographic information for patients who met inclusion criteria but declined to participate in presented in Table 2.Results", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36]]]], "c23daa21d8f2994d24f49126f6425c87f3d7cc32": [["IntroductionInfluenza is a highly contagious disease caused by negativestrand RNA viruses of the family Orthomyxoviridae.", [["Influenza", "DISEASE", 12, 21], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 104, 120], ["Influenza", "PROBLEM", 12, 21], ["a highly contagious disease", "PROBLEM", 25, 52]]], ["Seasonal outbreaks of influenza present global health problems involving morbidity, mortality, and economic losses.", [["influenza", "DISEASE", 22, 31], ["influenza", "PROBLEM", 22, 31], ["morbidity", "PROBLEM", 73, 82], ["economic losses", "PROBLEM", 99, 114], ["influenza", "OBSERVATION", 22, 31], ["economic losses", "OBSERVATION", 99, 114]]], ["Since 2003, the highly pathogenic avian influenza H5N1 virus has spread from Asia to Europe and Africa posing a pandemic threat of a highly lethal and contagious disease (Gambotto et al., 2008; Webster and Govorkova, 2006) .", [["avian influenza H5N1 virus", "DISEASE", 34, 60], ["avian influenza H5N1 virus", "ORGANISM", 34, 60], ["avian influenza H5N1 virus", "SPECIES", 34, 60], ["H5N1 virus", "SPECIES", 50, 60], ["the highly pathogenic avian influenza H5N1 virus", "PROBLEM", 12, 60], ["contagious disease", "PROBLEM", 151, 169], ["influenza H5N1", "OBSERVATION", 40, 54]]], ["A pandemic caused by swine-origin influenza virus (S-OIV) infection occurred in 2009 (Dawood et al., 2009; Itoh et al., 2009; Shinde et al., 2009 ) causing more than 18,849 deaths in more than 214 countries; the World Health Organization (WHO) announced on September 10, 2010, that the pandemic had transitioned into a post-pandemic phase (WHO, 2010a,b) .", [["swine-origin influenza virus (S-OIV) infection", "DISEASE", 21, 67], ["deaths", "DISEASE", 173, 179], ["swine-origin influenza virus", "ORGANISM", 21, 49], ["S-OIV", "ORGANISM", 51, 56], ["swine-origin influenza virus", "SPECIES", 21, 49], ["swine-origin influenza virus", "SPECIES", 21, 49], ["OIV", "SPECIES", 53, 56], ["A pandemic", "PROBLEM", 0, 10], ["influenza virus", "PROBLEM", 34, 49], ["infection", "PROBLEM", 58, 67]]], ["The occurrence of outbreaks and pandemics indicates that rapid subtyping of influenza viruses, including avian and swine-origin viruses, is a high priority for public health response systems; rapid virus detection is expected to improve the control of the pandemic spread of influenza and patient care.IntroductionQuantitative real-time PCR (qRT-PCR) is commonly used for detecting and subtyping viruses, including influenza viruses (van Elden et al., 2001; WHO, 2009a) .", [["influenza viruses", "DISEASE", 76, 93], ["influenza", "DISEASE", 275, 284], ["influenza viruses", "DISEASE", 415, 432], ["influenza viruses", "ORGANISM", 76, 93], ["swine-origin viruses", "ORGANISM", 115, 135], ["patient", "ORGANISM", 289, 296], ["influenza viruses", "ORGANISM", 415, 432], ["avian and swine", "SPECIES", 105, 120], ["patient", "SPECIES", 289, 296], ["swine-origin viruses", "SPECIES", 115, 135], ["outbreaks", "PROBLEM", 18, 27], ["pandemics", "PROBLEM", 32, 41], ["influenza viruses", "PROBLEM", 76, 93], ["avian and swine-origin viruses", "PROBLEM", 105, 135], ["rapid virus detection", "PROBLEM", 192, 213], ["influenza", "PROBLEM", 275, 284], ["IntroductionQuantitative real-time PCR", "TEST", 302, 340], ["qRT", "TEST", 342, 345], ["subtyping viruses", "PROBLEM", 386, 403], ["influenza viruses", "PROBLEM", 415, 432], ["outbreaks", "OBSERVATION", 18, 27], ["rapid", "OBSERVATION_MODIFIER", 57, 62], ["influenza viruses", "OBSERVATION", 76, 93], ["influenza", "OBSERVATION", 275, 284]]], ["This method offers high sensitivity and selectivity, but generally requires approximately 2 h per run; therefore, qRT-PCR is not appropriate for rapid virus detection or subtyping in outbreaks of fast-spreading and/or highly pathogenic viruses at public health centers, hospitals, airports, and other public transportation hubs.", [["qRT-PCR", "TEST", 114, 121], ["rapid virus detection", "TEST", 145, 166], ["pathogenic", "OBSERVATION_MODIFIER", 225, 235], ["viruses", "OBSERVATION", 236, 243]]], ["Super high-speed qRT-PCR (SHRT-PCR) is a recently developed version of qRT-PCR that is characterized by extremely short reaction times (less than 20 min per run for 40 cycles).", [["Super high-speed qRT", "TEST", 0, 20], ["PCR", "TEST", 21, 24], ["qRT-PCR", "PROBLEM", 71, 78], ["extremely short reaction", "PROBLEM", 104, 128], ["extremely", "OBSERVATION_MODIFIER", 104, 113], ["short", "OBSERVATION_MODIFIER", 114, 119]]], ["In this assay, reaction mixtures of qRT-PCR are applied to thin compact disc (CD)-type sample containers, sealed, and rotated on heat blocks at 3 different temperatures (for denaturing, annealing, and extension temperatures).IntroductionThe unique structural and thermodynamic properties of heat blocks fixed at 3 different temperatures are critical for the super high-speed polymerase reaction because the blocks allow rapid temperature changes within the samples.", [["samples", "ANATOMY", 457, 464], ["this assay", "TEST", 3, 13], ["qRT-PCR", "TREATMENT", 36, 43], ["thin compact disc (CD)", "TREATMENT", 59, 81], ["type sample containers", "TREATMENT", 82, 104], ["heat blocks", "TREATMENT", 129, 140], ["denaturing", "PROBLEM", 174, 184], ["extension temperatures", "TEST", 201, 223], ["heat blocks", "TREATMENT", 291, 302], ["the super high-speed polymerase reaction", "TREATMENT", 354, 394], ["the blocks", "PROBLEM", 403, 413], ["rapid temperature changes", "PROBLEM", 420, 445]]], ["While SHRT-PCR is a unique variant of qRT-PCR, it can be applied to detect many kinds of microbes.", [["SHRT", "GENE_OR_GENE_PRODUCT", 6, 10], ["SHRT-PCR", "DNA", 6, 14], ["qRT", "DNA", 38, 41], ["SHRT-PCR", "TEST", 6, 14], ["qRT-PCR", "TREATMENT", 38, 45], ["microbes", "OBSERVATION", 89, 97]]], ["In addition, the super high-speed reaction is well suited to the detection, diagnosis, and control of rapidly spreading pathogens such as those characteristic of seasonal pandemic influenza viruses.", [["influenza viruses", "DISEASE", 180, 197], ["influenza viruses", "ORGANISM", 180, 197], ["seasonal pandemic influenza", "SPECIES", 162, 189], ["the super high-speed reaction", "PROBLEM", 13, 42], ["the detection", "TEST", 61, 74], ["rapidly spreading pathogens", "PROBLEM", 102, 129], ["seasonal pandemic influenza viruses", "PROBLEM", 162, 197], ["seasonal", "OBSERVATION_MODIFIER", 162, 170], ["pandemic influenza viruses", "OBSERVATION", 171, 197]]], ["However, the clinical application of the disk-type qRT-PCR has not been reported at present.", [["the disk-type qRT-PCR", "TEST", 37, 58]]], ["This study establishes a new method for high-speed (<20 min) typing of influenza viruses using SHRT-PCR.", [["This study", "TEST", 0, 10], ["a new method", "TREATMENT", 23, 35], ["influenza viruses", "PROBLEM", 71, 88], ["influenza viruses", "OBSERVATION", 71, 88]]], ["The analysis targeted the nucleotide sequences of the matrix protein segment of influenza virus A (A-MP), influenza virus B (B-MP), and hemagglutinin (HA) of the 2009 pandemic S-OIV and H5N1 avian influenza viruses.", [["nucleotide", "CHEMICAL", 26, 36], ["avian influenza viruses", "DISEASE", 191, 214], ["nucleotide", "CHEMICAL", 26, 36], ["matrix", "CELLULAR_COMPONENT", 54, 60], ["influenza virus A", "ORGANISM", 80, 97], ["A-MP", "ORGANISM", 99, 103], ["influenza virus B", "ORGANISM", 106, 123], ["B-MP", "GENE_OR_GENE_PRODUCT", 125, 129], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 136, 149], ["S-OIV", "ORGANISM", 176, 181], ["H5N1", "ORGANISM", 186, 190], ["avian influenza viruses", "ORGANISM", 191, 214], ["matrix protein segment", "PROTEIN", 54, 76], ["hemagglutinin", "PROTEIN", 136, 149], ["influenza virus", "SPECIES", 80, 95], ["influenza virus", "SPECIES", 106, 121], ["H5N1 avian influenza", "SPECIES", 186, 206], ["influenza virus A", "SPECIES", 80, 97], ["S-OIV", "SPECIES", 176, 181], ["H5N1 avian influenza viruses", "SPECIES", 186, 214], ["The analysis", "TEST", 0, 12], ["the nucleotide sequences", "TEST", 22, 46], ["influenza virus", "PROBLEM", 80, 95], ["influenza virus B", "PROBLEM", 106, 123], ["hemagglutinin", "TEST", 136, 149], ["pandemic S", "TEST", 167, 177], ["OIV", "TREATMENT", 178, 181], ["H5N1 avian influenza viruses", "PROBLEM", 186, 214], ["influenza virus", "OBSERVATION", 80, 95], ["influenza viruses", "OBSERVATION", 197, 214]]], ["Using this system, 86 strains of influenza viruses isolated from hospitals in Tokyo and the Tokyo Metropolitan Institute of Public Health were rapidly analyzed and subtyped.", [["influenza viruses", "DISEASE", 33, 50], ["influenza viruses", "ORGANISM", 33, 50], ["influenza viruses", "PROBLEM", 33, 50]]], ["The typing results were correlated with those using a standardized qRT-PCR method.", [["The typing", "TEST", 0, 10], ["a standardized qRT-PCR method", "TREATMENT", 52, 81]]], ["SHRT-PCR is expected to provide new strategies for controlling the transmission of influenza viruses.Virus strains, clinical samples, and viral RNA isolationRegular laboratory strains, including A/WSN/33(H1N1), A/PR8/34(H1N1), A/Aichi/2/68(H3N2), and B/Mass/3/66 were obtained from the American Type Culture Collection (http://www.atcc.org).", [["samples", "ANATOMY", 125, 132], ["influenza viruses", "DISEASE", 83, 100], ["influenza viruses", "ORGANISM", 83, 100], ["Virus", "ORGANISM", 101, 106], ["samples", "CANCER", 125, 132], ["A/WSN/33(H1N1)", "ORGANISM", 195, 209], ["A/PR8/34(H1N1)", "ORGANISM", 211, 225], ["A/Aichi/2/68(H3N2)", "ORGANISM", 227, 245], ["B/Mass/3/66", "ORGANISM", 251, 262], ["A/WSN/33", "SPECIES", 195, 203], ["A/PR8/34", "SPECIES", 211, 219], ["A/Aichi/2/68(H3N2)", "SPECIES", 227, 245], ["B/Mass/3/66", "SPECIES", 251, 262], ["new strategies", "TREATMENT", 32, 46], ["influenza viruses", "PROBLEM", 83, 100], ["Virus strains", "PROBLEM", 101, 114], ["clinical samples", "TEST", 116, 132], ["viral RNA isolationRegular laboratory strains", "PROBLEM", 138, 183], ["A/WSN", "TEST", 195, 200], ["H1N1", "PROBLEM", 204, 208], ["A/PR8", "TEST", 211, 216], ["H1N1", "PROBLEM", 220, 224], ["A/Aichi", "TEST", 227, 234], ["H3N2", "PROBLEM", 240, 244], ["B/Mass", "TEST", 251, 257], ["influenza viruses", "OBSERVATION", 83, 100]]], ["A/Duck/Hokkaido/Vac-3/07 (H5N1), a low pathogenic H5N1 subtype vaccine strain, was generated by genetic reassortment between 2 low-pathogenic avian influenza viruses, A/Duck/Hokkaido/101/04 (H5N3) and A/Duck/Hokkaido/262/04 (H6N1) (Soda et al., 2008) .", [["avian influenza viruses", "DISEASE", 142, 165], ["Duck/Hokkaido/Vac-3/07 (H5N1", "ORGANISM", 2, 30], ["H5N1", "ORGANISM", 50, 54], ["avian influenza viruses", "ORGANISM", 142, 165], ["A/Duck/Hokkaido/101/04", "ORGANISM", 167, 189], ["A/Duck/Hokkaido/262/04", "ORGANISM", 201, 223], ["H5N1 subtype vaccine", "SPECIES", 50, 70], ["avian influenza viruses", "SPECIES", 142, 165], ["Duck/Hokkaido/Vac-3/07 (H5N1", "SPECIES", 2, 30], ["A/Duck/Hokkaido/101/04 (H5N3)", "SPECIES", 167, 196], ["A/Duck/Hokkaido/262/04 (H6N1)", "SPECIES", 201, 230], ["Vac", "TREATMENT", 16, 19], ["H5N1", "TREATMENT", 26, 30], ["a low pathogenic H5N1 subtype vaccine strain", "TREATMENT", 33, 77], ["Vac", "ANATOMY", 16, 19], ["influenza viruses", "OBSERVATION", 148, 165]]], ["A/Tokyo and B/Tokyo strains were isolated at Tokyo Metropolitan Institute of Public Health between 2006 and 2009 seasons by the use of Madin-Darby canine kidney cells (MDCK cells) (see Table 1 ).", [["kidney cells", "ANATOMY", 154, 166], ["MDCK cells", "ANATOMY", 168, 178], ["B/Tokyo strains", "ORGANISM", 12, 27], ["Madin-Darby canine kidney cells", "CELL", 135, 166], ["MDCK cells", "CELL", 168, 178], ["Madin-Darby canine kidney cells", "CELL_LINE", 135, 166], ["MDCK cells", "CELL_LINE", 168, 178], ["canine", "SPECIES", 147, 153], ["Madin", "TREATMENT", 135, 140], ["Darby canine kidney cells (MDCK cells", "TREATMENT", 141, 178], ["kidney", "ANATOMY", 154, 160]]], ["The institutional review boards of the Tokyo Metropolitan Institute of Medical Science and the Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, approved the procedures for use of clinical samples.", [["samples", "ANATOMY", 216, 223], ["Cancer", "DISEASE", 114, 120], ["Infectious Diseases", "DISEASE", 125, 144], ["clinical samples", "TEST", 207, 223]]], ["Samples were collected from the pharyngeal mucosa of patients who had a diagnosis of influenza-like respiratory disease on the basis of signs and symptoms such as fever.", [["Samples", "ANATOMY", 0, 7], ["pharyngeal mucosa", "ANATOMY", 32, 49], ["respiratory", "ANATOMY", 100, 111], ["influenza-like respiratory disease", "DISEASE", 85, 119], ["fever", "DISEASE", 163, 168], ["pharyngeal mucosa", "MULTI-TISSUE_STRUCTURE", 32, 49], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["Samples", "TEST", 0, 7], ["influenza", "PROBLEM", 85, 94], ["respiratory disease", "PROBLEM", 100, 119], ["signs and symptoms", "PROBLEM", 136, 154], ["fever", "PROBLEM", 163, 168], ["pharyngeal mucosa", "ANATOMY", 32, 49], ["influenza", "OBSERVATION", 85, 94], ["respiratory disease", "OBSERVATION", 100, 119]]], ["Viruses were detected using ESPLINE \u00ae (Fujirebio Diagnostics incorporated., Chuo-ku, Tokyo, Japan; http://www.fujirebio.co.jp), Table 2 Reaction mixtures for SHRT-PCR. immunochromatographic assays, and/or qRT-PCR (CFX96 TM Real-Time PCR Detection System; Promega, Madison, WI, USA; http://www.promega.com) using the protocols of the Centers for Disease Control and Prevention (CDC) (WHO, 2009a) .Virus strains, clinical samples, and viral RNA isolationTotal viral RNA was isolated from 140 L virus-containing cell culture medium or 140 L phosphate-buffered saline containing resuspended pharyngeal mucosal swabs using a QIAamp \u00ae viral RNA Mini Kit (Qiagen, Hilden, Germany; http://www.qiagen.com/).", [["samples", "ANATOMY", 420, 427], ["cell", "ANATOMY", 509, 513], ["pharyngeal mucosal swabs", "ANATOMY", 587, 611], ["phosphate", "CHEMICAL", 538, 547], ["phosphate", "CHEMICAL", 538, 547], ["Virus", "ORGANISM", 396, 401], ["samples", "CANCER", 420, 427], ["cell", "CELL", 509, 513], ["L phosphate-buffered saline", "SIMPLE_CHEMICAL", 536, 563], ["pharyngeal mucosal swabs", "ORGANISM_SUBSTANCE", 587, 611], ["viral RNA", "RNA", 433, 442], ["viral RNA", "RNA", 458, 467], ["L virus", "SPECIES", 490, 497], ["Viruses", "PROBLEM", 0, 7], ["Chuo", "TEST", 76, 80], ["SHRT", "TEST", 158, 162], ["PCR", "TEST", 163, 166], ["immunochromatographic assays", "TEST", 168, 196], ["qRT", "TEST", 205, 208], ["PCR", "TEST", 209, 212], ["Disease Control", "TREATMENT", 345, 360], ["Virus strains", "PROBLEM", 396, 409], ["clinical samples", "TEST", 411, 427], ["viral RNA isolation", "PROBLEM", 433, 452], ["Total viral RNA", "TEST", 452, 467], ["140 L virus", "TREATMENT", 486, 497], ["cell culture medium", "TEST", 509, 528], ["140 L phosphate", "TREATMENT", 532, 547], ["buffered saline", "TREATMENT", 548, 563], ["a QIAamp", "TREATMENT", 618, 626], ["pharyngeal mucosal", "ANATOMY", 587, 605]]], ["Viral RNA standard was isolated from a 10 4 plaque-forming unit (PFU) virus-containing cell culture medium as 10 4 PFU standard RNA.", [["cell", "ANATOMY", 87, 91], ["cell", "CELL", 87, 91], ["Viral RNA", "RNA", 0, 9], ["10 4 PFU standard RNA", "RNA", 110, 131], ["Viral RNA", "TEST", 0, 9], ["a 10 4 plaque-forming unit (PFU) virus", "TREATMENT", 37, 75], ["cell culture medium", "TEST", 87, 106]]], ["Lower-standard RNA (10 3 to 10 \u22122 PFU) was prepared from the 10 4 PFU standard RNA by serial dilution.Plasmid and RNA in vitro generationViral RNA was isolated from each virus subtype using a QIAamp viral RNA Mini Kit (Qiagen, Hilden, Germany; http://www.qiagen.com/).", [["Plasmid", "CELLULAR_COMPONENT", 102, 109], ["Viral", "ORGANISM", 137, 142], ["10 4 PFU standard RNA", "RNA", 61, 82], ["Viral RNA", "RNA", 137, 146], ["serial dilution", "TEST", 86, 101], ["Plasmid", "TREATMENT", 102, 109], ["RNA in vitro generationViral RNA", "PROBLEM", 114, 146], ["standard RNA", "OBSERVATION_MODIFIER", 6, 18], ["RNA", "OBSERVATION_MODIFIER", 114, 117], ["Viral RNA", "OBSERVATION", 137, 146]]], ["Extracted RNA was transcribed into cDNA using a ReverTra Ace Kit (Toyobo, Osaka, Japan http://www.toyobo.co.jp/e/) with the Uni12 primer (AGC AAA AGC AGG) and cloned into the pCR2-TOPO vector (Invitrogen, Carlsbad, CA, USA; http://www.invitrogen.com/) containing T7 promoter.", [["pCR2-TOPO", "GENE_OR_GENE_PRODUCT", 175, 184], ["T7", "GENE_OR_GENE_PRODUCT", 263, 265], ["cDNA", "DNA", 35, 39], ["Uni12 primer", "DNA", 124, 136], ["pCR2", "DNA", 175, 179], ["TOPO vector", "DNA", 180, 191], ["Invitrogen, Carlsbad, CA, USA; http://www.invitrogen.com/)", "DNA", 193, 251], ["T7 promoter", "DNA", 263, 274], ["a ReverTra Ace Kit", "TREATMENT", 46, 64], ["the Uni12 primer", "TREATMENT", 120, 136], ["AGC AAA AGC AGG", "TEST", 138, 153], ["the pCR2", "TEST", 171, 179], ["Invitrogen", "TEST", 193, 203], ["T7 promoter", "TREATMENT", 263, 274], ["T7", "ANATOMY", 263, 265]]], ["Standard RNA was transcribed using the T7 RiboMax Express Large Scale RNA Production System (Promega, Madison, WI, USA; http://www.promega.com/).", [["Standard RNA", "TREATMENT", 0, 12], ["T7", "ANATOMY", 39, 41], ["Large", "OBSERVATION_MODIFIER", 58, 63]]], ["RNA concentrations were measured Table 3 Reaction conditions for SHRT-PCR.Plasmid and RNA in vitro generationStepSHRT-PCRSHRT-PCR was conducted using a unique qRT-PCR testing unit: UR-104MK IV (Trust Medical, Hyogo, Japan; http://www.trustmedical.jp/).", [["Plasmid", "CELLULAR_COMPONENT", 74, 81], ["qRT-PCR testing unit", "DNA", 159, 179], ["RNA concentrations", "TEST", 0, 18], ["SHRT", "TEST", 65, 69], ["Plasmid", "TREATMENT", 74, 81], ["PCR", "TEST", 126, 129], ["UR", "TEST", 181, 183]]], ["Two reaction mixture recipes were used for the SHRT-PCR.", [["Two reaction mixture recipes", "TREATMENT", 0, 28], ["the SHRT-PCR", "TEST", 43, 55]]], ["The original reaction mixture includes RUSH TM DNA polymerase (Trust Medical, Hyogo, Japan; http://www.trustmedical.jp/) and ReverTra Ace (Toyobo, Osaka, Japan; http://www.toyobo.co.jp/e/).", [["DNA", "CELLULAR_COMPONENT", 47, 50], ["RUSH TM DNA polymerase", "PROTEIN", 39, 61], ["The original reaction mixture", "PROBLEM", 0, 29], ["ReverTra Ace", "TREATMENT", 125, 137]]], ["The commercial reaction mixture was from the qRT-PCR kit, RNA-Direct TM SYBR \u00ae Green Real-time PCR Master Mix (Toyobo, Osaka, Japan; http://www.toyobo.co.jp/e/).", [["The commercial reaction mixture", "PROBLEM", 0, 31], ["the qRT", "TEST", 41, 48], ["RNA", "TEST", 58, 61], ["Direct TM SYBR", "TEST", 62, 76]]], ["The DNA polymerase (derived from the thermophilic bacteria Thermus thermophiles) of the kit has reverse transcriptase activity.", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["kit", "GENE_OR_GENE_PRODUCT", 88, 91], ["DNA polymerase", "PROTEIN", 4, 18], ["reverse transcriptase", "PROTEIN", 96, 117], ["The DNA polymerase", "TEST", 0, 18], ["the thermophilic bacteria Thermus thermophiles", "TREATMENT", 33, 79], ["the kit", "TEST", 84, 91], ["transcriptase activity", "OBSERVATION", 104, 126]]], ["Therefore, the enzyme enables both the reverse transcription and PCR steps.", [["the enzyme", "TEST", 11, 21]]], ["The details of these recipes are described in Table 2 .SHRT-PCRThe reaction mixture (11 L) and extracted RNA (5 L) were added to a CD-type sample container with 12 sample wells.", [["SHRT", "SIMPLE_CHEMICAL", 55, 59], ["extracted RNA", "PROBLEM", 95, 108], ["a CD-type sample container", "TREATMENT", 129, 155]]], ["Then, the container was sealed with a sheet of film and placed in the UK-104MK IV.", [["a sheet of film", "TEST", 36, 51]]], ["The reaction conditions and primers are described in Tables 3 and 4 .PrimersBetween 2006 and 2009, consensus viral gene sequences and conserved bases were identified from at least 200 viral gene sequences according to the Influenza Virus Database of the National Center for Biotechnology Information.", [["PrimersBetween 2006 and 2009, consensus viral gene sequences", "DNA", 69, 129], ["viral gene sequences", "DNA", 184, 204], ["The reaction conditions and primers", "PROBLEM", 0, 35], ["consensus viral gene sequences", "TEST", 99, 129], ["viral gene sequences", "TREATMENT", 184, 204], ["bases", "ANATOMY_MODIFIER", 144, 149]]], ["Typing primers were designed to correspond to the conserved regions of the matrix gene segment of influenza A and B viruses.", [["matrix", "CELLULAR_COMPONENT", 75, 81], ["influenza A", "ORGANISM", 98, 109], ["B viruses", "ORGANISM", 114, 123], ["matrix gene segment", "DNA", 75, 94], ["influenza A", "SPECIES", 98, 109], ["B viruses", "SPECIES", 114, 123], ["Typing primers", "TEST", 0, 14], ["influenza A and B viruses", "PROBLEM", 98, 123], ["influenza", "OBSERVATION", 98, 107]]], ["Primers for the detection of S-OIV and H5 subtype viruses were designed to correspond to the conserved region of the HA gene segment for the S-OIV and H5 subtypes.", [["S-OIV", "ORGANISM", 29, 34], ["H5 subtype viruses", "ORGANISM", 39, 57], ["HA", "GENE_OR_GENE_PRODUCT", 117, 119], ["S-OIV", "GENE_OR_GENE_PRODUCT", 141, 146], ["HA gene segment", "DNA", 117, 132], ["H5 subtype viruses", "SPECIES", 39, 57], ["the detection", "TEST", 12, 25], ["S-OIV and H5 subtype viruses", "PROBLEM", 29, 57], ["the S-OIV and H5 subtypes", "PROBLEM", 137, 162], ["H5 subtypes", "OBSERVATION", 151, 162]]], ["In addition, subtyping primers were checked for mismatching consensus sequences of the HA gene segment of other subtypes (<50% matching).", [["consensus sequences", "DNA", 60, 79], ["HA gene segment", "DNA", 87, 102], ["subtyping primers", "TEST", 13, 30], ["mismatching consensus sequences", "PROBLEM", 48, 79], ["segment", "ANATOMY_MODIFIER", 95, 102]]], ["The fragment sizes of SHRT-PCR were 100-200 nucleotides.", [["nucleotides", "CHEMICAL", 44, 55], ["SHRT", "DNA", 22, 26], ["The fragment sizes", "TEST", 0, 18], ["SHRT", "TEST", 22, 26], ["PCR", "TEST", 27, 30], ["fragment", "OBSERVATION_MODIFIER", 4, 12], ["sizes", "OBSERVATION_MODIFIER", 13, 18]]], ["Multiple sets of primers were tested on SHRT-PCR, and the primers which have the best sensitivity for each gene were selected (Table 4 ).Analytical sensitivity of SHRT-PCR for the detection of influenza virusesThe goal of this study was to establish a highly sensitive, highspeed detection system for influenza viruses.", [["influenza viruses", "DISEASE", 193, 210], ["influenza viruses", "DISEASE", 301, 318], ["influenza viruses", "ORGANISM", 193, 210], ["SHRT", "DNA", 40, 44], ["SHRT", "DNA", 163, 167], ["influenza viruses", "SPECIES", 301, 318], ["Multiple sets of primers", "PROBLEM", 0, 24], ["SHRT", "TEST", 40, 44], ["PCR", "TEST", 45, 48], ["the primers", "TEST", 54, 65], ["Analytical sensitivity", "TEST", 137, 159], ["SHRT", "TEST", 163, 167], ["PCR", "TEST", 168, 171], ["the detection", "TEST", 176, 189], ["influenza viruses", "PROBLEM", 193, 210], ["this study", "TEST", 222, 232], ["influenza viruses", "PROBLEM", 301, 318], ["influenza viruses", "OBSERVATION", 193, 210]]], ["SHRT-PCR was used for detecting RNA segments of influenza viruses.", [["influenza viruses", "DISEASE", 48, 65], ["influenza viruses", "ORGANISM", 48, 65], ["SHRT", "DNA", 0, 4], ["SHRT-PCR", "TEST", 0, 8], ["RNA segments of influenza viruses", "PROBLEM", 32, 65], ["influenza viruses", "OBSERVATION", 48, 65]]], ["SHRT-PCR is a unique qRT-PCR technique characterized by extremely short reaction times.", [["SHRT", "DNA", 0, 4], ["a unique qRT", "TEST", 12, 24], ["PCR technique", "TEST", 25, 38], ["extremely short reaction times", "PROBLEM", 56, 86]]], ["Information about the methodology of SHRT-PCR is presented in Fig. 1 .Analytical sensitivity of SHRT-PCR for the detection of influenza virusesSHRT-PCR was performed on duplicates to generate and measure control RNA by in vitro transcription.", [["SHRT", "DNA", 37, 41], ["SHRT", "DNA", 96, 100], ["control RNA", "RNA", 204, 215], ["Analytical sensitivity", "TEST", 70, 92], ["SHRT", "TEST", 96, 100], ["PCR", "TEST", 101, 104], ["the detection", "TEST", 109, 122], ["influenza virusesSHRT", "PROBLEM", 126, 147], ["PCR", "TEST", 148, 151]]], ["Two types of RT-PCR enzyme mixture were used in the method: original mixture and RNA-Direct TM SYBR \u00ae Green Real-time PCR Master Mix.", [["RT-PCR enzyme mixture", "TREATMENT", 13, 34], ["RNA", "TEST", 81, 84], ["Direct TM SYBR", "TEST", 85, 99]]], ["The original mixture containing RUSH TM polymerase, whose reaction speed is slightly high, was optimized for SHRT-PCR; meanwhile, the RNA-Direct TM SYBR \u00ae Green Real-time PCR Master Mix is a commercial qRT-PCR kit that was taken into consideration because of the possibility of other enzymes that can be used for SHRT-PCR.", [["RUSH TM polymerase", "PROTEIN", 32, 50], ["enzymes", "PROTEIN", 284, 291], ["RUSH TM polymerase", "TEST", 32, 50], ["whose reaction speed", "PROBLEM", 52, 72], ["slightly high", "PROBLEM", 76, 89], ["SHRT", "TEST", 109, 113], ["PCR", "TEST", 114, 117], ["the RNA", "TEST", 130, 137], ["Direct TM SYBR", "TEST", 138, 152], ["other enzymes", "PROBLEM", 278, 291], ["SHRT", "TEST", 313, 317], ["PCR", "TEST", 318, 321]]], ["Under this condition using RNA-Direct TM SYBR \u00ae Green Real-time PCR Master Mix, the limits of detection (LOD) for the influenza A virus (A-MP), influenza B virus (B-MP), and S-OIV (HA gene) were 1 copy/reaction ( Fig. 2A, C, E) ; the LOD for the H5 subtype (HA gene) was 10 copies/reaction (Fig. 2G) .", [["influenza B", "DISEASE", 144, 155], ["influenza A virus", "ORGANISM", 118, 135], ["A-MP", "ORGANISM", 137, 141], ["influenza B virus", "ORGANISM", 144, 161], ["B-MP", "GENE_OR_GENE_PRODUCT", 163, 167], ["S-OIV", "GENE_OR_GENE_PRODUCT", 174, 179], ["HA gene", "GENE_OR_GENE_PRODUCT", 181, 188], ["HA gene", "DNA", 181, 188], ["HA gene", "DNA", 258, 265], ["influenza A virus", "SPECIES", 118, 135], ["influenza B virus", "SPECIES", 144, 161], ["influenza A virus", "SPECIES", 118, 135], ["influenza B virus", "SPECIES", 144, 161], ["S-OIV", "SPECIES", 174, 179], ["RNA", "TEST", 27, 30], ["LOD", "TEST", 105, 108], ["the influenza A virus", "PROBLEM", 114, 135], ["influenza B virus", "PROBLEM", 144, 161], ["S", "TEST", 174, 175], ["OIV (HA gene)", "PROBLEM", 176, 189], ["the LOD", "TEST", 230, 237], ["the H5 subtype (HA gene)", "PROBLEM", 242, 266]]], ["All analyses were performed within 15-20 min.", [["All analyses", "TEST", 0, 12]]], ["There was no marked difference in SHRT-PCR results between the 2 mixtures.", [["marked difference", "PROBLEM", 13, 30], ["SHRT", "TEST", 34, 38], ["PCR", "TEST", 39, 42], ["no", "UNCERTAINTY", 10, 12], ["marked", "OBSERVATION_MODIFIER", 13, 19], ["difference", "OBSERVATION_MODIFIER", 20, 30]]], ["RNA-Direct TM SYBR \u00ae Green Realtime PCR Master Mix was prepared as a premixed solution, meaning it has improved usability in clinical practice compared with the original mixture.", [["RNA", "TEST", 0, 3], ["Direct TM SYBR", "TEST", 4, 18], ["Green Realtime PCR Master Mix", "TREATMENT", 21, 50], ["a premixed solution", "TREATMENT", 67, 86]]], ["Thus, RNA-Direct TM SYBR \u00ae Green Real-time PCR Master Mix was selected for use in the following experiment.", [["RNA", "TEST", 6, 9], ["Direct TM SYBR", "TEST", 10, 24], ["Green Real-time PCR Master Mix", "TREATMENT", 27, 57]]], ["(9) 0% (0 of 9) 0% (0 of 9) 100% (9 of 9) (0) ND ND ND A and B negative (10) 0% (0 of 10) 0% (0 of 10) 0% (0 of 10)Analytical sensitivity of SHRT-PCR for the detection of influenza virusesLaboratory strains A/WSN/33 (H1N1), A/PR/8/34 (H1N1), A/Aichi/2/68 (H3N2), and B/Mass/3/66 as well as 86 other influenza viruses isolated at the Tokyo Metropolitan Institute of Public Health were tested by the system.", [["influenza viruses", "DISEASE", 171, 188], ["influenza viruses", "DISEASE", 299, 316], ["influenza viruses", "ORGANISM", 171, 188], ["WSN/33 (H1N1)", "ORGANISM", 209, 222], ["A/PR/8/34 (H1N1)", "ORGANISM", 224, 240], ["A/Aichi/2/68 (H3N2)", "ORGANISM", 242, 261], ["B/Mass/3/66", "ORGANISM", 267, 278], ["PR", "PROTEIN", 226, 228], ["A/WSN/33 (H1N1)", "SPECIES", 207, 222], ["A/PR/8/34 (H1N1)", "SPECIES", 224, 240], ["A/Aichi/2/68 (H3N2)", "SPECIES", 242, 261], ["B/Mass/3/66", "SPECIES", 267, 278], ["Analytical sensitivity", "TEST", 115, 137], ["SHRT", "TEST", 141, 145], ["PCR", "TEST", 146, 149], ["the detection", "TEST", 154, 167], ["influenza viruses", "PROBLEM", 171, 188], ["H1N1", "PROBLEM", 217, 221], ["A/PR", "TEST", 224, 228], ["H1N1", "PROBLEM", 235, 239], ["A/Aichi", "TEST", 242, 249], ["H3N2", "PROBLEM", 256, 260], ["B/Mass", "TEST", 267, 273], ["86 other influenza viruses", "PROBLEM", 290, 316], ["Mass", "OBSERVATION", 269, 273]]], ["All viruses could be detected by the appropriate primer sets.", [["All viruses", "PROBLEM", 0, 11], ["viruses", "OBSERVATION", 4, 11]]], ["Typical results using RNA-Direct TM SYBR \u00ae Green Real-time PCR Master Mix are illustrated for A/WSN/33 by A-MP (Fig. 2B) , B/Tokyo/15480/08 by B-MP (Fig. 2D) , and A/Tokyo/2619/09 (H1N1 pdm) by the S-OIV HA gene (Fig. 2F ) as well as A/Duck/Hokkaido/Vac-3/07 (H5N1) by the H5 HA gene (Fig. 2H) ; the LOD for all samples was 10 \u22121 PFU.", [["samples", "ANATOMY", 312, 319], ["A-MP", "GENE_OR_GENE_PRODUCT", 106, 110], ["Fig. 2B", "CELL", 112, 119], ["B-MP", "GENE_OR_GENE_PRODUCT", 143, 147], ["Tokyo/2619/09", "ORGANISM", 166, 179], ["H1N1", "ORGANISM", 181, 185], ["pdm", "GENE_OR_GENE_PRODUCT", 186, 189], ["S-OIV HA", "GENE_OR_GENE_PRODUCT", 198, 206], ["Duck", "ORGANISM", 236, 240], ["Hokkaido", "ORGANISM", 241, 249], ["Vac-3/07 (H5N1", "ORGANISM", 250, 264], ["S-OIV HA gene", "DNA", 198, 211], ["H5 HA gene", "DNA", 273, 283], ["A/Tokyo/2619/09 (H1N1 pdm", "SPECIES", 164, 189], ["A/Duck/Hokkaido/Vac-3/07 (H5N1", "SPECIES", 234, 264], ["RNA", "TEST", 22, 25], ["Direct TM SYBR", "TEST", 26, 40], ["Vac", "TREATMENT", 250, 253], ["the LOD", "TEST", 296, 303], ["all samples", "TEST", 308, 319], ["Vac", "ANATOMY", 250, 253]]], ["The number of PFUs was constantly 1-2 orders of magnitude less than the number of generated RNAs.", [["generated RNAs", "RNA", 82, 96], ["number", "OBSERVATION_MODIFIER", 4, 10], ["PFUs", "OBSERVATION", 14, 18]]], ["Influenza A virus from a total of 86 influenza viruses (25 strains of seasonal H1N1, 23 strains of seasonal H3N2, 29 strains of S-OIV, and 9 strains of virus B) isolated by the use of MDCK cells in the 2006-2009 seasons at the Tokyo Metropolitan Institute of Public Health (Table 5 ).", [["MDCK cells", "ANATOMY", 184, 194], ["Influenza A virus", "DISEASE", 0, 17], ["influenza viruses", "DISEASE", 37, 54], ["H1N1", "DISEASE", 79, 83], ["H3N2", "DISEASE", 108, 112], ["Influenza A virus", "ORGANISM", 0, 17], ["S-OIV", "ORGANISM", 128, 133], ["virus B", "ORGANISM", 152, 159], ["MDCK cells", "CELL", 184, 194], ["MDCK cells", "CELL_LINE", 184, 194], ["Influenza A virus", "SPECIES", 0, 17], ["seasonal H1N1", "SPECIES", 70, 83], ["seasonal H3N2", "SPECIES", 99, 112], ["Influenza A virus", "SPECIES", 0, 17], ["S-OIV", "SPECIES", 128, 133], ["Influenza A virus", "PROBLEM", 0, 17], ["86 influenza viruses", "PROBLEM", 34, 54], ["seasonal H1N1", "PROBLEM", 70, 83], ["seasonal H3N2", "TEST", 99, 112], ["S", "TEST", 128, 129], ["OIV", "TEST", 130, 133], ["9 strains of virus B", "PROBLEM", 139, 159], ["MDCK cells", "TREATMENT", 184, 194]]], ["The SHRT-PCR system successfully identified 100% (77 of 77) of influenza A virus (i.e., seasonal H1N1, seasonal H3N2, and S-OIV), 100% (29 of 29) of S-OIV, and 100% (9 of 9) of influenza B virus samples.", [["samples", "ANATOMY", 195, 202], ["influenza A virus", "DISEASE", 63, 80], ["seasonal H3N2, and S-OIV", "DISEASE", 103, 127], ["influenza B", "DISEASE", 177, 188], ["influenza A virus", "ORGANISM", 63, 80], ["influenza B virus", "ORGANISM", 177, 194], ["SHRT", "DNA", 4, 8], ["influenza A virus", "SPECIES", 63, 80], ["influenza B virus", "SPECIES", 177, 194], ["influenza A virus", "SPECIES", 63, 80], ["OIV", "SPECIES", 124, 127], ["S-OIV", "SPECIES", 149, 154], ["influenza B virus", "SPECIES", 177, 194], ["The SHRT-PCR system", "TEST", 0, 19], ["influenza A virus", "PROBLEM", 63, 80], ["seasonal H1N1", "TEST", 88, 101], ["seasonal H3N2", "TEST", 103, 116], ["S-OIV", "TEST", 122, 127], ["S", "TEST", 149, 150], ["OIV", "TEST", 151, 154], ["influenza B virus samples", "PROBLEM", 177, 202]]], ["No cross reactions with the incorrect type or subtype of influenza virus were identified.Identification of clinical samplesSHRT-PCR is a variant of quantitative real-time PCR.", [["influenza virus", "DISEASE", 57, 72], ["influenza virus", "ORGANISM", 57, 72], ["influenza virus", "SPECIES", 57, 72], ["influenza virus", "SPECIES", 57, 72], ["cross reactions", "PROBLEM", 3, 18], ["influenza virus", "PROBLEM", 57, 72], ["clinical samplesSHRT-PCR", "TEST", 107, 131], ["influenza virus", "OBSERVATION", 57, 72]]], ["However, the system has only 12 sample wells at present; thus, the maximum number of target samples with quantitative analysis is only 4 (2 for duplicated assay) because 2 negative control wells and at least 6 wells for standard RNAs are necessary.", [["samples", "ANATOMY", 92, 99], ["samples", "CANCER", 92, 99], ["quantitative analysis", "TEST", 105, 126], ["standard RNAs", "TREATMENT", 220, 233]]], ["Thus, based on actual clinical diagnoses, qualitative assays were conducted to identify clinical samples.", [["qualitative assays", "TEST", 42, 60], ["clinical samples", "TEST", 88, 104]]], ["A cutoff value of 10 copies was decided upon to avoid unpredicted nonspecific peaks from being misidentified as a positive signal.", [["A cutoff value", "TEST", 0, 14], ["unpredicted nonspecific peaks", "PROBLEM", 54, 83], ["a positive signal", "PROBLEM", 112, 129]]], ["This is because the fluorescence peak for 10 copies is completely separate from the nonspecific peaks of clinical samples.", [["samples", "ANATOMY", 114, 121], ["the fluorescence peak", "TEST", 16, 37], ["the nonspecific peaks of clinical samples", "PROBLEM", 80, 121], ["nonspecific", "OBSERVATION_MODIFIER", 84, 95]]], ["This cutoff value is also used in qRT-PCR in the CDC protocol.Identification of clinical samplesPharyngeal mucosal swabs from 27 patients with suspected respiratory disease were tested by SHRT-PCR, standard qRT-PCR using CDC protocols, and immunochromatography using ESPLINE \u00ae .", [["Pharyngeal mucosal swabs", "ANATOMY", 96, 120], ["respiratory", "ANATOMY", 153, 164], ["respiratory disease", "DISEASE", 153, 172], ["Pharyngeal mucosal swabs", "MULTI-TISSUE_STRUCTURE", 96, 120], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["This cutoff value", "TEST", 0, 17], ["clinical samples", "TEST", 80, 96], ["Pharyngeal mucosal swabs", "TEST", 96, 120], ["suspected respiratory disease", "PROBLEM", 143, 172], ["PCR", "TEST", 193, 196], ["CDC protocols", "TEST", 221, 234], ["immunochromatography", "TEST", 240, 260], ["Pharyngeal mucosal", "ANATOMY", 96, 114], ["respiratory disease", "OBSERVATION", 153, 172]]], ["The results of immunochromatography and SHRT-PCR matched exactly (Table 6) .", [["immunochromatography", "TEST", 15, 35], ["SHRT", "TEST", 40, 44], ["PCR", "TEST", 45, 48]]], ["Although 1 positive sample detected by immunochromatography and SHRT-PCR was identified as a negative sample by qRT-PCR, there were 5.41 copies of RNA, which is less than the 10-copy cutoff value; the SHRT-PCR reaction curve for this sample was slightly sharper than that for the 10-copy cutoff value.", [["sample", "ANATOMY", 20, 26], ["sample", "ANATOMY", 102, 108], ["sample", "ANATOMY", 234, 240], ["SHRT", "DNA", 64, 68], ["1 positive sample", "PROBLEM", 9, 26], ["immunochromatography", "TEST", 39, 59], ["SHRT-PCR", "TEST", 64, 72], ["PCR", "TEST", 116, 119], ["RNA", "TEST", 147, 150], ["the SHRT", "TEST", 197, 205], ["PCR reaction curve", "TEST", 206, 224], ["this sample", "TEST", 229, 240]]], ["These 2 qRT-PCR measurements indicate a similar case for the detection of very few copies of the sample.DiscussionClinical diagnostic tests for influenza viruses in outpatient departments or clinics are typically based on immunochromatographic detection of influenza virus antigens (Chan et al., 2007) .", [["influenza viruses", "DISEASE", 144, 161], ["influenza virus", "ORGANISM", 257, 272], ["These 2 qRT", "TEST", 0, 11], ["PCR measurements", "TEST", 12, 28], ["the detection", "TEST", 57, 70], ["DiscussionClinical diagnostic tests", "TEST", 104, 139], ["influenza viruses", "PROBLEM", 144, 161], ["immunochromatographic detection", "TEST", 222, 253], ["influenza virus antigens", "PROBLEM", 257, 281]]], ["The immunochromatographic assay is easy to use and provides immediate results; however, the LOD (about 10 2 -10 4 pfu/mL; Bai et al., 2006; Chan et al., 2007; Miyagawa et al., 2011) is insufficient for detecting influenza in preclinical stages, i.e., in the absence of signs and symptoms.", [["influenza", "DISEASE", 212, 221], ["The immunochromatographic assay", "TEST", 0, 31], ["the LOD", "TEST", 88, 95], ["influenza", "PROBLEM", 212, 221], ["signs and symptoms", "PROBLEM", 269, 287], ["influenza", "OBSERVATION", 212, 221]]], ["Additionally, immunochromatography is based on an antigen-antibody reaction, implying that it is not suitable for detecting emerging or re-emerging influenza viruses that are precursors of epidemics or pandemics.DiscussionIn contrast to clinical diagnoses, general surveillance of influenza viruses is usually based on genetic analyses such as qRT-PCR He et al., 2009; WHO, 2009a) .", [["influenza viruses", "DISEASE", 148, 165], ["influenza viruses", "DISEASE", 281, 298], ["influenza viruses", "ORGANISM", 148, 165], ["immunochromatography", "TEST", 14, 34], ["an antigen-antibody reaction", "TEST", 47, 75], ["re-emerging influenza viruses", "PROBLEM", 136, 165], ["epidemics", "PROBLEM", 189, 198], ["pandemics", "PROBLEM", 202, 211], ["influenza viruses", "PROBLEM", 281, 298], ["genetic analyses", "TEST", 319, 335]]], ["Although qRT-PCR is both highly sensitive (about 1-10 1 copies/reaction) and specific, it is more time consuming (>2 h) than immunochromatographic techniques.", [["qRT-PCR", "TEST", 9, 16], ["immunochromatographic techniques", "TEST", 125, 157]]], ["However, genetic analyses are more flexible than antigen-antibody-based approaches because the assays can be tailored to fit emerging and re-emerging influenza viral RNA on the basis of specific primers.DiscussionIn this study, an innovative qRT-PCR method is described with a greatly improved reaction speed for detecting and typing influenza viruses.", [["influenza viruses", "DISEASE", 334, 351], ["influenza viral RNA", "RNA", 150, 169], ["genetic analyses", "TEST", 9, 25], ["antigen", "TEST", 49, 56], ["the assays", "TEST", 91, 101], ["re-emerging influenza viral RNA", "PROBLEM", 138, 169], ["this study", "TEST", 216, 226], ["an innovative qRT-PCR method", "TEST", 228, 256], ["typing influenza viruses", "PROBLEM", 327, 351]]], ["SHRT-PCR completes the analysis within an extremely short time (<20 min) compared with conventional qRT-PCR systems.", [["SHRT", "DNA", 0, 4], ["PCR", "TEST", 5, 8], ["the analysis", "TEST", 19, 31]]], ["In addition, the LODs and specificities for detecting influenza viruses are equal to those of conventional methods (Table 7) .DiscussionThe SHRT-PCR system detects the highly conserved sequence of the corresponding viral genome, and the newly designed primer sets targeted for typing MP segments do not exhibit any cross reactions among other influenza viruses (Table 5 ).", [["influenza viruses", "DISEASE", 54, 71], ["influenza viruses", "DISEASE", 343, 360], ["influenza viruses", "ORGANISM", 343, 360], ["SHRT", "DNA", 140, 144], ["viral genome", "DNA", 215, 227], ["the LODs", "TEST", 13, 21], ["influenza viruses", "PROBLEM", 54, 71], ["The SHRT-PCR system", "TEST", 136, 155], ["the corresponding viral genome", "PROBLEM", 197, 227], ["typing MP segments", "PROBLEM", 277, 295], ["any cross reactions", "PROBLEM", 311, 330], ["other influenza viruses", "PROBLEM", 337, 360], ["viral genome", "OBSERVATION", 215, 227]]], ["The LODs range from 1 to 10 copies/reaction (Fig. 2) , which was sufficiently sensitive for detecting influenza viruses in 27 of 27 clinical cases ( Table 6 ).", [["influenza viruses", "DISEASE", 102, 119], ["The LODs range", "TEST", 0, 14], ["influenza viruses", "PROBLEM", 102, 119]]], ["The results indicate that SHRT-PCR provides the potential to rapidly diagnose and detect infections.", [["infections", "DISEASE", 89, 99], ["SHRT", "DNA", 26, 30], ["SHRT-PCR", "TEST", 26, 34], ["infections", "PROBLEM", 89, 99], ["infections", "OBSERVATION", 89, 99]]], ["Furthermore, SHRT-PCR is expected to be more advantageous than regular immunochromatography or qRT-PCR, especially in the emerging stages of epidemics or pandemics.DiscussionThe WHO defines 6 phases of the pandemic stage of a disease (WHO, 2009b) .", [["SHRT", "PROTEIN", 13, 17], ["SHRT-PCR", "TEST", 13, 21], ["regular immunochromatography", "TEST", 63, 91], ["qRT-PCR", "TEST", 95, 102], ["epidemics", "PROBLEM", 141, 150], ["pandemics", "PROBLEM", 154, 163], ["a disease", "PROBLEM", 224, 233]]], ["Phase 4 is defined as the verification of a community-level outbreak of an animal or reassortant virus and the implementation of a pandemic containment operation.", [["an animal or reassortant virus", "PROBLEM", 72, 102], ["a pandemic containment operation", "TREATMENT", 129, 161]]], ["Because the time for political and clinical preparation for next phase directly depends on the speed of containment of infectious patients, quick detection of the influenza virus is essential for the success of the operation.", [["influenza", "DISEASE", 163, 172], ["patients", "ORGANISM", 130, 138], ["influenza virus", "ORGANISM", 163, 178], ["patients", "SPECIES", 130, 138], ["influenza virus", "SPECIES", 163, 178], ["the influenza virus", "PROBLEM", 159, 178], ["the operation", "TREATMENT", 211, 224], ["infectious", "OBSERVATION", 119, 129]]], ["At phase 4, SHRT-PCR can play a critical role in diagnos- Table 7 Comparison of SHRT-PCR and currently existing detection methods.TargetTime/run Sensitivity Format SHRT-PCR Viral RNA 15-20 min 1-10 copy or 10 \u22121 pfu 12 well/plate Regular qRT-PCR Viral RNA 90-120 min 1-10 copy 96 or 384 well/plate Immunochromatography Viral protein 15 min 10 2 -10 4 pfu 1 sample/strip ing infected patients at public health centers, hospitals, and public transportation hubs (e.g., airports).", [["patients", "ORGANISM", 383, 391], ["SHRT", "DNA", 12, 16], ["SHRT", "DNA", 80, 84], ["patients", "SPECIES", 383, 391], ["SHRT", "TEST", 80, 84], ["PCR", "TEST", 85, 88], ["TargetTime", "TEST", 130, 140], ["Sensitivity", "TEST", 145, 156], ["Format", "TEST", 157, 163], ["SHRT", "TEST", 164, 168], ["Viral RNA", "TEST", 173, 182], ["plate", "TEST", 224, 229], ["qRT", "TEST", 238, 241], ["PCR", "TEST", 242, 245], ["Viral RNA", "TEST", 246, 255], ["plate Immunochromatography", "TEST", 292, 318], ["Viral protein", "TEST", 319, 332], ["sample/strip", "TEST", 357, 369]]], ["SHRT-PCR can also be applied to detect other rapidly spreading pathogens such as the SARS coronavirus (Poon et al., 2003; WHO, 2003) and foot-and-mouth disease virus (Oleksiewicz et al., 2001; Reid et al., 2001) .", [["SARS coronavirus", "DISEASE", 85, 101], ["foot-and-mouth disease", "DISEASE", 137, 159], ["SARS coronavirus", "ORGANISM", 85, 101], ["foot-and-mouth disease virus", "ORGANISM", 137, 165], ["foot-and-mouth disease virus", "SPECIES", 137, 165], ["SARS coronavirus", "SPECIES", 85, 101], ["foot-and-mouth disease virus", "SPECIES", 137, 165], ["rapidly spreading pathogens", "PROBLEM", 45, 72], ["the SARS coronavirus", "PROBLEM", 81, 101], ["foot", "TEST", 137, 141], ["mouth disease virus", "PROBLEM", 146, 165], ["foot", "ANATOMY", 137, 141], ["mouth", "ANATOMY", 146, 151]]], ["Rapid containment is critical for limiting the spread of these viruses, and containment depends on rapid and sensitive detection.", [["containment", "OBSERVATION", 6, 17], ["viruses", "OBSERVATION", 63, 70]]], ["Despite its advantages of rapidity and sensitivity, SHRT-PCT is subject to certain limitations.", [["rapidity", "TEST", 26, 34], ["sensitivity", "TEST", 39, 50], ["SHRT", "TEST", 52, 56]]], ["The SHRT-PCR system used in this study is limited to a sample capacity of 12.", [["SHRT", "DNA", 4, 8], ["The SHRT-PCR system", "TEST", 0, 19], ["this study", "TEST", 28, 38], ["a sample capacity", "TEST", 53, 70]]], ["It is necessary for a quantitative assay to generate a standard curve with multiple defined amounts of samples; thus, SHRT-PCR may be more useful for performing qualitative rather than quantitative assays.", [["samples", "ANATOMY", 103, 110], ["a quantitative assay", "TEST", 20, 40], ["a standard curve", "TEST", 53, 69], ["SHRT-PCR", "TEST", 118, 126], ["quantitative assays", "TEST", 185, 204]]], ["The limitation of the number of samples can be resolved by increasing the number of sample wells on the sample container and increasing the design capacity of the testing unit.", [["samples", "ANATOMY", 32, 39]]], ["For clinical applications for public health surveillance, SHRT-PCR will be more useful than immunochromatography but less useful than qRT-PCR for influenza virus typing.", [["influenza virus", "ORGANISM", 146, 161], ["influenza virus", "SPECIES", 146, 161], ["public health surveillance", "TEST", 30, 56], ["SHRT-PCR", "TEST", 58, 66], ["immunochromatography", "TEST", 92, 112], ["qRT", "TEST", 134, 137], ["PCR", "TEST", 138, 141], ["influenza virus typing", "PROBLEM", 146, 168]]], ["This is because surveillance programs should be able to deal with large numbers of clinical samples.", [["samples", "ANATOMY", 92, 99], ["samples", "CANCER", 92, 99], ["surveillance programs", "TREATMENT", 16, 37], ["clinical samples", "TEST", 83, 99]]], ["Overall, SHRT-PCR is a sufficiently powerful method to provide a basis for rapid pandemic containment at the WHO phase 4 stage.", [["SHRT", "DNA", 9, 13], ["rapid pandemic containment", "TREATMENT", 75, 101]]]], "a090930dd2eae8b81f9ce3c8031b5d9677ead532": [["| INTRODUCTIONThose who followed the CoViD-19 epidemic (and who did not?) watched with trepidation as the number of cases rose steadily.", [["trepidation", "TREATMENT", 87, 98]]], ["A glance at the plot of total number of cases vs. day showed a sigmoidal rise.", [["a sigmoidal rise", "PROBLEM", 61, 77], ["sigmoidal rise", "OBSERVATION", 63, 77]]], ["This curve is familiar to biochemists as the saturation plot for a protein that binds ligand cooperatively, that is, with a Hill coefficient \u2265 2.| INTRODUCTIONThere are a number of sophisticated mathematical models of infectious disease progression.", [["infectious disease", "DISEASE", 218, 236], ["the saturation plot", "TEST", 41, 60], ["infectious disease progression", "PROBLEM", 218, 248], ["infectious", "OBSERVATION_MODIFIER", 218, 228]]], ["[1] [2] [3] [4] They can be stochastic or deterministic, statistical or mechanistic.", [["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 0, 15]]], ["The most complex models can account for variables like reproduction number (R0 = infectivity), steady state, vaccination, social distancing, hospital capacity, etc. But wouldn't it be nice if there was a simple, familiar mathematical model that we all had access to and could use to model the severity and timeline of a pandemic?", [["a pandemic", "PROBLEM", 318, 328], ["most complex", "OBSERVATION_MODIFIER", 4, 16]]], ["Enter, the Hill equation.| INTRODUCTIONThe Hill equation describes how ligand binding to a protein receptor saturates with the concentration of free ligand, [L]:| INTRODUCTIONwhere f b is the fraction of total receptor that has bound n ligands, and K d is the PL n dissociation equilibrium constant; the exponent n is known as the Hill coefficient.", [["K", "CHEMICAL", 249, 250], ["[L]:|", "CHEMICAL", 157, 162], ["Nwhere f b", "GENE_OR_GENE_PRODUCT", 174, 184], ["K d", "GENE_OR_GENE_PRODUCT", 249, 252], ["protein receptor", "PROTEIN", 91, 107], ["a protein receptor saturates", "TREATMENT", 89, 117], ["K d", "TEST", 249, 252], ["the PL n dissociation equilibrium", "PROBLEM", 256, 289], ["dissociation", "OBSERVATION", 265, 277], ["equilibrium", "OBSERVATION_MODIFIER", 278, 289], ["constant", "OBSERVATION_MODIFIER", 290, 298]]], ["Because K d is the free ligand concentration that gives f b = 0.5, also known as [L] 50 , Equation (1) can be written as.| INTRODUCTIONFor an enzyme, the enzyme-substrate complex (E n = P n ) goes on to catalyze the reaction, so the Hill equation can be transformed to describe the dependence of initial reaction rate (v 0 ) on initial substrate concentration, [S] 0 :| INTRODUCTIONwhere V max is the asymptotic v 0 at saturating [S]| INTRODUCTIONHere t represents days, t 50 is the day that you reach half of the final number of cases (cases final ), and n controls the steepness of the sigmoidal rise.", [["K", "CHEMICAL", 8, 9], ["[S] 0", "CHEMICAL", 361, 366], ["K d", "GENE_OR_GENE_PRODUCT", 8, 11], ["enzyme-substrate complex", "PROTEIN", 154, 178], ["K d", "TEST", 8, 11], ["the free ligand concentration", "TEST", 15, 44], ["an enzyme", "TEST", 139, 148], ["the enzyme", "TEST", 150, 160], ["the reaction", "PROBLEM", 212, 224], ["initial reaction rate", "PROBLEM", 296, 317], ["initial substrate concentration", "TEST", 328, 359], ["sigmoidal rise", "OBSERVATION", 588, 602]]], ["Together, t 50 and n provide information on how long the outbreak will last.| INTRODUCTIONFor example, Figure 1a shows sigmoidal plots for n = 3, 5, and 8, given cases final = 100 and t 50 = 40 days.", [["sigmoidal plots", "TEST", 119, 134]]], ["Note that a lower n flattens the curve, so that the rate of increase of cases is shallower.", [["a lower n flattens the curve", "PROBLEM", 10, 38], ["shallower", "OBSERVATION_MODIFIER", 81, 90]]], ["The curve is also flattened by decreasing cases final (Figure 1b ) and by increasing t 50 (Figure 1c ).| INTRODUCTIONMany print media stories that discussed flattening the CoViD-19 epidemic curve illustrated the effect not with total cases vs. time curve, but with the bell-shaped daily cases vs. time curve.", [["the CoViD", "TEST", 168, 177], ["time curve", "TEST", 244, 254], ["flattened", "OBSERVATION_MODIFIER", 18, 27], ["decreasing", "OBSERVATION_MODIFIER", 31, 41]]], ["Lowering cases final (Figure 2a ) decreases the amplitude, that is, the number of daily cases on each day, but leaves the relative width and time-axis position of the bell-curve unchanged.", [["bell", "ANATOMY", 167, 171], ["unchanged", "OBSERVATION_MODIFIER", 178, 187]]], ["Lowering n (Figure 2b ) increases the relative width of the curve, and shifts its peak time to the left (to shorter times).", [["width", "OBSERVATION_MODIFIER", 47, 52], ["left", "ANATOMY_MODIFIER", 99, 103]]], ["This has the effect of increasing the number of daily new cases early and late in the epidemic (before day 25-30, and after day 55-60), while dramatically decreasing this number at the peak of the epidemic.", [["increasing", "OBSERVATION_MODIFIER", 23, 33], ["new", "OBSERVATION_MODIFIER", 54, 57]]], ["Finally, increasing t 50 (Figure 2c ) also increases the relative width of the curve, while shifting the peak time to the right (later times).", [["width", "OBSERVATION_MODIFIER", 66, 71], ["curve", "OBSERVATION_MODIFIER", 79, 84], ["right", "ANATOMY_MODIFIER", 122, 127]]], ["This spreads out the number of new daily cases, decreasing it early in the epidemic, while increasing it later on.| INTRODUCTIONFrom Figure 2c we can see that the curve is asymmetric-it rises faster than it falls.", [["new", "OBSERVATION_MODIFIER", 31, 34], ["asymmetric", "OBSERVATION_MODIFIER", 172, 182]]], ["Furthermore, this asymmetry declines as n increases (Figure 2b , n = 8).", [["this asymmetry", "PROBLEM", 13, 27], ["asymmetry", "OBSERVATION_MODIFIER", 18, 27], ["declines", "OBSERVATION_MODIFIER", 28, 36]]], ["Another surprising observation regarding the first derivative curve is that its peak is always \u2264 t 50 (vertical dotted line in Figure 2a ,b).", [["the first derivative curve", "TEST", 41, 67]]], ["The peak approaches t 50 as n increases, rising from about 0.6 \u00d7 t 50 for n = 2, to 0.975 \u00d7 t 50 for n = 8.", [["peak", "OBSERVATION_MODIFIER", 4, 8]]], ["To explore some real epidemic data sets, Figure 3 presents a plot of the number of CoViD-19 cases in China and South Korea.", [["CoViD", "TEST", 83, 88]]], ["Clearly, the sigmoidal fits to Equation (4) are good, although not perfect: For example, the early undershoot and late overshoot of the China curve are due to the fact that Chinese authorities changed their method of diagnosing the disease after day 24, suddenly increasing the number of cases.| INTRODUCTIONBefore we go any further, it is important to state up front that fitting infection data to the Hill equation is purely a statistical process.", [["infection", "DISEASE", 381, 390], ["the early undershoot", "PROBLEM", 89, 109], ["late overshoot of the China curve", "PROBLEM", 114, 147], ["the disease", "PROBLEM", 228, 239], ["fitting infection data", "PROBLEM", 373, 395], ["sigmoidal", "ANATOMY_MODIFIER", 13, 22], ["early", "OBSERVATION_MODIFIER", 93, 98], ["undershoot", "OBSERVATION_MODIFIER", 99, 109], ["late", "OBSERVATION_MODIFIER", 114, 118], ["overshoot", "OBSERVATION_MODIFIER", 119, 128], ["infection", "OBSERVATION", 381, 390]]], ["There is no theoretical model explaining why this equation fits the data, thus there is no way to connect the Hill equation parameters to viral or human biology, or to social policy implementation.", [["human", "ORGANISM", 147, 152], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 147, 152], ["no", "UNCERTAINTY", 9, 11]]], ["On the other hand, one might hypothesize that faster viral reproduction inside the host would raise both n and cases final ; the same would be expected for anything that raises infectivity, for example, more infectious viral particles, easier viral spread from asymptomatic individuals, higher frequency of close human contact, etc.| INTRODUCTIONHill equation fits are quite good for almost all data sets (R 2 = 0.9940-0.9997).", [["human", "ORGANISM", 313, 318], ["human", "SPECIES", 313, 318], ["human", "SPECIES", 313, 318], ["infectivity", "PROBLEM", 177, 188], ["more infectious viral particles", "PROBLEM", 203, 234], ["easier viral spread", "PROBLEM", 236, 255], ["asymptomatic individuals", "PROBLEM", 261, 285]]], ["Table 1 lists Equation (4) fitted parameters for data sets from 35 countries (fitted plots for each data set can be found in the Figures S2-S38 ).", [["S38", "PROTEIN", 140, 143], ["data sets", "TEST", 49, 58]]], ["The Hill coefficients (n) vary about two-fold (from 4 to 8), and half-times (t 50 ) vary about five-fold (from 20 to 100 days); on the other hand, cases final vary over 3,000-fold, from 384 for Taiwan to 1.4 million for the United States.| INTRODUCTIONAbove, we speculated that anything that enhanced infection rate might raise both n and cases final .", [["infection", "DISEASE", 301, 310], ["The Hill coefficients", "TEST", 0, 21], ["enhanced infection rate", "PROBLEM", 292, 315]]], ["In fact, the fitted data from 35 countries show no strong relationship between any of the three fit parameters ( Figure S1 ).", [["the fitted data", "TEST", 9, 24]]], ["For example, the United States had a cases final value almost six times higher than the next-highest country, but its t 50 and n Hill are in the middle of the range of values.", [["middle", "ANATOMY_MODIFIER", 145, 151]]], ["It seems logical that strong social intervention, including Table 1 T A B L E 1 Equation (4) wide-spread testing, contact tracing, and quarantining, would lower both t 50 and cases final .| INTRODUCTIONOnly three data sets were not well-fit by Equation (4), and their deviations allow some interesting speculation on the effectiveness of social intervention.", [["strong social intervention", "TREATMENT", 22, 48], ["wide-spread testing", "TEST", 93, 112], ["contact tracing", "TEST", 114, 129], ["social intervention", "TREATMENT", 338, 357]]], ["This could be because their interventions, after the first scores of cases were identified, were so effective that these initial cases did not lead to a sigmoidal rise; only after the first 120 cases appeared in Hong Kong did the disease spread as an epidemic, presumably via community transmission.| INTRODUCTIONThe South Korea data set showed a sigmoidal rise in cases until day 25, after which the cases numbers rose more slowly ( Figure 5 ).", [["a sigmoidal rise", "PROBLEM", 151, 167], ["the disease spread", "PROBLEM", 226, 244], ["The South Korea data", "TEST", 313, 333], ["a sigmoidal rise", "PROBLEM", 345, 361], ["the cases numbers", "TEST", 397, 414], ["disease", "OBSERVATION", 230, 237], ["sigmoidal", "OBSERVATION_MODIFIER", 347, 356], ["rise", "OBSERVATION_MODIFIER", 357, 361]]], ["One could speculate that South Korea, which was the second nation to experience an outbreak of CoViD-19, managed to mount an intensive social intervention around day 25, including for example, extensive testing, contact tracing, quarantining, etc. This would be another example of \"flattening the curve\".", [["CoViD", "TEST", 95, 100], ["an intensive social intervention", "TREATMENT", 122, 154], ["extensive testing", "TEST", 193, 210], ["contact tracing", "TEST", 212, 227], ["\"flattening the curve\"", "PROBLEM", 281, 303]]], ["Note that although the curve was indeed flattened from day 25-55, the number of cases final was unchanged by this intervention: 10,594 \u00b1 26 for the blue dashed curve (i.e., the normal sigmoidal rise without the intervention) vs. 10,550 \u00b1 110 for the red solid curve.", [["the curve", "TEST", 19, 28], ["the blue dashed curve", "TEST", 144, 165], ["the intervention", "TREATMENT", 207, 223], ["the red solid curve", "TEST", 246, 265], ["flattened", "OBSERVATION_MODIFIER", 40, 49], ["unchanged", "OBSERVATION_MODIFIER", 96, 105], ["sigmoidal", "OBSERVATION_MODIFIER", 184, 193]]], ["In this case, flattening the curve did not decrease the eventual number of cases, it just slowed the rate at which those cases appeared every day, allowing hospitals to accommodate the influx of patients.| INTRODUCTIONAs mentioned above, in the midst of a pandemic, one question on everyone's mind is \"when will it be over?\"", [["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["flattening the curve", "PROBLEM", 14, 34], ["flattening", "OBSERVATION", 14, 24]]], ["However, one can ask how long it would take to get close to the end, for example, within 90 or 95% of the maximum value.", [["the maximum value", "TEST", 102, 119]]], ["Manipulating Equation (4), we can show that if f is the fraction of the total you are interested in (e.g., 0.9 or 0.95), then the time to reach that value (t f ) can be calculated: (4) with a zero y-intercept (red curve), and with a non-zero intercept (black curve) of 122 \u00b1 4 cases F I G U R E 5 South Korea CoViD-19 cases fit to Equation (4) with all points (red solid curve), and with days 25-55 omitted (blue dashed curve)F I G U R E 4 Hong Kong CoViD-19 cases fit to EquationWe can see from Equation (6) that, unsurprisingly, t f increases linearly with t 50 , but it also decreases with n (larger n gives a steeper rise, which gives a shorter t f ).", [["a zero y-intercept (red curve", "TREATMENT", 190, 219], ["a non-zero intercept (black curve", "TREATMENT", 231, 264], ["South Korea CoViD", "TEST", 297, 314], ["red solid curve", "TEST", 361, 376], ["CoViD", "TEST", 450, 455], ["a steeper rise", "PROBLEM", 611, 625], ["decreases", "OBSERVATION_MODIFIER", 578, 587]]], ["Again, decreasing n flattens the curve, which spreads out the duration of the epidemic (Figure 2b ).", [["decreasing n flattens the curve", "PROBLEM", 7, 38], ["decreasing", "OBSERVATION_MODIFIER", 7, 17], ["curve", "OBSERVATION_MODIFIER", 33, 38]]], ["Using Equation (6) and fit parameters from Table 1 , t 90 for the United States and New York state come out to 92 and 72 days, respectively; that would be May 24 (2020) for the United States as a whole, and May 6 for New York state.F I G U R E 4 Hong Kong CoViD-19 cases fit to EquationA better way to judge if you are close enough to the end of an epidemic to ease social restrictions is to identify a target maximum number of new daily cases.", [["F", "CHEMICAL", 232, 233], ["F", "SPECIES", 232, 233], ["Kong CoViD", "TEST", 251, 261]]], ["The World Health Organization has stated that an outbreak is deemed \"contained\" when < 10% of tests for the disease are positive; to be even safer, we can aim for < 1%.", [["tests", "TEST", 94, 99], ["the disease", "PROBLEM", 104, 115], ["positive", "PROBLEM", 120, 128]]], ["Harvard University's Global Health Institute has opined that the \"bare minimum\" of testing capacity in the United States should be 500,000 per day (0.15% of the population), so 1% would be 5,000 positive tests per day.", [["testing capacity", "TEST", 83, 99]]], ["For New York, the target would be < 300 new daily cases (0.015% \u00d7 20 million), which should occur by day 106 (June 9).F I G U R E 4 Hong Kong CoViD-19 cases fit to EquationOf course, it is easy to fit an asymptotic curve when your data approach the asymptote, as they do in Figure 3 .", [["F", "CHEMICAL", 118, 119], ["F", "SPECIES", 118, 119], ["Kong CoViD", "TEST", 137, 147], ["an asymptotic curve", "TEST", 201, 220]]], ["And here the function and limitations of datafitting must be considered.", [["datafitting", "TREATMENT", 41, 52]]], ["By fitting an entire data set to a mathematical equation, we can then use the fit parameters to predict the value of the dependent variable (y) for a value of the independent variable (x) that has not been measured, but lies within the range of measured values.", [["a value", "TEST", 148, 155]]], ["Furthermore, the R 2 -value gives you a notion of the quality of the fit, and if we know the uncertainties in the fit parameters, we can calculate the uncertainty in the predicted y-value.F I G U R E 4 Hong Kong CoViD-19 cases fit to EquationHowever, that is not the situation in the middle of an epidemic.", [["F", "CHEMICAL", 188, 189], ["F", "SPECIES", 188, 189], ["Kong CoViD", "TEST", 207, 217], ["middle", "ANATOMY_MODIFIER", 284, 290], ["epidemic", "OBSERVATION", 297, 305]]], ["In this case, the R 2 value and the fit parameter uncertainties do not mean the same thing that they do when working with a complete data set.F I G U R E 4 Hong Kong CoViD-19 cases fit to EquationConsider the countries that were below 70% completion as of April 27, 2020, that is, the last ten countries in Table 1 .", [["F", "CHEMICAL", 142, 143], ["F", "SPECIES", 142, 143], ["the R 2 value", "TEST", 14, 27], ["Kong CoViD", "TEST", 161, 171]]], ["On the other hand, n Hill relative uncertainties are only slightly higher for these bottom 10 countries, compared to the other countries ( Figure 6) .", [["uncertainties", "OBSERVATION", 35, 48], ["slightly", "OBSERVATION_MODIFIER", 58, 66], ["higher", "OBSERVATION_MODIFIER", 67, 73]]], ["Table 2 affords a closer look at this effect.F I G U R E 4 Hong Kong CoViD-19 cases fit to EquationIt turns out that even the high uncertainties for the low-completion data sets are woefully underestimated.", [["F", "CHEMICAL", 45, 46], ["F", "SPECIES", 45, 46], ["CoViD", "TEST", 69, 74]]], ["And it goes almost without saying that an R 2 value above 0.99 for fitting a data set that is less than 50% complete is meaningless.", [["an R 2 value", "TEST", 39, 51]]], ["For example, Germany's data set was very well-fit by Equation (4), with R 2 = 0.9996, and its final reported number of total cases (from April 27) was 94% of the fitted cases final value.", [["Germany's data", "TEST", 13, 27]]], ["Thus, its fit parameters are extremely well-determined: cases final = 171,400 \u00b1 900; t 50 = 42.44 \u00b1 0.12 days; and n Hill = 5.48 \u00b1 0.06.", [["t", "TEST", 85, 86], ["Hill", "TEST", 117, 121]]], ["Removing points from the end of the data set allows us to examine the fit parameters at 90% completion, 80%, and so on.F I G U R E 4 Hong Kong CoViD-19 cases fit to EquationT A B L E 2 Average relative uncertainties (in %) for cases final , t 50 , and n Hill for all countries in Table 1 Completion \u226590% F I G U R E 6 Relative uncertainties for cases final (red), t 50 (blue), and n Hill (black), plotted against the percentage completion of the case load for all countries listed in Table 1 In Figure 7 we plot the fitted values for cases final at completion percentages of 94% down to 14.5% (below 14% the fitting process failed).", [["CoViD", "TEST", 143, 148], ["EquationT", "TEST", 165, 174]]], ["From this we learn that when using nonlinear regression to fit an incomplete data set, the reported uncertainties are greatly underestimated.", [["an incomplete data", "TEST", 63, 81]]], ["The second observation is that below 30% completion, the cases final value is far too low, by 2-to three-fold.", [["the cases final value", "TEST", 53, 74]]], ["Similar errors were noted for fitted values of t 50 and n Hill below 30% completion (data not shown).F I G U R E 4 Hong Kong CoViD-19 cases fit to EquationAnother way to look at this problem is to examine t 90 predictions at various points of completion %.", [["F", "CHEMICAL", 101, 102], ["F", "SPECIES", 101, 102], ["CoViD", "TEST", 125, 130]]], ["Figure 8 plots t 90 (calculated from the Equation (4) fitted parameters, using Equation (6)) for the Germany data set ending on day 31 (14.5% completion), day 32 (17% completion), etc., up to the full 68-day data set (94% completion).", [["Figure", "TEST", 0, 6], ["the Germany data", "TEST", 97, 113]]], ["This receding \"goal line\" is another example of the dangers of trying to fit an incomplete data set.F I G U R E 4 Hong Kong CoViD-19 cases fit to EquationConsider the Germany data set ending on day 34, which is 22% complete.", [["F", "CHEMICAL", 100, 101], ["F", "SPECIES", 100, 101], ["This receding \"goal line", "TREATMENT", 0, 24], ["Kong CoViD", "TEST", 119, 129], ["the Germany data", "TEST", 163, 179]]], ["At that point (day 39), the U.S. case load was 213,000, and fitting suggested cases final = 440,000 \u00b1 14,000 and t 90 = day 51.", [["the U.S. case load", "TEST", 24, 42]]], ["The bottom line is that one has to take these fitting results with a grain of salt, especially when conditions such as testing frequency and social intervention change during the course of the epidemic.", [["The bottom line", "TREATMENT", 0, 15], ["a grain of salt", "TREATMENT", 67, 82], ["testing frequency", "TEST", 119, 136], ["social intervention change", "TREATMENT", 141, 167], ["bottom line", "OBSERVATION", 4, 15]]], ["Of course there is an endless loop problem here, because one does not know the actual cases final until the data set is complete, so your calculation of % completion will have an uncertain denominator.", [["an endless loop problem", "PROBLEM", 19, 42], ["your calculation", "TEST", 133, 149], ["endless loop", "OBSERVATION", 22, 34]]], ["However, Figure 7 allows us to calculate that this error should be less than \u224810%.F I G U R E 4 Hong Kong CoViD-19 cases fit to EquationA word is in order concerning the use of diagnosed cases, as opposed to hospitalizations or deaths.", [["deaths", "DISEASE", 228, 234], ["F", "CHEMICAL", 82, 83], ["F", "SPECIES", 82, 83], ["Kong CoViD", "TEST", 101, 111]]], ["I have chosen to use reported cases because they are a current indicator of the epidemic, whereas deaths and hospitalizations are trailing indicators.", [["deaths", "DISEASE", 98, 104]]], ["However, it is definitely true that increasing testing during the course of the epidemic skews the fits.", [["increasing", "OBSERVATION_MODIFIER", 36, 46]]], ["This explains, at least partially, the modest rise in cases final seen in Figure 7 after 40% completion.", [["modest", "OBSERVATION_MODIFIER", 39, 45], ["rise", "OBSERVATION_MODIFIER", 46, 50]]], ["The skewing effect of increased testing can also be seen in the slight upward tilt of the California total cases curve after day 48 ( Figure S31) , and in the increase in cases final and t 50 , and decrease in n Hill and completion % from April 27 to May 3 for almost all of the countries that were re-fit on May 3 ( Table 1 ).", [["increased testing", "PROBLEM", 22, 39], ["increased", "OBSERVATION_MODIFIER", 22, 31], ["increase", "OBSERVATION_MODIFIER", 159, 167]]], ["The good news is that hospitalization and death data sets follow the same trend as total cases (only delayed by 1 or 3 weeks, respectively), and can also be fit to the Hill equation (total cases, Equation 4) and its first derivative (daily cases, Equation 5).F I G U R E 4 Hong Kong CoViD-19 cases fit to EquationLet us close with an example of the usefulness of this fitting procedure.", [["death", "DISEASE", 42, 47], ["F", "CHEMICAL", 259, 260], ["F", "SPECIES", 259, 260], ["death data", "TEST", 42, 52], ["Kong CoViD", "TEST", 278, 288], ["this fitting procedure", "TREATMENT", 363, 385], ["good", "OBSERVATION_MODIFIER", 4, 8]]], ["On April 8 (2020), the governor of New York announced that, based on the models his experts were using, he expected the peak of the COViD-19 outbreak would be reached in mid-June.", [["the COViD", "TEST", 128, 137]]], ["Assuming that by \"peak\" he meant the maximum of the new daily cases (first derivative) curve, simple plotting and fitting would have shown him that New York state had in fact already passed its peak of new infections earlier that week, on April 4!", [["infections", "DISEASE", 206, 216], ["simple plotting", "TEST", 94, 109], ["new infections", "PROBLEM", 202, 216], ["new", "OBSERVATION_MODIFIER", 202, 205], ["infections", "OBSERVATION", 206, 216]]], ["Some experts predict that the world will have to deal with a resurgence of CoViD-19 in the fall of 2020, and perhaps even in years afterward.", [["CoViD", "TEST", 75, 80]]], ["In the meantime, biochemistry students can be regaled with the unexpected usefulness of the Hill equation in predicting the progression of epidemics.F I G U R E 4 Hong Kong CoViD-19 cases fit to EquationACKNOWLEDGMENTS I wish to thank my colleagues J. Charles Williamson for his data-fitting insight, and Mark Janeba for his help with equation differentiation, and my partner Rosalie Schele for her help with data entry.ORCIDTodd P. Silverstein https://orcid.org/0000-0003-3349-2876SUPPORTING INFORMATIONAdditional supporting information may be found online in the Supporting Information section at the end of this article.SUPPORTING INFORMATIONHow to cite this article: Silverstein TP.", [["TP", "GENE_OR_GENE_PRODUCT", 683, 685], ["epidemics", "PROBLEM", 139, 148], ["CoViD", "TEST", 173, 178], ["progression", "OBSERVATION_MODIFIER", 124, 135]]], ["CoViD-19 epidemic follows the \"kinetics\" of enzymes with cooperative substrate binding.", [["CoViD-19", "CHEMICAL", 0, 8], ["enzymes", "PROTEIN", 44, 51], ["CoViD", "TEST", 0, 5], ["epidemic", "PROBLEM", 9, 17], ["cooperative substrate binding", "PROBLEM", 57, 86]]]], "PMC7174921": [["IntroductionIn Canada, the growing number of newcomer families underscores the need for effective pedagogical support in an evolving global landscape (Cheng et al. 2009).", [["effective pedagogical support", "TREATMENT", 88, 117], ["growing", "OBSERVATION_MODIFIER", 27, 34], ["number", "OBSERVATION_MODIFIER", 35, 41]]], ["There exists a new reality of language learning needs based on the influx of newcomer students in Canada using technology for the acquisition of twenty-first century literacy skills.", [["new", "OBSERVATION_MODIFIER", 15, 18]]], ["To add to these challenges, the digital divide persists along racial and class lines (Machado-Casas et al. 2014).", [["these challenges", "TREATMENT", 10, 26], ["class lines", "OBSERVATION", 73, 84]]], ["In this article, we not only nuance the catch-all notion of \u2018twenty-first century learning skills\u2019 through glimpses of 40 families\u2019 experiences of digital literacies, but also we expose some of the more invisible aspects of digital divides in suburban communities.IntroductionThinking across the literature, Mirazchiyski (2016) reports on a large international corpus of data focusing on grade 8 students\u2019socio-economic status (SES) and their computer and information literacy.", [["digital literacies", "PROBLEM", 147, 165]]], ["Still, there is a divide between students in low and high SES homes in the type of device used.", [["the type of device", "TREATMENT", 71, 89], ["low", "OBSERVATION_MODIFIER", 45, 48]]], ["In keeping with this notion, there are recent examples of family digital literacy programs that enhance the literacy skills of the children and the digital literacy of their parents (e.g., Lee et al. 2018).", [["children", "ORGANISM", 131, 139], ["children", "SPECIES", 131, 139]]], ["Noguer\u00f3n-Liu (2017a, 2017b) examined the digital access, use, and beliefs of immigrant parents whose children had access to devices at school and the parents themselves who engaged in technology support workshops.", [["children", "ORGANISM", 101, 109], ["children", "SPECIES", 101, 109]]], ["Such findings highlight strong connections between what Dolan (2016) calls the cans and cannots when it comes to digital literacy skills.", [["strong", "OBSERVATION_MODIFIER", 24, 30]]], ["Davidson (2012) found that through discussion, children\u2019s research for a project became a topic of social conversation stemming from the images and videos found.", [["children", "ORGANISM", 47, 55], ["children", "SPECIES", 47, 55], ["the images", "TEST", 133, 143]]], ["Davidson also discovered that children had to make meaning of the verbal instructions given to them by parents or teachers, and translate those instructions into action using their devices.", [["children", "ORGANISM", 30, 38], ["children", "SPECIES", 30, 38]]], ["This process of meaning-making through digital literacies becomes a key aspect of childrens\u2019 multimedia use and learning and if parents, especially newcomer parents, are not familiar with these interactions, the children may not develop the adept ability to navigate their devices for learning.IntroductionWith regard to social discussion, Davies\u2019 (2011) study examined the relationship between parents and their children\u2019s technology use at home; ultimately finding that as children grow into adolescents, parents tend to lose control over their children\u2019s technology use.", [["children", "ORGANISM", 212, 220], ["children", "ORGANISM", 413, 421], ["children", "ORGANISM", 475, 483], ["children", "ORGANISM", 547, 555], ["children", "SPECIES", 212, 220], ["children", "SPECIES", 413, 421], ["children", "SPECIES", 475, 483], ["children", "SPECIES", 547, 555]]], ["However, children who are exposed to a positive relationship between technology and their parents, are likely to develop higher personal autonomy while monitoring or moderating their uses of technology when not monitored by their parents in adolescence.", [["children", "ORGANISM", 9, 17], ["children", "SPECIES", 9, 17]]], ["Those adolescents also make digital choices that would be deemed as acceptable by the parents (Davies 2011).", [["adolescents", "SPECIES", 6, 17]]], ["Davies also mentions that parents are often anxious about their children\u2019s technology use, especially for social purposes, but tend to see the value of some technology for educational purposes.", [["children", "ORGANISM", 64, 72], ["children", "SPECIES", 64, 72]]], ["Livingstone and Helsper (2008) support Davies\u2019 statements explaining that \u201cparents seem engaged in a constant battle with their children as they seek to balance the educational and social advantages of media use and the negative effects that some content... might have on children\u2019s attitudes, behaviour, or safety\u201d (p.", [["children", "ORGANISM", 128, 136], ["children", "ORGANISM", 272, 280], ["children", "SPECIES", 128, 136], ["children", "SPECIES", 272, 280]]], ["The development of a child\u2019s skill-set, information base, and familiarity with technology may stem from the strength of parental interaction, guidance, and mediation.IntroductionWithin the parent-child relationship and experiences using technology at home, Hamlin and Flessa (2018) highlight several key barriers to parent involvement in their childrens\u2019 technology use: costs associated with personal technology devices; culturally diverse families\u2019 unfamiliarity with their new environment; rural versus urban access; and retraction of parental participation in higher grade levels.", [["personal technology devices", "TREATMENT", 393, 420], ["rural versus urban access", "TREATMENT", 493, 518], ["retraction of parental participation", "TREATMENT", 524, 560]]], ["Specifically, Hamlin and Flessa discovered that large urban areas need more multilingual support for culturally diverse parents and stronger parental supports for safety while using technology (while parents monitor their children).", [["children", "ORGANISM", 222, 230], ["children", "SPECIES", 222, 230], ["multilingual support", "TREATMENT", 76, 96], ["large", "OBSERVATION_MODIFIER", 48, 53], ["urban", "OBSERVATION_MODIFIER", 54, 59]]], ["In Ontario, Canada, the government proposed a Parents Reaching Out Grant Program to aid in parental participation in the many contexts of their children\u2019s lives, including the school community.", [["children", "ORGANISM", 144, 152], ["children", "SPECIES", 144, 152]]], ["Recently, 11% of all province-wide initiatives were focused on developing culturally diverse parents\u2019 connections with the school and their children\u2019s learning via technology or other communication systems (Hamlin and Flessa 2018).IntroductionDiallo (2014) contends that mobile devices and apps are instructional tools that are changing English language learning in homes and pedagogy in classrooms.", [["children", "ORGANISM", 140, 148], ["children", "SPECIES", 140, 148], ["mobile devices", "TREATMENT", 271, 285]]], ["This project explored how schools partner with a local university to use digital resources as tools to co-create learning with newcomer parents in their community.", [["digital resources", "TREATMENT", 73, 90]]], ["The project began with a purview of the type and usage of home technology.", [["home technology", "TREATMENT", 58, 73]]], ["Specifically, the project gathered information on how to engage parents as they support their children with twenty-first century literacies.Instrument and data collection ::: Project description and survey methodsThe survey (see Appendix A) was designed by the research team and based on the need to capture current, Canadian data on the twenty-first century resources that families are accessing in their homes and parents\u2019 beliefs about technology usage.", [["children", "ORGANISM", 94, 102], ["children", "SPECIES", 94, 102]]], ["There were nine demographic questions (e.g., gender; ethnicity; first language speak/read/write; number of children) and then questions regarding home technology and usage for the parent and with their child(ren) (e.g., television; computer; tablet; SMART phone; video games; internet connection; email).", [["children", "ORGANISM", 107, 115], ["children", "SPECIES", 107, 115]]], ["Finally, some questions asked parent participants about home technology practices such as their daily activities that require technology, and the duration and use of home technology for their child(ren).", [["participants", "SPECIES", 37, 49], ["home technology practices", "TREATMENT", 56, 81], ["home technology", "TREATMENT", 166, 181]]], ["Consent to participate in the survey was garnered within the introduction and choice to move beyond the first page.Participants ::: Project description and survey methodsThe survey was administered to parents in two medium-to-large publicly funded schools in the Niagara Region, Ontario, Canada.", [["Participants", "SPECIES", 115, 127]]], ["In this region, 14% of the population between the ages of 25 and 64 has not completed their high school education; over 27% of families with children are single-parents; over 10% of the population has immigrated to the region (Niagara Region 2015).", [["children", "ORGANISM", 141, 149], ["children", "SPECIES", 141, 149]]], ["There are 8.8% of the population that identify as a visible minority and 96.4% as English First-language spoken (Statistics Canada 2017a, 2017b).", [["8.8%", "OBSERVATION_MODIFIER", 10, 14]]], ["The unemployment rate in the Niagara Region is 6.2% and 12% of people living in Niagara are considered to be low income (Employment and Social Development Canada 2013).Participants ::: Project description and survey methodsThe schools that participated in this survey are in the same aggregate dissemination area according to Statistics Canada, 2016 Census of Population (2017).", [["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69], ["Participants", "SPECIES", 168, 180], ["The unemployment rate", "TEST", 0, 21]]], ["For this school community area, 10.5% of the population between the ages of 25 and 64 has not completed their high school education; 18% of families with children are single-parents; 21.5% of the population has immigrated to the community.", [["children", "ORGANISM", 154, 162], ["children", "SPECIES", 154, 162]]], ["The unemployment rate in the school community area is 8.5% and 15.5% are considered to be low income.Participants ::: Project description and survey methodsIn sum, when compared to the Niagara Region as a whole, the parent population for this school community was more likely to be an immigrant, identifying as a visible minority and holding a post-secondary education.", [["Participants", "SPECIES", 101, 113], ["The unemployment rate", "TEST", 0, 21], ["a post-secondary education", "TREATMENT", 342, 368]]], ["These parents were less likely to be in a single-parent family dynamic, but more likely to be unemployed and low income.Participants ::: Project description and survey methodsThere were 70 parent/guardian respondents (68% female; 32% male; mean age 39 years) each representing a single case or unique family.", [["respondents", "ORGANISM", 205, 216], ["Participants", "SPECIES", 120, 132]]], ["Based on the total school dissemination, the parent participant response rate was 17.5%.", [["the parent participant response rate", "TEST", 41, 77]]], ["The parent respondents had a mode of 2 children (x\u0304= 2.26) with a minimum to a maximum range of 1 to 5.", [["children", "ORGANISM", 39, 47], ["children", "SPECIES", 39, 47]]], ["The age of the first-born child was tri-modal (8, 9, 10 years old); the age of the second-born child was a mode of 6 years old.", [["child", "ORGANISM", 26, 31], ["child", "ORGANISM", 95, 100]]], ["Table 1. is a summary of the demographic characteristics of the parent sample (additional demographics are available on request).Data analysis ::: Project description and survey methodsSurvey responses were culled in a GOOGLE document and then converted into files for analyses in SPSS (2014).", [["Data analysis", "TEST", 129, 142]]], ["The data that were categorical were nominally coded and frequency counts and percentages were calculated.", [["The data", "TEST", 0, 8], ["frequency counts", "TEST", 56, 72], ["percentages", "TEST", 77, 88]]], ["Where scale data existed (e.g., age; number of children), measures of central tendency were calculated.", [["children", "ORGANISM", 47, 55], ["children", "SPECIES", 47, 55], ["central tendency", "PROBLEM", 70, 86], ["central tendency", "OBSERVATION", 70, 86]]], ["These descriptive statistics are presented in Tables 2, 3, 4, 5 and 6 below.Data analysis ::: Project description and survey methodsTo answer the research questions that query whether there are associations among demographic characteristics and technology use, the Chi-Square Test of Independence was used within SPSS (Field 2009).", [["Data analysis", "TEST", 76, 89]]], ["This non-parametric test determines whether there is an association between categorical variables, or whether the variables are independent or related.", [["This non-parametric test", "TEST", 0, 24], ["an association between categorical variables", "PROBLEM", 53, 97]]], ["Significance level was set at p \u2265 0.05 for all of the potential question responses, collapsing into aggregated clusters was done in advance of calculating the Chi-Square Tests of Independence.", [["Significance level", "TEST", 0, 18], ["collapsing into aggregated clusters", "PROBLEM", 84, 119]]], ["Then the Chi Square analyses were re-calculated.ResultsTo respond to the first research question, \u201cWhat are the home technology usages of parents and their elementary school aged children?\u201d descriptive statistics were calculated for the questions that related to parents\u2019 technology use in the home and the parents\u2019 perceptions of their child(ren)\u2018s technology use.", [["children", "ORGANISM", 179, 187], ["children", "SPECIES", 179, 187], ["the Chi Square analyses", "TEST", 5, 28]]], ["Table 3. presents descriptive findings for the parents\u2019, children\u2019s, and family technology use by device.", [["children", "ORGANISM", 57, 65], ["children", "SPECIES", 57, 65]]], ["The mode or dominant response is presented as a percentage of the sample in parentheses.ResultsThe following summary, Table 4., presents the parent respondents\u2019 daily technology activities and practices in the home.", [["dominant", "OBSERVATION_MODIFIER", 12, 20], ["response", "OBSERVATION_MODIFIER", 21, 29]]], ["The percentages are a portion of the total sample of respondents.ResultsParent respondents were asked how much home technology use they believe is appropriate for their child(ren).", [["percentages", "OBSERVATION_MODIFIER", 4, 15]]], ["For the second research question, \u201cAre there associations among the parents\u2019 and their elementary school aged children\u2019s home technology usages?\u201d there was a significant association between parents\u2019 number of hours on their phone and their child(ren)\u2018s number of hours on their phone(s) (\u03a72(1) > = 4.493, p = 0.034).", [["children", "ORGANISM", 110, 118], ["children", "SPECIES", 110, 118]]], ["The majority of the parents spent 1\u201322 h on their phones and their child(ren) spent 1\u20137 h on their phones.ResultsFor the third research question, \u201cAre there associations among parents\u2019 technology usage and their beliefs about their elementary school-aged children\u2019s home technology usage?\u201d there was a significant association between parents\u2019 use of social media in the home and their beliefs about their child(ren)\u2018s amount of home technology use (\u03a72(2) > = 6.798, p = 0.033).", [["children", "ORGANISM", 255, 263], ["children", "SPECIES", 255, 263], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["The majority of the parents were social media users and believed that their child(ren) should have some home technology use.ResultsThere were several significant results for the fourth research question, \u201cAre there associations among the demographic characteristics of parents and the types of activities they do with technology and their beliefs about their elementary school-aged children\u2019s home technology usages?\u201d", [["children", "ORGANISM", 382, 390], ["children", "SPECIES", 382, 390], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["There was a significant association between parents\u2019 age and their child(ren)\u2018s number of hours on television (\u03a72(1) > = 9.727, p = 0.002).", [["significant", "OBSERVATION_MODIFIER", 12, 23]]], ["The majority of the parents who were 20\u201339 years old had children that spent 1\u201313 h/week on television.", [["children", "ORGANISM", 57, 65], ["children", "SPECIES", 57, 65]]], ["Similarly, there was a significant association between parents\u2019 age and the parents\u2019 use of technology for leisure activities (\u03a72(1) > = 3.688, p = 0.05).", [["leisure activities", "TEST", 107, 125], ["significant", "OBSERVATION_MODIFIER", 23, 34]]], ["The majority of the parents who were 40+ years old used technology for leisure time.ResultsThere was a significant association between parents\u2019 ethnicity (i.e., White; Latino) and the parents\u2019 use of technology for leisure activities (\u03a72(1) > = 4.696, p = 0.03).", [["leisure activities", "TEST", 215, 233], ["significant", "OBSERVATION_MODIFIER", 103, 114]]], ["In a related fashion, a significant association existed between parents\u2019 birth country (i.e., Canada; Latin America) and the parents\u2019 use of technology for transit and maps (\u03a72(1) > = 4.760, p = 0.029).", [["transit and maps", "TEST", 156, 172]]], ["The majority of the parents who were not native to Canada (USA/UK/Central-Latin America) used technology for transit/maps.ResultsAs well, there was a significant association between parents\u2019 highest level of education (i.e., high school; bachelor\u2019s degree) and the parents\u2019 use of technology for information and news (\u03a72(1) > = 4.001, p = 0.045).", [["transit/maps", "TREATMENT", 109, 121]]], ["The majority of the parents who were English-first speaking have a tablet in the home, (\u03a72(2) > = 9.484, p = 0.009), whereas parents speaking Spanish or other languages tend not to have a tablet in the home.ResultsThe next group of three significant associations also relate to parents\u2019 first language and connections to their beliefs about their child(ren)s\u2019 technology use.", [["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["There was a significant association between parents\u2019 first language that they speak (i.e., English) and how parents\u2019 prefer to have their children use technology in the home (\u03a72(2) > =13.165, p = 0.001) such that the majority of the parents who were English speaking prefer their children to use technology in the home for entertainment (e.g., playing games, watching movies), whereas parents speaking Spanish or other languages tend not to have this preference.", [["children", "ORGANISM", 138, 146], ["children", "ORGANISM", 280, 288], ["children", "SPECIES", 138, 146], ["children", "SPECIES", 280, 288], ["significant", "OBSERVATION_MODIFIER", 12, 23]]], ["Second, there was a significant association between parents\u2019 first language that they speak and if parents prefer to have their children use technology in the home to communicate with friends and family (\u03a72(2) > =6.436, p = 0.040); specifically, the majority of the parents who were English speaking prefer their children to use technology in the home for communicating with family and friends, whereas parents speaking Spanish or other languages tend not to have this preference.", [["children", "ORGANISM", 128, 136], ["children", "ORGANISM", 313, 321], ["children", "SPECIES", 128, 136], ["children", "SPECIES", 313, 321], ["significant", "OBSERVATION_MODIFIER", 20, 31]]], ["Third, there was a significant association between parents\u2019 first language that they speak and if parents prefer to have their children use technology in the home to communicate with the school (\u03a72(2) > =7.787, p = 0.020); interestingly, the majority of the parents who were English speaking prefer their children not to use technology in the home for communicating with school, whereas parents speaking Spanish or other languages do not have this preference.ResultsThe final group of three significant associations relate to parents\u2019 gender (specifically female/mother figure) and associations with their beliefs about their child(ren)s\u2019 technology use.", [["children", "ORGANISM", 127, 135], ["children", "ORGANISM", 305, 313], ["children", "SPECIES", 127, 135], ["children", "SPECIES", 305, 313], ["significant", "OBSERVATION_MODIFIER", 19, 30]]], ["First, there was a significant association between parents\u2019 gender and how parents prefer to have their child(ren) use technology in the home for social media (e.g., Snapchat, Instagram, Facebook) (\u03a72(1) > =10.455, p = 0.001).", [["significant", "OBSERVATION_MODIFIER", 19, 30]]], ["The majority of the female parents/guardians prefer their children not to use technology in the home for social media.", [["children", "ORGANISM", 58, 66], ["children", "SPECIES", 58, 66]]], ["There was a significant association between parents\u2019 gender and how parents prefer to have their children use technology in the home to communicate with friends/family (\u03a72(1) > =4.733, p = 0.03).", [["children", "ORGANISM", 97, 105], ["children", "SPECIES", 97, 105], ["significant", "OBSERVATION_MODIFIER", 12, 23]]], ["The majority of the female parents/guardians prefer their children to use technology in the home for communicating with family and friends.", [["children", "ORGANISM", 58, 66], ["children", "SPECIES", 58, 66]]], ["There was a significant association between parents\u2019 gender and how parents prefer to have their child(ren) use technology in the home to communicate with school (\u03a72(1) > =4.179, p = 0.041).", [["significant", "OBSERVATION_MODIFIER", 12, 23]]], ["The majority of the female parents/guardians prefer their children not to use technology in the home for communicating with school.Discussion and conclusionsWe have highlighted the results for the newcomer families in order to foreground their needs.", [["children", "ORGANISM", 58, 66], ["children", "SPECIES", 58, 66]]], ["As a whole, this project sought to explore ways for parents to engage with their children in contemporary ways for using, communicating and thinking through new technologies.", [["children", "ORGANISM", 81, 89], ["children", "SPECIES", 81, 89]]], ["For example, this study concluded that 96.7% (n = 60) of parents prefer their children to use technology for school while only 11.7% of parents want their children using technology for social media; while 73.3% of those parents use social media at home themselves, but only 53.3% of them use technology at home for work purposes.", [["parents", "ORGANISM", 57, 64], ["children", "ORGANISM", 78, 86], ["parents", "ORGANISM", 136, 143], ["children", "ORGANISM", 155, 163], ["children", "SPECIES", 78, 86], ["children", "SPECIES", 155, 163], ["this study", "TEST", 13, 23]]], ["These levels of access and use varied in terms of the quantity of new technologies as well as the types of literacy practices that families engage in.", [["new technologies", "TREATMENT", 66, 82], ["literacy practices", "TREATMENT", 107, 125]]], ["Reflecting on March 2020, for instance, with the ubiquitous use of and leveraging of social media to teach elementary and secondary students during the COVID-19 crisis, understanding the ways that social media works, communicates, and converges films, podcasts, and newsfeeds are essential to do well in school.", [["social media", "TREATMENT", 85, 97]]], ["The fact that parents discourage social media use where higher SES families might encourage it, signals a key finding about disparate framings of what successful twenty-first century is and looks like.Discussion and conclusionsThe research also points to anxieties that parents have about the kinds of technology that their children access and their sharing of private information.", [["children", "ORGANISM", 324, 332], ["children", "SPECIES", 324, 332]]], ["Pervasively, parents are also concerned about the amount of time that their children spend on phones, television and social media.", [["children", "ORGANISM", 76, 84], ["children", "SPECIES", 76, 84]]], ["The study\u2019s third research question, although not significant, descriptively explains that more immigrant parents like their children using technology for social media in the home versus Canadian parents (ratio of 5:3).", [["children", "ORGANISM", 125, 133], ["children", "SPECIES", 125, 133], ["The study", "TEST", 0, 9]]], ["Noguer\u00f3n-Liu (2017b) found that immigrant adults have varied understandings of online privacy and digital practices that range from being critical consumers and adept users of social media and software to those who have no online experience.", [["adults", "ORGANISM", 42, 48]]], ["Again, this type of finding spotlights a misconception by newcomer families that technologies take away from academic learning when in fact much of it is about critically framing content, digital practices, and curating the right and accurate types of texts to complete academic tasks and create content.Discussion and conclusionsEducators who are interested in enhancing the benefits of using digital resources for their newcomer students should review the ways that technology is used by parents and their children.", [["children", "ORGANISM", 508, 516], ["children", "SPECIES", 508, 516], ["digital resources", "TREATMENT", 394, 411], ["right", "ANATOMY_MODIFIER", 224, 229]]], ["The age of the children can also be a mitigating factor.", [["children", "ORGANISM", 15, 23], ["children", "SPECIES", 15, 23]]], ["For example, a recent study of newcomer children found that participating in video gaming communities promoted their socialization, technology use and multimodality (Duran 2017).", [["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48], ["a recent study", "TEST", 13, 27]]], ["Moreover, video-game based language instruction has been used by H\u00e9ctor (2015) to ameliorate the difficulties surrounding English learning needs of newcomer students from different socio-economic backgrounds.Discussion and conclusionsThere should be an attempt to assist newcomer parents to provide responsive twenty-first century literacy support for their children.", [["children", "ORGANISM", 358, 366], ["children", "SPECIES", 358, 366]]], ["150) engaged Latina/o immigrant parents in a technology program that encouraged them to use \u201ctechnology as a bridge for connecting with their children, getting involved with the school, and becoming part of the local and global 21st century community.\u201d", [["children", "ORGANISM", 142, 150], ["children", "SPECIES", 142, 150]]], ["In another example, Levinson and Barron (2018) documented the positive outcomes of Latina/o immigrant families\u2019 supported use of digital resources (i.e., tablets) to help themselves as parents along with their children learn literacy related content and English.", [["children", "ORGANISM", 210, 218], ["children", "SPECIES", 210, 218]]], ["A promising example is found with Lee et al. (2018) who facilitated a program supplying refurbished laptops, literacy and technology resources (including bilingual and culturally relevant children\u2019s books) and parent workshops for the immigrant parents of elementary children.", [["children", "ORGANISM", 188, 196], ["children", "ORGANISM", 267, 275], ["children", "SPECIES", 188, 196], ["children", "SPECIES", 267, 275]]], ["It was found that the technology supported parents\u2019 and their children to co-construct literacy learning and agency at home.", [["children", "ORGANISM", 62, 70], ["children", "SPECIES", 62, 70]]], ["Noguer\u00f3n-Liu (2017a) also found that it is critical for the school to provide families with devices and training.", [["devices and training", "TREATMENT", 92, 112]]], ["Such training should include the benefits of utilizing technology to support twenty-first century skills, with a greater focus on content creation, problem solving tasks, and creativity and innovation.", [["Such training", "TREATMENT", 0, 13]]], ["Yet, ultimately, parents still hold distinct beliefs about their role as parents and their children\u2019s ethical and appropriate technology use.", [["children", "ORGANISM", 91, 99], ["children", "SPECIES", 91, 99]]], ["As parental beliefs and choices dictate the technological actions of the child, it is imperative that better supports for this interaction are required.", [["child", "ORGANISM", 73, 78]]], ["There is an ongoing need for family digital literacy programs and support for digital equity in newcomer communities to ultimately allow for a stronger partnership between newcomer parents, children, and school systems.", [["children", "ORGANISM", 190, 198], ["children", "SPECIES", 190, 198], ["family digital literacy programs", "TREATMENT", 29, 61], ["support", "TREATMENT", 66, 73]]]], "f5755a0d8201253f39f3ebaf8ca258d82d363510": [["IntroductionAt the end of December 2019, it was reported an outbreak of many pneumonia cases in Wuhan, China .", [["pneumonia", "DISEASE", 77, 86], ["many pneumonia cases", "PROBLEM", 72, 92], ["many", "OBSERVATION_MODIFIER", 72, 76], ["pneumonia", "OBSERVATION", 77, 86]]], ["Hereafter, according to the Chinese Center for Disease Control, this anomalous amount of cases was caused by a novel coronavirus.", [["coronavirus", "DISEASE", 117, 128], ["coronavirus", "ORGANISM", 117, 128], ["Disease Control", "TREATMENT", 47, 62], ["a novel coronavirus", "PROBLEM", 109, 128]]], ["Initially, this coronavirus was called as 2019-nCoV (2019-novel coronavirus) by World Health Organization (WHO) in January 2020.", [["coronavirus", "ORGANISM", 16, 27], ["coronavirus", "ORGANISM", 64, 75]]], ["Now, it has been officially renamed to SARS-CoV-2 (severe acute respiratory syndrome 2) (Guarner, 2020) and the disease caused by this coronavirus is known as COVID-19.", [["SARS", "DISEASE", 39, 43], ["acute respiratory syndrome", "DISEASE", 58, 84], ["coronavirus", "DISEASE", 135, 146], ["SARS-CoV-2", "ORGANISM", 39, 49], ["coronavirus", "ORGANISM", 135, 146], ["coronavirus", "SPECIES", 135, 146], ["SARS-CoV", "SPECIES", 39, 47], ["SARS", "TEST", 39, 43], ["CoV", "TEST", 44, 47], ["severe acute respiratory syndrome", "PROBLEM", 51, 84], ["the disease", "PROBLEM", 108, 119], ["this coronavirus", "PROBLEM", 130, 146], ["COVID", "TEST", 159, 164], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["respiratory syndrome", "OBSERVATION", 64, 84], ["disease", "OBSERVATION", 112, 119]]], ["Due to the COVID-19 outbreak rapidly spread worldwide, it was declared on 11 March 2020 as a pandemic disease by the WHO.", [["a pandemic disease", "PROBLEM", 91, 109]]], ["To date at 14 March 2020, there are 216 countries affected by the COVID-19, which 4,307,287 cases and 295,101 deaths were confirmed (https://www.who.int/emergencies/diseases/novel-coronavirus-2019).IntroductionThe symptoms of COVID-19 may appear between 2 and 14 days after exposure to the SARS-CoV-2 with main signs: cough, runny nose, fever, sore throat, headache and difficulty to breath .", [["deaths", "DISEASE", 110, 116], ["SARS", "DISEASE", 290, 294], ["cough", "DISEASE", 318, 323], ["runny nose", "DISEASE", 325, 335], ["fever", "DISEASE", 337, 342], ["sore throat", "DISEASE", 344, 355], ["headache", "DISEASE", 357, 365], ["difficulty to breath", "DISEASE", 370, 390], ["COVID-19", "CHEMICAL", 226, 234], ["the COVID", "TEST", 62, 71], ["The symptoms", "PROBLEM", 210, 222], ["COVID", "TEST", 226, 231], ["the SARS", "TEST", 286, 294], ["cough", "PROBLEM", 318, 323], ["runny nose", "PROBLEM", 325, 335], ["fever", "PROBLEM", 337, 342], ["sore throat", "PROBLEM", 344, 355], ["headache", "PROBLEM", 357, 365], ["difficulty to breath", "PROBLEM", 370, 390], ["cough", "OBSERVATION", 318, 323], ["runny nose", "ANATOMY", 325, 335], ["fever", "OBSERVATION", 337, 342], ["sore throat", "ANATOMY", 344, 355]]], ["The SARS-CoV-2 is belong the SARS-CoV family as verified by Xu et al. (Xu et al., 2020) from comparison of its sequence with others coronavirus.", [["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "ORGANISM", 4, 14], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 29, 37], ["SARS-CoV family", "PROTEIN", 29, 44], ["SARS-CoV", "SPECIES", 4, 12], ["SARS-CoV", "SPECIES", 29, 37], ["The SARS", "TEST", 0, 8], ["others coronavirus", "PROBLEM", 125, 143]]], ["Therefore, SARS-CoV-2 is composed by glycosylated spike protein (S-protein), membrane protein, envelope protein and nucleocapsid protein (Chen et al., 2006; Boopathi et al., 2020) .", [["SARS", "DISEASE", 11, 15], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 11, 21], ["glycosylated spike protein", "GENE_OR_GENE_PRODUCT", 37, 63], ["S-protein", "GENE_OR_GENE_PRODUCT", 65, 74], ["membrane", "CELLULAR_COMPONENT", 77, 85], ["glycosylated spike protein", "PROTEIN", 37, 63], ["S-protein", "PROTEIN", 65, 74], ["membrane protein", "PROTEIN", 77, 93], ["envelope protein", "PROTEIN", 95, 111], ["nucleocapsid protein", "PROTEIN", 116, 136], ["SARS-CoV", "TEST", 11, 19], ["glycosylated spike protein", "TEST", 37, 63], ["membrane protein", "TEST", 77, 93], ["envelope protein", "TEST", 95, 111], ["nucleocapsid protein", "TEST", 116, 136]]], ["Likewise, the SARS family, the SARS-CoV-2 infect the cell human using the angiotensin-converting enzyme 2 (ACE2) as receptor, which was confirmed by Ou et al. (Ou et al., 2020; Shang et al., 2020) .Recent molecular modeling study developed by Xu et al. (2020) revealed that the S-protein from SARS-CoV-2 presents strong binding affinity with the ACE2 receptor.IntroductionThe S-protein has the functional S1 and S2 subunits and they are responsible by the human cell attachment and membrane fusion, respectively (Boopathi et al., 2020) .", [["cell", "ANATOMY", 53, 57], ["cell", "ANATOMY", 462, 466], ["membrane", "ANATOMY", 482, 490], ["SARS", "DISEASE", 14, 18], ["angiotensin", "CHEMICAL", 74, 85], ["SARS-CoV-2", "ORGANISM", 31, 41], ["cell", "CELL", 53, 57], ["human", "ORGANISM", 58, 63], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 74, 105], ["ACE2", "GENE_OR_GENE_PRODUCT", 107, 111], ["SARS-CoV-2", "ORGANISM", 293, 303], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 346, 359], ["S-protein", "GENE_OR_GENE_PRODUCT", 376, 385], ["S1", "GENE_OR_GENE_PRODUCT", 405, 407], ["S2", "GENE_OR_GENE_PRODUCT", 412, 414], ["human", "ORGANISM", 456, 461], ["cell", "CELL", 462, 466], ["membrane", "CELLULAR_COMPONENT", 482, 490], ["angiotensin-converting enzyme 2", "PROTEIN", 74, 105], ["ACE2", "PROTEIN", 107, 111], ["S-protein", "PROTEIN", 278, 287], ["ACE2 receptor", "PROTEIN", 346, 359], ["S-protein", "PROTEIN", 376, 385], ["functional S1 and S2 subunits", "PROTEIN", 394, 423], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 456, 461], ["SARS-CoV", "SPECIES", 31, 39], ["human", "SPECIES", 58, 63], ["SARS-CoV", "SPECIES", 293, 301], ["human", "SPECIES", 456, 461], ["the SARS", "TEST", 27, 35], ["the angiotensin-converting enzyme", "TREATMENT", 70, 103], ["Recent molecular modeling study", "TEST", 198, 229], ["the S-protein from SARS", "PROBLEM", 274, 297], ["CoV", "TEST", 298, 301], ["strong binding affinity", "PROBLEM", 313, 336], ["the ACE2 receptor", "TREATMENT", 342, 359], ["membrane fusion", "TREATMENT", 482, 497], ["human cell attachment", "OBSERVATION", 456, 477], ["membrane fusion", "OBSERVATION", 482, 497]]], ["In the S1 subunit is located the receptor-binding domain (RBD) which binds to human ACE2 and mediates the viral fusion and cellular membranes (Song et al., 2018) .", [["cellular membranes", "ANATOMY", 123, 141], ["human", "ORGANISM", 78, 83], ["ACE2", "GENE_OR_GENE_PRODUCT", 84, 88], ["cellular membranes", "CELLULAR_COMPONENT", 123, 141], ["S1 subunit", "PROTEIN", 7, 17], ["receptor-binding domain", "PROTEIN", 33, 56], ["RBD", "PROTEIN", 58, 61], ["human ACE2", "PROTEIN", 78, 88], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["human ACE2", "TEST", 78, 88], ["the viral fusion", "TREATMENT", 102, 118], ["S1", "ANATOMY_MODIFIER", 7, 9], ["viral fusion", "OBSERVATION", 106, 118], ["cellular membranes", "OBSERVATION", 123, 141]]], ["However, the RBD from SARS-CoV-2 has highest affinity with the ACE2 than SARS-CoV as confirmed and evidenced by experimental (Wrapp et al., 2020; Wan et al., 2020) , and theoretical data .", [["RBD", "DISEASE", 13, 16], ["SARS", "DISEASE", 22, 26], ["SARS-CoV-2", "ORGANISM", 22, 32], ["ACE2", "GENE_OR_GENE_PRODUCT", 63, 67], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 73, 81], ["RBD", "PROTEIN", 13, 16], ["ACE2", "PROTEIN", 63, 67], ["SARS-CoV", "SPECIES", 22, 30], ["SARS-CoV", "SPECIES", 73, 81], ["the RBD", "TEST", 9, 16], ["SARS", "TEST", 22, 26], ["CoV", "TEST", 27, 30], ["highest affinity", "PROBLEM", 37, 53], ["RBD", "OBSERVATION", 13, 16]]], ["In these studies, the authors suggest that the large spread from human to human can be attributed the higher affinity between the SARS-CoV-2 and human ACE2.", [["human", "ORGANISM", 65, 70], ["human", "ORGANISM", 74, 79], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 130, 140], ["human", "ORGANISM", 145, 150], ["ACE2", "GENE_OR_GENE_PRODUCT", 151, 155], ["SARS-CoV-2 and human ACE2", "PROTEIN", 130, 155], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 74, 79], ["SARS-CoV", "SPECIES", 130, 138], ["human", "SPECIES", 145, 150], ["these studies", "TEST", 3, 16], ["human ACE2", "TREATMENT", 145, 155], ["large", "OBSERVATION_MODIFIER", 47, 52], ["spread", "OBSERVATION", 53, 59]]], ["Moreover, the optimized mutation in the RBD residues has evidenced high-affinity binding with ACE2 and suggest that the SARS-CoV-2 surged from a natural selection process instead of a human manipulation (Andersen et al., 2020) .IntroductionThus, S-protein emerges an interesting target to drug design for the SARS-CoV-2 inhibition, which blocking the RBD by a drug can prevent coupling between the S-protein and ACE2.", [["SARS", "DISEASE", 309, 313], ["RBD", "DISEASE", 351, 354], ["ACE2", "GENE_OR_GENE_PRODUCT", 94, 98], ["human", "ORGANISM", 184, 189], ["S-protein", "GENE_OR_GENE_PRODUCT", 246, 255], ["CoV-2", "GENE_OR_GENE_PRODUCT", 314, 319], ["RBD", "GENE_OR_GENE_PRODUCT", 351, 354], ["S-protein", "GENE_OR_GENE_PRODUCT", 398, 407], ["ACE2", "GENE_OR_GENE_PRODUCT", 412, 416], ["RBD residues", "PROTEIN", 40, 52], ["ACE2", "PROTEIN", 94, 98], ["RBD", "PROTEIN", 351, 354], ["S-protein", "PROTEIN", 398, 407], ["ACE2", "PROTEIN", 412, 416], ["human", "SPECIES", 184, 189], ["human", "SPECIES", 184, 189], ["the optimized mutation", "PROBLEM", 10, 32], ["the RBD residues", "PROBLEM", 36, 52], ["high-affinity binding", "PROBLEM", 67, 88], ["ACE2", "TEST", 94, 98], ["the SARS", "TEST", 116, 124], ["a natural selection process", "TREATMENT", 143, 170], ["a human manipulation", "TREATMENT", 182, 202], ["the SARS-CoV-2 inhibition", "TREATMENT", 305, 330], ["the RBD", "PROBLEM", 347, 354], ["a drug", "TREATMENT", 358, 364]]], ["Consequently, the initial step of fusion of the SARS-CoV-2 and human cell may be avoided inducing the virus death or at least no replication.IntroductionAlthough the S-protein is very important in the initial stage of infection, there is not experimental work reporting their use on drug design.", [["cell", "ANATOMY", 69, 73], ["SARS", "DISEASE", 48, 52], ["death", "DISEASE", 108, 113], ["infection", "DISEASE", 218, 227], ["SARS-CoV-2", "ORGANISM", 48, 58], ["human", "ORGANISM", 63, 68], ["cell", "CELL", 69, 73], ["S-protein", "GENE_OR_GENE_PRODUCT", 166, 175], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["the SARS", "TEST", 44, 52], ["CoV", "TEST", 53, 56], ["the virus death", "PROBLEM", 98, 113], ["infection", "PROBLEM", 218, 227], ["infection", "OBSERVATION", 218, 227]]], ["On the other hand, there are various theoretical studies in the literature using the S-protein as target to provide its inhibition.", [["S-protein", "GENE_OR_GENE_PRODUCT", 85, 94], ["S-protein", "PROTEIN", 85, 94], ["various theoretical studies", "TEST", 29, 56], ["the S-protein", "TREATMENT", 81, 94]]], ["For instance, Zhang et al. carried out docking calculations using Chinese medical herbs to S-protein inhibition, and they found 13 compounds with potential SARS-CoV-2 activity.", [["S-protein", "SIMPLE_CHEMICAL", 91, 100], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 156, 166], ["docking calculations", "TREATMENT", 39, 59], ["Chinese medical herbs", "TREATMENT", 66, 87], ["S-protein inhibition", "TREATMENT", 91, 111], ["potential SARS", "PROBLEM", 146, 160]]], ["In another study, the Smith et al. (Smith & Smith, 2020) used molecular dynamics simulation to generate an ensemble docking of the S-protein@ACE2 complex.", [["S-protein@ACE2", "GENE_OR_GENE_PRODUCT", 131, 145], ["S-protein@ACE2 complex", "PROTEIN", 131, 153], ["another study", "TEST", 3, 16]]], ["In their docking calculations, it was found 19 potent candidates to bind at the S-protein:ACE2 interface and 30 top-scoring compounds were predicted to bind in the isolated S-protein.", [["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["S-protein", "GENE_OR_GENE_PRODUCT", 173, 182], ["ACE2", "PROTEIN", 90, 94], ["S-protein", "PROTEIN", 173, 182], ["S-protein", "OBSERVATION", 173, 182]]], ["In same way, the Sandeep & McGregor (Sandeep & McGregor, 2020) used the S-protein:ACE2 interface to predict the binding of the hydroxychloroquine and azithromycin using docking calculations.", [["hydroxychloroquine", "CHEMICAL", 127, 145], ["azithromycin", "CHEMICAL", 150, 162], ["hydroxychloroquine", "CHEMICAL", 127, 145], ["azithromycin", "CHEMICAL", 150, 162], ["ACE2", "GENE_OR_GENE_PRODUCT", 82, 86], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 127, 145], ["azithromycin", "SIMPLE_CHEMICAL", 150, 162], ["ACE2", "PROTEIN", 82, 86], ["ACE2 interface", "TREATMENT", 82, 96], ["the hydroxychloroquine", "TREATMENT", 123, 145], ["azithromycin", "TREATMENT", 150, 162], ["docking calculations", "TREATMENT", 169, 189]]], ["Then Utomo et al. (Utomo et al., 2020) used the Sprotein RBD domain as target in docking calculations using compounds presented in Curcuma sp., Citrus sp., Alpinia galanga, and Caesalpinia sappan.", [["Curcuma sp.", "ORGANISM", 131, 142], ["Citrus sp.", "ORGANISM", 144, 154], ["Alpinia galanga", "ORGANISM", 156, 171], ["Caesalpinia sappan", "ORGANISM", 177, 195], ["Sprotein RBD domain", "PROTEIN", 48, 67], ["Curcuma sp.", "SPECIES", 131, 142], ["Citrus sp.", "SPECIES", 144, 154], ["Alpinia galanga", "SPECIES", 156, 171], ["Curcuma sp.", "SPECIES", 131, 142], ["Citrus sp.", "SPECIES", 144, 154], ["Alpinia galanga", "SPECIES", 156, 171], ["Caesalpinia sappan", "SPECIES", 177, 195], ["the Sprotein RBD domain", "TREATMENT", 44, 67], ["docking calculations using compounds", "TREATMENT", 81, 117], ["Citrus sp.", "TREATMENT", 144, 154], ["Alpinia galanga", "TREATMENT", 156, 171], ["Caesalpinia sappan", "TREATMENT", 177, 195]]], ["Likewise, herein we used virtual screening and molecular modeling to study the SARS-CoV-2 S-protein with the main insight to obtain potent candidates to inhibit the SARS-CoV-2.IntroductionOur approach adopted here differs from those studies in the following way: the isolated S-protein receptor for docking calculations will be obtained from molecular dynamics (MD) simulation, and not directly from crystal structure or S-protein@ACE2 complex.", [["SARS", "DISEASE", 165, 169], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 165, 175], ["S-protein receptor", "GENE_OR_GENE_PRODUCT", 276, 294], ["S-protein@ACE2", "GENE_OR_GENE_PRODUCT", 421, 435], ["SARS-CoV-2 S-protein", "PROTEIN", 79, 99], ["S-protein receptor", "PROTEIN", 276, 294], ["S-protein@ACE2 complex", "PROTEIN", 421, 443], ["SARS-CoV", "SPECIES", 165, 173], ["virtual screening", "TEST", 25, 42], ["molecular modeling", "TEST", 47, 65], ["the SARS", "TEST", 75, 83], ["CoV", "TEST", 84, 87], ["the SARS", "TEST", 161, 169], ["CoV", "TEST", 170, 173], ["those studies", "TEST", 227, 240], ["the isolated S-protein receptor", "TREATMENT", 263, 294], ["docking calculations", "TEST", 299, 319], ["S-protein@ACE2 complex", "PROBLEM", 421, 443]]], ["Where, in our understanding, the coupling of full structural flexibility accounted from MD technique and flexible docking calculations provide an efficient strategy to be used in virtual screening.", [["flexible docking calculations", "TEST", 105, 134], ["an efficient strategy", "TREATMENT", 143, 164], ["virtual screening", "TEST", 179, 196]]], ["In addition, the investigation of approved drugs is a straightforward way to repurpose quickly a good candidate against the virus.", [["drugs", "TREATMENT", 43, 48], ["the virus", "PROBLEM", 120, 129]]], ["It is interesting to point that, up to date, there is not drug or vaccine against the COVID-19 and the social isolation is one way to control this outbreak as recommended by WHO.Molecular dynamics simulationThe initial structure of the SARS-CoV-2 viral S-protein was obtained by deleting the ACE2 enzyme from the S-protein@ACE2 complex elaborated by Shah et al. (Shah et al., 2020) .", [["SARS", "DISEASE", 236, 240], ["SARS-CoV-2", "ORGANISM", 236, 246], ["ACE2", "GENE_OR_GENE_PRODUCT", 292, 296], ["S-protein@ACE2", "GENE_OR_GENE_PRODUCT", 313, 327], ["SARS-CoV-2 viral S-protein", "DNA", 236, 262], ["ACE2 enzyme", "PROTEIN", 292, 303], ["S-protein@ACE2 complex", "PROTEIN", 313, 335], ["vaccine", "TREATMENT", 66, 73], ["the COVID", "TEST", 82, 91], ["the social isolation", "TREATMENT", 99, 119], ["the SARS", "TEST", 232, 240], ["CoV", "TEST", 241, 244], ["the ACE2 enzyme", "TEST", 288, 303]]], ["The isolated S-protein was merged into a box with edge of 16.1 \u00c2 16.7 \u00c2 18.5 nm with 147,803 water molecules included.", [["S-protein", "SIMPLE_CHEMICAL", 13, 22], ["S-protein", "PROTEIN", 13, 22], ["The isolated S-protein", "PROBLEM", 0, 22], ["edge", "TEST", 50, 54], ["water molecules", "TEST", 93, 108], ["S-protein", "OBSERVATION", 13, 22]]], ["Six chloride ions were added to keep the system neutralized.", [["chloride", "CHEMICAL", 4, 12], ["chloride", "CHEMICAL", 4, 12], ["chloride ions", "SIMPLE_CHEMICAL", 4, 17], ["Six chloride ions", "TREATMENT", 0, 17]]], ["The GROMOS54a7 force field (Schmid et al., 2011) was used to describe the structural and energetic parameters for the S-protein, and for water the SPC model (Berendsen et al., 1981) was considered.", [["the S-protein", "TEST", 114, 127], ["water the SPC model", "TREATMENT", 137, 156]]], ["Periodic boundary conditions were considered within 1.0 nm cut-off for nonbonded interactions.", [["Periodic boundary conditions", "PROBLEM", 0, 28], ["boundary conditions", "OBSERVATION", 9, 28]]], ["The NpT ensemble was used to keep the constant pressure at 1 bar using the Berendsen barostat (Berendsen et al., 1984) (with coupling time of 5 ps) and the temperature at 310 K using the stochastic velocity rescaling method (Bussi et al., 2007) (with coupling time of 0.1 ps).", [["The NpT ensemble", "TREATMENT", 0, 16], ["the Berendsen barostat", "TREATMENT", 71, 93], ["the temperature", "TEST", 152, 167]]], ["Long-range electrostatic forces were taken into account using the smooth Particle-Mesh Ewald (PME) method (Berendsen, 2007 , Deserno & Holm, 1998 ) with a real space interactions truncated at 1.0 nm cut-off.", [["Long-range electrostatic forces", "TREATMENT", 0, 31], ["a real space interactions", "TREATMENT", 153, 178]]], ["The system was minimized by the steepest descent method (Morse & Feshbach, 1953) to avoid unfavorable contacts between the atoms, and the convergence was archived at potential energy below 500 kJ/mol\u00c1nm.", [["unfavorable contacts between the atoms", "PROBLEM", 90, 128]]], ["The water molecules were relaxed for 300 ps of MD simulation keeping S-protein rigid by means of a position restraint potential with a force constant of 1000 kJ/mol\u00c1nm.", [["S-protein rigid", "PROBLEM", 69, 84], ["a position restraint potential", "TREATMENT", 97, 127]]], ["The total energy, temperature, pressure and the root mean square deviation (RMSD) of the Sprotein were used to monitor the system equilibration.", [["root", "ANATOMY", 48, 52], ["Sprotein", "PROTEIN", 89, 97], ["The total energy", "TEST", 0, 16], ["temperature", "TEST", 18, 29], ["pressure", "TEST", 31, 39], ["total", "OBSERVATION_MODIFIER", 4, 9], ["pressure", "OBSERVATION_MODIFIER", 31, 39], ["root", "OBSERVATION_MODIFIER", 48, 52]]], ["The equations of motions were integrated using the leap-frog algorithm (Berendsen, 2007) with an integration step of 2 fs.", [["the leap-frog algorithm", "TREATMENT", 47, 70]]], ["The covalent bonds to the hydrogen atoms were fixed using the P-LINCS method (Hess et al., 1997; Hess et al., 2008) .Docking calculationsMD equilibrated structure of the SARS-CoV-2 viral S-protein was used as input for docking calculations.", [["hydrogen", "CHEMICAL", 26, 34], ["SARS", "DISEASE", 170, 174], ["hydrogen", "CHEMICAL", 26, 34], ["hydrogen atoms", "SIMPLE_CHEMICAL", 26, 40], ["SARS-CoV-2 viral S-protein", "DNA", 170, 196], ["Docking calculations", "TEST", 117, 137], ["the SARS", "PROBLEM", 166, 174], ["CoV", "TEST", 175, 178], ["2 viral S-protein", "TREATMENT", 179, 196], ["docking calculations", "TEST", 219, 239], ["covalent bonds", "OBSERVATION", 4, 18], ["hydrogen atoms", "OBSERVATION", 26, 40]]], ["The AutoDockTools software (ADT) (Morris et al., 2009 ) was employed to build the protein-ligand complexes.", [["protein-ligand complexes", "PROTEIN", 82, 106]]], ["The AutoDock Vina method (Trott & Olson, 2010) was used in virtual screening calculations for docking the ligands into the S-protein RDB domain.", [["S-protein RDB domain", "PROTEIN", 123, 143], ["virtual screening calculations", "TEST", 59, 89], ["docking the ligands", "TREATMENT", 94, 113]]], ["The searching for ligands by docking calculations was done in a grid size of 1.8 \u00c2 4.8 \u00c2 2.2 nm, which was centered at 9.0226 \u00c2 9.3000 \u00c2 2.9897 nm in the RDB region.", [["RDB region", "DNA", 154, 164], ["docking calculations", "TEST", 29, 49], ["a grid size", "TEST", 62, 73], ["RDB", "ANATOMY_MODIFIER", 154, 157], ["region", "ANATOMY_MODIFIER", 158, 164]]], ["The S-protein and ligands structures were considered rigid and flexible, respectively, along the docking calculations.", [["S-protein", "SIMPLE_CHEMICAL", 4, 13], ["S-protein", "PROTEIN", 4, 13], ["the docking calculations", "TEST", 93, 117], ["S-protein", "OBSERVATION", 4, 13]]], ["The ligands were retrieved from the SWEETLEAD library (Novick et al., 2013) and this was chosen because it was elaborated using approved drugs in USA, India, China, Brazil, WHO Essential Medicines List and others.Docking calculationsMoreover, the use of approved drug in virtual screening calculations is an efficient way to decrease the drug discovery costs and the time spend in research.", [["Docking calculations", "TEST", 213, 233], ["virtual screening calculations", "TEST", 271, 301]]], ["Recently, Smith et al. (Smith & Smith, 2020) has been used this library to identify small molecules to inhibit the SARS-CoV-2 using a different approach than adopted here.", [["SARS", "DISEASE", 115, 119], ["small molecules", "PROBLEM", 84, 99], ["a different approach", "TREATMENT", 132, 152]]], ["Thus, here 9091 of these ligands and some their respectively isomers with PDBQT format were downloaded from the supplementary material available by Smith et al. (Smith & Smith, 2020) and used in docking calculations.", [["PDBQT", "SIMPLE_CHEMICAL", 74, 79], ["these ligands", "TEST", 19, 32], ["PDBQT format", "PROBLEM", 74, 86]]], ["For each ligand, 20 binding modes were generated.", [["each ligand, 20 binding modes", "TEST", 4, 33]]], ["The visualization software PyMol (DeLano, 2009) and Discovery Studio Visualizer (Discovery Studio Visualizer Software, 2020) were used to prepare the figures and to analyze the results.Binding free energyMD simulations were carried out for the three best-scored ligands complexed to S-protein previously obtained from docking calculations.", [["S-protein", "GENE_OR_GENE_PRODUCT", 283, 292], ["S-protein", "PROTEIN", 283, 292], ["Binding free energyMD simulations", "TEST", 185, 218], ["S-protein", "TEST", 283, 292], ["docking calculations", "TEST", 318, 338]]], ["The ATB version 3.0 (http://compbio. chemistry.uq.edu.au/atb/) (Stroet et al., 2018) was used to generate the GROMOS force field for all ligands.", [["The ATB version", "TEST", 0, 15]]], ["Herein, we used the same protocol adopted in the Molecular Dynamics simulation section.", [["the same protocol", "TREATMENT", 16, 33]]], ["Afterwards, the binding free energy (DG bind. ) was calculated using the MM/PBSA method (Kollman et al., 2000) for each complex along 18 ns of equilibrated MD simulation.", [["the MM/PBSA method", "TREATMENT", 69, 87]]], ["For each system, 60 snapshots were extracted at interval of 300 ps along the trajectory.Binding free energyThe DG bind is calculated with the following equation,Binding free energywhere G complex is the Gibbs free-energy of the ligand@S-protein complex, while G S-protein and G ligand are the total G of Sprotein and the ligands in the presence of the solvent, respectively.", [["DG", "SIMPLE_CHEMICAL", 111, 113], ["G S-protein", "SIMPLE_CHEMICAL", 260, 271], ["G ligand", "GENE_OR_GENE_PRODUCT", 276, 284], ["Sprotein", "SIMPLE_CHEMICAL", 304, 312], ["G complex", "PROTEIN", 186, 195], ["ligand@S", "PROTEIN", 228, 236], ["protein complex", "PROTEIN", 237, 252], ["G S-protein", "PROTEIN", 260, 271], ["G ligand", "PROTEIN", 276, 284], ["Sprotein", "PROTEIN", 304, 312], ["G S-protein", "TEST", 260, 271], ["G ligand", "TEST", 276, 284], ["Sprotein", "TEST", 304, 312], ["free energy", "OBSERVATION", 96, 107]]], ["The individual G for complex, S-protein, and ligands was calculated with equation:Binding free energywhere hE MM i is the average of the potential energy obtained from the MD simulation in vacuum.", [["S-protein", "SIMPLE_CHEMICAL", 30, 39], ["G for complex", "PROTEIN", 15, 28], ["S-protein", "PROTEIN", 30, 39], ["vacuum", "OBSERVATION", 189, 195]]], ["The hG solv. i is the Gibbs free energy of solvation and its was calculated with the equation,Binding free energywhere G polar is the electrostatic contributions and it is calculated by solving the Poisson-Boltzmann equation (Honig & Nicholls, 1995; Srinivasan et al., 1998; Baker et al., 2001) .", [["The hG solv", "TREATMENT", 0, 11], ["hG solv", "OBSERVATION", 4, 11], ["electrostatic contributions", "OBSERVATION", 134, 161]]], ["The G nonpolar is calculated from the solvent-acessible surface area (SASA).", [["The G nonpolar", "TREATMENT", 0, 14], ["G nonpolar", "OBSERVATION_MODIFIER", 4, 14], ["solvent", "OBSERVATION_MODIFIER", 38, 45], ["surface", "OBSERVATION_MODIFIER", 56, 63]]], ["The APBS program (Baker et al., 2001 ) was used to calculate the energy components (G polar and G nonpolar ).", [["G polar and G nonpolar", "TREATMENT", 84, 106]]], ["The g_mmpbsa subroutine implemented in the GROMACS package by Kumari (Kumari et al., 2014) was used in the calculations.Results and discussionTo our best knowledge, this work is shedding light on the potential candidates to inhibit the action of the SARS-CoV-2 S-protein on binding to ACE2 and then starting the replication in the human cell.MD SimulationIn this section, relevant results obtained from the MD trajectory are described.", [["cell", "ANATOMY", 337, 341], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 250, 260], ["ACE2", "GENE_OR_GENE_PRODUCT", 285, 289], ["human", "ORGANISM", 331, 336], ["cell", "CELL", 337, 341], ["SARS-CoV-2 S-protein", "PROTEIN", 250, 270], ["ACE2", "PROTEIN", 285, 289], ["human cell", "CELL_TYPE", 331, 341], ["human", "SPECIES", 331, 336], ["human", "SPECIES", 331, 336], ["The g_mmpbsa subroutine", "TREATMENT", 0, 23], ["the SARS", "TEST", 246, 254], ["CoV", "TEST", 255, 258], ["ACE2", "TEST", 285, 289], ["the replication in the human cell", "TREATMENT", 308, 341], ["human cell", "OBSERVATION", 331, 341]]], ["As shown in Figure S1 , the potential energy, temperature and pressure were equilibrated.", [["pressure", "TEST", 62, 70], ["pressure", "OBSERVATION_MODIFIER", 62, 70]]], ["Figure 1 presents the RMSD of the C-alpha atoms of the S-Protein along the MD trajectory, showing that 10 ns was enough to reach a stable and well behaved structure.", [["S-Protein", "SIMPLE_CHEMICAL", 55, 64], ["C-alpha atoms", "PROTEIN", 34, 47], ["S-Protein", "PROTEIN", 55, 64], ["S-Protein", "OBSERVATION", 55, 64], ["stable", "OBSERVATION", 131, 137]]], ["RMSD values were calculated by the superposition of the S-protein structure along the trajectory with their initial structure (at 0 ps), increasing rapidly until 6 ns with a fluctuation around 0.65 nm and standard deviation of 0.015 nm at end of the simulation.", [["S-protein structure", "PROTEIN", 56, 75], ["RMSD values", "TEST", 0, 11], ["the S-protein structure", "PROBLEM", 52, 75], ["the simulation", "TEST", 246, 260], ["S-protein", "OBSERVATION", 56, 65], ["trajectory", "OBSERVATION_MODIFIER", 86, 96], ["increasing", "OBSERVATION_MODIFIER", 137, 147], ["rapidly", "OBSERVATION_MODIFIER", 148, 155]]], ["Considering the large size of the protein, the RMSD value of 0.65 nm implies that the S-protein does not suffer significant structural change along the simulation.", [["S-protein", "PROTEIN", 86, 95], ["the RMSD value", "TEST", 43, 57], ["significant structural change", "PROBLEM", 112, 141], ["large", "OBSERVATION_MODIFIER", 16, 21], ["size", "OBSERVATION_MODIFIER", 22, 26], ["significant", "OBSERVATION_MODIFIER", 112, 123], ["structural", "OBSERVATION", 124, 134]]], ["The inset in Figure 1 shows the RMSF (root mean square fluctuation) values, which indicate lowest fluctuation of the amino acids of the S-protein.", [["amino acids", "CHEMICAL", 117, 128], ["amino acids", "CHEMICAL", 117, 128], ["amino acids", "AMINO_ACID", 117, 128], ["S-protein", "GENE_OR_GENE_PRODUCT", 136, 145], ["S-protein", "PROTEIN", 136, 145], ["The inset in Figure", "TEST", 0, 19], ["the amino acids", "TEST", 113, 128], ["inset", "OBSERVATION_MODIFIER", 4, 9], ["RMSF", "OBSERVATION", 32, 36]]], ["The highest RMSF values are attributed the N-and C-terminals, and loop regions.", [["N", "CHEMICAL", 43, 44], ["RMSF", "PROTEIN", 12, 16], ["N-and C-terminals", "PROTEIN", 43, 60], ["loop regions", "PROTEIN", 66, 78], ["The highest RMSF values", "TEST", 0, 23], ["the N", "TEST", 39, 44], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["RMSF", "OBSERVATION", 12, 16]]], ["Figure 2 reveals that the initial overall S-protein structure remains quite similar after 18 ns of MD simulation, in agreement with the low RMSD values (Figure 1 ).", [["the initial overall S-protein structure", "PROBLEM", 22, 61], ["S-protein", "OBSERVATION", 42, 51]]], ["In general, the main difference observed is located in the loop regions, which is expected due to its high flexibility compared to helix motif.MD SimulationFrom MD trajectory was observed an important change in RBD region (Figure 2 , highlighted), which is dislocated along the simulation from the \"up\" to \"down\" conformation into direction of the S-protein center.", [["loop regions", "PROTEIN", 59, 71], ["helix motif", "PROTEIN", 131, 142], ["RBD region", "PROTEIN", 211, 221], ["its high flexibility", "PROBLEM", 98, 118], ["an important change in RBD region", "PROBLEM", 188, 221], ["main", "OBSERVATION_MODIFIER", 16, 20], ["difference", "OBSERVATION", 21, 31], ["loop", "ANATOMY_MODIFIER", 59, 63], ["regions", "ANATOMY_MODIFIER", 64, 71], ["high flexibility", "OBSERVATION", 102, 118], ["RBD", "ANATOMY", 211, 214], ["region", "ANATOMY_MODIFIER", 215, 221], ["dislocated", "OBSERVATION", 257, 267]]], ["Therefore, it indicates that when the RBD is in \"down\" configuration and it approximates to ACE2, a change is needed to the \"up\" conformation for an efficient interaction with the ACE2 receptor.", [["RBD", "DISEASE", 38, 41], ["ACE2", "GENE_OR_GENE_PRODUCT", 92, 96], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 180, 193], ["RBD", "PROTEIN", 38, 41], ["ACE2", "PROTEIN", 92, 96], ["ACE2 receptor", "PROTEIN", 180, 193], ["the RBD", "PROBLEM", 34, 41], ["the ACE2 receptor", "TREATMENT", 176, 193], ["RBD", "OBSERVATION", 38, 41]]], ["In this transition, the angle formed by the C-alpha atoms of the D405, V622 and V991 residues decreases from 54.3 (\"up\" at 0 ns) to 43.0 degrees (\"down\" at 18 ns).", [["C-alpha atoms", "CHEMICAL", 44, 57], ["C", "CHEMICAL", 44, 45], ["D405", "CHEMICAL", 65, 69], ["V622", "CHEMICAL", 71, 75], ["V991", "CHEMICAL", 80, 84], ["C-alpha", "GENE_OR_GENE_PRODUCT", 44, 51], ["C-alpha atoms", "PROTEIN", 44, 57], ["D405", "PROTEIN", 65, 69], ["V622", "PROTEIN", 71, 75], ["angle", "OBSERVATION_MODIFIER", 24, 29], ["decreases", "OBSERVATION_MODIFIER", 94, 103], ["43.0 degrees", "OBSERVATION_MODIFIER", 132, 144]]], ["These data are in agreement with the Peng et al. , which showed that the \"up\" angle between 84.8 and 52.2 degrees is accessible by ACE receptor and the \"down\" angle that ranges from 31.6 to 52.2 degrees is not accessible by the ACE2 human receptor.", [["ACE receptor", "GENE_OR_GENE_PRODUCT", 131, 143], ["ACE2", "GENE_OR_GENE_PRODUCT", 228, 232], ["human", "ORGANISM", 233, 238], ["ACE receptor", "PROTEIN", 131, 143], ["ACE2 human receptor", "PROTEIN", 228, 247], ["human", "SPECIES", 233, 238], ["human", "SPECIES", 233, 238], ["ACE receptor", "TEST", 131, 143], ["52.2 degrees", "OBSERVATION_MODIFIER", 101, 113]]], ["The RMSD value of the RBD region (C336-C525) is 0.33 nm (standard deviation of 0.02 nm) after 6 ns of simulation.", [["RBD region", "PROTEIN", 22, 32], ["The RMSD value", "TEST", 0, 14], ["C336", "TEST", 34, 38], ["6 ns of simulation", "TREATMENT", 94, 112], ["RMSD", "OBSERVATION_MODIFIER", 4, 8], ["RBD", "ANATOMY", 22, 25], ["region", "ANATOMY_MODIFIER", 26, 32]]], ["In this region, the RMSF values are lowest than 0.32 nm, except for G482, V483, E484, G485 and F486, which remain the RMSF of 0.42, 0.64, 0.60 and 0.50 nm, respectively.MD SimulationIt is important to emphasize again that the initial S-protein model was obtained from the S-protein@ACE2 complex (Shah et al., 2020) .", [["S-protein@ACE2", "GENE_OR_GENE_PRODUCT", 272, 286], ["S-protein@ACE2 complex", "PROTEIN", 272, 294], ["the RMSF values", "TEST", 16, 31], ["E484", "TEST", 80, 84], ["the initial S-protein model", "TEST", 222, 249], ["region", "ANATOMY_MODIFIER", 8, 14], ["RMSF", "OBSERVATION", 20, 24]]], ["Therefore, the results show that there is a significant structural difference between the RBD in isolated S-protein and that one when complexed with the human ACE2 receptor.", [["RBD", "DISEASE", 90, 93], ["human", "ORGANISM", 153, 158], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 159, 172], ["RBD", "PROTEIN", 90, 93], ["S-protein", "PROTEIN", 106, 115], ["human ACE2 receptor", "PROTEIN", 153, 172], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 153, 158], ["a significant structural difference between the RBD", "PROBLEM", 42, 93], ["the human ACE2 receptor", "TREATMENT", 149, 172], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["structural", "OBSERVATION_MODIFIER", 56, 66], ["difference", "OBSERVATION", 67, 77], ["RBD", "OBSERVATION", 90, 93], ["S-protein", "OBSERVATION", 106, 115]]], ["It implies that RBD domain is very sensitive to the chemical environment, temperature and solvent effects.", [["RBD domain", "PROTEIN", 16, 26], ["RBD domain", "PROBLEM", 16, 26], ["RBD", "OBSERVATION", 16, 19]]], ["Thus, in drug design these differences must be considered in the search of compounds to inhibit the S-protein.MD SimulationConsidering this, in the next section we used the final structure generated in the MD simulation to find good candidates for the SARS-CoV-2 S-protein inhibition using docking calculations.Virtual screeningAutoDock Vina was used for docking calculations of 9091 approved drugs to obtain potential candidates for inhibition of the SARS-CoV-2 S-protein.", [["SARS", "DISEASE", 252, 256], ["S-protein", "GENE_OR_GENE_PRODUCT", 100, 109], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 452, 462], ["S-protein", "PROTEIN", 100, 109], ["SARS-CoV-2 S-protein", "PROTEIN", 452, 472], ["the SARS", "TEST", 248, 256], ["CoV", "TEST", 257, 260], ["protein inhibition", "TREATMENT", 265, 283], ["docking calculations", "TEST", 290, 310], ["Virtual screening", "TEST", 311, 328], ["docking calculations", "TEST", 355, 375], ["drugs", "TREATMENT", 393, 398], ["the SARS", "TEST", 448, 456], ["CoV", "TEST", 457, 460], ["S-protein", "OBSERVATION", 100, 109]]], ["Differently from other works Smith & Smith, 2020; Sandeep & McGregor, 2020; Utomo et al., 2020) , the isolated S-protein receptor was previously equilibrated by MD simulation, providing a realistic structure when the virus infects humans.", [["S-protein receptor", "GENE_OR_GENE_PRODUCT", 111, 129], ["humans", "ORGANISM", 231, 237], ["S-protein receptor", "PROTEIN", 111, 129], ["humans", "SPECIES", 231, 237], ["humans", "SPECIES", 231, 237], ["the isolated S-protein receptor", "PROBLEM", 98, 129], ["the virus infects humans", "PROBLEM", 213, 237]]], ["Then, the solvent and temperature effects are taking into account in the S-protein conformation.", [["the solvent and temperature effects", "TREATMENT", 6, 41]]], ["Figures 3 presents the binding affinity or energy for all ligands obtained in Docking calculations.", [["Docking calculations", "TEST", 78, 98]]], ["Overall, all ligands docked in the RDB region has favorable energy.", [["RDB region", "DNA", 35, 45], ["ligands docked", "OBSERVATION", 13, 27], ["favorable", "OBSERVATION_MODIFIER", 50, 59], ["energy", "OBSERVATION", 60, 66]]], ["It is interesting to notice that the Smith et al. (Smith & Smith, 2020) has been used the present ligands library in docking calculation for S-protein.", [["S-protein", "SIMPLE_CHEMICAL", 141, 150], ["S-protein", "PROTEIN", 141, 150], ["S-protein", "PROBLEM", 141, 150]]], ["Therein the isolated protein receptor was retrieved from the S-protein@ACE2 complex previously obtained by their MD simulation.", [["S-protein@ACE2", "GENE_OR_GENE_PRODUCT", 61, 75], ["isolated protein receptor", "PROTEIN", 12, 37], ["S-protein@ACE2 complex", "PROTEIN", 61, 83], ["the isolated protein receptor", "PROBLEM", 8, 37], ["protein receptor", "OBSERVATION", 21, 37]]], ["However, our MD results showed that the RBD region suffer significantly structural change from the S-protein@ACE2 complex to the isolated S-protein.", [["S-protein@ACE2", "CHEMICAL", 99, 113], ["S-protein@ACE2", "GENE_OR_GENE_PRODUCT", 99, 113], ["S-protein", "GENE_OR_GENE_PRODUCT", 138, 147], ["RBD region", "PROTEIN", 40, 50], ["S-protein@ACE2 complex", "PROTEIN", 99, 121], ["S-protein", "PROTEIN", 138, 147], ["the RBD region", "PROBLEM", 36, 50], ["significantly structural change", "PROBLEM", 58, 89], ["the S-protein@ACE2 complex", "PROBLEM", 95, 121], ["the isolated S-protein", "PROBLEM", 125, 147], ["significantly", "OBSERVATION_MODIFIER", 58, 71], ["structural change", "OBSERVATION", 72, 89], ["isolated", "OBSERVATION_MODIFIER", 129, 137], ["S-protein", "OBSERVATION", 138, 147]]], ["For instance, the Smith et al. (Smith & Smith, 2020) identify only 30 compounds with binding affinity between -6.3 and -7.2 kcal/mol.", [["binding affinity", "TEST", 85, 101]]], ["However, as shown in Figure 3 it is possible to identify thousand compounds in this interval of energy, which indicates that our approach is more efficient to explore the S-protein RBD region than the strategy adopted by Smith et al. (Smith & Smith, 2020) .", [["S-protein RBD region", "PROTEIN", 171, 191], ["the S-protein RBD region", "PROBLEM", 167, 191]]], ["There are 536 ranking docking poses of ligands (including isomers) with binding energy between -7.2 and -8.0 kcal/ mol.", [["binding energy", "TEST", 72, 86]]], ["In the Table 1, we present the results obtained from the docking calculations.", [["the docking calculations", "TEST", 53, 77]]], ["Recently, the azithromycin, hydroxychloroquine and chloroquine have been tested as possible treatment of the COVID-19 outbreak with some potential results (Juurlink, 2020; Gautret et al., 2020; Touret & de Lamballerie, 2020) , but with undesirable side effects.", [["azithromycin", "CHEMICAL", 14, 26], ["hydroxychloroquine", "CHEMICAL", 28, 46], ["chloroquine", "CHEMICAL", 51, 62], ["azithromycin", "CHEMICAL", 14, 26], ["hydroxychloroquine", "CHEMICAL", 28, 46], ["chloroquine", "CHEMICAL", 51, 62], ["azithromycin", "SIMPLE_CHEMICAL", 14, 26], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 28, 46], ["chloroquine", "SIMPLE_CHEMICAL", 51, 62], ["the azithromycin", "TREATMENT", 10, 26], ["hydroxychloroquine", "TREATMENT", 28, 46], ["chloroquine", "TREATMENT", 51, 62], ["the COVID", "TEST", 105, 114], ["undesirable side effects", "PROBLEM", 236, 260]]], ["However, our results shows high binding energy of the -6.8, \u00c05.1 and -4.7 kcal/mol, respectively.", [["high binding energy", "PROBLEM", 27, 46]]], ["Therefore, these values indicate that these drugs may act in the S-protein RDB region, but with lowest efficiency than our best-scored ligands in the same concentration.", [["S-protein RDB region", "DNA", 65, 85], ["these values", "TEST", 11, 23], ["these drugs", "TREATMENT", 38, 49]]], ["The advantages of this type of therapeutics is due the cheap cost, little side effects, good availability and local cultural aspects.", [["little side effects", "PROBLEM", 67, 86]]], ["On the other hands, 10 approved drugs were selected from the docking calculations.", [["drugs", "TREATMENT", 32, 37], ["the docking calculations", "TEST", 57, 81], ["hands", "ANATOMY", 13, 18]]], ["Thus, the laboratories specialized can buy these drugs and test those to verify their efficiency against COVID-9 outbreak.", [["COVID-9", "CHEMICAL", 105, 112], ["the laboratories", "TEST", 6, 22], ["these drugs", "TREATMENT", 43, 54], ["COVID", "TEST", 105, 110]]], ["The most scored-ligands presented in Table 1 are rich in hydroxyl group and eight (Lig6982, Lig6982, Lig7089, Lig8121, Lig8283, Lig8402, Lig8541 and Lig8757) has the presence at least one monosaccharides group attached in their structures.Virtual screeningThis finding is very interesting because the S-protein is a glycoprotein, which has high affinity with oligosaccharides and various sugar chains are covalently linked.", [["hydroxyl", "CHEMICAL", 57, 65], ["Lig8757", "CHEMICAL", 149, 156], ["hydroxyl", "CHEMICAL", 57, 65], ["Lig6982", "CHEMICAL", 83, 90], ["Lig6982", "CHEMICAL", 92, 99], ["Lig7089", "CHEMICAL", 101, 108], ["Lig8121", "CHEMICAL", 110, 117], ["Lig8283", "CHEMICAL", 119, 126], ["Lig8402", "CHEMICAL", 128, 135], ["Lig8541", "CHEMICAL", 137, 144], ["Lig8757", "CHEMICAL", 149, 156], ["monosaccharides", "CHEMICAL", 188, 203], ["sugar", "CHEMICAL", 388, 393], ["hydroxyl", "SIMPLE_CHEMICAL", 57, 65], ["Lig8757", "AMINO_ACID", 149, 156], ["S-protein", "GENE_OR_GENE_PRODUCT", 301, 310], ["sugar chains", "SIMPLE_CHEMICAL", 388, 400], ["S-protein", "PROTEIN", 301, 310], ["glycoprotein", "PROTEIN", 316, 328], ["Virtual screening", "TEST", 239, 256], ["a glycoprotein", "PROBLEM", 314, 328], ["high affinity with oligosaccharides and various sugar chains", "PROBLEM", 340, 400], ["monosaccharides group", "OBSERVATION", 188, 209], ["sugar chains", "OBSERVATION", 388, 400]]], ["Therefore, we suggest that a drug against SARS-CoV-9 S-protein may have the presence of the oligosaccharide groups, which is important in recognition of S-protein.", [["SARS", "DISEASE", 42, 46], ["SARS-CoV", "ORGANISM", 42, 50], ["S-protein", "GENE_OR_GENE_PRODUCT", 153, 162], ["SARS-CoV-9 S-protein", "PROTEIN", 42, 62], ["S-protein", "PROTEIN", 153, 162], ["a drug against SARS", "TEST", 27, 46], ["CoV", "TEST", 47, 50], ["S-protein", "OBSERVATION", 153, 162]]], ["Analyzing the interacting residues with the S-protein (Table 1) , we found that the R403, R405, Y449, L455, G496 and Y505 residues are common in the most ligands.", [["R403", "CHEMICAL", 84, 88], ["R405", "CHEMICAL", 90, 94], ["Y449", "CHEMICAL", 96, 100], ["L455", "CHEMICAL", 102, 106], ["G496", "CHEMICAL", 108, 112], ["Y505", "CHEMICAL", 117, 121], ["S-protein (Table 1", "GENE_OR_GENE_PRODUCT", 44, 62], ["R403", "GENE_OR_GENE_PRODUCT", 84, 88], ["Y505", "AMINO_ACID", 117, 121], ["S-protein", "PROTEIN", 44, 53], ["interacting residues", "OBSERVATION", 14, 34]]], ["Thereby, we suggest that in drug design these residues can be used do draw a candidate to S-protein inhibition.Virtual screeningAlthough the lopinavir and emetine drugs does not appear in the Table 1 , the binding energy obtained in our docking calculations were -7.0 and -6.5 kcal/mol, respectively, see supporting information.", [["lopinavir", "CHEMICAL", 141, 150], ["emetine", "CHEMICAL", 155, 162], ["lopinavir", "CHEMICAL", 141, 150], ["emetine", "CHEMICAL", 155, 162], ["S-protein", "GENE_OR_GENE_PRODUCT", 90, 99], ["lopinavir", "SIMPLE_CHEMICAL", 141, 150], ["emetine", "SIMPLE_CHEMICAL", 155, 162], ["S-protein", "PROTEIN", 90, 99], ["S-protein inhibition", "TREATMENT", 90, 110], ["Virtual screening", "TEST", 111, 128], ["the lopinavir and emetine drugs", "TREATMENT", 137, 168], ["our docking calculations", "TEST", 233, 257]]], ["These results are interesting because recently the Choy et al. (Choy et al., 2020) showed that these drugs inhibit the SARS-CoV-2 replication with EC 50 under 100 lM.", [["EC", "ANATOMY", 147, 149], ["SARS", "DISEASE", 119, 123], ["CoV-2", "GENE_OR_GENE_PRODUCT", 124, 129], ["EC", "CELL", 147, 149], ["these drugs", "TREATMENT", 95, 106], ["the SARS", "PROBLEM", 115, 123]]], ["On the other hands, Muralidharan et al. (Muralidharan et al., 2020) obtained from docking calculations a binding energy of -4.1 kcal/mol using the SARS-CoV-2 protease and lopinavir drug, respectively, as receptor and ligand.", [["lopinavir", "CHEMICAL", 171, 180], ["lopinavir", "CHEMICAL", 171, 180], ["lopinavir", "SIMPLE_CHEMICAL", 171, 180], ["protease", "PROTEIN", 158, 166], ["the SARS", "TREATMENT", 143, 151], ["CoV-2 protease", "TREATMENT", 152, 166], ["lopinavir drug", "TREATMENT", 171, 185], ["hands", "ANATOMY", 13, 18]]], ["Thus, the lopinavir may act preferentially in the S-protein than protease, due the lowest binding energy (-7.0 kcal/mol), predicted using the S-protein as receptor.Virtual screeningFor best visualization of the interacting residues of the Sprotein and the best-scored ligand, in the Figure 4 is presented the 2 D ligand interaction diagram and molecular electrostatic map (MEP) for the four ligand with lowest binding affinity.", [["lopinavir", "CHEMICAL", 10, 19], ["lopinavir", "CHEMICAL", 10, 19], ["lopinavir", "SIMPLE_CHEMICAL", 10, 19], ["S-protein", "GENE_OR_GENE_PRODUCT", 50, 59], ["Sprotein", "GENE_OR_GENE_PRODUCT", 239, 247], ["S-protein", "PROTEIN", 50, 59], ["protease", "PROTEIN", 65, 73], ["S-protein", "PROTEIN", 142, 151], ["Sprotein", "PROTEIN", 239, 247], ["the lopinavir", "TREATMENT", 6, 19], ["the S-protein than protease", "TREATMENT", 46, 73], ["the S-protein as receptor", "TREATMENT", 138, 163], ["Virtual screening", "TEST", 164, 181]]], ["In the supporting information ( Figure S2 ), we present the 2 D diagram for all compounds in the Table 1 .Virtual screeningOverall, in the 2 D diagram, the p-p stacking, p-cation and hydrogen bond are the most interactions observed in the ligands@S-protein RBD complexes.", [["p-p", "CHEMICAL", 156, 159], ["hydrogen", "CHEMICAL", 183, 191], ["p-cation", "SIMPLE_CHEMICAL", 170, 178], ["ligands@S-protein RBD complexes", "PROTEIN", 239, 270], ["the 2 D diagram", "TREATMENT", 56, 71], ["Virtual screening", "TEST", 106, 123], ["the p-p stacking, p-cation and hydrogen bond", "TREATMENT", 152, 196], ["RBD complexes", "OBSERVATION", 257, 270]]], ["For best visualization, in Figure 2 , the MEP was showed only for the RDB region and its position is in front compared with RDB highlighted in the Figure 1 .", [["RDB region", "DNA", 70, 80], ["the MEP", "TEST", 38, 45], ["position", "OBSERVATION_MODIFIER", 89, 97]]], ["In the MEP, it can see that all ligands interact with a negative (intense red color) of the RDB region.", [["RDB region", "DNA", 92, 102], ["RDB", "ANATOMY", 92, 95], ["region", "ANATOMY_MODIFIER", 96, 102]]], ["Contrary, the ligands bind with RBD in a region with partial positive (light blue color) charge.Virtual screeningAlong the manuscript written, the ivermectin drug has been tested as anti-SARS-CoV-2 (Caly et al., 2020) and their results showed a reduction of $500 times the cell culture of the virus in 48 h.", [["cell", "ANATOMY", 273, 277], ["ivermectin", "CHEMICAL", 147, 157], ["ivermectin", "CHEMICAL", 147, 157], ["ivermectin", "SIMPLE_CHEMICAL", 147, 157], ["cell", "CELL", 273, 277], ["RBD", "PROTEIN", 32, 35], ["RBD", "PROBLEM", 32, 35], ["partial positive (light blue color", "PROBLEM", 53, 87], ["Virtual screening", "TEST", 96, 113], ["the ivermectin drug", "TREATMENT", 143, 162], ["anti-SARS", "TEST", 182, 191], ["CoV", "TEST", 192, 195], ["the cell culture", "TEST", 269, 285], ["the virus", "TREATMENT", 289, 298], ["RBD", "OBSERVATION", 32, 35], ["partial", "OBSERVATION_MODIFIER", 53, 60], ["positive", "OBSERVATION", 61, 69]]], ["The authors also highlighted the anti-viral activity of the ivermectin against a broad range of viruses in vitro (Tay et al., 2013; Wagstaff et al., 2012) .", [["ivermectin", "CHEMICAL", 60, 70], ["ivermectin", "CHEMICAL", 60, 70], ["ivermectin", "SIMPLE_CHEMICAL", 60, 70], ["the ivermectin", "TREATMENT", 56, 70], ["viruses", "OBSERVATION", 96, 103]]], ["This finding is very promising since the second best-scored ligand also an anti-parasitic agent like the Lig8301 (selamectin) and Lig8568 (doramectin) drugs, Table 1 .", [["Lig8301", "CHEMICAL", 105, 112], ["selamectin", "CHEMICAL", 114, 124], ["Lig8568", "CHEMICAL", 130, 137], ["doramectin", "CHEMICAL", 139, 149], ["Lig8301", "CHEMICAL", 105, 112], ["selamectin", "CHEMICAL", 114, 124], ["Lig8568", "CHEMICAL", 130, 137], ["doramectin", "CHEMICAL", 139, 149], ["Lig8301", "SIMPLE_CHEMICAL", 105, 112], ["selamectin", "SIMPLE_CHEMICAL", 114, 124], ["Lig8568", "SIMPLE_CHEMICAL", 130, 137], ["doramectin", "SIMPLE_CHEMICAL", 139, 149], ["an anti-parasitic agent", "TREATMENT", 72, 95], ["the Lig8301 (selamectin)", "TREATMENT", 101, 125], ["Lig8568 (doramectin) drugs", "TREATMENT", 130, 156], ["very", "OBSERVATION_MODIFIER", 16, 20], ["promising", "OBSERVATION_MODIFIER", 21, 30]]], ["Moreover, the main interacting residues with the S-protein are: R403, I418, Y489 and F490.", [["R403", "CHEMICAL", 64, 68], ["I418", "CHEMICAL", 70, 74], ["Y489", "CHEMICAL", 76, 80], ["F490", "CHEMICAL", 85, 89], ["S-protein", "GENE_OR_GENE_PRODUCT", 49, 58], ["S-protein", "PROTEIN", 49, 58], ["main", "OBSERVATION_MODIFIER", 14, 18], ["interacting residues", "OBSERVATION", 19, 39]]], ["In this way, our calculations indicate that the ivermectin drug may bind in the RBD region, inhibiting the coupling of the SARS-CoV-2 S-protein with the human ACE2 receptor.", [["ivermectin", "CHEMICAL", 48, 58], ["ivermectin", "CHEMICAL", 48, 58], ["ivermectin", "SIMPLE_CHEMICAL", 48, 58], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 123, 133], ["human", "ORGANISM", 153, 158], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 159, 172], ["RBD region", "PROTEIN", 80, 90], ["SARS-CoV-2 S-protein", "PROTEIN", 123, 143], ["human ACE2 receptor", "PROTEIN", 153, 172], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 153, 158], ["our calculations", "TEST", 13, 29], ["the ivermectin drug", "TREATMENT", 44, 63], ["the SARS", "TEST", 119, 127], ["CoV", "TEST", 128, 131], ["the human ACE2 receptor", "TREATMENT", 149, 172], ["RBD", "ANATOMY", 80, 83], ["region", "ANATOMY_MODIFIER", 84, 90]]], ["Recently, Fan et al. (Fan et al., 2020) showed that the selamectin (lig8301) inhibits completely the spike protein of coronavirus GX_P2V, which shares 92.2% amino acid identity with the 2019-nCoV.Binding free energy analysisAlthough docking calculations are useful to predict the binding of a ligand into a protein, they are limited due to the lack of temperature and solvent effects, which have an important role in the stability and conformational flexibility of a system.", [["selamectin", "CHEMICAL", 56, 66], ["lig8301", "CHEMICAL", 68, 75], ["amino acid", "CHEMICAL", 157, 167], ["selamectin", "CHEMICAL", 56, 66], ["lig8301", "CHEMICAL", 68, 75], ["amino acid", "CHEMICAL", 157, 167], ["selamectin", "SIMPLE_CHEMICAL", 56, 66], ["lig8301", "SIMPLE_CHEMICAL", 68, 75], ["coronavirus", "ORGANISM", 118, 129], ["GX_P2V", "GENE_OR_GENE_PRODUCT", 130, 136], ["amino acid", "AMINO_ACID", 157, 167], ["spike protein", "PROTEIN", 101, 114], ["P2V", "PROTEIN", 133, 136], ["nCoV", "PROTEIN", 191, 195], ["coronavirus GX_P2V", "SPECIES", 118, 136], ["amino acid identity", "TEST", 157, 176], ["Binding free energy analysis", "TEST", 196, 224], ["docking calculations", "TEST", 233, 253], ["temperature and solvent effects", "PROBLEM", 352, 383]]], ["Therefore, we carried out 18 ns of MD simulation for the three best-scored ligands complexed with the S-protein.", [["S-protein", "GENE_OR_GENE_PRODUCT", 102, 111], ["S-protein", "PROTEIN", 102, 111], ["MD simulation", "TREATMENT", 35, 48]]], ["Figure 5 depicts some relevant properties obtained along the MD trajectories.Binding free energy analysisOverall, Figure 5 highlights that the S-protein is equilibrated at the last 5 ns of MD simulation for all system, as shown by RMSD ( Figure 5(A) ) of the S-protein, in which the values were $0.28 nm with a standard deviation of 0.02 nm for the three complexes.", [["S-protein", "GENE_OR_GENE_PRODUCT", 143, 152], ["S-protein", "PROTEIN", 143, 152], ["S-protein", "PROTEIN", 259, 268], ["the S-protein", "TEST", 255, 268]]], ["This imply that the presence of the ligands does not change significantly the S-protein structure along the MD simulation.", [["S-protein structure", "PROTEIN", 78, 97], ["the S-protein structure", "PROBLEM", 74, 97], ["ligands", "OBSERVATION", 36, 43], ["S-protein structure", "OBSERVATION", 78, 97]]], ["Likewise, the RMSF per residues using their C-alpha atoms ( Figure 5(B) ) was calculated to determine and to identify the flexibility of the S-protein regions.", [["C-alpha atoms", "CHEMICAL", 44, 57], ["C-alpha", "GENE_OR_GENE_PRODUCT", 44, 51], ["C-alpha atoms", "PROTEIN", 44, 57], ["S-protein regions", "PROTEIN", 141, 158], ["their C-alpha atoms", "TREATMENT", 38, 57], ["RMSF", "OBSERVATION", 14, 18]]], ["Comparing the RMSF of the ligands@S-protein complexes with the apo S-protein (Figure 1) , it is possible to see that the residues have lowest flexibility in the presence of the ligands.Binding free energy analysisHowever, it is important to empathize that we used an equilibrated S-protein as an initial configuration in the MD simulation of the complexes.", [["apo S-protein", "GENE_OR_GENE_PRODUCT", 63, 76], ["RMSF", "PROTEIN", 14, 18], ["ligands@S", "PROTEIN", 26, 35], ["protein complexes", "PROTEIN", 36, 53], ["apo S-protein", "PROTEIN", 63, 76], ["Figure 1", "PROTEIN", 78, 86], ["the residues", "PROBLEM", 117, 129], ["Binding free energy analysis", "TEST", 185, 213], ["an equilibrated S-protein", "PROBLEM", 264, 289], ["ligands", "ANATOMY", 177, 184]]], ["In addition, all ligands are positioned in the S-protein RDB domain, which is composed by the atoms CA26100 (C336)-CA28081 (C525 residue).", [["CA26100", "CHEMICAL", 100, 107], ["CA28081", "CHEMICAL", 115, 122], ["C525", "CHEMICAL", 124, 128], ["CA26100", "SIMPLE_CHEMICAL", 100, 107], ["S-protein RDB domain", "PROTEIN", 47, 67]]], ["In this region is observed low residue fluctuations, keeping the RMSF values below $0.3 nm (Figure 5(B) ).", [["observed low residue fluctuations", "PROBLEM", 18, 51], ["the RMSF values", "TEST", 61, 76], ["low residue fluctuations", "OBSERVATION", 27, 51]]], ["The compactness of the S-protein was achieved by the radius of gyration ( Figure 5(C) ).", [["S-protein", "PROTEIN", 23, 32], ["the S-protein", "PROBLEM", 19, 32], ["compactness", "OBSERVATION_MODIFIER", 4, 15], ["S-protein", "OBSERVATION", 23, 32], ["radius", "OBSERVATION_MODIFIER", 53, 59]]], ["The S-Protein complexed with Lig8522 and Lig8970 ligands present a similar compactness along the entire MD simulation.", [["Lig8522", "CHEMICAL", 29, 36], ["Lig8522", "CHEMICAL", 29, 36], ["Lig8970", "CHEMICAL", 41, 48], ["Lig8522", "SIMPLE_CHEMICAL", 29, 36], ["Lig8970 ligands", "GENE_OR_GENE_PRODUCT", 41, 56], ["S-Protein", "PROTEIN", 4, 13]]], ["For Lig6843, the Rg of the protein remains low fluctuation at the last 7 ns of the trajectory.", [["Lig6843", "CHEMICAL", 4, 11], ["Lig6843", "CHEMICAL", 4, 11], ["Lig6843", "SIMPLE_CHEMICAL", 4, 11], ["low fluctuation", "PROBLEM", 43, 58], ["low fluctuation", "OBSERVATION", 43, 58]]], ["Overall, the S-protein in all systems (apo e holo forms) is compact with Rg value of $4.35 nm.", [["apo e holo", "GENE_OR_GENE_PRODUCT", 39, 49], ["S-protein", "PROTEIN", 13, 22], ["Rg value", "TEST", 73, 81], ["S-protein", "OBSERVATION", 13, 22]]], ["In general, the RMSD, RMSF and Rg analyzes show that the S-protein has low conformation change at the last 6 ns of the MD trajectories.", [["S-protein", "CHEMICAL", 57, 66], ["S-protein", "GENE_OR_GENE_PRODUCT", 57, 66], ["S-protein", "PROTEIN", 57, 66], ["Rg analyzes", "TEST", 31, 42], ["the S-protein", "PROBLEM", 53, 66], ["low conformation change", "PROBLEM", 71, 94], ["low conformation", "OBSERVATION", 71, 87]]], ["Thus, as expected, the S-protein present a similar solvent accessible surface area ( Figure 5(C) ), retaining its accessibility in the last 6 ns of the MD simulations.Binding free energy analysisIn Figure 6 , we present the representation of the initial and final structures obtained in simulations.Binding free energy analysisAs one can see in Figure 6 , the ligands are attached on the S-protein RBD along the MD trajectory, in which only the Lig6843 differs from its initial configuration, but it remains in the RBD region.", [["surface area", "ANATOMY", 70, 82], ["Lig6843", "CHEMICAL", 445, 452], ["Lig6843", "GENE_OR_GENE_PRODUCT", 445, 452], ["S-protein RBD", "PROTEIN", 388, 401], ["Lig6843", "PROTEIN", 445, 452], ["RBD region", "PROTEIN", 515, 525], ["Binding free energy analysisAs", "TEST", 299, 329], ["the S-protein RBD", "PROBLEM", 384, 401], ["similar", "OBSERVATION_MODIFIER", 43, 50], ["solvent", "OBSERVATION_MODIFIER", 51, 58], ["accessible", "OBSERVATION_MODIFIER", 59, 69], ["surface", "OBSERVATION_MODIFIER", 70, 77], ["accessibility", "OBSERVATION_MODIFIER", 114, 127], ["RBD", "ANATOMY", 515, 518], ["region", "ANATOMY_MODIFIER", 519, 525]]], ["Table 2 shows the binding energetic components obtained in the MM/PBSA calculations.Binding free energy analysisAlthough the binding energy obtained from MM/PBSA method differs from the docking calculations, they follow the same energetic order.", [["PBSA", "PROTEIN", 157, 161], ["the MM/PBSA calculations", "TREATMENT", 59, 83], ["Binding free energy analysis", "TEST", 84, 112], ["the binding energy", "TEST", 121, 139], ["MM/PBSA method", "TREATMENT", 154, 168], ["the docking calculations", "TEST", 182, 206]]], ["Lig8522 and Lig8970 present the same binding energy with similar van der Waals and apolar solvation (SASA) energies.", [["Lig8522", "CHEMICAL", 0, 7], ["Lig8970", "CHEMICAL", 12, 19], ["Lig8522", "CHEMICAL", 0, 7], ["Lig8970", "CHEMICAL", 12, 19], ["Lig8522", "SIMPLE_CHEMICAL", 0, 7], ["Lig8970", "SIMPLE_CHEMICAL", 12, 19], ["similar van der Waals and apolar solvation (SASA) energies", "TREATMENT", 57, 115]]], ["However, the electrostatic and polar solvation energies are very different due to the large negatively charge (-6e) of the Lig8970 salt.", [["Lig8970 salt", "CHEMICAL", 123, 135], ["Lig8970 salt", "SIMPLE_CHEMICAL", 123, 135], ["the electrostatic and polar solvation energies", "PROBLEM", 9, 55], ["electrostatic", "OBSERVATION_MODIFIER", 13, 26], ["polar", "OBSERVATION_MODIFIER", 31, 36], ["solvation energies", "OBSERVATION", 37, 55], ["large", "OBSERVATION_MODIFIER", 86, 91]]], ["The positive value of the binding energy for the Lig6843 was an unexpected result.", [["Lig6843", "CHEMICAL", 49, 56], ["Lig6843", "SIMPLE_CHEMICAL", 49, 56], ["positive", "OBSERVATION_MODIFIER", 4, 12]]], ["However, this result is a consequence of the Lig6843 reorientation along the MD simulation, see Figure 6 .", [["Lig6843", "CHEMICAL", 45, 52], ["Lig6843", "SIMPLE_CHEMICAL", 45, 52]]], ["In this process, the initial position of the Lig6843 (charge \u00fe2e) is favorable for interactions with two negative regions of the RBD (Figure 4) .", [["RBD", "DISEASE", 129, 132], ["Lig6843", "CHEMICAL", 45, 52], ["Lig6843", "SIMPLE_CHEMICAL", 45, 52], ["RBD", "PROTEIN", 129, 132], ["Figure 4", "PROTEIN", 134, 142], ["RBD", "ANATOMY", 129, 132]]], ["However, in the MD trajectory it is dislocated for an unfavorable positive region.", [["an unfavorable positive region", "PROBLEM", 51, 81], ["dislocated", "OBSERVATION", 36, 46], ["unfavorable", "OBSERVATION_MODIFIER", 54, 65], ["positive", "OBSERVATION", 66, 74]]], ["Moreover, the large error in the binding energy of this ligand indicate that is necessary more time to be simulated in the MD simulation.", [["the large error", "PROBLEM", 10, 25], ["large", "OBSERVATION_MODIFIER", 14, 19], ["error", "OBSERVATION", 20, 25]]], ["Therefore, the Lig6841 remain binding in the RBD region by the van der Waals interactions along the 18 ns of the MD simulation.", [["Lig6841", "CHEMICAL", 15, 22], ["Lig6841", "CHEMICAL", 15, 22], ["Lig6841", "SIMPLE_CHEMICAL", 15, 22], ["Lig6841", "PROTEIN", 15, 22], ["RBD region", "PROTEIN", 45, 55], ["the MD simulation", "TREATMENT", 109, 126], ["RBD", "ANATOMY", 45, 48], ["region", "ANATOMY_MODIFIER", 49, 55]]], ["Forthcomingly, when in vitro activity were disposable in the literature, we will do receiver operating characteristic (ROC) curve analysis from machine learning to identify possible true positive ligands.ConclusionsCurrently, we are surviving at a global health crisis caused by the SARS-CoV-2 virus, which is responsible by the COVID-19 outbreak since the end of the 2019.", [["SARS", "DISEASE", 283, 287], ["SARS-CoV-2 virus", "ORGANISM", 283, 299], ["CoV-2 virus", "SPECIES", 288, 299], ["SARS-CoV-2 virus", "SPECIES", 283, 299], ["curve analysis", "TEST", 124, 138], ["true positive ligands", "PROBLEM", 182, 203], ["the SARS-CoV-2 virus", "PROBLEM", 279, 299], ["positive ligands", "OBSERVATION", 187, 203]]], ["To date, there is not a vaccine against COVID-19 and the social isolation is the main strategy adopted to avoid the spread of this novel coronavirus.", [["coronavirus", "DISEASE", 137, 148], ["coronavirus", "ORGANISM", 137, 148], ["a vaccine", "TREATMENT", 22, 31], ["COVID", "TEST", 40, 45], ["the social isolation", "TREATMENT", 53, 73], ["this novel coronavirus", "PROBLEM", 126, 148]]], ["Therefore, herein we used molecular dynamics (MD) simulation and docking calculations to study the SARS-CoV-2 S-protein with the main goal to obtain possible drugs candidates for repurposing them against to COVID-19.", [["COVID-19", "CHEMICAL", 207, 215], ["SARS-CoV-2 S-protein", "PROTEIN", 99, 119], ["docking calculations", "TEST", 65, 85], ["the SARS", "TEST", 95, 103], ["CoV", "TEST", 104, 107], ["drugs", "TREATMENT", 158, 163], ["COVID", "TEST", 207, 212]]], ["Our approach was study the SARS-CoV-2 S-protein before it bounded with the human angiotensin-converting enzyme 2 receptor preventing the human cell infection.", [["cell", "ANATOMY", 143, 147], ["angiotensin", "CHEMICAL", 81, 92], ["human cell infection", "DISEASE", 137, 157], ["human", "ORGANISM", 75, 80], ["angiotensin-converting enzyme 2 receptor", "GENE_OR_GENE_PRODUCT", 81, 121], ["human", "ORGANISM", 137, 142], ["cell", "CELL", 143, 147], ["SARS-CoV-2 S-protein", "PROTEIN", 27, 47], ["human angiotensin-converting enzyme 2 receptor", "PROTEIN", 75, 121], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 137, 142], ["the SARS", "TEST", 23, 31], ["CoV", "TEST", 32, 35], ["the human angiotensin", "TREATMENT", 71, 92], ["converting enzyme 2 receptor", "TREATMENT", 93, 121], ["the human cell infection", "PROBLEM", 133, 157], ["human cell infection", "OBSERVATION", 137, 157]]], ["Overall, the Sprotein does not undergo significantly structural change along the 18 ns MD simulation equilibration in water solvent.", [["Sprotein", "PROTEIN", 13, 21], ["significantly structural change", "PROBLEM", 39, 70], ["simulation equilibration in water solvent", "TREATMENT", 90, 131]]], ["The main change occurs in the receptor-binding domain (RBD) which was converted from \"up\" (angle of 54.3 degrees) to \"down\" (angle of 43.0 degrees) conformation.", [["receptor-binding domain", "PROTEIN", 30, 53], ["RBD", "PROTEIN", 55, 58], ["main", "OBSERVATION_MODIFIER", 4, 8], ["change", "OBSERVATION", 9, 15]]], ["In this transition, the RBD increased surface area enhanced the possibility of interactions with the solvent and also with the possible drugs.", [["surface area", "ANATOMY", 38, 50], ["RBD", "PROTEIN", 24, 27], ["the RBD increased surface area", "PROBLEM", 20, 50], ["the solvent", "TREATMENT", 97, 108], ["RBD", "OBSERVATION_MODIFIER", 24, 27], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["surface", "OBSERVATION_MODIFIER", 38, 45], ["area", "OBSERVATION_MODIFIER", 46, 50]]], ["In this way, we carried out virtual screening by docking calculations using the S-protein at 18 ns of the MD simulation as receptor and 9091 approved drugs as ligands.", [["virtual screening", "TEST", 28, 45], ["the S-protein", "TREATMENT", 76, 89]]], ["In these calculations, 14 traditional herbal isolate and 10 approved drugs were obtained as a potent candidates to inhibit the SARS-CoV-2 S-protein with binding affinity bellow -8.1 kcal/mol.", [["SARS-CoV-2 S-protein", "PROTEIN", 127, 147], ["these calculations", "TEST", 3, 21], ["14 traditional herbal isolate", "TREATMENT", 23, 52], ["drugs", "TREATMENT", 69, 74], ["the SARS", "TEST", 123, 131], ["CoV", "TEST", 132, 135]]], ["In addition, our calculations were successful to predict the binding of the ivermectin in ACE2, which this drug was used recently with high efficiency to control viral replication in vitro.", [["ivermectin", "CHEMICAL", 76, 86], ["ivermectin", "CHEMICAL", 76, 86], ["ivermectin", "SIMPLE_CHEMICAL", 76, 86], ["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["ACE2", "PROTEIN", 90, 94], ["our calculations", "TEST", 13, 29], ["the ivermectin in ACE2", "TREATMENT", 72, 94], ["viral replication", "TREATMENT", 162, 179], ["viral replication", "OBSERVATION", 162, 179]]], ["Overall, the R403, R405, Y449, L455, G496 and Y505 residues are the most interacting with ligands.", [["R403, R405, Y449, L455, G496 and Y505", "CHEMICAL", 13, 50]]], ["MD simulations of the three ligands@complexes show that the ligands remain bounded in the RBD region along the simulation.", [["RBD region", "PROTEIN", 90, 100], ["the ligands", "PROBLEM", 56, 67], ["ligands", "OBSERVATION", 60, 67], ["RBD", "ANATOMY", 90, 93], ["region", "ANATOMY_MODIFIER", 94, 100]]], ["Where the binding energies obtained from MM/MBSA calculations were -38.51 (\u00b1 1.59), \u00c040.43 (\u00b1 1.92) and 2.67 (\u00b1 1.18) kcal/mol for Lig8522, Lig8970 and Lig6843, respectively.", [["Lig8522", "CHEMICAL", 131, 138], ["Lig8970", "CHEMICAL", 140, 147], ["Lig6843", "CHEMICAL", 152, 159], ["the binding energies", "TEST", 6, 26], ["MM/MBSA calculations", "TEST", 41, 61]]], ["Finally, herein we highlight some important issues to be taken into account for repurposing known drugs for the COVID-19 outbreak.", [["repurposing known drugs", "TREATMENT", 80, 103], ["the COVID", "TEST", 108, 117]]]], "e96b011c26501fc8432fd96787fe0aba49a08e0b": [["IntroductionAn unprecedented major epidemic of Ebola virus disease (EVD) has occurred in West African countries, most notably Guinea, Liberia and Sierra Leone between 2013 and 2016.", [["Ebola virus disease", "DISEASE", 47, 66], ["EVD", "DISEASE", 68, 71], ["Ebola virus", "ORGANISM", 47, 58], ["Ebola virus", "SPECIES", 47, 58], ["Ebola virus", "SPECIES", 47, 58], ["Ebola virus disease", "PROBLEM", 47, 66], ["EVD", "PROBLEM", 68, 71], ["major", "OBSERVATION_MODIFIER", 29, 34], ["epidemic", "OBSERVATION_MODIFIER", 35, 43], ["Ebola virus disease", "OBSERVATION", 47, 66]]], ["Since its emergence in late 2013, the epidemic has involved at least 28,599 cases and 11,299 deaths as of the end of 2015 [1] .", [["deaths", "DISEASE", 93, 99]]], ["No licensed vaccines were available before the epidemic and there is no established, specific treatment for EVD, which permitted its initial growth to be nearly exponential [2] .", [["EVD", "DISEASE", 108, 111], ["licensed vaccines", "TREATMENT", 3, 20], ["EVD", "TREATMENT", 108, 111]]], ["The disease posed a substantial risk of global spread during its early growth phase, and thus, the risk of observing substantial number of deaths.", [["deaths", "DISEASE", 139, 145], ["The disease", "PROBLEM", 0, 11], ["global spread", "PROBLEM", 40, 53], ["disease", "OBSERVATION", 4, 11], ["substantial", "OBSERVATION_MODIFIER", 20, 31], ["global", "OBSERVATION_MODIFIER", 40, 46], ["spread", "OBSERVATION", 47, 53], ["growth phase", "OBSERVATION_MODIFIER", 71, 83]]], ["The majority of preventative measures to reduce EVD transmission have been limited to non-pharmaceutical interventions, including case isolation, contact tracing and quarantine, as well as entry and exit screening at borders.IntroductionIn line with the control and regulation of international travel, International Health Regulations (IHR) have acted as binding international legislation that give the World Health Organization (WHO) legal authority to impose any travel ban or restriction.", [["preventative measures", "TREATMENT", 16, 37], ["EVD transmission", "TREATMENT", 48, 64], ["non-pharmaceutical interventions", "TREATMENT", 86, 118], ["case isolation", "TREATMENT", 130, 144], ["contact tracing", "TEST", 146, 161], ["exit screening", "TEST", 199, 213], ["IntroductionIn line", "TREATMENT", 225, 244]]], ["The WHO described the unfolding EVD epidemic as a public health emergency of international concern in August 2014.", [["the unfolding EVD epidemic", "PROBLEM", 18, 44]]], ["The declaration aimed to strengthen surveillance and monitoring of the virus on a global scale, including in Guinea, Liberia and Sierra Leone.", [["strengthen surveillance", "TEST", 25, 48], ["the virus", "PROBLEM", 67, 76], ["a global scale", "TEST", 80, 94]]], ["The WHO has never recommended travel restrictions to delay or prevent the international spread of EVD [4] .", [["EVD", "DISEASE", 98, 101], ["travel restrictions", "TREATMENT", 30, 49]]], ["Nevertheless, unlike past epidemics of other infectious diseases, and perhaps because of the rapid geographic spread of EVD to cities with international airports, including Nigeria, a substantial number of countries at risk have adopted national policies to respond to the risk of EVD importation at borders.", [["infectious diseases", "DISEASE", 45, 64], ["EVD", "DISEASE", 120, 123], ["other infectious diseases", "PROBLEM", 39, 64], ["EVD importation", "TREATMENT", 281, 296], ["infectious", "OBSERVATION", 45, 55], ["substantial", "OBSERVATION_MODIFIER", 184, 195], ["EVD", "OBSERVATION", 281, 284]]], ["These large scale travel restrictions were implemented based on individual decisions of member countries.IntroductionBecause of the rapid geographic dissemination of emerging infectious diseases via airline travel, many mathematical modeling studies of global epidemics using airline transportation network data have been reported in the literature [5] [6] [7] [8] [9] [10] .", [["infectious diseases", "DISEASE", 175, 194], ["[5] [6] [7] [8] [9]", "CHEMICAL", 349, 368], ["[5] [6] [7] [8] [9] [10]", "SIMPLE_CHEMICAL", 349, 373], ["emerging infectious diseases", "PROBLEM", 166, 194], ["global epidemics", "PROBLEM", 253, 269], ["large", "OBSERVATION_MODIFIER", 6, 11], ["scale", "OBSERVATION_MODIFIER", 12, 17], ["rapid", "OBSERVATION_MODIFIER", 132, 137]]], ["A data-assimilation study using epidemic modeling in metapopulation systems enabled researchers to offer real-time forecasting of the geographic spread of EVD [11] .", [["EVD", "DISEASE", 155, 158], ["A data-assimilation study", "TEST", 0, 25], ["epidemic modeling in metapopulation systems", "PROBLEM", 32, 75]]], ["A comparative study of entry and exit screening for EVD emphasized that the cost-effectiveness of entry screening among all incoming travelers at risk is likely to be limited, and argued that exit screening in affected countries would be more beneficial [12] .", [["EVD", "DISEASE", 52, 55], ["travelers", "ORGANISM", 133, 142], ["A comparative study", "TEST", 0, 19], ["exit screening", "TEST", 33, 47], ["EVD", "TREATMENT", 52, 55], ["entry screening", "TEST", 98, 113], ["exit screening", "TEST", 192, 206]]], ["Another large-scale simulation study offered rapid feedback with respect to the delay effect of the EVD epidemic attributable to travel restrictions, estimating that travel restrictions led to a delay of EVD outbreaks for approximately 30 days in AFRO countries [13] .", [["Another large-scale simulation study", "TEST", 0, 36], ["the EVD epidemic", "PROBLEM", 96, 112], ["EVD outbreaks", "TREATMENT", 204, 217], ["large", "OBSERVATION_MODIFIER", 8, 13]]], ["Moreover, a report issued by the World Bank quantified the economic impact of the 2013-16 EVD epidemic, indicating that there was negative economic growth in affected countries in 2015 [14] .IntroductionDespite these findings, a post-epidemic evaluation of the effectiveness of travel restrictions using epidemiological data using a simple, tractable method has yet to be reported.", [["a post-epidemic evaluation", "TEST", 227, 253], ["travel restrictions", "TREATMENT", 278, 297], ["epidemiological data", "TEST", 304, 324], ["a simple, tractable method", "TREATMENT", 331, 357], ["economic", "OBSERVATION_MODIFIER", 139, 147], ["growth", "OBSERVATION_MODIFIER", 148, 154]]], ["Because the major route of EVD transmission is via direct contact or through sexual intercourse [15, 16] , there may be additional predictors of EVD, other than travel to describe the increased risk of infection in particular individuals, such as social-cultural factors (e.g. a group of people sharing the same language or religion may lead to increased contact).", [["infection", "DISEASE", 202, 211], ["people", "ORGANISM", 288, 294], ["people", "SPECIES", 288, 294], ["EVD transmission", "TREATMENT", 27, 43], ["EVD", "TREATMENT", 145, 148], ["infection", "PROBLEM", 202, 211], ["infection", "OBSERVATION", 202, 211]]], ["In fact, the importance of accounting for socioeconomic predictors has been highlighted in epidemic modeling studies [17] and should be explicitly tested using empirical data.", [["socioeconomic predictors", "PROBLEM", 42, 66], ["epidemic modeling studies", "TEST", 91, 116], ["empirical data", "TEST", 160, 174]]], ["Employing a simplistic hazard-based regression approach, travel-associated risks and contact behaviors could be modelled in combination with measures of these cultural risk factors.", [["these cultural risk factors", "PROBLEM", 153, 180]]], ["The purpose of the present study is to estimate the effectiveness of travel restrictions, in all countries, that occurred from August to September 2014, using a simple statistical model and exploring additional explanatory variables of the risk of EVD importation.Secondary data sourceEpidemiological datasets of the date of importation of EVD, as well as the dates and duration of travel restrictions were extracted from publicly available secondary data sources [1, 13] .", [["the present study", "TEST", 15, 32], ["a simple statistical model", "TREATMENT", 159, 185], ["EVD importation", "TREATMENT", 248, 263], ["EVD", "TREATMENT", 340, 343], ["travel restrictions", "TREATMENT", 382, 401], ["EVD", "OBSERVATION", 340, 343]]], ["For travel restriction data, a list of countries in which travel restrictions were implemented was collected with the first and last dates of implementation [13] .Secondary data sourceTo capture the airline transportation network-based distance of EVD-free countries from three affected countries in West Africa (Guinea, Liberia and Sierra Leone), network data were obtained from an open source (OpenFlights) [18] .", [["Secondary data source", "PROBLEM", 163, 184], ["EVD", "TREATMENT", 248, 251], ["network data", "TEST", 348, 360]]], ["OpenFlights yielded the network data for direct flights between each pair of countries and the total number of direct flight routes was calculated, consisting of 227 nodes (i.e. 227 countries) with 4,598 edges (i.e. 4,598 flights) as of the 10th November 2012.Secondary data sourceTo explore the potential usefulness of additional explanatory variables, country-specific socio-cultural data were obtained from open access databases [19] [20] [21] [22] [23] .", [["[19] [20] [21] [22]", "CHEMICAL", 432, 451], ["20] [21] [22] [23]", "SIMPLE_CHEMICAL", 438, 456], ["Secondary data source", "PROBLEM", 260, 281], ["nodes", "OBSERVATION", 166, 171]]], ["Because EVD is transmitted through contact with body fluids, we focused on socio-cultural variables that could potentially mirror physical closeness, including common language (English or French versus others) and religion (Christian or Muslim versus others), the presence of trade, international immigration and policies of exempting entry visas for tourism.", [["body fluids", "ANATOMY", 48, 59], ["body", "ORGANISM_SUBDIVISION", 48, 52], ["EVD", "TREATMENT", 8, 11], ["body fluids", "TREATMENT", 48, 59]]], ["English/French and Christian/Muslim were selected because they are widely found in the three countries in this study.", [["this study", "TEST", 106, 116]]], ["Furthermore, to compare the effectiveness of travel restrictions by the group of countries, classified by geographic areas, we obtained dataset of regional groups defined by WHO.A hazard based modelTo determine the risk of transmission on a global airline transportation network in a simplistic manner, the so-called \"effective distance\", D eff , invented by Brockmann and Helbing [24] was employed.", [["network", "MULTI-TISSUE_STRUCTURE", 271, 278]]], ["Briefly, the effective distance is calculated as the minimum distance between a pair of countries, accounting for the length of path and degree (i.e. number of edges), by employing an adjacent matrix.", [["matrix", "CELLULAR_COMPONENT", 193, 199], ["degree", "OBSERVATION_MODIFIER", 137, 143]]], ["As the shortest path dominantly predicts the most likely global spread of infectious diseases, the effective distance appeared to be an excellent predictor of arrival time (i.e. the time from emergence to importation of a novel infectious disease) [24] .", [["infectious diseases", "DISEASE", 74, 93], ["infectious disease", "DISEASE", 228, 246], ["infectious diseases", "PROBLEM", 74, 93], ["most likely", "UNCERTAINTY", 45, 56], ["global", "OBSERVATION_MODIFIER", 57, 63], ["spread", "OBSERVATION_MODIFIER", 64, 70], ["infectious", "OBSERVATION", 74, 84]]], ["The validity of predictive performance of the effective distance has been theoretically and empirically argued by Brockmann and Helbing [24] with reference to the global spread of severe acute respiratory syndrome (SARS) and influenza (H1N1-2009).", [["acute respiratory syndrome", "DISEASE", 187, 213], ["SARS", "DISEASE", 215, 219], ["influenza", "DISEASE", 225, 234], ["severe acute respiratory syndrome", "PROBLEM", 180, 213], ["SARS", "PROBLEM", 215, 219], ["influenza", "PROBLEM", 225, 234], ["H1N1", "PROBLEM", 236, 240], ["severe", "OBSERVATION_MODIFIER", 180, 186], ["acute", "OBSERVATION_MODIFIER", 187, 192], ["respiratory syndrome", "OBSERVATION", 193, 213]]], ["Moreover, the effective distance has been repeatedly used for other application areas including the real time forecasting of the spread of Middle East respiratory syndrome (MERS) and Zika virus [25, 26] .", [["Middle East respiratory syndrome", "DISEASE", 139, 171], ["Zika virus", "ORGANISM", 183, 193], ["Zika virus", "SPECIES", 183, 193], ["Middle East respiratory syndrome (MERS)", "SPECIES", 139, 178], ["Zika virus", "SPECIES", 183, 193], ["other application areas", "TREATMENT", 62, 85], ["Middle East respiratory syndrome", "PROBLEM", 139, 171], ["Zika virus", "PROBLEM", 183, 193], ["spread", "OBSERVATION_MODIFIER", 129, 135], ["Middle", "ANATOMY_MODIFIER", 139, 145], ["respiratory syndrome", "OBSERVATION", 151, 171]]], ["The inverse of effective distance D eff is taken, because this formulation allows the median time of importation to be proportional to D eff , which is consistent with Brockmann and Helbing [24] .", [["effective distance D eff", "TREATMENT", 15, 39], ["effective", "OBSERVATION_MODIFIER", 15, 24], ["consistent with", "UNCERTAINTY", 152, 167]]], ["Under travel restrictions, \u03b2 i and D eff in both Eqs (1) and (2) are varied because of the change in the network structure. \u03b2 i was statistically estimated, while D eff was manually set in advance of statistical inference.", [["D eff", "GENE_OR_GENE_PRODUCT", 35, 40], ["D eff", "PROTEIN", 35, 40], ["\u03b2 i and D eff", "TEST", 27, 40], ["the change in the network structure", "PROBLEM", 87, 122], ["change", "OBSERVATION", 91, 97], ["network structure", "OBSERVATION", 105, 122]]], ["Following an earlier study [13] , we assumed that 75% of corresponding flight routes were cancelled during travel restrictions as a default assumption.", [["an earlier study", "TEST", 10, 26]]], ["The arrival time was counted from the 15 th of July, 2014 because exponential growth was continuously seen around that time [27] [28] [29] [30] .", [["exponential growth", "PROBLEM", 66, 84]]], ["The declining phase of the epidemic was excluded from our analysis to permit a simple model using the time-independent hazard function.A hazard based modelA total of 224 countries were divided into three different groups; (i) countries that imported an EVD case before travel restrictions, (ii) countries that imported an EVD cases after travel restrictions, and (iii) countries that did not import any EVD cases.", [["EVD", "DISEASE", 403, 406], ["our analysis", "TEST", 54, 66], ["an EVD case", "TREATMENT", 250, 261], ["declining", "OBSERVATION_MODIFIER", 4, 13], ["phase", "OBSERVATION_MODIFIER", 14, 19]]], ["The total likelihood was given by the product L 1 L 2 L 3 and the maximum likelihood method was employed to infer parameters.", [["the maximum likelihood method", "TREATMENT", 62, 91], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["The 95% confidence intervals (CI) were derived from the profile likelihood.Identifying useful predictorsTo identify useful predictors of the risk of importation, we examined the improvement in model fit by adding each single dichotomous variable to two different null models (i.e. a model without any explanatory variables and another model with effective distance only).", [["CI", "TEST", 30, 32]]], ["A likelihood ratio test was used to detect any significant improvement in model fit.", [["A likelihood ratio test", "TEST", 0, 23], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["improvement", "OBSERVATION", 59, 70], ["model fit", "OBSERVATION", 74, 83]]], ["Subsequently, a multivariate model was developed.", [["a multivariate model", "TEST", 14, 34]]], ["To identify the best fit multivariate model, Akaike's Information Criterion (AIC) and a backward selection method with the same methodological principle was employed.Reductions in absolute and relative risksBecause the best fit model does not necessarily yield the best predictive performance, two different models for the assessment of travel restrictions were used (i.e. a model with effective distance only and the best fit model).", [["a backward selection method", "TREATMENT", 86, 113], ["the assessment", "TEST", 319, 333], ["travel restrictions", "TREATMENT", 337, 356], ["absolute", "OBSERVATION_MODIFIER", 180, 188]]], ["That is, as part of the evacuation procedure for medical treatment purposes, those working on the ground and who were infected, especially infected physicians and healthcare workers, were admitted to a hospital in their home country.", [["the evacuation procedure", "TREATMENT", 20, 44], ["medical treatment purposes", "TREATMENT", 49, 75]]], ["Therefore, we analyzed two different datasets for arrival time; one that included all countries with importation and one that excluded countries that intentionally imported cases for treatment purposes.", [["treatment purposes", "TREATMENT", 183, 201]]], ["Epidemiological assessment of travel restrictions was conducted by calculating the cumulative risk of importation for each country and comparing estimates in two scenarios.", [["Epidemiological assessment", "TEST", 0, 26]]], ["Since the hazard is assumed as constant before and after travel restrictions, the cumulative risk of importation is given by one minus the cumulative risk of escaping importation for the period of t a and t b -t a days.", [["constant", "OBSERVATION_MODIFIER", 31, 39], ["escaping", "OBSERVATION", 158, 166]]], ["The second scenario is a hypothetical scenario in which no travel restriction takes place.Reductions in absolute and relative risksAbsolute risk difference because of travel restrictions was then calculated as r i0 -r i1 .", [["i0", "DNA", 212, 214], ["travel restriction", "TREATMENT", 59, 77], ["Absolute risk difference", "PROBLEM", 131, 155], ["hypothetical scenario", "OBSERVATION", 25, 46], ["absolute", "OBSERVATION_MODIFIER", 104, 112]]], ["The effectiveness was calculated as the relative risk reduction, i.e. 1-r i1 /r i0 .", [["the relative risk reduction", "TREATMENT", 36, 63]]], ["The distribution of these risk reductions were visually investigated as a global map of individual countries and were also examined by WHO region.Sensitivity analysisSensitivity of the effectiveness of the length of the exponential window was examined.", [["these risk reductions", "PROBLEM", 20, 41], ["Sensitivity analysisSensitivity", "TEST", 146, 177], ["distribution", "OBSERVATION_MODIFIER", 4, 16]]], ["Although the end date of analysis was the 15 th of September, 2014 as a default, we also varied the time window from the 12 th of September to the 18 th of September, 2014.", [["analysis", "TEST", 25, 33]]], ["Similarly, sensitivity of the effectiveness of different reductions of travel volume was also examined.", [["travel volume", "TEST", 71, 84]]], ["Though we assumed a reduction of 75% of flights as a default, we also tested scenarios of 50% and 100% reductions of flights as alternative assumptions.Ethical considerationsThe present study reanalyzed publicly available WHO data.", [["The present study", "TEST", 174, 191], ["reduction", "OBSERVATION_MODIFIER", 20, 29]]], ["As such, the datasets used in our study have been deemed as exempt from ethical approval.Availability of supporting dataThe present study used publicly available data, and essential components of the epidemiological data are downloadable from the WHO website [1] .", [["our study", "TEST", 30, 39], ["The present study", "TEST", 120, 137]]], ["Table 1 shows the list of countries that have experienced importation of EVD in 2014, excluding Guinea, Liberia and Sierra Leone.", [["EVD", "DISEASE", 73, 76], ["EVD", "TREATMENT", 73, 76]]], ["Of these, only three importation events were not associated with medical evacuation.", [["medical evacuation", "TREATMENT", 65, 83], ["not associated with", "UNCERTAINTY", 45, 64]]], ["Of these, four importation events were for medical evacuation purposes.", [["medical evacuation purposes", "TEST", 43, 70]]], ["Table 2 shows the result from the likelihood ratio test to identify useful univariate predictor(s) of importation.", [["the likelihood ratio test", "TEST", 30, 55]]], ["Compared with null models, the presence of trade and immigration with one of the three affected countries appeared to significantly improve the model fit for the case in which we included a total of six imported countries.", [["trade", "OBSERVATION_MODIFIER", 43, 48]]], ["When only two countries were included in our analysis, visa exemption was the only variable that improved model fit.Identifying predictorsIn the multivariate model eq (2), the use of trade and immigration, in addition to effective distance, appeared to be the best fitting model with minimum AIC value (AIC = 94.1), for a model including importation for treatment purposes (n = 6).", [["our analysis", "TEST", 41, 53], ["AIC", "TEST", 303, 306], ["treatment purposes", "TREATMENT", 354, 372]]], ["This finding that the use of trade and immigration variables improved model fit, agreed with that of univariate analysis.", [["univariate analysis", "TEST", 101, 120]]], ["Using the best fit model, the coefficient \u03b2 i was estimated at 0.19 (95% CI: 0.06, 0.32).", [["CI", "TEST", 73, 75]]], ["If we exclude Estimates of effectiveness (Fig 1A) , and the best model for analysis of arrival time in all imported countries (n = 6; Fig 1C) , the median value of absolute risk reduction was 0.6% (25-75 percentiles: 0.6-0.7) and 0.0% (25-75 percentiles: 0.0-0.1), respectively.", [["absolute risk reduction", "TREATMENT", 164, 187]]], ["Effectiveness, i.e. relative risk reduction, for these models was estimated at 20.1% SEARO (Southeast Asian Region) and WPRO (Western Pacific Region) countries were similarly distributed.", [["these models", "TEST", 49, 61], ["WPRO (Western Pacific Region)", "TREATMENT", 120, 149]]], ["Again, the qualitative patterns were similar even when we excluded the four countries that imported cases for treatment purposes.Sensitivity analysisResults from the sensitivity analyses are shown in Fig 4.", [["treatment purposes", "TREATMENT", 110, 128], ["Sensitivity analysisResults", "TEST", 129, 156], ["the sensitivity analyses", "TEST", 162, 186]]], ["The estimated effectiveness was slightly elevated when we extended the last date of exponential growth of cases; and this pattern was consistent for different models and datasets.", [["slightly elevated", "PROBLEM", 32, 49], ["exponential growth of cases", "PROBLEM", 84, 111], ["consistent for", "UNCERTAINTY", 134, 148]]], ["As we decreased the volume of flights, the effectiveness appeared to decrease (given the same empirical data).", [["the volume of flights", "TREATMENT", 16, 37]]], ["This effect was more consistently observed in estimates derived from the best fit model than from the model that used the effective distance only.DiscussionThe present study estimated the effectiveness of travel restrictions for international dissemination of EVD cases, using a hazard-based model and effective distance.", [["The present study", "TEST", 156, 173], ["travel restrictions", "TREATMENT", 205, 224], ["international dissemination of EVD cases", "TREATMENT", 229, 269], ["a hazard-based model and effective distance", "TREATMENT", 277, 320]]], ["In particular, the present study is the first to conveniently use the effective distance in evaluating the effectiveness of travel restrictions using existing empirical data.", [["the present study", "TEST", 15, 32], ["travel restrictions", "TREATMENT", 124, 143], ["existing empirical data", "TEST", 150, 173]]], ["When we analyzed arrival time data from July to September 2014, during which local preventative measures had yet to be deemed successful, all the models showed that travel restrictions resulted in very small estimates of absolute risk reduction (< 1%) and a relative risk reduction of approximately 20%.", [["absolute risk reduction", "PROBLEM", 221, 244], ["a relative risk reduction", "PROBLEM", 256, 281], ["very", "OBSERVATION_MODIFIER", 197, 201], ["small", "OBSERVATION_MODIFIER", 202, 207], ["reduction", "OBSERVATION_MODIFIER", 272, 281]]], ["The effectiveness of travel restrictions tended to be greatest among AFRO countries, which instituted travel restrictions earliest between August and September 2014.", [["travel restrictions", "TREATMENT", 21, 40]]], ["The European countries had the lowest estimated effectiveness, but this is expected because of high connectivity with African countries by air transportation, the acceptance of medical evacuation for international aid workers and their historical context.", [["medical evacuation", "TREATMENT", 177, 195]]], ["This study highlights that travel restrictions were not as effective as anticipated.", [["This study", "TEST", 0, 10], ["travel restrictions", "TREATMENT", 27, 46]]], ["Further, this very limited effectiveness has been consistently indicated by extensive modeling studies of pandemic preparedness planning [31, 32] .", [["extensive modeling studies", "TEST", 76, 102]]], ["Preventative measures at borders may be effective in conjunction with concerted control efforts, including improvement in awareness of the epidemic's current situation among the public.", [["Preventative measures", "TREATMENT", 0, 21]]], ["Rather than expecting border control to be effective, it is better to give priority to locally controlling the spread of disease upon emergence [32, 33] .", [["disease", "PROBLEM", 121, 128]]], ["Although the international spread of EVD was limited from 2013-16, our results imply that limited global spread is attributable to successful local control, mainly in the three affected countries, since the effective reproductive number for all three affected countries had fallen to value close to 1 by late September 2014.", [["EVD", "DISEASE", 37, 40], ["EVD", "TEST", 37, 40], ["limited global spread", "PROBLEM", 90, 111]]], ["These effective local interventions included health system strengthening, construction of healthcare facilities, contact tracing efforts and safe burial measures at source [28, 34] .DiscussionTechnical improvements in the present study allowed us to obtain our results using a simple model.", [["safe burial measures", "TREATMENT", 141, 161], ["the present study", "TEST", 218, 235]]], ["We have shown that, when a strong correlation exists between the effective distance and arrival time, the effectiveness of travel restrictions can be quantified, even without employing a metapopulation-based epidemic model.", [["travel restrictions", "TREATMENT", 123, 142]]], ["To our knowledge, the present study is the first to apply the concept of effective distance to evaluate preventative measures against the global spread of EVD.", [["EVD", "DISEASE", 155, 158], ["the present study", "TEST", 18, 35], ["preventative measures", "TREATMENT", 104, 125], ["the global spread of EVD", "PROBLEM", 134, 158], ["global", "OBSERVATION_MODIFIER", 138, 144], ["spread", "OBSERVATION_MODIFIER", 145, 151], ["EVD", "OBSERVATION", 155, 158]]], ["Although the precision of our findings may be less than those of simulation studies reported elsewhere [8, 11, 13] , the present approach captures the key contribution of air travel to the time and risk of importation.DiscussionFurther analyses to investigate other epidemics and more specific data (i.e., individualbased data), will be essential to fully understand why the presence of trade, immigration and tourist visa exemptions were present in the best fit model.", [["simulation studies", "TEST", 65, 83], ["tourist visa exemptions", "TREATMENT", 410, 433], ["may be", "UNCERTAINTY", 39, 45], ["air travel", "OBSERVATION", 171, 181]]], ["In the case of EVD, the total number of imported countries was very small, and rather than strictly selecting variables with practical (or causal) explanations, it is possible that a few variables that simply statistically improved the goodness-of-fit might have been selected.", [["EVD", "TREATMENT", 15, 18], ["EVD", "OBSERVATION", 15, 18], ["small", "OBSERVATION_MODIFIER", 68, 73]]], ["For this reason, we have also estimated the effectiveness using only the effective distance, throughout the present study.", [["the present study", "TEST", 104, 121], ["effective", "OBSERVATION_MODIFIER", 73, 82]]], ["The predictive performance is expected to be improved by selecting truly insightful variables and specific countries particularly at-risk of importation, therefore the present study has shown the potential approaches to exploring epidemiological predictors of importation risk in addition to airline transportation network data.DiscussionOur study had some limitations.", [["The predictive performance", "TEST", 0, 26], ["the present study", "TEST", 164, 181], ["DiscussionOur study", "TEST", 328, 347]]], ["Rather than overcoming these limitations in the network data, greater weight was given to the use of simple open source data [26, 35] ; however, we believe that using flight route data in our approach was well justified in the context of regression-based modeling using the effective distance.", [["simple open source data", "TEST", 101, 124]]], ["Third, previous studies based on airline transportation network data have used the incorrect assumption that the infected, exporting individual is randomly selected from a source country [36] .", [["previous studies", "TEST", 7, 23], ["the infected", "PROBLEM", 109, 121], ["infected", "OBSERVATION", 113, 121]]], ["Although this assumption was not overcome in the present study, it should be noted that our approach will be able to partially address that assumption by adding key predictive data, such as socioeconomic strata.DiscussionIn summary, the present study estimated the effectiveness of travel restrictions for EVD importation across the world.", [["the present study", "TEST", 233, 250], ["travel restrictions", "TREATMENT", 282, 301], ["EVD importation", "TREATMENT", 306, 321]]], ["The relative risk reduction resulting from travel restrictions was estimated to be approximately 20%; this was not considered a substantial risk reduction to prevent the global epidemic of EVD.", [["EVD", "DISEASE", 189, 192], ["The relative risk reduction", "PROBLEM", 0, 27], ["a substantial risk reduction", "TREATMENT", 126, 154], ["the global epidemic of EVD", "PROBLEM", 166, 192], ["risk reduction", "OBSERVATION", 13, 27], ["EVD", "OBSERVATION", 189, 192]]], ["Our study highlights the need to strengthen local capacities for disease monitoring and control, rather than relying heavily on border control [37, 38] .", [["Our study", "TEST", 0, 9], ["disease monitoring", "TEST", 65, 83]]], ["In addition to local capacity-building and preparedness, we also suggest that rapid local containment should be achieved through coordinated and expedited international cooperation, especially in capacity-limited settings, as was the case with the EVD epidemic [39] [40] [41] .", [["rapid local containment", "TREATMENT", 78, 101]]]], "e54be814c721ec270866d4fbc1129369accfdd0e": [["INTRODUCTIONThe outbreak of the novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing novel coronavirus disease was first reported in late December 2019.", [["coronavirus", "DISEASE", 38, 49], ["acute respiratory syndrome coronavirus", "DISEASE", 66, 104], ["coronavirus disease", "DISEASE", 134, 153], ["coronavirus", "ORGANISM", 38, 49], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 59, 106], ["SARS-CoV-2", "ORGANISM", 108, 118], ["coronavirus", "ORGANISM", 134, 145], ["coronavirus", "SPECIES", 38, 49], ["CoV-2", "SPECIES", 113, 118], ["severe acute respiratory syndrome coronavirus", "SPECIES", 59, 104], ["SARS-CoV-2", "SPECIES", 108, 118], ["the novel coronavirus", "PROBLEM", 28, 49], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 59, 104], ["SARS", "TEST", 108, 112], ["CoV", "TEST", 113, 116], ["novel coronavirus disease", "PROBLEM", 128, 153], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["respiratory syndrome", "OBSERVATION", 72, 92], ["coronavirus disease", "OBSERVATION", 134, 153]]], ["As of May 24, 2020, there were over 5,370,893 cases and 343,617 deaths worldwide, with these numbers continuing to rise at an alarming rate [1] .", [["deaths", "DISEASE", 64, 70]]], ["Data from 72,314 patients with COVID-19 indicate that 81% of patients have mild disease while the remaining 19% have severe or critical disease [2] .", [["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 61, 69], ["Data", "TEST", 0, 4], ["COVID", "TEST", 31, 36], ["mild disease", "PROBLEM", 75, 87], ["severe or critical disease", "PROBLEM", 117, 143], ["mild", "OBSERVATION_MODIFIER", 75, 79], ["disease", "OBSERVATION", 80, 87], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["critical", "OBSERVATION_MODIFIER", 127, 135], ["disease", "OBSERVATION", 136, 143]]], ["Eleven biologic medications have been approved by the US Food and Drug Administration (FDA) for the treatment of psoriasis and these biologic medications modulate the immune system by inhibiting tumor necrosis factor alpha (TNFa), interleukin-17 (IL-17), or IL-23.", [["immune system", "ANATOMY", 167, 180], ["psoriasis", "DISEASE", 113, 122], ["tumor", "DISEASE", 195, 200], ["immune system", "ANATOMICAL_SYSTEM", 167, 180], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 195, 222], ["TNFa", "GENE_OR_GENE_PRODUCT", 224, 228], ["interleukin-17", "GENE_OR_GENE_PRODUCT", 231, 245], ["IL-17", "GENE_OR_GENE_PRODUCT", 247, 252], ["IL-23", "GENE_OR_GENE_PRODUCT", 258, 263], ["tumor necrosis factor alpha", "PROTEIN", 195, 222], ["TNFa", "PROTEIN", 224, 228], ["interleukin-17 (IL-17", "PROTEIN", 231, 252], ["IL-23", "PROTEIN", 258, 263], ["Eleven biologic medications", "TREATMENT", 0, 27], ["the treatment", "TREATMENT", 96, 109], ["psoriasis", "PROBLEM", 113, 122], ["these biologic medications", "TREATMENT", 127, 153], ["the immune system", "TREATMENT", 163, 180], ["inhibiting tumor necrosis", "PROBLEM", 184, 209], ["TNFa", "TEST", 224, 228], ["interleukin", "TEST", 231, 242], ["IL", "TEST", 247, 249], ["IL", "TEST", 258, 260], ["psoriasis", "OBSERVATION", 113, 122], ["tumor", "OBSERVATION_MODIFIER", 195, 200], ["necrosis", "OBSERVATION", 201, 209]]], ["Many patients with psoriasis on biologic therapy have asked their medical providers about the effect of biologics on COVID-19.", [["psoriasis", "DISEASE", 19, 28], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["psoriasis", "PROBLEM", 19, 28], ["biologic therapy", "TREATMENT", 32, 48], ["biologics on COVID", "TREATMENT", 104, 122], ["psoriasis", "OBSERVATION", 19, 28]]], ["Known risk factors for COVID-19 mortality include increasing age and comorbidities such as cardiovascular disease, hypertension, lung disease, diabetes, and cancer.", [["cardiovascular", "ANATOMY", 91, 105], ["lung", "ANATOMY", 129, 133], ["cancer", "ANATOMY", 157, 163], ["COVID", "DISEASE", 23, 28], ["cardiovascular disease", "DISEASE", 91, 113], ["hypertension", "DISEASE", 115, 127], ["lung disease", "DISEASE", 129, 141], ["diabetes", "DISEASE", 143, 151], ["cancer", "DISEASE", 157, 163], ["lung", "ORGAN", 129, 133], ["cancer", "CANCER", 157, 163], ["Known risk factors", "PROBLEM", 0, 18], ["COVID", "TEST", 23, 28], ["increasing age and comorbidities", "PROBLEM", 50, 82], ["cardiovascular disease", "PROBLEM", 91, 113], ["hypertension", "PROBLEM", 115, 127], ["lung disease", "PROBLEM", 129, 141], ["diabetes", "PROBLEM", 143, 151], ["cancer", "PROBLEM", 157, 163], ["cardiovascular", "ANATOMY", 91, 105], ["disease", "OBSERVATION", 106, 113], ["hypertension", "OBSERVATION", 115, 127], ["lung", "ANATOMY", 129, 133], ["disease", "OBSERVATION", 134, 141], ["diabetes", "OBSERVATION", 143, 151], ["cancer", "OBSERVATION", 157, 163]]], ["However, it is currently unknown how biologic therapy for psoriasis might impact patients with psoriasis and COVID-19.", [["psoriasis", "DISEASE", 58, 67], ["psoriasis", "DISEASE", 95, 104], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["biologic therapy", "TREATMENT", 37, 53], ["psoriasis", "PROBLEM", 58, 67], ["psoriasis", "PROBLEM", 95, 104], ["COVID", "TEST", 109, 114]]], ["In this article, we report two patients on biologic medication for psoriasis who developed COVID-19 and successfully recovered from SARS-CoV-2 infection.", [["psoriasis", "DISEASE", 67, 76], ["COVID-19", "CHEMICAL", 91, 99], ["SARS-CoV-2 infection", "DISEASE", 132, 152], ["patients", "ORGANISM", 31, 39], ["SARS-CoV-2", "ORGANISM", 132, 142], ["patients", "SPECIES", 31, 39], ["SARS-CoV-2", "SPECIES", 132, 142], ["biologic medication", "TREATMENT", 43, 62], ["psoriasis", "PROBLEM", 67, 76], ["COVID", "TEST", 91, 96], ["SARS", "PROBLEM", 132, 136], ["CoV-2 infection", "PROBLEM", 137, 152], ["SARS", "OBSERVATION", 132, 136], ["infection", "OBSERVATION", 143, 152]]], ["Patients provided written informed consent for presentation of de-identified medical data.Case 1Patient 1 is an individual in their 30s with widespread plaque psoriasis who was treated with the TNF inhibitor adalimumab for 6 months prior to developing COVID-19.", [["plaque", "ANATOMY", 152, 158], ["plaque psoriasis", "DISEASE", 152, 168], ["adalimumab", "CHEMICAL", 208, 218], ["Patients", "ORGANISM", 0, 8], ["TNF", "GENE_OR_GENE_PRODUCT", 194, 197], ["adalimumab", "SIMPLE_CHEMICAL", 208, 218], ["TNF", "PROTEIN", 194, 197], ["Patients", "SPECIES", 0, 8], ["de-identified medical data", "TEST", 63, 89], ["widespread plaque psoriasis", "PROBLEM", 141, 168], ["the TNF inhibitor adalimumab", "TREATMENT", 190, 218], ["COVID", "TEST", 252, 257], ["widespread", "OBSERVATION_MODIFIER", 141, 151], ["plaque", "OBSERVATION_MODIFIER", 152, 158], ["psoriasis", "OBSERVATION", 159, 168]]], ["The patient's psoriasis began in childhood and at the time of adalimumab initiation, the patient had 20% body surface area involvement (BSA).", [["body surface area", "ANATOMY", 105, 122], ["psoriasis", "DISEASE", 14, 23], ["patient", "ORGANISM", 4, 11], ["adalimumab", "SIMPLE_CHEMICAL", 62, 72], ["patient", "ORGANISM", 89, 96], ["body", "ORGANISM_SUBDIVISION", 105, 109], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 89, 96], ["The patient's psoriasis", "PROBLEM", 0, 23], ["adalimumab initiation", "TREATMENT", 62, 83], ["psoriasis", "OBSERVATION", 14, 23]]], ["The patient's past medical history was significant for sleep apnea, and concomitant medications included trazadone for sleep difficulty and gabapentin for chronic nerve pain.", [["nerve", "ANATOMY", 163, 168], ["sleep apnea", "DISEASE", 55, 66], ["trazadone", "CHEMICAL", 105, 114], ["sleep difficulty", "DISEASE", 119, 135], ["gabapentin", "CHEMICAL", 140, 150], ["chronic nerve pain", "DISEASE", 155, 173], ["trazadone", "CHEMICAL", 105, 114], ["gabapentin", "CHEMICAL", 140, 150], ["patient", "ORGANISM", 4, 11], ["trazadone", "SIMPLE_CHEMICAL", 105, 114], ["gabapentin", "SIMPLE_CHEMICAL", 140, 150], ["patient", "SPECIES", 4, 11], ["sleep apnea", "PROBLEM", 55, 66], ["concomitant medications", "TREATMENT", 72, 95], ["trazadone", "TREATMENT", 105, 114], ["sleep difficulty", "PROBLEM", 119, 135], ["gabapentin", "TREATMENT", 140, 150], ["chronic nerve pain", "PROBLEM", 155, 173], ["sleep apnea", "OBSERVATION", 55, 66], ["nerve", "ANATOMY", 163, 168], ["pain", "OBSERVATION", 169, 173]]], ["The patient improved on adalimumab 40 mg subcutaneously every other week with a reduction to 3% affected BSA 4 months after initiation.", [["adalimumab", "CHEMICAL", 24, 34], ["patient", "ORGANISM", 4, 11], ["adalimumab", "SIMPLE_CHEMICAL", 24, 34], ["patient", "SPECIES", 4, 11], ["adalimumab", "TREATMENT", 24, 34], ["a reduction", "TREATMENT", 78, 89]]], ["The patient tolerated treatment well, reporting a single upper respiratory tract infection 3 months after starting adalimumab, which lasted only a few days longer than normal.Case 1The patient's initial symptoms of COVID-19 began 4 days after the last adalimumab injection.", [["upper respiratory tract", "ANATOMY", 57, 80], ["respiratory tract infection", "DISEASE", 63, 90], ["adalimumab", "CHEMICAL", 115, 125], ["adalimumab", "CHEMICAL", 252, 262], ["COVID-19", "CHEMICAL", 215, 223], ["patient", "ORGANISM", 4, 11], ["upper respiratory", "ORGANISM_SUBDIVISION", 57, 74], ["tract", "ORGANISM_SUBDIVISION", 75, 80], ["adalimumab", "SIMPLE_CHEMICAL", 115, 125], ["patient", "ORGANISM", 185, 192], ["adalimumab", "SIMPLE_CHEMICAL", 252, 262], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 185, 192], ["treatment", "TREATMENT", 22, 31], ["a single upper respiratory tract infection", "PROBLEM", 48, 90], ["adalimumab", "TREATMENT", 115, 125], ["COVID", "TEST", 215, 220], ["the last adalimumab injection", "TREATMENT", 243, 272], ["upper", "ANATOMY_MODIFIER", 57, 62], ["respiratory tract", "ANATOMY", 63, 80], ["infection", "OBSERVATION", 81, 90]]], ["Symptoms included sore throat (lasting for 5 days), fever to 101.5\u00b0F (lasting 5 days), and mild dry cough (lasting 8 days).", [["sore throat", "DISEASE", 18, 29], ["fever", "DISEASE", 52, 57], ["dry cough", "DISEASE", 96, 105], ["Symptoms", "PROBLEM", 0, 8], ["sore throat", "PROBLEM", 18, 29], ["fever", "PROBLEM", 52, 57], ["mild dry cough", "PROBLEM", 91, 105], ["sore throat", "ANATOMY", 18, 29], ["mild", "OBSERVATION_MODIFIER", 91, 95], ["dry", "OBSERVATION_MODIFIER", 96, 99], ["cough", "OBSERVATION", 100, 105]]], ["The patient denied any diarrhea or loss of smell or taste but did report some non-specific gastrointestinal upset.", [["gastrointestinal", "ANATOMY", 91, 107], ["diarrhea", "DISEASE", 23, 31], ["loss of smell or taste", "DISEASE", 35, 57], ["patient", "ORGANISM", 4, 11], ["gastrointestinal", "ORGAN", 91, 107], ["patient", "SPECIES", 4, 11], ["diarrhea", "PROBLEM", 23, 31], ["loss of smell or taste", "PROBLEM", 35, 57], ["some non-specific gastrointestinal upset", "PROBLEM", 73, 113], ["non-specific", "OBSERVATION_MODIFIER", 78, 90], ["gastrointestinal", "ANATOMY", 91, 107], ["upset", "OBSERVATION", 108, 113]]], ["The patient presented to the emergency department (ED) 4 days after symptom onset, was tested for SARS-CoV-2, and received a positive result in 48 h.", [["SARS", "DISEASE", 98, 102], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["SARS-CoV", "SPECIES", 98, 106], ["symptom onset", "PROBLEM", 68, 81], ["SARS", "PROBLEM", 98, 102], ["CoV", "TEST", 103, 106]]], ["The patient was discharged home for self-quarantine and supportive care.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["self-quarantine", "TREATMENT", 36, 51], ["supportive care", "TREATMENT", 56, 71]]], ["The patient contacted our office and we advised to hold adalimumab given the active symptoms.Case 1The patient was recovering well at home and nearly symptom-free, but 2 weeks after symptom onset awoke with shortness of breath, respiratory discomfort, fatigue, and diaphoresis.", [["respiratory", "ANATOMY", 228, 239], ["adalimumab", "CHEMICAL", 56, 66], ["shortness of breath", "DISEASE", 207, 226], ["respiratory discomfort", "DISEASE", 228, 250], ["fatigue", "DISEASE", 252, 259], ["diaphoresis", "DISEASE", 265, 276], ["patient", "ORGANISM", 4, 11], ["adalimumab", "SIMPLE_CHEMICAL", 56, 66], ["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 103, 110], ["adalimumab", "TREATMENT", 56, 66], ["the active symptoms", "PROBLEM", 73, 92], ["symptom", "PROBLEM", 182, 189], ["shortness of breath", "PROBLEM", 207, 226], ["respiratory discomfort", "PROBLEM", 228, 250], ["fatigue", "PROBLEM", 252, 259], ["diaphoresis", "PROBLEM", 265, 276], ["respiratory", "ANATOMY", 228, 239], ["discomfort", "OBSERVATION", 240, 250], ["fatigue", "OBSERVATION", 252, 259]]], ["Of note, the patient had had a fall 2 days prior, striking the left chest.", [["left chest", "ANATOMY", 63, 73], ["patient", "ORGANISM", 13, 20], ["chest", "ORGAN", 68, 73], ["patient", "SPECIES", 13, 20], ["left", "ANATOMY_MODIFIER", 63, 67], ["chest", "ANATOMY", 68, 73]]], ["This led to an evaluation in the ED with electrocardiogram, chest radiograph, complete blood count, and comprehensive metabolic panel.", [["blood", "ANATOMY", 87, 92], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["an evaluation", "TEST", 12, 25], ["electrocardiogram", "TEST", 41, 58], ["chest radiograph", "TEST", 60, 76], ["complete blood count", "TEST", 78, 98], ["comprehensive metabolic panel", "TEST", 104, 133], ["chest", "ANATOMY", 60, 65]]], ["The differential diagnosis given in the ED included rib fracture, lower respiratory tract infection, pleuritis, pericarditis, and ongoing COVID-19 infection.", [["rib", "ANATOMY", 52, 55], ["lower respiratory tract", "ANATOMY", 66, 89], ["rib fracture", "DISEASE", 52, 64], ["lower respiratory tract infection", "DISEASE", 66, 99], ["pleuritis", "DISEASE", 101, 110], ["pericarditis", "DISEASE", 112, 124], ["infection", "DISEASE", 147, 156], ["rib", "ORGANISM_SUBDIVISION", 52, 55], ["tract", "ORGANISM_SUBDIVISION", 84, 89], ["rib fracture", "PROBLEM", 52, 64], ["lower respiratory tract infection", "PROBLEM", 66, 99], ["pleuritis", "PROBLEM", 101, 110], ["pericarditis", "PROBLEM", 112, 124], ["ongoing COVID-19 infection", "PROBLEM", 130, 156], ["rib", "ANATOMY", 52, 55], ["fracture", "OBSERVATION", 56, 64], ["lower", "ANATOMY_MODIFIER", 66, 71], ["respiratory tract", "ANATOMY", 72, 89], ["infection", "OBSERVATION", 90, 99], ["pleuritis", "OBSERVATION", 101, 110], ["pericarditis", "OBSERVATION", 112, 124], ["infection", "OBSERVATION", 147, 156]]], ["Given a normal electrocardiogram, clear lung exam, and normal chest radiograph along with absence of hypoxia/tachypnea/cough, the patient was again sent home for supportive care and was told to return to the ED if high fever, oxygen saturation below 92% (self-monitored with a home oxygen saturation device), or worsening shortness of breath occured.", [["lung", "ANATOMY", 40, 44], ["chest", "ANATOMY", 62, 67], ["hypoxia", "DISEASE", 101, 108], ["tachypnea", "DISEASE", 109, 118], ["cough", "DISEASE", 119, 124], ["fever", "DISEASE", 219, 224], ["oxygen", "CHEMICAL", 226, 232], ["oxygen", "CHEMICAL", 282, 288], ["shortness of breath", "DISEASE", 322, 341], ["oxygen", "CHEMICAL", 226, 232], ["oxygen", "CHEMICAL", 282, 288], ["lung", "ORGAN", 40, 44], ["patient", "ORGANISM", 130, 137], ["oxygen", "SIMPLE_CHEMICAL", 226, 232], ["oxygen", "SIMPLE_CHEMICAL", 282, 288], ["patient", "SPECIES", 130, 137], ["clear lung exam", "TEST", 34, 49], ["normal chest radiograph", "TEST", 55, 78], ["hypoxia", "PROBLEM", 101, 108], ["tachypnea", "PROBLEM", 109, 118], ["cough", "PROBLEM", 119, 124], ["supportive care", "TREATMENT", 162, 177], ["high fever", "PROBLEM", 214, 224], ["oxygen saturation", "TEST", 226, 243], ["a home oxygen saturation device", "TREATMENT", 275, 306], ["worsening shortness of breath", "PROBLEM", 312, 341], ["lung", "ANATOMY", 40, 44], ["chest", "ANATOMY", 62, 67], ["hypoxia", "OBSERVATION", 101, 108], ["tachypnea", "OBSERVATION", 109, 118], ["cough", "OBSERVATION", 119, 124], ["worsening", "OBSERVATION_MODIFIER", 312, 321]]], ["The patient received no treatments for COVID-19 but decided to take calcium and zinc supplements.Case 1Twenty-one days after COVID-19 symptom onset, the patient reported resolution of all symptoms.", [["calcium", "CHEMICAL", 68, 75], ["zinc", "CHEMICAL", 80, 84], ["COVID-19", "CHEMICAL", 39, 47], ["calcium", "CHEMICAL", 68, 75], ["zinc", "CHEMICAL", 80, 84], ["patient", "ORGANISM", 4, 11], ["calcium", "SIMPLE_CHEMICAL", 68, 75], ["zinc", "SIMPLE_CHEMICAL", 80, 84], ["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 153, 160], ["treatments", "TREATMENT", 24, 34], ["COVID", "TEST", 39, 44], ["calcium and zinc supplements", "TREATMENT", 68, 96], ["COVID", "TEST", 125, 130], ["all symptoms", "PROBLEM", 184, 196]]], ["The patient reported that while the COVID-19 symptoms were similar to previous colds and influenza infections experienced, the COVID-19 symptoms lasted longer.", [["colds", "DISEASE", 79, 84], ["influenza infections", "DISEASE", 89, 109], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["the COVID", "TEST", 32, 41], ["symptoms", "PROBLEM", 45, 53], ["previous colds", "PROBLEM", 70, 84], ["influenza infections", "PROBLEM", 89, 109], ["the COVID", "TEST", 123, 132], ["symptoms", "PROBLEM", 136, 144]]], ["As directed, the patient plans to hold the next dose of adalimumab until being symptom free for 1 month.Case 2Patient 2 is an individual in their 40s with generalized plaque psoriasis for over 20 years who had received the IL-12/IL-23 inhibitor ustekinumab for 3 years prior to COVID-19 diagnosis.", [["plaque", "ANATOMY", 167, 173], ["adalimumab", "CHEMICAL", 56, 66], ["plaque psoriasis", "DISEASE", 167, 183], ["patient", "ORGANISM", 17, 24], ["adalimumab", "SIMPLE_CHEMICAL", 56, 66], ["IL-12", "GENE_OR_GENE_PRODUCT", 223, 228], ["IL-23", "GENE_OR_GENE_PRODUCT", 229, 234], ["ustekinumab", "SIMPLE_CHEMICAL", 245, 256], ["patient", "SPECIES", 17, 24], ["adalimumab", "TREATMENT", 56, 66], ["generalized plaque psoriasis", "PROBLEM", 155, 183], ["the IL", "TREATMENT", 219, 225], ["IL", "TREATMENT", 229, 231], ["COVID", "TEST", 278, 283], ["generalized", "OBSERVATION_MODIFIER", 155, 166], ["plaque", "OBSERVATION", 167, 173]]], ["The patient's dose of ustekinumab was 90 mg every 3 months, which had been increased from 45 mg 2 years prior because of gradually worsening disease.", [["ustekinumab", "CHEMICAL", 22, 33], ["patient", "ORGANISM", 4, 11], ["ustekinumab", "SIMPLE_CHEMICAL", 22, 33], ["patient", "SPECIES", 4, 11], ["ustekinumab", "TREATMENT", 22, 33], ["gradually worsening disease", "PROBLEM", 121, 148], ["gradually", "OBSERVATION_MODIFIER", 121, 130], ["worsening", "OBSERVATION_MODIFIER", 131, 140], ["disease", "OBSERVATION", 141, 148]]], ["Since starting ustekinumab, the patient has not noticed any differences in frequency of upper respiratory tract infections.", [["upper respiratory tract", "ANATOMY", 88, 111], ["ustekinumab", "CHEMICAL", 15, 26], ["respiratory tract infections", "DISEASE", 94, 122], ["ustekinumab", "SIMPLE_CHEMICAL", 15, 26], ["patient", "ORGANISM", 32, 39], ["upper respiratory", "ORGANISM_SUBDIVISION", 88, 105], ["tract", "ORGANISM_SUBDIVISION", 106, 111], ["patient", "SPECIES", 32, 39], ["upper respiratory tract infections", "PROBLEM", 88, 122], ["upper", "ANATOMY_MODIFIER", 88, 93], ["respiratory tract", "ANATOMY", 94, 111], ["infections", "OBSERVATION", 112, 122]]], ["The patient does not take other medications and has no significant past medical history.Case 2The patient first noticed symptoms of COVID-19 11 weeks after the last ustekinumab dose.", [["COVID", "DISEASE", 132, 137], ["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 98, 105], ["other medications", "TREATMENT", 26, 43], ["symptoms", "PROBLEM", 120, 128], ["COVID", "TEST", 132, 137], ["the last ustekinumab dose", "TREATMENT", 156, 181], ["no", "UNCERTAINTY", 52, 54]]], ["The patient is unsure as to how the illness was contracted as the patient did not have an exposure to a patient with known COVID-19.", [["illness", "DISEASE", 36, 43], ["COVID-19", "CHEMICAL", 123, 131], ["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 66, 73], ["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 66, 73], ["patient", "SPECIES", 104, 111], ["known COVID", "TEST", 117, 128]]], ["The patient first experienced a fever of 100.8\u00b0F and fatigue, both lasting 8 days.", [["fever", "DISEASE", 32, 37], ["fatigue", "DISEASE", 53, 60], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["a fever", "PROBLEM", 30, 37], ["fatigue", "PROBLEM", 53, 60], ["fatigue", "OBSERVATION", 53, 60]]], ["The day after fever onset, the patient developed shortness of breath, which lasted 7 days.", [["fever", "DISEASE", 14, 19], ["shortness of breath", "DISEASE", 49, 68], ["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["fever", "PROBLEM", 14, 19], ["shortness of breath", "PROBLEM", 49, 68]]], ["The patient also reported mild nausea for the first 3 days following initial symptoms.", [["nausea", "DISEASE", 31, 37], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["mild nausea", "PROBLEM", 26, 37], ["initial symptoms", "PROBLEM", 69, 85], ["mild", "OBSERVATION_MODIFIER", 26, 30], ["nausea", "OBSERVATION", 31, 37]]], ["The patient denied any loss of smell or taste.", [["loss of smell", "DISEASE", 23, 36], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["any loss of smell or taste", "PROBLEM", 19, 45]]], ["The patient was evaluated in the emergency department 2 days after symptoms began and received a positive SARS-CoV-2 result in 24 h.Case 2The patient was not hospitalized for the disease and received no medications for COVID-19.", [["COVID-19", "CHEMICAL", 219, 227], ["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 142, 149], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 142, 149], ["symptoms", "PROBLEM", 67, 75], ["a positive SARS", "PROBLEM", 95, 110], ["the disease", "PROBLEM", 175, 186], ["medications", "TREATMENT", 203, 214], ["COVID", "TEST", 219, 224]]], ["Symptoms were treated at home with rest and acetaminophen, which reduced the fever.", [["acetaminophen", "CHEMICAL", 44, 57], ["fever", "DISEASE", 77, 82], ["acetaminophen", "CHEMICAL", 44, 57], ["acetaminophen", "SIMPLE_CHEMICAL", 44, 57], ["Symptoms", "PROBLEM", 0, 8], ["rest", "TREATMENT", 35, 39], ["acetaminophen", "TREATMENT", 44, 57], ["the fever", "PROBLEM", 73, 82], ["fever", "OBSERVATION", 77, 82]]], ["The patient reports becoming symptom free 9 days after COVID-19 symptom onset.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["symptom free", "PROBLEM", 29, 41], ["COVID", "TEST", 55, 60]]], ["Compared to prior colds and influenza infections, the patient reports COVID-19 illness lasted about as long.", [["colds", "DISEASE", 18, 23], ["influenza infections", "DISEASE", 28, 48], ["illness", "DISEASE", 79, 86], ["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["prior colds", "PROBLEM", 12, 23], ["influenza infections", "PROBLEM", 28, 48], ["COVID", "TEST", 70, 75], ["influenza infections", "OBSERVATION", 28, 48]]], ["However, with COVID-19, the patient experienced more fatigue and shortness of breath.", [["fatigue", "DISEASE", 53, 60], ["shortness of breath", "DISEASE", 65, 84], ["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["COVID", "TEST", 14, 19], ["more fatigue", "PROBLEM", 48, 60], ["shortness of breath", "PROBLEM", 65, 84]]], ["The patient plans to restart ustekinumab after one full month of being symptom free.DISCUSSIONThe recent COVID-19 pandemic raises the question of how patients with psoriasis receiving biologic therapies fare with this infection.DISCUSSIONAs of 2015, it is estimated that over 300 million patients worldwide have benefited from biologic therapy; thus data on infection course in this population is important to understand [3] .DISCUSSIONThe two patients reported here were younger than age 60 and did not have COVID-19 risk factors such as cardiovascular disease, hypertension, lung disease diabetes, or cancer.", [["cardiovascular", "ANATOMY", 539, 553], ["lung", "ANATOMY", 577, 581], ["cancer", "ANATOMY", 603, 609], ["ustekinumab", "CHEMICAL", 29, 40], ["psoriasis", "DISEASE", 164, 173], ["infection", "DISEASE", 218, 227], ["infection", "DISEASE", 358, 367], ["cardiovascular disease", "DISEASE", 539, 561], ["hypertension", "DISEASE", 563, 575], ["lung disease diabetes", "DISEASE", 577, 598], ["cancer", "DISEASE", 603, 609], ["patient", "ORGANISM", 4, 11], ["patients", "ORGANISM", 150, 158], ["patients", "ORGANISM", 288, 296], ["patients", "ORGANISM", 444, 452], ["lung", "ORGAN", 577, 581], ["cancer", "CANCER", 603, 609], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 150, 158], ["patients", "SPECIES", 288, 296], ["patients", "SPECIES", 444, 452], ["ustekinumab", "TREATMENT", 29, 40], ["COVID", "TEST", 105, 110], ["pandemic", "PROBLEM", 114, 122], ["psoriasis", "PROBLEM", 164, 173], ["biologic therapies", "TREATMENT", 184, 202], ["this infection", "PROBLEM", 213, 227], ["biologic therapy", "TREATMENT", 327, 343], ["infection course", "TREATMENT", 358, 374], ["cardiovascular disease", "PROBLEM", 539, 561], ["hypertension", "PROBLEM", 563, 575], ["lung disease diabetes", "PROBLEM", 577, 598], ["cancer", "PROBLEM", 603, 609], ["psoriasis", "OBSERVATION", 164, 173], ["infection", "OBSERVATION", 218, 227], ["cardiovascular", "ANATOMY", 539, 553], ["disease", "OBSERVATION", 554, 561], ["hypertension", "OBSERVATION", 563, 575], ["lung", "ANATOMY", 577, 581], ["disease", "OBSERVATION", 582, 589], ["cancer", "OBSERVATION", 603, 609]]], ["Both patients reported COVID-19 symptoms of fever, cough/shortness of breath, and nausea or gastrointestinal symptoms.", [["gastrointestinal", "ANATOMY", 92, 108], ["fever", "DISEASE", 44, 49], ["cough", "DISEASE", 51, 56], ["shortness of breath", "DISEASE", 57, 76], ["nausea", "DISEASE", 82, 88], ["gastrointestinal symptoms", "DISEASE", 92, 117], ["patients", "ORGANISM", 5, 13], ["gastrointestinal", "ORGANISM_SUBDIVISION", 92, 108], ["patients", "SPECIES", 5, 13], ["COVID", "TEST", 23, 28], ["symptoms", "PROBLEM", 32, 40], ["fever", "PROBLEM", 44, 49], ["cough", "PROBLEM", 51, 56], ["shortness of breath", "PROBLEM", 57, 76], ["nausea", "PROBLEM", 82, 88], ["gastrointestinal symptoms", "PROBLEM", 92, 117], ["gastrointestinal", "ANATOMY", 92, 108]]], ["Neither patient required hospitalization or supplemental oxygen and both did well with supportive therapy.", [["oxygen", "CHEMICAL", 57, 63], ["oxygen", "CHEMICAL", 57, 63], ["patient", "ORGANISM", 8, 15], ["oxygen", "SIMPLE_CHEMICAL", 57, 63], ["patient", "SPECIES", 8, 15], ["hospitalization", "TREATMENT", 25, 40], ["supplemental oxygen", "TREATMENT", 44, 63], ["supportive therapy", "TREATMENT", 87, 105]]], ["Patient 1, receiving a TNF inhibitor, recovered after approximately 21 days, while patient 2, receiving an IL-12/IL-23 inhibitor, recovered after 9 days.", [["TNF", "GENE_OR_GENE_PRODUCT", 23, 26], ["patient", "ORGANISM", 83, 90], ["IL-12", "GENE_OR_GENE_PRODUCT", 107, 112], ["IL-23", "GENE_OR_GENE_PRODUCT", 113, 118], ["TNF", "PROTEIN", 23, 26], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 83, 90], ["a TNF inhibitor", "TREATMENT", 21, 36], ["an IL-12/IL", "TREATMENT", 104, 115]]], ["However, as a result of the small number of patients reported here, no firm conclusions can be drawn about the impact of specific therapies on disease outcomes.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["firm conclusions", "PROBLEM", 71, 87], ["specific therapies", "TREATMENT", 121, 139], ["disease outcomes", "TREATMENT", 143, 159], ["small", "OBSERVATION_MODIFIER", 28, 33]]], ["In terms of hospitalization, Quartuccio et al. studied 5596 patients on biologic therapy with a diagnosis of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and severe psoriasis.", [["rheumatoid arthritis", "DISEASE", 109, 129], ["ankylosing spondylitis", "DISEASE", 131, 153], ["psoriatic arthritis", "DISEASE", 155, 174], ["psoriasis", "DISEASE", 187, 196], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["biologic therapy", "TREATMENT", 72, 88], ["rheumatoid arthritis", "PROBLEM", 109, 129], ["ankylosing spondylitis", "PROBLEM", 131, 153], ["psoriatic arthritis", "PROBLEM", 155, 174], ["severe psoriasis", "PROBLEM", 180, 196], ["rheumatoid arthritis", "OBSERVATION", 109, 129], ["ankylosing spondylitis", "OBSERVATION", 131, 153], ["psoriatic arthritis", "OBSERVATION", 155, 174], ["severe", "OBSERVATION_MODIFIER", 180, 186], ["psoriasis", "OBSERVATION", 187, 196]]], ["They found that 4.2% were hospitalized because of infection, with upper and lower respiratory tract infections being the most common [4] .DISCUSSIONWhile there are no data for how biologic therapy affects patients' risk of acquiring SARS-CoV-2 specifically, data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) showed that the rates of serious infection were not greater for ustekinumab or etanercept, but higher for adalimumab and infliximab, compared to patients on non-biologic/nonmethotrexate psoriasis therapy [5] .", [["lower respiratory tract", "ANATOMY", 76, 99], ["infection", "DISEASE", 50, 59], ["respiratory tract infections", "DISEASE", 82, 110], ["SARS", "DISEASE", 233, 237], ["Psoriasis", "DISEASE", 272, 281], ["infection", "DISEASE", 361, 370], ["ustekinumab", "CHEMICAL", 392, 403], ["etanercept", "CHEMICAL", 407, 417], ["adalimumab", "CHEMICAL", 434, 444], ["infliximab", "CHEMICAL", 449, 459], ["nonmethotrexate", "CHEMICAL", 498, 513], ["psoriasis", "DISEASE", 514, 523], ["upper", "ORGANISM_SUBDIVISION", 66, 71], ["tract", "ORGANISM_SUBDIVISION", 94, 99], ["patients", "ORGANISM", 205, 213], ["ustekinumab", "SIMPLE_CHEMICAL", 392, 403], ["etanercept", "SIMPLE_CHEMICAL", 407, 417], ["adalimumab", "SIMPLE_CHEMICAL", 434, 444], ["infliximab", "SIMPLE_CHEMICAL", 449, 459], ["patients", "ORGANISM", 473, 481], ["nonmethotrexate", "SIMPLE_CHEMICAL", 498, 513], ["patients", "SPECIES", 205, 213], ["patients", "SPECIES", 473, 481], ["infection", "PROBLEM", 50, 59], ["upper and lower respiratory tract infections", "PROBLEM", 66, 110], ["biologic therapy", "TREATMENT", 180, 196], ["the Psoriasis", "TEST", 268, 281], ["Longitudinal Assessment", "TEST", 282, 305], ["serious infection", "PROBLEM", 353, 370], ["ustekinumab", "TREATMENT", 392, 403], ["etanercept", "TREATMENT", 407, 417], ["adalimumab", "TREATMENT", 434, 444], ["infliximab", "TREATMENT", 449, 459], ["non-biologic/nonmethotrexate psoriasis therapy", "TREATMENT", 485, 531], ["infection", "OBSERVATION", 50, 59], ["upper", "ANATOMY_MODIFIER", 66, 71], ["lower", "ANATOMY_MODIFIER", 76, 81], ["respiratory tract", "ANATOMY", 82, 99], ["infections", "OBSERVATION", 100, 110], ["serious", "OBSERVATION_MODIFIER", 353, 360], ["infection", "OBSERVATION", 361, 370]]], ["The cumulative incidence rate of serious infections was 1.45 per 100 patient-years across treatment cohorts, and the rates were 0.83, 1.47, 1.97, and 2.49 per 100 patient-years in the ustekinumab, etanercept, adalimumab, and infliximab cohorts, respectively, and 1.05 per 100 patientyears in the non-methotrexate/non-biologics cohort.", [["infections", "DISEASE", 41, 51], ["etanercept", "CHEMICAL", 197, 207], ["adalimumab", "CHEMICAL", 209, 219], ["infliximab", "CHEMICAL", 225, 235], ["non-methotrexate", "CHEMICAL", 296, 312], ["non-methotrexate", "CHEMICAL", 296, 312], ["patient", "ORGANISM", 69, 76], ["patient", "ORGANISM", 163, 170], ["etanercept", "SIMPLE_CHEMICAL", 197, 207], ["adalimumab", "SIMPLE_CHEMICAL", 209, 219], ["infliximab", "SIMPLE_CHEMICAL", 225, 235], ["patient", "SPECIES", 69, 76], ["patient", "SPECIES", 163, 170], ["serious infections", "PROBLEM", 33, 51], ["treatment cohorts", "TREATMENT", 90, 107], ["the rates", "TEST", 113, 122], ["the ustekinumab", "TREATMENT", 180, 195], ["etanercept", "TREATMENT", 197, 207], ["adalimumab", "TREATMENT", 209, 219], ["infliximab cohorts", "TREATMENT", 225, 243], ["cumulative", "OBSERVATION_MODIFIER", 4, 14], ["serious", "OBSERVATION_MODIFIER", 33, 40], ["infections", "OBSERVATION", 41, 51]]], ["A prospective study from the Association of British Dermatologists Biologic Intervention Register (BADBIR) did not find a significantly higher risk of serious infections for etanercept, adalimumab, and ustekinumab compared with non-biologic therapies for patients with psoriasis [6] .", [["infections", "DISEASE", 159, 169], ["etanercept", "CHEMICAL", 174, 184], ["adalimumab", "CHEMICAL", 186, 196], ["ustekinumab", "CHEMICAL", 202, 213], ["psoriasis", "DISEASE", 269, 278], ["etanercept", "SIMPLE_CHEMICAL", 174, 184], ["adalimumab", "SIMPLE_CHEMICAL", 186, 196], ["ustekinumab", "SIMPLE_CHEMICAL", 202, 213], ["patients", "ORGANISM", 255, 263], ["patients", "SPECIES", 255, 263], ["A prospective study", "TEST", 0, 19], ["serious infections", "PROBLEM", 151, 169], ["etanercept", "TREATMENT", 174, 184], ["adalimumab", "TREATMENT", 186, 196], ["ustekinumab", "TREATMENT", 202, 213], ["non-biologic therapies", "TREATMENT", 228, 250], ["psoriasis", "PROBLEM", 269, 278], ["serious", "OBSERVATION_MODIFIER", 151, 158], ["infections", "OBSERVATION", 159, 169]]], ["The incidence rates of serious infections per 1000 person-years were 14.18, 15.25, 13.78, and 15.07 for non-biologic therapy, etanercept, adalimumab, and ustekinumab respectively.", [["infections", "DISEASE", 31, 41], ["etanercept", "CHEMICAL", 126, 136], ["adalimumab", "CHEMICAL", 138, 148], ["ustekinumab", "CHEMICAL", 154, 165], ["etanercept", "SIMPLE_CHEMICAL", 126, 136], ["adalimumab", "SIMPLE_CHEMICAL", 138, 148], ["ustekinumab", "SIMPLE_CHEMICAL", 154, 165], ["person", "SPECIES", 51, 57], ["serious infections", "PROBLEM", 23, 41], ["non-biologic therapy", "TREATMENT", 104, 124], ["etanercept", "TREATMENT", 126, 136], ["adalimumab", "TREATMENT", 138, 148], ["ustekinumab", "TREATMENT", 154, 165], ["serious", "OBSERVATION_MODIFIER", 23, 30], ["infections", "OBSERVATION", 31, 41]]], ["Risk factors for contracting a serious infection while on biologic therapy included female gender, the presence of comorbidities such as chronic obstructive pulmonary disease (COPD), alcohol use, infliximab use, and retired patients [7] .", [["pulmonary", "ANATOMY", 157, 166], ["infection", "DISEASE", 39, 48], ["chronic obstructive pulmonary disease", "DISEASE", 137, 174], ["COPD", "DISEASE", 176, 180], ["alcohol", "CHEMICAL", 183, 190], ["infliximab", "CHEMICAL", 196, 206], ["alcohol", "CHEMICAL", 183, 190], ["pulmonary", "ORGAN", 157, 166], ["infliximab", "SIMPLE_CHEMICAL", 196, 206], ["patients", "ORGANISM", 224, 232], ["patients", "SPECIES", 224, 232], ["Risk factors", "PROBLEM", 0, 12], ["contracting a serious infection", "PROBLEM", 17, 48], ["biologic therapy", "TREATMENT", 58, 74], ["comorbidities", "PROBLEM", 115, 128], ["chronic obstructive pulmonary disease", "PROBLEM", 137, 174], ["COPD", "PROBLEM", 176, 180], ["serious", "OBSERVATION_MODIFIER", 31, 38], ["infection", "OBSERVATION", 39, 48], ["chronic", "OBSERVATION_MODIFIER", 137, 144], ["obstructive", "OBSERVATION_MODIFIER", 145, 156], ["pulmonary", "ANATOMY", 157, 166], ["disease", "OBSERVATION", 167, 174], ["COPD", "OBSERVATION", 176, 180]]], ["Furthermore, an analysis of pivotal clinical trials and long-term registry data reveal that on the whole, psoriasis biologics do not show substantial increases in infection risk compared to placebo [8] .DISCUSSIONAn area of open investigation is whether immunomodulators may be beneficial to prevent tissue damage caused by the inflammatory response to SARS-CoV-2.", [["tissue", "ANATOMY", 300, 306], ["psoriasis", "DISEASE", 106, 115], ["infection", "DISEASE", 163, 172], ["SARS", "DISEASE", 353, 357], ["tissue", "TISSUE", 300, 306], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 353, 363], ["an analysis", "TEST", 13, 24], ["the whole, psoriasis biologics", "TREATMENT", 95, 125], ["substantial increases in infection risk", "PROBLEM", 138, 177], ["open investigation", "TEST", 224, 242], ["immunomodulators", "TREATMENT", 254, 270], ["tissue damage", "PROBLEM", 300, 313], ["the inflammatory response", "PROBLEM", 324, 349], ["CoV", "TEST", 358, 361], ["substantial", "OBSERVATION_MODIFIER", 138, 149], ["increases", "OBSERVATION_MODIFIER", 150, 159], ["infection", "OBSERVATION", 163, 172], ["damage", "OBSERVATION", 307, 313], ["inflammatory", "OBSERVATION_MODIFIER", 328, 340]]], ["A study of 522 patients with COVID-19 from China revealed elevated serum TNFa, IL-6, and IL-10 in those patients with more severe disease [9] .", [["serum", "ANATOMY", 67, 72], ["patients", "ORGANISM", 15, 23], ["serum", "ORGANISM_SUBSTANCE", 67, 72], ["TNFa", "GENE_OR_GENE_PRODUCT", 73, 77], ["IL-6", "GENE_OR_GENE_PRODUCT", 79, 83], ["IL-10", "GENE_OR_GENE_PRODUCT", 89, 94], ["patients", "ORGANISM", 104, 112], ["serum TNFa", "PROTEIN", 67, 77], ["IL", "PROTEIN", 89, 91], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 104, 112], ["A study", "TEST", 0, 7], ["COVID", "TEST", 29, 34], ["elevated serum TNFa", "PROBLEM", 58, 77], ["IL", "TEST", 79, 81], ["IL", "TEST", 89, 91], ["more severe disease", "PROBLEM", 118, 137], ["elevated", "OBSERVATION", 58, 66], ["severe", "OBSERVATION_MODIFIER", 123, 129], ["disease", "OBSERVATION", 130, 137]]], ["Currently, there are clinical trials underway investigating adalimumab [10] , the JAK inhibitor ruxolitinib [11] , and IL-6 inhibitors for the mitigation of cytokine storm in patients with COVID-19 [12, 13] .", [["adalimumab", "CHEMICAL", 60, 70], ["ruxolitinib", "CHEMICAL", 96, 107], ["ruxolitinib", "CHEMICAL", 96, 107], ["COVID-19", "CHEMICAL", 189, 197], ["adalimumab", "SIMPLE_CHEMICAL", 60, 70], ["JAK", "GENE_OR_GENE_PRODUCT", 82, 85], ["ruxolitinib", "SIMPLE_CHEMICAL", 96, 107], ["IL-6", "GENE_OR_GENE_PRODUCT", 119, 123], ["patients", "ORGANISM", 175, 183], ["JAK", "PROTEIN", 82, 85], ["cytokine", "PROTEIN", 157, 165], ["patients", "SPECIES", 175, 183], ["adalimumab", "TREATMENT", 60, 70], ["the JAK inhibitor ruxolitinib", "TREATMENT", 78, 107], ["IL", "TREATMENT", 119, 121], ["cytokine storm", "TREATMENT", 157, 171], ["COVID", "TEST", 189, 194], ["cytokine storm", "OBSERVATION", 157, 171]]], ["However, it is important to note that these trials are primarily targeting patients with established, severe COVID-19 disease, and the results may not translate into understanding the effect of these immunomodulatory agents on SARS-CoV-2 acquisition or in patients with mild COVID-19 disease.CONCLUSIONThese two cases add to the existing literature on infection and biologic therapy for psoriasis given that little is known about the pathogenicity of SARS-CoV-2 in patients on biologic therapy for psoriasis.", [["infection", "DISEASE", 352, 361], ["psoriasis", "DISEASE", 387, 396], ["SARS", "DISEASE", 451, 455], ["psoriasis", "DISEASE", 498, 507], ["patients", "ORGANISM", 75, 83], ["SARS-CoV-2", "ORGANISM", 227, 237], ["patients", "ORGANISM", 256, 264], ["SARS-CoV-2", "ORGANISM", 451, 461], ["patients", "ORGANISM", 465, 473], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 256, 264], ["patients", "SPECIES", 465, 473], ["SARS-CoV", "SPECIES", 451, 459], ["severe COVID-19 disease", "PROBLEM", 102, 125], ["these immunomodulatory agents", "TREATMENT", 194, 223], ["mild COVID-19 disease.CONCLUSIONThese", "PROBLEM", 270, 307], ["infection", "PROBLEM", 352, 361], ["biologic therapy", "TREATMENT", 366, 382], ["psoriasis", "PROBLEM", 387, 396], ["SARS", "PROBLEM", 451, 455], ["CoV", "TEST", 456, 459], ["biologic therapy", "TREATMENT", 477, 493], ["psoriasis", "PROBLEM", 498, 507], ["mild", "OBSERVATION_MODIFIER", 270, 274], ["infection", "OBSERVATION", 352, 361], ["psoriasis", "OBSERVATION", 498, 507]]], ["This article describes two patients who contracted COVID-19 on biologic therapy for psoriasis and successfully recovered.", [["psoriasis", "DISEASE", 84, 93], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["COVID", "TEST", 51, 56], ["biologic therapy", "TREATMENT", 63, 79], ["psoriasis", "PROBLEM", 84, 93], ["psoriasis", "OBSERVATION", 84, 93]]], ["These two patients experienced fever, respiratory symptoms, and gastrointestinal symptoms but did well with supportive therapy without the need for hospitalization.", [["respiratory", "ANATOMY", 38, 49], ["gastrointestinal", "ANATOMY", 64, 80], ["fever", "DISEASE", 31, 36], ["respiratory symptoms", "DISEASE", 38, 58], ["gastrointestinal symptoms", "DISEASE", 64, 89], ["patients", "ORGANISM", 10, 18], ["gastrointestinal", "ORGAN", 64, 80], ["patients", "SPECIES", 10, 18], ["fever", "PROBLEM", 31, 36], ["respiratory symptoms", "PROBLEM", 38, 58], ["gastrointestinal symptoms", "PROBLEM", 64, 89], ["supportive therapy", "TREATMENT", 108, 126], ["hospitalization", "TREATMENT", 148, 163], ["gastrointestinal", "ANATOMY", 64, 80]]], ["It is important for patients on biologic therapy for psoriasis to have informed conversations with their healthcare providers regarding risks and benefits of continuing or starting treatment.", [["psoriasis", "DISEASE", 53, 62], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["biologic therapy", "TREATMENT", 32, 48], ["psoriasis", "PROBLEM", 53, 62], ["treatment", "TREATMENT", 181, 190]]], ["While more research is needed, it is reassuring to know that successful recovery is possible after COVID-19 infection in patients on biologic therapy for psoriasis.ACKNOWLEDGEMENTSFunding.", [["infection", "DISEASE", 108, 117], ["psoriasis", "DISEASE", 154, 163], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["COVID-19 infection", "PROBLEM", 99, 117], ["biologic therapy", "TREATMENT", 133, 149], ["psoriasis", "PROBLEM", 154, 163], ["infection", "OBSERVATION", 108, 117], ["psoriasis", "OBSERVATION", 154, 163]]], ["No funding or sponsorship was received for this study or publication of this article.ACKNOWLEDGEMENTSAuthorship.", [["this study", "TEST", 43, 53], ["funding", "OBSERVATION", 3, 10]]], ["All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.ACKNOWLEDGEMENTSDisclosures.", [["this version", "TREATMENT", 224, 236]]], ["Wilson Liao is funded in part by grants from the National Institutes of Health (5U01AI119125) and Abbvie, Amgen, Janssen, Novartis, Regeneron, Sanofi, and TRex Bio.", [["Regeneron", "TREATMENT", 132, 141], ["Sanofi", "TREATMENT", 143, 149]]], ["Tina Bhutani is currently an investigator for Celgene, Janssen, Merck, and Regeneron.", [["Celgene", "TREATMENT", 46, 53], ["Regeneron", "TREATMENT", 75, 84]]], ["Patients provided written informed consent for presentation of de-identified medical data.ACKNOWLEDGEMENTSData Availability.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["de-identified medical data", "TEST", 63, 89]]], ["Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.Open Access.", [["the current study", "TEST", 96, 113], ["Open Access", "TREATMENT", 114, 125]]], ["The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.", [["The images", "TEST", 0, 10]]]], "PMC7263511": [["IntroductionIn December 2019, a novel viral pneumonia, now referred to as Coronavirus Disease 2019 (COVID-19), was observed in Wuhan, China [1].", [["viral pneumonia", "DISEASE", 38, 53], ["Coronavirus Disease", "DISEASE", 74, 93], ["a novel viral pneumonia", "PROBLEM", 30, 53], ["Coronavirus Disease", "PROBLEM", 74, 93], ["COVID", "TEST", 100, 105], ["viral", "OBSERVATION_MODIFIER", 38, 43], ["pneumonia", "OBSERVATION", 44, 53]]], ["Severe Acute Respiratory Syndrome (SARS)- Coronavirus (CoV)-2, the causative agent of COVID-19, has caused more than 3, 000, 000 infections and 200, 000 deaths in 187 countries.", [["Acute Respiratory Syndrome", "DISEASE", 7, 33], ["SARS", "DISEASE", 35, 39], ["COVID-19", "CHEMICAL", 86, 94], ["infections", "DISEASE", 129, 139], ["deaths", "DISEASE", 153, 159], ["CoV)-2", "ORGANISM", 55, 61], ["Severe Acute Respiratory Syndrome", "PROBLEM", 0, 33], ["SARS", "PROBLEM", 35, 39], ["Coronavirus (CoV)", "TEST", 42, 59], ["COVID", "TEST", 86, 91], ["Acute", "OBSERVATION_MODIFIER", 7, 12], ["Respiratory Syndrome", "OBSERVATION", 13, 33]]], ["There are currently no approved drugs or vaccines for the treatment or prevention of COVID-19.", [["drugs", "TREATMENT", 32, 37], ["vaccines", "TREATMENT", 41, 49], ["the treatment", "TREATMENT", 54, 67], ["COVID", "TEST", 85, 90]]], ["Enhanced understanding of viral pathogenesis at the cellular and molecular level is critical for enhanced prognostic tools and novel therapeutics.", [["cellular", "ANATOMY", 52, 60], ["cellular", "CELL", 52, 60], ["viral pathogenesis", "PROBLEM", 26, 44], ["enhanced prognostic tools", "PROBLEM", 97, 122], ["novel therapeutics", "TREATMENT", 127, 145], ["viral pathogenesis", "OBSERVATION", 26, 44]]], ["Presentation is highly variable ranging from asymptomatic infection to acute respiratory distress syndrome and death [2].IntroductionCoVs are enveloped viruses with positive-sense, single-stranded RNA genomes ranging from 26\u201330 kb [3].", [["respiratory", "ANATOMY", 77, 88], ["infection", "DISEASE", 58, 67], ["acute respiratory distress syndrome", "DISEASE", 71, 106], ["death", "DISEASE", 111, 116], ["single-stranded RNA genomes", "DNA", 181, 208], ["asymptomatic infection", "PROBLEM", 45, 67], ["acute respiratory distress syndrome", "PROBLEM", 71, 106], ["death", "PROBLEM", 111, 116], ["IntroductionCoVs", "TREATMENT", 121, 137], ["asymptomatic", "OBSERVATION_MODIFIER", 45, 57], ["infection", "OBSERVATION", 58, 67], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["respiratory distress", "OBSERVATION", 77, 97]]], ["Six human CoVs have been previously identified: HCoV-NL63 and HCoV-229E, which belong to the Alphacoronavirus genus; and HCoV-OC43, HCoV-HKU1, SARS-CoV, and Middle East Respiratory Syndrome CoV (MERS-CoV), which belong to the Betacoronavirus genus [4].", [["SARS-CoV", "DISEASE", 143, 151], ["Middle East Respiratory Syndrome", "DISEASE", 157, 189], ["human", "ORGANISM", 4, 9], ["CoVs", "GENE_OR_GENE_PRODUCT", 10, 14], ["HCoV-NL63", "ORGANISM", 48, 57], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 62, 71], ["Alphacoronavirus genus", "ORGANISM", 93, 115], ["HCoV-OC43", "ORGANISM", 121, 130], ["HCoV-HKU1", "ORGANISM", 132, 141], ["SARS-CoV", "ORGANISM", 143, 151], ["Middle East Respiratory Syndrome CoV", "ORGANISM", 157, 193], ["MERS-CoV", "ORGANISM", 195, 203], ["human CoVs", "PROTEIN", 4, 14], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["HCoV-229E", "SPECIES", 62, 71], ["HCoV-OC43", "SPECIES", 121, 130], ["SARS-CoV", "SPECIES", 143, 151], ["Middle East Respiratory Syndrome CoV", "SPECIES", 157, 193], ["MERS-CoV", "SPECIES", 195, 203], ["Six human CoVs", "TEST", 0, 14], ["HCoV", "TEST", 48, 52], ["HCoV", "TEST", 62, 66], ["the Alphacoronavirus genus", "TEST", 89, 115], ["HCoV", "TEST", 121, 125], ["OC43", "TEST", 126, 130], ["HCoV", "TEST", 132, 136], ["HKU1", "TEST", 137, 141], ["SARS", "PROBLEM", 143, 147], ["CoV", "TEST", 148, 151], ["Middle East Respiratory Syndrome CoV", "PROBLEM", 157, 193], ["Middle", "ANATOMY_MODIFIER", 157, 163], ["Respiratory Syndrome", "OBSERVATION", 169, 189]]], ["In the past two decades, CoVs have become a major public health concern due to potential zoonotic transmission, as revealed by the emergence of SARS-CoV in 2002, which infected 8, 000 people worldwide with a mortality rate of 10\u201315%, and MERS-CoV in 2012 and 2019, which infected 2, 500 people with a mortality rate of 35%, and now SARS-CoV-2 (WHO).IntroductionTissue and cell tropism are key determinants of viral pathogenesis.", [["cell", "ANATOMY", 372, 376], ["SARS-CoV", "DISEASE", 144, 152], ["CoVs", "GENE_OR_GENE_PRODUCT", 25, 29], ["SARS-CoV", "ORGANISM", 144, 152], ["people", "ORGANISM", 184, 190], ["MERS-CoV", "ORGANISM", 238, 246], ["people", "ORGANISM", 287, 293], ["cell", "CELL", 372, 376], ["people", "SPECIES", 184, 190], ["people", "SPECIES", 287, 293], ["SARS-CoV", "SPECIES", 144, 152], ["MERS-CoV", "SPECIES", 238, 246], ["CoVs", "PROBLEM", 25, 29], ["SARS", "PROBLEM", 144, 148], ["a mortality rate", "TEST", 206, 222], ["a mortality rate", "TEST", 299, 315], ["IntroductionTissue and cell tropism", "TREATMENT", 349, 384], ["viral pathogenesis", "PROBLEM", 409, 427], ["cell tropism", "OBSERVATION", 372, 384], ["viral pathogenesis", "OBSERVATION", 409, 427]]], ["SARS-CoV-2 entry into cells depends on the binding of the viral spike (S) protein to its cognate receptor angiotensin-converting enzyme II (ACE2) on the cell surface [2].", [["cells", "ANATOMY", 22, 27], ["cell surface", "ANATOMY", 153, 165], ["SARS", "DISEASE", 0, 4], ["angiotensin", "CHEMICAL", 106, 117], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["cells", "CELL", 22, 27], ["angiotensin-converting enzyme II", "GENE_OR_GENE_PRODUCT", 106, 138], ["ACE2", "GENE_OR_GENE_PRODUCT", 140, 144], ["cell surface", "CELLULAR_COMPONENT", 153, 165], ["viral spike (S) protein", "PROTEIN", 58, 81], ["cognate receptor angiotensin-converting enzyme II", "PROTEIN", 89, 138], ["ACE2", "PROTEIN", 140, 144], ["SARS", "TEST", 0, 4], ["the viral spike", "PROBLEM", 54, 69], ["angiotensin", "TEST", 106, 117]]], ["ACE2 is also the receptor for SARS-CoV and HCoV-NL63, yet these viruses induce profoundly different morbidity and mortality suggesting unknown determinants of coronavirus pathogenesis [5, 6].", [["coronavirus", "DISEASE", 159, 170], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 30, 38], ["HCoV", "GENE_OR_GENE_PRODUCT", 43, 47], ["NL63", "GENE_OR_GENE_PRODUCT", 48, 52], ["coronavirus", "ORGANISM", 159, 170], ["ACE2", "PROTEIN", 0, 4], ["SARS-CoV", "SPECIES", 30, 38], ["SARS", "PROBLEM", 30, 34], ["CoV", "TEST", 35, 38], ["HCoV", "TEST", 43, 47], ["NL63", "TREATMENT", 48, 52], ["these viruses", "PROBLEM", 58, 71], ["profoundly different morbidity", "PROBLEM", 79, 109], ["coronavirus pathogenesis", "PROBLEM", 159, 183], ["coronavirus", "OBSERVATION", 159, 170]]], ["Additionally, proteolytic priming of the S protein by host proteases is also critical for viral entry [7].", [["S protein", "PROTEIN", 41, 50], ["host proteases", "PROTEIN", 54, 68], ["host proteases", "TEST", 54, 68]]], ["The cellular serine protease Type II transmembrane (TMPRSS2) is used by SARS-CoV-2 for S protein priming [8, 7, 9, 10].", [["cellular", "ANATOMY", 4, 12], ["serine", "CHEMICAL", 13, 19], ["cellular", "CELL", 4, 12], ["Type II transmembrane", "GENE_OR_GENE_PRODUCT", 29, 50], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 52, 59], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 72, 82], ["S protein", "GENE_OR_GENE_PRODUCT", 87, 96], ["cellular serine protease Type II transmembrane", "PROTEIN", 4, 50], ["TMPRSS2", "PROTEIN", 52, 59], ["S protein", "PROTEIN", 87, 96], ["The cellular serine protease Type II transmembrane (TMPRSS2)", "TREATMENT", 0, 60], ["CoV", "TEST", 77, 80], ["S protein priming", "TEST", 87, 104]]], ["This is also used by SARS-CoV alongside the endosomal cysteine proteases cathepsin B and L [11, 12].", [["endosomal", "ANATOMY", 44, 53], ["cysteine", "CHEMICAL", 54, 62], ["SARS-CoV", "ORGANISM", 21, 29], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 73, 84], ["endosomal cysteine proteases", "PROTEIN", 44, 72], ["cathepsin B", "PROTEIN", 73, 84], ["L [11, 12", "PROTEIN", 89, 98], ["SARS-CoV", "SPECIES", 21, 29], ["the endosomal cysteine proteases cathepsin", "TREATMENT", 40, 82]]], ["Another host protease, furin, has been suggested to mediate SARS-CoV-2 pathogenesis; however, the precise role of host proteases in SARS-CoV-2 entry remains to be determined [13, 10].IntroductionSARS-CoV and MERS-CoV caused fatal pneumonia associated with rapid virus replication, elevation of proinflammatory cytokines, and immune cell infiltration [14].", [["immune cell", "ANATOMY", 325, 336], ["SARS", "DISEASE", 132, 136], ["pneumonia", "DISEASE", 230, 239], ["furin", "GENE_OR_GENE_PRODUCT", 23, 28], ["SARS-CoV-2", "ORGANISM", 60, 70], ["SARS-CoV-2", "ORGANISM", 132, 142], ["IntroductionSARS-CoV", "GENE_OR_GENE_PRODUCT", 183, 203], ["MERS-CoV", "ORGANISM", 208, 216], ["immune cell", "CELL", 325, 336], ["protease", "PROTEIN", 13, 21], ["furin", "PROTEIN", 23, 28], ["host proteases", "PROTEIN", 114, 128], ["proinflammatory cytokines", "PROTEIN", 294, 319], ["SARS-CoV", "SPECIES", 132, 140], ["MERS-CoV", "SPECIES", 208, 216], ["Another host protease", "TREATMENT", 0, 21], ["host proteases", "PROBLEM", 114, 128], ["SARS", "TEST", 132, 136], ["CoV", "TEST", 137, 140], ["IntroductionSARS", "TEST", 183, 199], ["MERS", "PROBLEM", 208, 212], ["CoV", "PROBLEM", 213, 216], ["fatal pneumonia", "PROBLEM", 224, 239], ["rapid virus replication", "PROBLEM", 256, 279], ["elevation of proinflammatory cytokines", "PROBLEM", 281, 319], ["immune cell infiltration", "PROBLEM", 325, 349], ["fatal", "OBSERVATION_MODIFIER", 224, 229], ["pneumonia", "OBSERVATION", 230, 239], ["elevation", "OBSERVATION_MODIFIER", 281, 290], ["proinflammatory cytokines", "OBSERVATION", 294, 319], ["immune cell infiltration", "OBSERVATION", 325, 349]]], ["These characteristics are similarly observed in SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 48, 68], ["SARS-CoV-2", "ORGANISM", 48, 58], ["SARS-CoV-2", "SPECIES", 48, 58], ["SARS", "PROBLEM", 48, 52], ["2 infection", "PROBLEM", 57, 68], ["SARS", "OBSERVATION", 48, 52], ["CoV", "OBSERVATION_MODIFIER", 53, 56], ["infection", "OBSERVATION", 59, 68]]], ["COVID-19 patients have increased levels of proinflammatory effector cytokines, such as TNF\u03b1, IL1B, and IL6, as well as chemokines, such as CCL2 and CXCL10, especially in those who are critically ill [15, 16, 17, 18].", [["critically ill", "DISEASE", 184, 198], ["patients", "ORGANISM", 9, 17], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 87, 91], ["IL1B", "GENE_OR_GENE_PRODUCT", 93, 97], ["IL6", "GENE_OR_GENE_PRODUCT", 103, 106], ["CCL2", "GENE_OR_GENE_PRODUCT", 139, 143], ["CXCL10", "GENE_OR_GENE_PRODUCT", 148, 154], ["proinflammatory effector cytokines", "PROTEIN", 43, 77], ["TNF\u03b1", "PROTEIN", 87, 91], ["IL1B", "PROTEIN", 93, 97], ["IL6", "PROTEIN", 103, 106], ["chemokines", "PROTEIN", 119, 129], ["CCL2", "PROTEIN", 139, 143], ["CXCL10", "PROTEIN", 148, 154], ["patients", "SPECIES", 9, 17], ["COVID", "TEST", 0, 5], ["proinflammatory effector cytokines", "PROBLEM", 43, 77], ["IL1B", "TREATMENT", 93, 97], ["IL6", "TREATMENT", 103, 106], ["CXCL10", "TREATMENT", 148, 154], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["proinflammatory effector cytokines", "OBSERVATION", 43, 77]]], ["These studies suggest that an over exuberant immune response characterized by cytokine storm rather than direct virus-induced damage may be responsible for COVID-19 pathogenesis.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 156, 164], ["cytokine", "PROTEIN", 78, 86], ["These studies", "TEST", 0, 13], ["an over exuberant immune response", "PROBLEM", 27, 60], ["cytokine storm", "PROBLEM", 78, 92], ["direct virus", "PROBLEM", 105, 117], ["induced damage", "PROBLEM", 118, 132], ["COVID", "TEST", 156, 161], ["cytokine storm", "OBSERVATION", 78, 92]]], ["The cell types and mechanisms underlying this immune response are unclear for SARS-CoV-2.IntroductionOur knowledge of SARS-CoV-2 biology and pathogenesis is limited.", [["cell", "ANATOMY", 4, 8], ["SARS", "DISEASE", 118, 122], ["cell", "CELL", 4, 8], ["SARS-CoV-2", "ORGANISM", 78, 88], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 118, 128], ["SARS-CoV", "SPECIES", 78, 86], ["SARS", "PROBLEM", 78, 82], ["CoV", "TEST", 83, 86], ["SARS", "TEST", 118, 122], ["CoV", "TEST", 123, 126], ["pathogenesis", "PROBLEM", 141, 153], ["cell types", "OBSERVATION", 4, 14]]], ["To address this gap, we performed single-cell (sc) RNA sequencing (RNA-seq) on organotypic human bronchial epithelial cells (HBECs) infected with SARS-CoV-2.", [["bronchial epithelial cells", "ANATOMY", 97, 123], ["HBECs", "ANATOMY", 125, 130], ["human", "ORGANISM", 91, 96], ["bronchial epithelial cells", "CELL", 97, 123], ["HBECs", "CELL", 125, 130], ["SARS-CoV-2", "ORGANISM", 146, 156], ["organotypic human bronchial epithelial cells", "CELL_TYPE", 79, 123], ["HBECs", "CELL_TYPE", 125, 130], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96], ["SARS-CoV", "SPECIES", 146, 154], ["RNA sequencing", "TEST", 51, 65], ["RNA", "TEST", 67, 70], ["organotypic human bronchial epithelial cells", "TREATMENT", 79, 123], ["bronchial", "ANATOMY", 97, 106], ["epithelial cells", "OBSERVATION", 107, 123]]], ["This culture system supports epithelial cell differentiation and mimics key aspects of the mucosal epithelium.", [["culture system", "ANATOMY", 5, 19], ["epithelial cell", "ANATOMY", 29, 44], ["mucosal epithelium", "ANATOMY", 91, 109], ["epithelial cell", "CELL", 29, 44], ["mucosal epithelium", "TISSUE", 91, 109], ["This culture system", "TEST", 0, 19], ["epithelial cell differentiation", "PROBLEM", 29, 60], ["epithelial cell differentiation", "OBSERVATION", 29, 60], ["mucosal epithelium", "ANATOMY", 91, 109]]], ["By utilizing scRNA-seq and electron microscopy, we revealed that ciliated cells are a major target of SARS-CoV-2 infection.", [["ciliated cells", "ANATOMY", 65, 79], ["infection", "DISEASE", 113, 122], ["ciliated cells", "CELL", 65, 79], ["SARS-CoV-2", "ORGANISM", 102, 112], ["ciliated cells", "CELL_TYPE", 65, 79], ["SARS-CoV-2", "SPECIES", 102, 112], ["electron microscopy", "TEST", 27, 46], ["ciliated cells", "PROBLEM", 65, 79], ["SARS", "PROBLEM", 102, 106], ["CoV-2 infection", "PROBLEM", 107, 122], ["ciliated cells", "OBSERVATION", 65, 79], ["SARS", "OBSERVATION", 102, 106], ["infection", "OBSERVATION", 113, 122]]], ["During the course of infection, cell tropism of SARS-CoV-2 extend to other epithelial cells including basal and club cells.", [["cell", "ANATOMY", 32, 36], ["epithelial cells", "ANATOMY", 75, 91], ["basal", "ANATOMY", 102, 107], ["club cells", "ANATOMY", 112, 122], ["infection", "DISEASE", 21, 30], ["cell", "CELL", 32, 36], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 48, 58], ["epithelial cells", "CELL", 75, 91], ["basal", "CELL", 102, 107], ["club cells", "CELL", 112, 122], ["epithelial cells", "CELL_TYPE", 75, 91], ["basal and club cells", "CELL_TYPE", 102, 122], ["SARS-CoV", "SPECIES", 48, 56], ["infection", "PROBLEM", 21, 30], ["cell tropism", "TEST", 32, 44], ["SARS", "PROBLEM", 48, 52], ["CoV", "TEST", 53, 56], ["basal and club cells", "PROBLEM", 102, 122], ["infection", "OBSERVATION", 21, 30], ["cell tropism", "OBSERVATION", 32, 44], ["epithelial cells", "ANATOMY", 75, 91], ["basal", "ANATOMY_MODIFIER", 102, 107], ["club cells", "OBSERVATION", 112, 122]]], ["Furthermore, SARS-CoV-2 infection elicited intrinsic expression of type I and type III interferons and IL6 but not IL1 transcripts.", [["infection", "DISEASE", 24, 33], ["SARS-CoV-2", "ORGANISM", 13, 23], ["type I", "GENE_OR_GENE_PRODUCT", 67, 73], ["type III interferons", "GENE_OR_GENE_PRODUCT", 78, 98], ["IL6", "GENE_OR_GENE_PRODUCT", 103, 106], ["IL1", "GENE_OR_GENE_PRODUCT", 115, 118], ["type I and type III interferons", "PROTEIN", 67, 98], ["IL6", "PROTEIN", 103, 106], ["IL1 transcripts", "RNA", 115, 130], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "PROBLEM", 13, 17], ["CoV-2 infection", "PROBLEM", 18, 33], ["type I and type III interferons and IL6", "PROBLEM", 67, 106], ["IL1 transcripts", "PROBLEM", 115, 130], ["type I", "OBSERVATION_MODIFIER", 67, 73], ["type III", "OBSERVATION_MODIFIER", 78, 86]]], ["Interferon stimulated gene (ISG) expression was observed in both infected and bystander cell populations.", [["cell", "ANATOMY", 88, 92], ["Interferon stimulated gene", "GENE_OR_GENE_PRODUCT", 0, 26], ["ISG", "GENE_OR_GENE_PRODUCT", 28, 31], ["bystander cell populations", "CELL", 78, 104], ["Interferon stimulated gene", "DNA", 0, 26], ["ISG", "DNA", 28, 31], ["Interferon stimulated gene (ISG) expression", "TREATMENT", 0, 43], ["infected", "OBSERVATION", 65, 73], ["bystander cell populations", "OBSERVATION", 78, 104]]], ["Here, we provide a detailed analysis of SARS-CoV-2 infection in HBECs, characterizing SARS-CoV-2 transcription, cell tropism, host gene expression and cell state related to infection.Viral infection dynamics ::: ResultsTo characterize SARS-CoV-2 interactions with the human airway, we performed single-cell RNA sequencing of SARS-CoV-2 infected airway epithelium.", [["HBECs", "ANATOMY", 64, 69], ["cell", "ANATOMY", 112, 116], ["cell", "ANATOMY", 151, 155], ["airway", "ANATOMY", 274, 280], ["airway epithelium", "ANATOMY", 345, 362], ["infection", "DISEASE", 51, 60], ["infection", "DISEASE", 173, 182], ["Viral infection", "DISEASE", 183, 198], ["SARS-CoV-2", "ORGANISM", 40, 50], ["HBECs", "CANCER", 64, 69], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 86, 96], ["cell", "CELL", 112, 116], ["cell", "CELL", 151, 155], ["CoV-2", "GENE_OR_GENE_PRODUCT", 240, 245], ["human", "ORGANISM", 268, 273], ["airway", "MULTI-TISSUE_STRUCTURE", 274, 280], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 325, 335], ["airway epithelium", "TISSUE", 345, 362], ["HBECs", "CELL_TYPE", 64, 69], ["human", "SPECIES", 268, 273], ["SARS-CoV-2", "SPECIES", 40, 50], ["SARS-CoV", "SPECIES", 86, 94], ["human", "SPECIES", 268, 273], ["SARS-CoV-2", "SPECIES", 325, 335], ["a detailed analysis", "TEST", 17, 36], ["SARS", "PROBLEM", 40, 44], ["CoV", "PROBLEM", 45, 48], ["2 infection in HBECs", "PROBLEM", 49, 69], ["SARS", "TEST", 86, 90], ["CoV-2 transcription", "TREATMENT", 91, 110], ["cell tropism", "TREATMENT", 112, 124], ["host gene expression", "TREATMENT", 126, 146], ["cell state", "PROBLEM", 151, 161], ["infection", "PROBLEM", 173, 182], ["Viral infection dynamics", "PROBLEM", 183, 207], ["SARS", "PROBLEM", 235, 239], ["SARS", "PROBLEM", 325, 329], ["CoV", "TEST", 330, 333], ["infected airway epithelium", "PROBLEM", 336, 362], ["cell tropism", "OBSERVATION", 112, 124], ["infection", "OBSERVATION", 173, 182], ["infection", "OBSERVATION", 189, 198], ["airway", "ANATOMY", 274, 280], ["airway", "ANATOMY", 345, 351], ["epithelium", "ANATOMY_MODIFIER", 352, 362]]], ["We cultured primary HBECs at an air-liquid interface (ALI) for 28 days and then challenged the apical surface of the epithelium with 104 plaque forming units (PFU) of SARS-CoV-2 (Fig 1A).", [["HBECs", "ANATOMY", 20, 25], ["apical surface", "ANATOMY", 95, 109], ["epithelium", "ANATOMY", 117, 127], ["plaque", "ANATOMY", 137, 143], ["HBECs", "CELL", 20, 25], ["apical surface", "CELLULAR_COMPONENT", 95, 109], ["epithelium", "TISSUE", 117, 127], ["cultured primary HBECs", "CELL_LINE", 3, 25], ["SARS-CoV", "SPECIES", 167, 175], ["an air-liquid interface", "TREATMENT", 29, 52], ["SARS", "TEST", 167, 171], ["CoV", "TEST", 172, 175], ["apical", "ANATOMY_MODIFIER", 95, 101], ["surface", "ANATOMY_MODIFIER", 102, 109], ["epithelium", "ANATOMY", 117, 127], ["104 plaque", "OBSERVATION_MODIFIER", 133, 143]]], ["Exponential viral replication over the course of the experiment was demonstrated by qRT-PCR of cell lysate for the SARS-CoV-2 nucleocapsid (N) gene (Fig 1B).", [["cell lysate", "ANATOMY", 95, 106], ["cell", "CELL", 95, 99], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 115, 125], ["SARS-CoV-2 nucleocapsid (N) gene", "DNA", 115, 147], ["SARS-CoV", "SPECIES", 115, 123], ["Exponential viral replication", "TREATMENT", 0, 29], ["qRT", "TEST", 84, 87], ["cell lysate", "TEST", 95, 106], ["the SARS", "TEST", 111, 119], ["CoV", "TEST", 120, 123], ["viral replication", "OBSERVATION", 12, 29]]], ["At 1, 2, and 3 days post-infection (dpi), a single cell suspension was generated and 3\u2019 single-cell RNA sequencing was performed on 77,143 cells across four samples cells per sample with an average of 31,383 reads per cell (Fig 1C, S1A).", [["cell", "ANATOMY", 51, 55], ["cells", "ANATOMY", 139, 144], ["samples cells", "ANATOMY", 157, 170], ["sample", "ANATOMY", 175, 181], ["cell", "ANATOMY", 218, 222], ["infection", "DISEASE", 25, 34], ["cell", "CELL", 51, 55], ["cells", "CELL", 139, 144], ["cells", "CELL", 165, 170], ["cell", "CELL", 218, 222], ["S1A", "GENE_OR_GENE_PRODUCT", 232, 235], ["77,143 cells", "CELL_LINE", 132, 144], ["infection", "PROBLEM", 25, 34], ["a single cell suspension", "TEST", 42, 66], ["single-cell RNA sequencing", "TEST", 88, 114], ["infection", "OBSERVATION", 25, 34]]], ["To define SARS-CoV-2 infected cells, we mapped reads to the viral reference genome and quantified viral transcript abundance on a per cell basis (Fig 1D).", [["cells", "ANATOMY", 30, 35], ["cell", "ANATOMY", 134, 138], ["SARS-CoV-2", "CELL", 10, 20], ["cells", "CELL", 30, 35], ["cell", "CELL", 134, 138], ["SARS-CoV-2 infected cells", "CELL_LINE", 10, 35], ["viral reference genome", "DNA", 60, 82], ["SARS-CoV", "SPECIES", 10, 18], ["SARS", "PROBLEM", 10, 14], ["2 infected cells", "PROBLEM", 19, 35], ["infected cells", "OBSERVATION", 21, 35], ["viral transcript", "OBSERVATION", 98, 114]]], ["We defined productively infected cells as those with at least ten viral transcripts per cell, which controls for background due to misaligned reads in the mock sample.", [["cells", "ANATOMY", 33, 38], ["cell", "ANATOMY", 88, 92], ["sample", "ANATOMY", 160, 166], ["cells", "CELL", 33, 38], ["cell", "CELL", 88, 92], ["productively infected cells", "CELL_TYPE", 11, 38], ["viral transcripts", "RNA", 66, 83], ["productively infected cells", "PROBLEM", 11, 38], ["productively", "OBSERVATION_MODIFIER", 11, 23], ["infected cells", "OBSERVATION", 24, 38], ["viral transcripts", "OBSERVATION", 66, 83]]], ["Consistent with the viral genome replication (Fig 1B), we observed a time-dependent increase in the abundance of infected cells from 1 to 3 dpi (Fig 1E, S1B).Viral infection dynamics ::: ResultsWe first characterized the SARS-CoV-2 transcriptome at the single-cell level.", [["cells", "ANATOMY", 122, 127], ["single-cell", "ANATOMY", 253, 264], ["Viral infection", "DISEASE", 158, 173], ["cells", "CELL", 122, 127], ["single-cell", "CELL", 253, 264], ["viral genome", "DNA", 20, 32], ["infected cells", "CELL_TYPE", 113, 127], ["SARS-CoV-2 transcriptome", "DNA", 221, 245], ["SARS-CoV", "SPECIES", 221, 229], ["the viral genome replication", "TREATMENT", 16, 44], ["infected cells", "PROBLEM", 113, 127], ["Viral infection dynamics", "PROBLEM", 158, 182], ["the SARS", "TEST", 217, 225], ["CoV", "TEST", 226, 229], ["viral genome", "OBSERVATION", 20, 32], ["increase", "OBSERVATION_MODIFIER", 84, 92], ["infected cells", "OBSERVATION", 113, 127], ["infection", "OBSERVATION", 164, 173], ["SARS", "OBSERVATION", 221, 225]]], ["In addition to the reads expected to align immediately upstream of the canonical SARS-CoV-2 poly-A tail, our results show additional reads aligning elsewhere in the genome suggesting the existence of non-canonical, poly-adenylated sub-genomic RNAs (sgRNAs) (Fig 1F, G).", [["SARS-CoV-2 poly-A tail", "DNA", 81, 103], ["non-canonical, poly-adenylated sub-genomic RNAs", "DNA", 200, 247], ["sgRNAs", "DNA", 249, 255], ["the canonical SARS", "TEST", 67, 85], ["non-canonical, poly-adenylated sub-genomic RNAs", "PROBLEM", 200, 247], ["tail", "ANATOMY", 99, 103]]], ["The distribution of polyadenylated viral transcripts shifts from 3\u2019 to 5\u2019 during the infection time-course (Fig 1F,G,S1C).", [["infection", "DISEASE", 85, 94], ["polyadenylated viral transcripts", "RNA", 20, 52], ["polyadenylated viral transcripts", "PROBLEM", 20, 52], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["polyadenylated viral transcripts", "OBSERVATION", 20, 52]]], ["Mapping of productive infected cells reveals multiple infected cell clusters that expand over time and are not present in the mock sample (Fig 1H).", [["cells", "ANATOMY", 31, 36], ["cell", "ANATOMY", 63, 67], ["sample", "ANATOMY", 131, 137], ["cells", "CELL", 31, 36], ["cell", "CELL", 63, 67], ["productive infected cells", "CELL_TYPE", 11, 36], ["productive infected cells", "PROBLEM", 11, 36], ["multiple infected cell clusters", "PROBLEM", 45, 76], ["productive", "OBSERVATION_MODIFIER", 11, 21], ["infected cells", "OBSERVATION", 22, 36], ["multiple", "OBSERVATION_MODIFIER", 45, 53], ["infected cell clusters", "OBSERVATION", 54, 76]]], ["Using RTPCR, we successfully validate two unique peaks, one that mapped in the middle of the Open Reading Frame (ORF)1ab region, and a second peak that mapped near the ORF6 boundary (Fig S1D, top panel).", [["RTPCR", "DNA", 6, 11], ["Open Reading Frame (ORF)1ab region", "DNA", 93, 127], ["ORF6 boundary", "DNA", 168, 181], ["RTPCR", "TEST", 6, 11], ["a second peak", "PROBLEM", 133, 146], ["top panel", "TEST", 192, 201], ["peaks", "OBSERVATION_MODIFIER", 49, 54], ["middle", "ANATOMY_MODIFIER", 79, 85]]], ["Our results confirm that RT-PCR products corresponding to each of the two peaks appears after 2 dpi (Fig S1D, bottom panel, red arrows).", [["RT-PCR products", "TREATMENT", 25, 40], ["bottom panel", "TEST", 110, 122]]], ["Importantly, the absence of these RT-PCR bands in the mock and 1 dpi samples suggests they are not the result of non-specific oligo-d(T) priming of cellular or viral RNAs.", [["dpi samples", "ANATOMY", 65, 76], ["cellular", "ANATOMY", 148, 156], ["cellular", "CELL", 148, 156], ["RT-PCR bands", "DNA", 34, 46], ["cellular or viral RNAs", "RNA", 148, 170], ["these RT-PCR bands", "TEST", 28, 46], ["1 dpi samples", "TEST", 63, 76], ["non-specific oligo-d(T) priming of cellular or viral RNAs", "PROBLEM", 113, 170], ["viral RNAs", "OBSERVATION", 160, 170]]], ["We included two positive controls, amplifying RT-PCR products of increasing length from the canonical SARS-CoV-2 poly-A tail (Fig S1D, bottom panel, green arrows).", [["SARS-CoV-2 poly-A tail", "DNA", 102, 124], ["two positive controls", "TREATMENT", 12, 33], ["RT-PCR products", "TREATMENT", 46, 61], ["increasing length", "PROBLEM", 65, 82], ["the canonical SARS", "TEST", 88, 106], ["CoV", "TEST", 107, 110], ["bottom panel", "TEST", 135, 147], ["increasing", "OBSERVATION_MODIFIER", 65, 75], ["length", "OBSERVATION_MODIFIER", 76, 82], ["tail", "ANATOMY", 120, 124]]], ["These RT-PCR bands appear as early as 1 dpi, are specific to infected cells and run at their expected lengths.", [["cells", "ANATOMY", 70, 75], ["cells", "CELL", 70, 75], ["RT-PCR bands", "DNA", 6, 18], ["infected cells", "CELL_TYPE", 61, 75], ["These RT-PCR bands", "TEST", 0, 18], ["infected cells", "PROBLEM", 61, 75], ["infected cells", "OBSERVATION", 61, 75], ["lengths", "OBSERVATION_MODIFIER", 102, 109]]], ["These positive controls validate that we are able to capture known poly-adenylated viral transcripts with this RT-PCR priming strategy.Identification of the cell tropism of SARS-CoV-2 ::: ResultsThe human airway is comprised of diverse epithelial cell types with critical functions in gas exchange, structure, and immunity.", [["cell", "ANATOMY", 157, 161], ["airway", "ANATOMY", 205, 211], ["epithelial cell", "ANATOMY", 236, 251], ["SARS", "DISEASE", 173, 177], ["cell", "CELL", 157, 161], ["SARS-CoV", "ORGANISM", 173, 181], ["human", "ORGANISM", 199, 204], ["airway", "MULTI-TISSUE_STRUCTURE", 205, 211], ["epithelial cell", "CELL", 236, 251], ["poly-adenylated viral transcripts", "RNA", 67, 100], ["epithelial cell types", "CELL_TYPE", 236, 257], ["human", "SPECIES", 199, 204], ["human", "SPECIES", 199, 204], ["adenylated viral transcripts", "TREATMENT", 72, 100], ["this RT-PCR priming strategy", "TREATMENT", 106, 134], ["diverse epithelial cell types", "PROBLEM", 228, 257], ["cell tropism", "OBSERVATION", 157, 169], ["airway", "ANATOMY", 205, 211], ["diverse epithelial cell types", "OBSERVATION", 228, 257], ["gas exchange", "OBSERVATION", 285, 297]]], ["We sought to determine the cellular tropism of SARS-CoV-2 in the bronchial epithelium, as the airway is a critical target of viral pathogenesis.", [["cellular", "ANATOMY", 27, 35], ["bronchial epithelium", "ANATOMY", 65, 85], ["airway", "ANATOMY", 94, 100], ["SARS", "DISEASE", 47, 51], ["cellular", "CELL", 27, 35], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 57], ["bronchial epithelium", "TISSUE", 65, 85], ["airway", "MULTI-TISSUE_STRUCTURE", 94, 100], ["SARS-CoV", "SPECIES", 47, 55], ["SARS", "PROBLEM", 47, 51], ["CoV", "TEST", 52, 55], ["viral pathogenesis", "PROBLEM", 125, 143], ["SARS", "OBSERVATION", 47, 51], ["bronchial", "ANATOMY", 65, 74], ["epithelium", "ANATOMY_MODIFIER", 75, 85], ["airway", "ANATOMY", 94, 100], ["viral pathogenesis", "OBSERVATION", 125, 143]]], ["Clustering a BB-kNN graph by Louvain community detection resulted in identification of eight major clusters comprising canonical epithelial cell types: ciliated cells, basal cells, club cells, goblet cells, neuroendocrine cells, ionocytes, and tuft cells (Fig 2A, S2A).", [["epithelial cell", "ANATOMY", 129, 144], ["ciliated cells", "ANATOMY", 152, 166], ["basal cells", "ANATOMY", 168, 179], ["club cells", "ANATOMY", 181, 191], ["goblet cells", "ANATOMY", 193, 205], ["neuroendocrine cells", "ANATOMY", 207, 227], ["ionocytes", "ANATOMY", 229, 238], ["tuft cells", "ANATOMY", 244, 254], ["epithelial cell", "CELL", 129, 144], ["ciliated cells", "CELL", 152, 166], ["basal cells", "CELL", 168, 179], ["club cells", "CELL", 181, 191], ["goblet cells", "CELL", 193, 205], ["neuroendocrine cells", "CELL", 207, 227], ["ionocytes", "CELL", 229, 238], ["tuft cells", "CELL", 244, 254], ["Fig 2A", "CELL", 256, 262], ["S2A", "GENE_OR_GENE_PRODUCT", 264, 267], ["BB-kNN graph", "DNA", 13, 25], ["canonical epithelial cell types", "CELL_TYPE", 119, 150], ["ciliated cells", "CELL_TYPE", 152, 166], ["basal cells", "CELL_TYPE", 168, 179], ["club cells", "CELL_TYPE", 181, 191], ["goblet cells", "CELL_TYPE", 193, 205], ["neuroendocrine cells", "CELL_TYPE", 207, 227], ["ionocytes", "CELL_TYPE", 229, 238], ["tuft cells", "CELL_TYPE", 244, 254], ["S2A", "PROTEIN", 264, 267], ["a BB", "TEST", 11, 15], ["ciliated cells", "PROBLEM", 152, 166], ["basal cells", "PROBLEM", 168, 179], ["club cells", "TEST", 181, 191], ["goblet cells", "TEST", 193, 205], ["neuroendocrine cells", "TEST", 207, 227], ["ionocytes", "TEST", 229, 238], ["tuft cells", "PROBLEM", 244, 254], ["canonical epithelial cell types", "OBSERVATION", 119, 150], ["ciliated cells", "OBSERVATION", 152, 166], ["basal cells", "OBSERVATION", 168, 179], ["club cells", "OBSERVATION", 181, 191], ["goblet cells", "OBSERVATION", 193, 205], ["neuroendocrine cells", "OBSERVATION", 207, 227], ["tuft cells", "OBSERVATION", 244, 254]]], ["We also observed a cell population intermediate between basal cells and club cells (BC/Club) likely representing basal stem cells differentiating into club cells.", [["cell", "ANATOMY", 19, 23], ["basal cells", "ANATOMY", 56, 67], ["club cells", "ANATOMY", 72, 82], ["BC/Club", "ANATOMY", 84, 91], ["basal stem cells", "ANATOMY", 113, 129], ["club cells", "ANATOMY", 151, 161], ["cell", "CELL", 19, 23], ["basal cells", "CELL", 56, 67], ["club cells", "CELL", 72, 82], ["BC/Club", "CELL", 84, 91], ["basal stem cells", "CELL", 113, 129], ["club cells", "CELL", 151, 161], ["basal cells", "CELL_TYPE", 56, 67], ["club cells", "CELL_TYPE", 72, 82], ["Club", "PROTEIN", 87, 91], ["basal stem cells", "CELL_TYPE", 113, 129], ["club cells", "CELL_TYPE", 151, 161], ["a cell population", "PROBLEM", 17, 34], ["BC", "TEST", 84, 86], ["basal stem cells", "PROBLEM", 113, 129], ["cell population", "OBSERVATION", 19, 34], ["basal cells", "OBSERVATION", 56, 67], ["club cells", "OBSERVATION", 72, 82], ["likely representing", "UNCERTAINTY", 93, 112], ["basal stem cells", "OBSERVATION", 113, 129], ["club cells", "OBSERVATION", 151, 161]]], ["Analysis of differentially expressed genes reveal these cell clusters express classical epithelial cell type-specific markers (Fig 2B).", [["cell", "ANATOMY", 56, 60], ["epithelial cell", "ANATOMY", 88, 103], ["cell", "CELL", 56, 60], ["epithelial cell", "CELL", 88, 103], ["classical epithelial cell type-specific markers", "PROTEIN", 78, 125], ["these cell clusters", "PROBLEM", 50, 69], ["classical epithelial cell type-specific markers", "PROBLEM", 78, 125], ["cell clusters", "OBSERVATION", 56, 69], ["epithelial cell", "OBSERVATION", 88, 103]]], ["Mapping viral infected cells within specified epithelial cell types reveals that ciliated, basal, club, and BC/Club cells are susceptible to SARS-CoV-2 infection whereas goblet, neuroendocrine, tuft cells, and ionocytes are relatively resistant to infection (Fig 2C,D).", [["cells", "ANATOMY", 23, 28], ["epithelial cell", "ANATOMY", 46, 61], ["ciliated", "ANATOMY", 81, 89], ["BC/Club cells", "ANATOMY", 108, 121], ["goblet", "ANATOMY", 170, 176], ["neuroendocrine", "ANATOMY", 178, 192], ["tuft cells", "ANATOMY", 194, 204], ["ionocytes", "ANATOMY", 210, 219], ["infection", "DISEASE", 152, 161], ["infection", "DISEASE", 248, 257], ["cells", "CELL", 23, 28], ["epithelial cell", "CELL", 46, 61], ["BC/Club cells", "CELL", 108, 121], ["SARS-CoV-2", "ORGANISM", 141, 151], ["goblet", "CELL", 170, 176], ["neuroendocrine", "CELL", 178, 192], ["tuft cells", "CELL", 194, 204], ["ionocytes", "CELL", 210, 219], ["viral infected cells", "CELL_TYPE", 8, 28], ["epithelial cell types", "CELL_TYPE", 46, 67], ["ciliated, basal, club, and BC/Club cells", "CELL_TYPE", 81, 121], ["goblet, neuroendocrine, tuft cells", "CELL_TYPE", 170, 204], ["ionocytes", "CELL_TYPE", 210, 219], ["SARS-CoV", "SPECIES", 141, 149], ["Mapping viral infected cells", "PROBLEM", 0, 28], ["specified epithelial cell types", "TEST", 36, 67], ["BC/Club cells", "PROBLEM", 108, 121], ["SARS", "TEST", 141, 145], ["CoV", "TEST", 146, 149], ["2 infection", "PROBLEM", 150, 161], ["tuft cells", "PROBLEM", 194, 204], ["ionocytes", "PROBLEM", 210, 219], ["infection", "PROBLEM", 248, 257], ["infected cells", "OBSERVATION", 14, 28], ["epithelial cell types", "OBSERVATION", 46, 67], ["ciliated", "OBSERVATION_MODIFIER", 81, 89], ["basal", "ANATOMY_MODIFIER", 91, 96], ["BC", "ANATOMY", 108, 110], ["Club cells", "OBSERVATION", 111, 121], ["tuft cells", "OBSERVATION", 194, 204], ["infection", "OBSERVATION", 248, 257]]], ["At 1 dpi, ciliated cells represent 83% of infected cells and continue to comprise the majority of infected cells throughout infection (Fig 2E,F).", [["ciliated cells", "ANATOMY", 10, 24], ["cells", "ANATOMY", 51, 56], ["cells", "ANATOMY", 107, 112], ["infection", "DISEASE", 124, 133], ["ciliated cells", "CELL", 10, 24], ["cells", "CELL", 51, 56], ["cells", "CELL", 107, 112], ["ciliated cells", "CELL_TYPE", 10, 24], ["infected cells", "CELL_TYPE", 42, 56], ["infected cells", "CELL_TYPE", 98, 112], ["ciliated cells", "TEST", 10, 24], ["infected cells", "PROBLEM", 42, 56], ["infected cells throughout infection", "PROBLEM", 98, 133], ["infected cells", "OBSERVATION", 42, 56], ["infected cells", "OBSERVATION", 98, 112]]], ["However, during productive infection, the number of infected basal, club, and BC/Club cells also increases, suggesting that these cells are major secondary targets (Fig 2E,F).", [["BC/Club cells", "ANATOMY", 78, 91], ["cells", "ANATOMY", 130, 135], ["infection", "DISEASE", 27, 36], ["BC/Club cells", "CELL", 78, 91], ["cells", "CELL", 130, 135], ["Club cells", "CELL_TYPE", 81, 91], ["productive infection", "PROBLEM", 16, 36], ["infected basal, club, and BC/Club cells", "PROBLEM", 52, 91], ["these cells", "PROBLEM", 124, 135], ["productive", "OBSERVATION_MODIFIER", 16, 26], ["infection", "OBSERVATION", 27, 36], ["infected", "OBSERVATION_MODIFIER", 52, 60], ["basal", "OBSERVATION_MODIFIER", 61, 66], ["club", "OBSERVATION_MODIFIER", 68, 72], ["BC", "ANATOMY", 78, 80], ["Club cells", "OBSERVATION", 81, 91]]], ["The distribution of polyadenylated viral transcripts along the length of the genome is similar across infected cell types (Fig S2C).Identification of the cell tropism of SARS-CoV-2 ::: ResultsTo independently verify SARS-CoV-2 cell tropism, HBECs cultured under identical conditions as for scRNA-seq were assessed by transmission electron microscopy.", [["cell", "ANATOMY", 111, 115], ["cell", "ANATOMY", 154, 158], ["cell", "ANATOMY", 227, 231], ["HBECs", "ANATOMY", 241, 246], ["cell", "CELL", 111, 115], ["cell", "CELL", 154, 158], ["SARS-CoV", "ORGANISM", 170, 178], ["SARS-CoV-2 cell", "CELL", 216, 231], ["HBECs", "CELL", 241, 246], ["scRNA-seq", "GENE_OR_GENE_PRODUCT", 290, 299], ["polyadenylated viral transcripts", "RNA", 20, 52], ["infected cell types", "CELL_TYPE", 102, 121], ["HBECs", "CELL_TYPE", 241, 246], ["scRNA-seq", "DNA", 290, 299], ["SARS-CoV", "SPECIES", 170, 178], ["SARS-CoV", "SPECIES", 216, 224], ["polyadenylated viral transcripts", "PROBLEM", 20, 52], ["CoV", "TEST", 175, 178], ["SARS", "TEST", 216, 220], ["CoV", "TEST", 221, 224], ["2 cell tropism", "PROBLEM", 225, 239], ["HBECs cultured", "TEST", 241, 255], ["scRNA", "TEST", 290, 295], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["polyadenylated viral transcripts", "OBSERVATION", 20, 52], ["length", "OBSERVATION_MODIFIER", 63, 69], ["genome", "ANATOMY", 77, 83], ["similar", "OBSERVATION_MODIFIER", 87, 94], ["across", "OBSERVATION_MODIFIER", 95, 101], ["infected cell types", "OBSERVATION", 102, 121], ["cell tropism", "OBSERVATION", 154, 166]]], ["At 2 dpi, we observed numerous virus particles approximately 80 nm in size in ciliated cells (Fig 2G).", [["ciliated cells", "ANATOMY", 78, 92], ["ciliated cells", "CELL", 78, 92], ["Fig 2G", "CELL", 94, 100], ["ciliated cells", "CELL_TYPE", 78, 92], ["numerous virus particles", "PROBLEM", 22, 46], ["numerous", "OBSERVATION_MODIFIER", 22, 30], ["virus", "OBSERVATION", 31, 36], ["80 nm", "OBSERVATION_MODIFIER", 61, 66], ["size", "OBSERVATION_MODIFIER", 70, 74], ["ciliated cells", "OBSERVATION", 78, 92]]], ["This is consistent with the known size distribution of coronaviruses [19].", [["coronaviruses", "PROBLEM", 55, 68], ["consistent with", "UNCERTAINTY", 8, 23], ["size", "OBSERVATION_MODIFIER", 34, 38], ["distribution", "OBSERVATION_MODIFIER", 39, 51], ["coronaviruses", "OBSERVATION", 55, 68]]], ["Together, this confirms that ciliated cells are a major target of SARS-CoV-2 infection in the human bronchus.Determinants of cell tropism ::: ResultsNext, we sought to determine the host transcriptional correlates of SARS-CoV-2 cell tropism.", [["ciliated cells", "ANATOMY", 29, 43], ["bronchus", "ANATOMY", 100, 108], ["cell", "ANATOMY", 125, 129], ["cell", "ANATOMY", 228, 232], ["infection", "DISEASE", 77, 86], ["ciliated cells", "CELL", 29, 43], ["SARS-CoV-2", "ORGANISM", 66, 76], ["human", "ORGANISM", 94, 99], ["bronchus", "ORGAN", 100, 108], ["cell", "CELL", 125, 129], ["CoV-2 cell", "CELL", 222, 232], ["ciliated cells", "CELL_TYPE", 29, 43], ["human", "SPECIES", 94, 99], ["SARS-CoV-2", "SPECIES", 66, 76], ["human", "SPECIES", 94, 99], ["SARS-CoV", "SPECIES", 217, 225], ["ciliated cells", "PROBLEM", 29, 43], ["SARS", "PROBLEM", 66, 70], ["CoV-2 infection in the human bronchus", "PROBLEM", 71, 108], ["SARS", "PROBLEM", 217, 221], ["CoV", "TEST", 222, 225], ["2 cell tropism", "PROBLEM", 226, 240], ["ciliated cells", "OBSERVATION", 29, 43], ["major", "OBSERVATION_MODIFIER", 50, 55], ["target", "OBSERVATION_MODIFIER", 56, 62], ["SARS", "OBSERVATION", 66, 70], ["CoV", "OBSERVATION_MODIFIER", 71, 74], ["infection", "OBSERVATION", 77, 86], ["human bronchus", "ANATOMY", 94, 108], ["cell tropism", "OBSERVATION", 125, 137], ["cell tropism", "OBSERVATION", 228, 240]]], ["As viral entry is the major determinant of cell tropism, we first investigated whether expression of the SARS-CoV-2 receptor ACE2 predicted infection.", [["cell", "ANATOMY", 43, 47], ["infection", "DISEASE", 140, 149], ["cell", "CELL", 43, 47], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 105, 115], ["ACE2", "GENE_OR_GENE_PRODUCT", 125, 129], ["SARS-CoV-2 receptor", "PROTEIN", 105, 124], ["ACE2", "PROTEIN", 125, 129], ["cell tropism", "PROBLEM", 43, 55], ["the SARS", "PROBLEM", 101, 109], ["CoV", "TEST", 110, 113], ["receptor ACE2 predicted infection", "PROBLEM", 116, 149], ["cell tropism", "OBSERVATION", 43, 55], ["infection", "OBSERVATION", 140, 149]]], ["We observed ACE2 expression at low levels across ciliated, basal, club and BC/club cells in the mock condition (Fig 3).", [["ciliated", "ANATOMY", 49, 57], ["BC/club cells", "ANATOMY", 75, 88], ["ACE2", "GENE_OR_GENE_PRODUCT", 12, 16], ["BC/club cells", "CELL", 75, 88], ["ACE2", "PROTEIN", 12, 16], ["ciliated, basal, club and BC/club cells", "CELL_TYPE", 49, 88], ["ACE2 expression", "TEST", 12, 27], ["ACE2 expression", "OBSERVATION", 12, 27], ["basal", "ANATOMY_MODIFIER", 59, 64], ["club cells", "OBSERVATION", 78, 88]]], ["Surprisingly, ACE2 expression was poorly correlated with SARS-CoV-2 infection on a per cell basis (Spearman\u2019s r between viral genome and ACE2 in ciliated cells, \u22120.06, and between ACE2 and infection score in ciliated cells, 0.09).", [["cell", "ANATOMY", 87, 91], ["ciliated cells", "ANATOMY", 145, 159], ["ciliated cells", "ANATOMY", 208, 222], ["infection", "DISEASE", 68, 77], ["infection", "DISEASE", 189, 198], ["ACE2", "GENE_OR_GENE_PRODUCT", 14, 18], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 57, 67], ["cell", "CELL", 87, 91], ["ACE2", "GENE_OR_GENE_PRODUCT", 137, 141], ["ciliated cells", "CELL", 145, 159], ["ACE2", "GENE_OR_GENE_PRODUCT", 180, 184], ["ciliated cells", "CELL", 208, 222], ["ACE2", "PROTEIN", 14, 18], ["viral genome", "DNA", 120, 132], ["ACE2", "PROTEIN", 137, 141], ["ciliated cells", "CELL_TYPE", 145, 159], ["ACE2", "PROTEIN", 180, 184], ["ciliated cells", "CELL_TYPE", 208, 222], ["SARS-CoV", "SPECIES", 57, 65], ["SARS", "PROBLEM", 57, 61], ["CoV-2 infection", "PROBLEM", 62, 77], ["a per cell basis", "TEST", 81, 97], ["Spearman\u2019s", "TEST", 99, 109], ["viral genome", "TEST", 120, 132], ["ACE2 in ciliated cells", "TEST", 137, 159], ["ACE2", "TEST", 180, 184], ["infection score in ciliated cells", "PROBLEM", 189, 222], ["infection", "OBSERVATION", 68, 77], ["viral genome", "OBSERVATION", 120, 132], ["ciliated cells", "ANATOMY", 145, 159], ["infection", "OBSERVATION", 189, 198]]], ["However, ACE2 expression was increased in the four susceptible cell populations: ciliated, basal, club, and BC/club relative to the non-susceptible cell types: neuroendocrine, ionocytes, goblet, and tuft cells (Fig S3).", [["cell", "ANATOMY", 63, 67], ["ciliated", "ANATOMY", 81, 89], ["cell", "ANATOMY", 148, 152], ["neuroendocrine", "ANATOMY", 160, 174], ["ionocytes", "ANATOMY", 176, 185], ["goblet", "ANATOMY", 187, 193], ["tuft cells", "ANATOMY", 199, 209], ["ACE2", "GENE_OR_GENE_PRODUCT", 9, 13], ["cell populations", "CELL", 63, 79], ["cell", "CELL", 148, 152], ["neuroendocrine", "CELL", 160, 174], ["ionocytes", "CELL", 176, 185], ["goblet", "CELL", 187, 193], ["tuft cells", "CELL", 199, 209], ["Fig S3", "CELL", 211, 217], ["ACE2", "PROTEIN", 9, 13], ["non-susceptible cell types", "CELL_TYPE", 132, 158], ["neuroendocrine, ionocytes, goblet, and tuft cells", "CELL_TYPE", 160, 209], ["ACE2 expression", "TEST", 9, 24], ["BC", "TEST", 108, 110], ["neuroendocrine, ionocytes", "TEST", 160, 185], ["goblet", "TEST", 187, 193], ["increased", "OBSERVATION_MODIFIER", 29, 38], ["susceptible cell populations", "OBSERVATION", 51, 79], ["basal", "ANATOMY_MODIFIER", 91, 96], ["BC", "ANATOMY", 108, 110], ["non-susceptible cell types", "OBSERVATION", 132, 158], ["neuroendocrine", "ANATOMY", 160, 174], ["tuft cells", "OBSERVATION", 199, 209]]], ["Notably, expression of ACE and CLTRN which are structural homologs of ACE2 and the aminopeptideases ANPEP and DPP4 (the MERS receptor) were also poorly correlated with SARS-CoV-2 susceptibility (Fig 3B\u2013E).Determinants of cell tropism ::: ResultsACE2 was recently demonstrated to be an ISG [20].", [["cell", "ANATOMY", 221, 225], ["ACE", "GENE_OR_GENE_PRODUCT", 23, 26], ["CLTRN", "GENE_OR_GENE_PRODUCT", 31, 36], ["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["aminopeptideases ANPEP", "GENE_OR_GENE_PRODUCT", 83, 105], ["DPP4", "GENE_OR_GENE_PRODUCT", 110, 114], ["MERS receptor", "GENE_OR_GENE_PRODUCT", 120, 133], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 168, 178], ["cell", "CELL", 221, 225], ["ResultsACE2", "GENE_OR_GENE_PRODUCT", 238, 249], ["ACE", "PROTEIN", 23, 26], ["CLTRN", "PROTEIN", 31, 36], ["ACE2", "PROTEIN", 70, 74], ["aminopeptideases", "PROTEIN", 83, 99], ["ANPEP", "PROTEIN", 100, 105], ["DPP4", "PROTEIN", 110, 114], ["MERS receptor", "PROTEIN", 120, 133], ["ResultsACE2", "PROTEIN", 238, 249], ["SARS-CoV", "SPECIES", 168, 176], ["ACE", "TREATMENT", 23, 26], ["CLTRN", "TREATMENT", 31, 36], ["ACE2", "TEST", 70, 74], ["the aminopeptideases ANPEP", "TREATMENT", 79, 105], ["DPP4 (the MERS receptor", "TREATMENT", 110, 133], ["SARS", "TEST", 168, 172], ["CoV", "TEST", 173, 176], ["an ISG", "TEST", 282, 288], ["cell tropism", "OBSERVATION", 221, 233]]], ["Here we observe a modest increase in ACE2 expression in both infected and bystander cells relative to the mock sample consistent with dynamic regulation of ACE2 expression by the host innate immune response to SARS-CoV-2 (Fig 3B\u2013E).", [["bystander cells", "ANATOMY", 74, 89], ["sample", "ANATOMY", 111, 117], ["ACE2", "GENE_OR_GENE_PRODUCT", 37, 41], ["bystander cells", "CELL", 74, 89], ["ACE2", "GENE_OR_GENE_PRODUCT", 156, 160], ["SARS-CoV-2", "ORGANISM", 210, 220], ["Fig 3B\u2013E", "ORGANISM", 222, 230], ["ACE2", "PROTEIN", 37, 41], ["bystander cells", "CELL_TYPE", 74, 89], ["ACE2", "PROTEIN", 156, 160], ["SARS-CoV", "SPECIES", 210, 218], ["a modest increase in ACE2 expression", "PROBLEM", 16, 52], ["the mock sample", "TEST", 102, 117], ["ACE2 expression", "TREATMENT", 156, 171], ["SARS", "TEST", 210, 214], ["CoV", "TEST", 215, 218], ["modest", "OBSERVATION_MODIFIER", 18, 24], ["increase", "OBSERVATION_MODIFIER", 25, 33], ["ACE2 expression", "OBSERVATION", 37, 52], ["infected", "OBSERVATION_MODIFIER", 61, 69]]], ["To examine whether expression of other potentially pro-viral genes explain SARS-CoV-2 cell tropism, we assessed the expression of the proteases that may potentiate SARS-CoV-2 infection.", [["cell", "ANATOMY", 86, 90], ["infection", "DISEASE", 175, 184], ["CoV-2 cell", "CELL", 80, 90], ["SARS-CoV-2", "ORGANISM", 164, 174], ["pro-viral genes", "DNA", 51, 66], ["proteases", "PROTEIN", 134, 143], ["SARS-CoV", "SPECIES", 75, 83], ["SARS-CoV-2", "SPECIES", 164, 174], ["other potentially pro-viral genes", "PROBLEM", 33, 66], ["SARS", "PROBLEM", 75, 79], ["CoV-2 cell tropism", "PROBLEM", 80, 98], ["the proteases", "PROBLEM", 130, 143], ["SARS", "PROBLEM", 164, 168], ["CoV-2 infection", "PROBLEM", 169, 184], ["infection", "OBSERVATION", 175, 184]]], ["The transmembrane serine protease TMPRSS2 and cathepsin L have been implicated in SARS-CoV-2 entry [21].", [["transmembrane", "ANATOMY", 4, 17], ["serine", "CHEMICAL", 18, 24], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 34, 41], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 46, 57], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 82, 92], ["transmembrane serine protease", "PROTEIN", 4, 33], ["TMPRSS2", "PROTEIN", 34, 41], ["cathepsin L", "PROTEIN", 46, 57], ["The transmembrane serine protease TMPRSS2", "TREATMENT", 0, 41], ["cathepsin L", "TREATMENT", 46, 57]]], ["We also examined the related protease TMPRSS4 which cleaves influenza hemaglutinin, similar to TMPRSS2, and may also play a role in SARSCoV-2 entry [21, 22].", [["TMPRSS4", "GENE_OR_GENE_PRODUCT", 38, 45], ["hemaglutinin", "GENE_OR_GENE_PRODUCT", 70, 82], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 95, 102], ["SARSCoV-2", "GENE_OR_GENE_PRODUCT", 132, 141], ["protease", "PROTEIN", 29, 37], ["TMPRSS4", "PROTEIN", 38, 45], ["influenza hemaglutinin", "PROTEIN", 60, 82], ["TMPRSS2", "PROTEIN", 95, 102], ["the related protease TMPRSS4", "TREATMENT", 17, 45], ["influenza hemaglutinin", "TREATMENT", 60, 82]]], ["TMPRSS2 and CTSL were expressed predominantly in basal, club and ciliated cells while TMPRSS4 was broadly expressed in all epithelial cell types.", [["basal", "ANATOMY", 49, 54], ["ciliated cells", "ANATOMY", 65, 79], ["epithelial cell", "ANATOMY", 123, 138], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 0, 7], ["CTSL", "GENE_OR_GENE_PRODUCT", 12, 16], ["club", "CELL", 56, 60], ["ciliated cells", "CELL", 65, 79], ["TMPRSS4", "GENE_OR_GENE_PRODUCT", 86, 93], ["epithelial cell", "CELL", 123, 138], ["TMPRSS2", "PROTEIN", 0, 7], ["CTSL", "PROTEIN", 12, 16], ["basal, club and ciliated cells", "CELL_TYPE", 49, 79], ["TMPRSS4", "PROTEIN", 86, 93], ["epithelial cell types", "CELL_TYPE", 123, 144], ["TMPRSS2", "TEST", 0, 7], ["CTSL", "TEST", 12, 16], ["ciliated cells", "PROBLEM", 65, 79], ["TMPRSS4", "TEST", 86, 93], ["predominantly", "OBSERVATION_MODIFIER", 32, 45], ["basal", "ANATOMY_MODIFIER", 49, 54], ["club", "OBSERVATION_MODIFIER", 56, 60], ["ciliated cells", "OBSERVATION", 65, 79], ["all epithelial cell types", "OBSERVATION", 119, 144]]], ["The specific role of proteases in governing SARS-CoV-2 tropism in the human airway epithelium remains to be further elucidated.Innate immune response to SARS-CoV-2 infection ::: ResultsWe investigated the transcriptome to assess the host immune response to SARS-CoV-2 infection at single-cell resolution in the human airway epithelium.", [["airway epithelium", "ANATOMY", 76, 93], ["cell", "ANATOMY", 288, 292], ["airway epithelium", "ANATOMY", 317, 334], ["SARS", "DISEASE", 153, 157], ["infection", "DISEASE", 164, 173], ["infection", "DISEASE", 268, 277], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 44, 54], ["human", "ORGANISM", 70, 75], ["airway epithelium", "TISSUE", 76, 93], ["SARS-CoV-2", "ORGANISM", 153, 163], ["SARS-CoV-2", "ORGANISM", 257, 267], ["single-cell", "CELL", 281, 292], ["human", "ORGANISM", 311, 316], ["airway epithelium", "TISSUE", 317, 334], ["proteases", "PROTEIN", 21, 30], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 311, 316], ["human", "SPECIES", 70, 75], ["SARS-CoV-2", "SPECIES", 153, 163], ["SARS-CoV-2", "SPECIES", 257, 267], ["human", "SPECIES", 311, 316], ["proteases", "TEST", 21, 30], ["governing SARS", "TEST", 34, 48], ["CoV", "TEST", 49, 52], ["SARS", "PROBLEM", 153, 157], ["SARS", "PROBLEM", 257, 261], ["CoV", "TEST", 262, 265], ["2 infection", "PROBLEM", 266, 277], ["human", "ANATOMY_MODIFIER", 70, 75], ["airway", "ANATOMY", 76, 82], ["epithelium", "ANATOMY_MODIFIER", 83, 93], ["infection", "OBSERVATION", 164, 173], ["infection", "OBSERVATION", 268, 277], ["human", "ANATOMY_MODIFIER", 311, 316], ["airway", "ANATOMY", 317, 323], ["epithelium", "ANATOMY_MODIFIER", 324, 334]]], ["We observed robust induction of both type I interferon (IFNB1) and type III interferons (IFNL1, IFNL2, and IFNL3) in ciliated, basal, club, and BC/club cells co-expressing SARS-CoV-2 transcripts (Fig 4).", [["club", "ANATOMY", 134, 138], ["BC/club cells", "ANATOMY", 144, 157], ["type I interferon", "GENE_OR_GENE_PRODUCT", 37, 54], ["IFNB1", "GENE_OR_GENE_PRODUCT", 56, 61], ["type III interferons", "GENE_OR_GENE_PRODUCT", 67, 87], ["IFNL1", "GENE_OR_GENE_PRODUCT", 89, 94], ["IFNL2", "GENE_OR_GENE_PRODUCT", 96, 101], ["IFNL3", "GENE_OR_GENE_PRODUCT", 107, 112], ["BC/club cells", "CELL", 144, 157], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 172, 182], ["type I interferon", "PROTEIN", 37, 54], ["IFNB1", "PROTEIN", 56, 61], ["type III interferons", "PROTEIN", 67, 87], ["IFNL1", "PROTEIN", 89, 94], ["IFNL2", "PROTEIN", 96, 101], ["IFNL3", "PROTEIN", 107, 112], ["ciliated, basal, club, and BC/club cells", "CELL_TYPE", 117, 157], ["both type I interferon (IFNB1)", "TREATMENT", 32, 62], ["type III interferons", "PROBLEM", 67, 87], ["BC", "TEST", 144, 146], ["SARS", "PROBLEM", 172, 176], ["CoV", "TEST", 177, 180], ["basal", "ANATOMY_MODIFIER", 127, 132], ["BC", "ANATOMY", 144, 146], ["club cells", "OBSERVATION", 147, 157]]], ["Interestingly, the kinetics of IFNB1 induction were delayed relative to type III interferon.", [["IFNB1", "GENE_OR_GENE_PRODUCT", 31, 36], ["type III interferon", "GENE_OR_GENE_PRODUCT", 72, 91], ["IFNB1", "PROTEIN", 31, 36], ["type III interferon", "PROTEIN", 72, 91], ["IFNB1 induction", "TREATMENT", 31, 46], ["type III interferon", "TREATMENT", 72, 91]]], ["In contrast, there was scant IFN induction in uninfected ciliated, basal, club, and BC/club cells.", [["BC/club cells", "ANATOMY", 84, 97], ["IFN", "GENE_OR_GENE_PRODUCT", 29, 32], ["BC/club cells", "CELL", 84, 97], ["IFN", "PROTEIN", 29, 32], ["uninfected ciliated, basal, club, and BC/club cells", "CELL_TYPE", 46, 97], ["scant IFN induction", "PROBLEM", 23, 42], ["BC/club cells", "PROBLEM", 84, 97], ["scant", "OBSERVATION_MODIFIER", 23, 28], ["basal", "ANATOMY_MODIFIER", 67, 72], ["BC", "ANATOMY", 84, 86], ["club cells", "OBSERVATION", 87, 97]]], ["We also did not observe IFN induction in neuroendocrine, ionocytes, goblet, or tuft cells consistent with these cell types not being major target cells of SARS-CoV-2 (Fig S4).", [["neuroendocrine", "ANATOMY", 41, 55], ["ionocytes", "ANATOMY", 57, 66], ["goblet", "ANATOMY", 68, 74], ["tuft cells", "ANATOMY", 79, 89], ["cell", "ANATOMY", 112, 116], ["cells", "ANATOMY", 146, 151], ["IFN", "GENE_OR_GENE_PRODUCT", 24, 27], ["neuroendocrine", "CELL", 41, 55], ["ionocytes", "CELL", 57, 66], ["goblet", "CELL", 68, 74], ["tuft cells", "CELL", 79, 89], ["cell", "CELL", 112, 116], ["cells", "CELL", 146, 151], ["SARS-CoV-2", "ORGANISM", 155, 165], ["Fig S4", "GENE_OR_GENE_PRODUCT", 167, 173], ["IFN", "PROTEIN", 24, 27], ["neuroendocrine, ionocytes, goblet, or tuft cells", "CELL_TYPE", 41, 89], ["IFN induction", "TREATMENT", 24, 37], ["neuroendocrine, ionocytes", "TEST", 41, 66], ["tuft cells", "PROBLEM", 79, 89], ["these cell types", "PROBLEM", 106, 122], ["SARS", "TEST", 155, 159], ["CoV", "TEST", 160, 163], ["tuft cells", "OBSERVATION", 79, 89], ["consistent with", "UNCERTAINTY", 90, 105]]], ["This demonstrates direct viral infection of a given cell is critical for interferon induction.", [["cell", "ANATOMY", 52, 56], ["infection", "DISEASE", 31, 40], ["cell", "CELL", 52, 56], ["interferon", "GENE_OR_GENE_PRODUCT", 73, 83], ["interferon", "PROTEIN", 73, 83], ["direct viral infection", "PROBLEM", 18, 40], ["interferon induction", "TREATMENT", 73, 93], ["viral", "OBSERVATION_MODIFIER", 25, 30], ["infection", "OBSERVATION", 31, 40]]], ["Type I and III interferons signal through IFNAR and IFNLR, respectively, resulting in expression of hundreds of ISGs.", [["Type I and III interferons", "GENE_OR_GENE_PRODUCT", 0, 26], ["IFNAR", "GENE_OR_GENE_PRODUCT", 42, 47], ["IFNLR", "GENE_OR_GENE_PRODUCT", 52, 57], ["Type I and III interferons", "PROTEIN", 0, 26], ["IFNAR", "PROTEIN", 42, 47], ["IFNLR", "PROTEIN", 52, 57], ["ISGs", "DNA", 112, 116], ["Type I and III interferons signal", "PROBLEM", 0, 33], ["ISGs", "PROBLEM", 112, 116], ["ISGs", "OBSERVATION", 112, 116]]], ["Consistent with this, we observed broad ISG induction (IFI27, IFITM3, IFI6, MX1, and ISG15) in both infected and bystander cells of all cell types (Fig 4, S4) suggesting IFN from infected cells is actingin trans on both infected cells and uninfected bystander cells.Innate immune response to SARS-CoV-2 infection ::: ResultsThe host anti-viral response also results in chemokine induction leading to recruitment of immune cells, a hallmark of severe COVID-19.", [["bystander cells", "ANATOMY", 113, 128], ["cell", "ANATOMY", 136, 140], ["cells", "ANATOMY", 188, 193], ["cells", "ANATOMY", 229, 234], ["bystander cells", "ANATOMY", 250, 265], ["immune cells", "ANATOMY", 415, 427], ["SARS", "DISEASE", 292, 296], ["infection", "DISEASE", 303, 312], ["ISG", "GENE_OR_GENE_PRODUCT", 40, 43], ["IFI27", "GENE_OR_GENE_PRODUCT", 55, 60], ["IFITM3", "GENE_OR_GENE_PRODUCT", 62, 68], ["IFI6", "GENE_OR_GENE_PRODUCT", 70, 74], ["MX1", "GENE_OR_GENE_PRODUCT", 76, 79], ["ISG15", "GENE_OR_GENE_PRODUCT", 85, 90], ["bystander cells", "CELL", 113, 128], ["cell", "CELL", 136, 140], ["S4", "GENE_OR_GENE_PRODUCT", 155, 157], ["IFN", "GENE_OR_GENE_PRODUCT", 170, 173], ["cells", "CELL", 188, 193], ["actingin trans", "SIMPLE_CHEMICAL", 197, 211], ["cells", "CELL", 229, 234], ["bystander cells", "CELL", 250, 265], ["SARS-CoV-2", "ORGANISM", 292, 302], ["immune cells", "CELL", 415, 427], ["IFI27", "PROTEIN", 55, 60], ["IFITM3", "PROTEIN", 62, 68], ["IFI6", "PROTEIN", 70, 74], ["MX1", "PROTEIN", 76, 79], ["ISG15", "PROTEIN", 85, 90], ["bystander cells", "CELL_TYPE", 113, 128], ["IFN", "PROTEIN", 170, 173], ["infected cells", "CELL_TYPE", 179, 193], ["infected cells", "CELL_TYPE", 220, 234], ["uninfected bystander cells", "CELL_TYPE", 239, 265], ["chemokine", "PROTEIN", 369, 378], ["immune cells", "CELL_TYPE", 415, 427], ["SARS-CoV-2", "SPECIES", 292, 302], ["broad ISG induction", "TREATMENT", 34, 53], ["IFITM3", "TEST", 62, 68], ["IFI6", "TEST", 70, 74], ["MX1", "TEST", 76, 79], ["Fig", "TEST", 148, 151], ["IFN", "PROBLEM", 170, 173], ["infected cells", "PROBLEM", 179, 193], ["both infected cells", "PROBLEM", 215, 234], ["SARS", "PROBLEM", 292, 296], ["chemokine induction", "TREATMENT", 369, 388], ["immune cells", "PROBLEM", 415, 427], ["severe COVID", "PROBLEM", 443, 455], ["infected", "OBSERVATION_MODIFIER", 100, 108], ["bystander cells", "OBSERVATION", 113, 128], ["all cell", "OBSERVATION", 132, 140], ["infected cells", "OBSERVATION", 179, 193], ["infected cells", "OBSERVATION", 220, 234], ["uninfected", "OBSERVATION_MODIFIER", 239, 249], ["bystander cells", "OBSERVATION", 250, 265], ["infection", "OBSERVATION", 303, 312], ["immune cells", "OBSERVATION", 415, 427], ["severe", "OBSERVATION_MODIFIER", 443, 449]]], ["Here, we observe induction of CXCL9, CXCL10, and CXCL11 which propagate signals through the cognate CXCR3 receptor to recruit activated T cells and NK cells (Fig 4).", [["T cells", "ANATOMY", 136, 143], ["NK cells", "ANATOMY", 148, 156], ["CXCL9", "GENE_OR_GENE_PRODUCT", 30, 35], ["CXCL10", "GENE_OR_GENE_PRODUCT", 37, 43], ["CXCL11", "GENE_OR_GENE_PRODUCT", 49, 55], ["CXCR3", "GENE_OR_GENE_PRODUCT", 100, 105], ["T cells", "CELL", 136, 143], ["NK cells", "CELL", 148, 156], ["Fig 4", "CELL", 158, 163], ["CXCL9", "PROTEIN", 30, 35], ["CXCL10", "PROTEIN", 37, 43], ["CXCL11", "PROTEIN", 49, 55], ["CXCR3 receptor", "PROTEIN", 100, 114], ["activated T cells", "CELL_TYPE", 126, 143], ["NK cells", "CELL_TYPE", 148, 156], ["CXCL9", "TEST", 30, 35], ["CXCL10", "TEST", 37, 43], ["CXCL11", "TREATMENT", 49, 55], ["the cognate CXCR3 receptor", "TEST", 88, 114], ["activated T cells", "PROBLEM", 126, 143], ["NK cells", "TEST", 148, 156], ["Fig", "TEST", 158, 161]]], ["This induction was evident in infected but not bystander cells (Fig 4).", [["bystander cells", "ANATOMY", 47, 62], ["bystander cells", "CELL", 47, 62], ["bystander cells", "CELL_TYPE", 47, 62], ["This induction", "TREATMENT", 0, 14], ["infected", "OBSERVATION", 30, 38]]], ["In contrast, CCL2 and CXCL16 which recruit monocytes and T cells, respectively, were not dynamically regulated over the conditions evaluated (Fig 4 and S4).", [["monocytes", "ANATOMY", 43, 52], ["T cells", "ANATOMY", 57, 64], ["CCL2", "GENE_OR_GENE_PRODUCT", 13, 17], ["CXCL16", "GENE_OR_GENE_PRODUCT", 22, 28], ["monocytes", "CELL", 43, 52], ["T cells", "CELL", 57, 64], ["CCL2", "PROTEIN", 13, 17], ["CXCL16", "PROTEIN", 22, 28], ["monocytes", "CELL_TYPE", 43, 52], ["T cells", "CELL_TYPE", 57, 64], ["CCL2", "TEST", 13, 17], ["CXCL16", "TEST", 22, 28], ["monocytes", "TEST", 43, 52]]], ["We also observed substantial induction of the pro-inflammatory cytokine IL-6 in infected ciliated, basal, club, and BC/club cells but not in uninfected bystander cells of these same populations.", [["club", "ANATOMY", 106, 110], ["BC/club cells", "ANATOMY", 116, 129], ["bystander cells", "ANATOMY", 152, 167], ["IL-6", "GENE_OR_GENE_PRODUCT", 72, 76], ["ciliated", "CELL", 89, 97], ["club", "CELL", 106, 110], ["BC/club cells", "CELL", 116, 129], ["bystander cells", "CELL", 152, 167], ["pro-inflammatory cytokine IL-6", "PROTEIN", 46, 76], ["infected ciliated, basal, club, and BC/club cells", "CELL_TYPE", 80, 129], ["uninfected bystander cells", "CELL_TYPE", 141, 167], ["the pro-inflammatory cytokine IL", "TEST", 42, 74], ["BC/club cells", "PROBLEM", 116, 129], ["substantial", "OBSERVATION_MODIFIER", 17, 28], ["basal", "ANATOMY_MODIFIER", 99, 104], ["club", "ANATOMY", 106, 110], ["BC", "ANATOMY", 116, 118], ["club cells", "OBSERVATION", 119, 129]]], ["Interestingly, expression of pro-inflammatory IL-1 was modestly downregulated in all cell types after infection whereas IL-10 and TNF\u03b1 expression were not significantly regulated by infection in this system (Fig 4).Differentially expressed genes in response to SARS-CoV-2 infection ::: ResultsTo determine how SARS-CoV-2 infection perturbed the cellular transcriptome, we computationally pooled the three infected samples and analyzed the top 100 differentially expressed genes between infected and uninfected bystander cells of a given cell type within the 1, 2, and 3 dpi samples (Fig 5A).", [["cell", "ANATOMY", 85, 89], ["cellular", "ANATOMY", 345, 353], ["samples", "ANATOMY", 414, 421], ["cells", "ANATOMY", 520, 525], ["cell", "ANATOMY", 537, 541], ["infection", "DISEASE", 102, 111], ["infection", "DISEASE", 182, 191], ["SARS", "DISEASE", 261, 265], ["infection", "DISEASE", 272, 281], ["infection", "DISEASE", 321, 330], ["IL-1", "GENE_OR_GENE_PRODUCT", 46, 50], ["cell", "CELL", 85, 89], ["IL-10", "GENE_OR_GENE_PRODUCT", 120, 125], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 130, 134], ["SARS-CoV-2", "ORGANISM", 261, 271], ["SARS-CoV-2", "ORGANISM", 310, 320], ["cellular", "CELL", 345, 353], ["samples", "CANCER", 414, 421], ["bystander cells", "CELL", 510, 525], ["cell type", "CELL", 537, 546], ["pro-inflammatory IL-1", "PROTEIN", 29, 50], ["TNF\u03b1", "PROTEIN", 130, 134], ["infected and uninfected bystander cells", "CELL_TYPE", 486, 525], ["SARS-CoV", "SPECIES", 261, 269], ["SARS-CoV", "SPECIES", 310, 318], ["pro-inflammatory IL", "TEST", 29, 48], ["infection", "PROBLEM", 102, 111], ["IL", "TEST", 120, 122], ["TNF\u03b1 expression", "TEST", 130, 145], ["infection", "PROBLEM", 182, 191], ["SARS", "PROBLEM", 261, 265], ["SARS", "PROBLEM", 310, 314], ["CoV", "PROBLEM", 315, 318], ["2 infection", "PROBLEM", 319, 330], ["pro-inflammatory", "OBSERVATION_MODIFIER", 29, 45], ["all cell", "OBSERVATION_MODIFIER", 81, 89], ["infection", "OBSERVATION", 102, 111], ["infection", "OBSERVATION", 182, 191], ["infection", "OBSERVATION", 321, 330], ["cellular transcriptome", "OBSERVATION", 345, 367], ["infected", "OBSERVATION_MODIFIER", 486, 494], ["uninfected bystander cells", "OBSERVATION", 499, 525]]], ["PANTHER gene ontology analysis revealed infected ciliated cells had increased expression of genes involved in apoptosis (e.g. PMAIP1, SQSTM1, ATF3), translation initiation and viral gene expression (e.g. RPS12, RPL37A) and inflammation (e.g. NFKBIA and NFKBIZ) compared to bystander cells (Fig 5B,C and differentially expressed gene lists in Supplemental Files).", [["ciliated cells", "ANATOMY", 49, 63], ["bystander cells", "ANATOMY", 273, 288], ["inflammation", "DISEASE", 223, 235], ["ciliated cells", "CELL", 49, 63], ["PMAIP1", "GENE_OR_GENE_PRODUCT", 126, 132], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 134, 140], ["ATF3", "GENE_OR_GENE_PRODUCT", 142, 146], ["RPS12", "GENE_OR_GENE_PRODUCT", 204, 209], ["RPL37A", "GENE_OR_GENE_PRODUCT", 211, 217], ["NFKBIZ", "GENE_OR_GENE_PRODUCT", 253, 259], ["bystander cells", "CELL", 273, 288], ["ciliated cells", "CELL_TYPE", 49, 63], ["PMAIP1", "PROTEIN", 126, 132], ["SQSTM1", "PROTEIN", 134, 140], ["ATF3", "PROTEIN", 142, 146], ["RPS12", "PROTEIN", 204, 209], ["RPL37A", "PROTEIN", 211, 217], ["NFKBIA", "PROTEIN", 242, 248], ["NFKBIZ", "PROTEIN", 253, 259], ["bystander cells", "CELL_TYPE", 273, 288], ["C and differentially expressed gene lists", "DNA", 297, 338], ["PANTHER gene ontology analysis", "TEST", 0, 30], ["infected ciliated cells", "PROBLEM", 40, 63], ["apoptosis", "PROBLEM", 110, 119], ["PMAIP1", "TEST", 126, 132], ["viral gene expression", "PROBLEM", 176, 197], ["RPS12", "TEST", 204, 209], ["inflammation (e.g. NFKBIA and NFKBIZ)", "PROBLEM", 223, 260], ["infected", "OBSERVATION_MODIFIER", 40, 48], ["ciliated cells", "OBSERVATION", 49, 63], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["inflammation", "OBSERVATION", 223, 235]]], ["Similar genes are enriched in other infected cell populations (Fig S5).", [["cell", "ANATOMY", 45, 49], ["cell populations", "CELL", 45, 61], ["Fig S5", "CELL", 63, 69], ["infected cell populations", "CELL_TYPE", 36, 61], ["enriched", "OBSERVATION_MODIFIER", 18, 26], ["infected", "OBSERVATION_MODIFIER", 36, 44], ["cell populations", "OBSERVATION", 45, 61], ["Fig S5", "OBSERVATION_MODIFIER", 63, 69]]], ["In contrast, infected ciliated cells showed significant downregulation of genes included in biological processes involved in cilium function (e.g. DYNLL1), calcium signaling (e.g. CALM1, CALM2), and iron homeostasis (e.g. FTH1, FTL; Fig 5B,C and S5).", [["ciliated cells", "ANATOMY", 22, 36], ["cilium", "ANATOMY", 125, 131], ["calcium", "CHEMICAL", 156, 163], ["iron", "CHEMICAL", 199, 203], ["calcium", "CHEMICAL", 156, 163], ["iron", "CHEMICAL", 199, 203], ["ciliated cells", "CELL", 22, 36], ["cilium", "MULTI-TISSUE_STRUCTURE", 125, 131], ["DYNLL1", "GENE_OR_GENE_PRODUCT", 147, 153], ["calcium", "SIMPLE_CHEMICAL", 156, 163], ["CALM1", "GENE_OR_GENE_PRODUCT", 180, 185], ["CALM2", "GENE_OR_GENE_PRODUCT", 187, 192], ["iron", "SIMPLE_CHEMICAL", 199, 203], ["C", "GENE_OR_GENE_PRODUCT", 240, 241], ["S5", "GENE_OR_GENE_PRODUCT", 246, 248], ["infected ciliated cells", "CELL_TYPE", 13, 36], ["DYNLL1", "PROTEIN", 147, 153], ["CALM1", "PROTEIN", 180, 185], ["CALM2", "PROTEIN", 187, 192], ["FTH1", "PROTEIN", 222, 226], ["FTL", "PROTEIN", 228, 231], ["S5", "PROTEIN", 246, 248], ["infected ciliated cells", "PROBLEM", 13, 36], ["significant downregulation of genes", "PROBLEM", 44, 79], ["cilium function", "TEST", 125, 140], ["DYNLL1", "TEST", 147, 153], ["calcium signaling", "TEST", 156, 173], ["CALM1", "TEST", 180, 185], ["CALM2", "TEST", 187, 192], ["iron homeostasis", "TEST", 199, 215], ["FTH1", "TEST", 222, 226], ["FTL", "TEST", 228, 231], ["Fig", "TEST", 233, 236], ["infected", "OBSERVATION_MODIFIER", 13, 21], ["ciliated cells", "OBSERVATION", 22, 36], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["downregulation", "OBSERVATION", 56, 70], ["iron homeostasis", "OBSERVATION", 199, 215]]], ["Together this suggests that SARS-CoV-2 infection reprograms the cellular transcriptome, resulting in promotion of viral infection and potentially resulting in cell dysfunction and apoptosis that contributes to COVID-19 pathogenesis.DiscussionTo effectively treat COVID-19, we must first understand how SARS-CoV-2 causes disease and why the clinical presentation varies from asymptomatic infection to lethal disease.", [["cellular", "ANATOMY", 64, 72], ["cell", "ANATOMY", 159, 163], ["infection", "DISEASE", 39, 48], ["viral infection", "DISEASE", 114, 129], ["SARS", "DISEASE", 302, 306], ["infection", "DISEASE", 387, 396], ["SARS-CoV-2", "ORGANISM", 28, 38], ["cellular", "CELL", 64, 72], ["cell", "CELL", 159, 163], ["COVID-19", "GENE_OR_GENE_PRODUCT", 210, 218], ["SARS-CoV-2", "ORGANISM", 302, 312], ["SARS", "PROBLEM", 28, 32], ["CoV", "PROBLEM", 33, 36], ["2 infection", "PROBLEM", 37, 48], ["the cellular transcriptome", "PROBLEM", 60, 86], ["viral infection", "PROBLEM", 114, 129], ["cell dysfunction", "PROBLEM", 159, 175], ["apoptosis", "PROBLEM", 180, 189], ["COVID", "TEST", 210, 215], ["pathogenesis", "PROBLEM", 219, 231], ["COVID", "TEST", 263, 268], ["disease", "PROBLEM", 320, 327], ["asymptomatic infection", "PROBLEM", 374, 396], ["lethal disease", "PROBLEM", 400, 414], ["SARS", "OBSERVATION", 28, 32], ["CoV", "OBSERVATION_MODIFIER", 33, 36], ["infection", "OBSERVATION", 39, 48], ["cellular transcriptome", "OBSERVATION", 64, 86], ["viral", "OBSERVATION_MODIFIER", 114, 119], ["infection", "OBSERVATION", 120, 129], ["cell dysfunction", "OBSERVATION", 159, 175], ["asymptomatic", "OBSERVATION_MODIFIER", 374, 386], ["infection", "OBSERVATION", 387, 396]]], ["Here, we report the first longitudinal single-cell transcriptomic analysis of SARS-CoV-2 infected respiratory epithelium using an established organoid model that reproduces the orientation of airway epithelium.", [["cell", "ANATOMY", 46, 50], ["respiratory epithelium", "ANATOMY", 98, 120], ["organoid", "ANATOMY", 142, 150], ["airway epithelium", "ANATOMY", 192, 209], ["cell", "CELL", 46, 50], ["SARS-CoV-2", "ORGANISM", 78, 88], ["respiratory epithelium", "TISSUE", 98, 120], ["airway epithelium", "TISSUE", 192, 209], ["SARS-CoV-2", "SPECIES", 78, 88], ["SARS", "PROBLEM", 78, 82], ["CoV", "TEST", 83, 86], ["infected respiratory epithelium", "PROBLEM", 89, 120], ["respiratory epithelium", "ANATOMY", 98, 120], ["organoid model", "OBSERVATION", 142, 156], ["airway epithelium", "OBSERVATION", 192, 209]]], ["The transcriptional data generated is of high quality, with an average of between 2,400 to 3,600 unique genes detected per condition.", [["The transcriptional data", "TEST", 0, 24], ["high", "OBSERVATION_MODIFIER", 41, 45]]], ["Our data reveals several novel viral transcripts and our methodology differentiates infected from bystander cells.", [["bystander cells", "ANATOMY", 98, 113], ["bystander cells", "CELL", 98, 113], ["viral transcripts", "RNA", 31, 48], ["bystander cells", "CELL_TYPE", 98, 113], ["Our data", "TEST", 0, 8], ["several novel viral transcripts", "PROBLEM", 17, 48], ["viral transcripts", "OBSERVATION", 31, 48], ["bystander cells", "OBSERVATION", 98, 113]]], ["Further, we demonstrate that ciliated cells are the major target cell of SARS-CoV-2 infection in the bronchial epithelium at the onset of infection and that cell tropism expands to basal, club, and BC/club cells over time.", [["ciliated cells", "ANATOMY", 29, 43], ["cell", "ANATOMY", 65, 69], ["bronchial epithelium", "ANATOMY", 101, 121], ["cell", "ANATOMY", 157, 161], ["BC/club cells", "ANATOMY", 198, 211], ["infection", "DISEASE", 84, 93], ["infection", "DISEASE", 138, 147], ["ciliated cells", "CELL", 29, 43], ["cell", "CELL", 65, 69], ["SARS-CoV-2", "ORGANISM", 73, 83], ["bronchial epithelium", "TISSUE", 101, 121], ["cell", "CELL", 157, 161], ["BC/club cells", "CELL", 198, 211], ["ciliated cells", "CELL_TYPE", 29, 43], ["basal, club, and BC/club cells", "CELL_TYPE", 181, 211], ["SARS-CoV", "SPECIES", 73, 81], ["ciliated cells", "PROBLEM", 29, 43], ["SARS", "PROBLEM", 73, 77], ["CoV", "TEST", 78, 81], ["2 infection", "PROBLEM", 82, 93], ["the bronchial epithelium", "PROBLEM", 97, 121], ["infection", "PROBLEM", 138, 147], ["cell tropism", "PROBLEM", 157, 169], ["basal, club", "TEST", 181, 192], ["BC", "TEST", 198, 200], ["ciliated cells", "OBSERVATION", 29, 43], ["major", "OBSERVATION_MODIFIER", 52, 57], ["target cell", "OBSERVATION", 58, 69], ["CoV", "OBSERVATION_MODIFIER", 78, 81], ["infection", "OBSERVATION", 84, 93], ["bronchial epithelium", "ANATOMY", 101, 121], ["infection", "OBSERVATION", 138, 147], ["cell tropism", "OBSERVATION", 157, 169], ["basal", "ANATOMY_MODIFIER", 181, 186], ["club cells", "OBSERVATION", 201, 211]]], ["We also reveal that SARS-CoV-2 potently induces IFN in infected cells resulting in broad ISG expression in both infected and bystander cells.", [["cells", "ANATOMY", 64, 69], ["bystander cells", "ANATOMY", 125, 140], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 20, 30], ["IFN", "GENE_OR_GENE_PRODUCT", 48, 51], ["cells", "CELL", 64, 69], ["ISG", "GENE_OR_GENE_PRODUCT", 89, 92], ["bystander cells", "CELL", 125, 140], ["IFN", "PROTEIN", 48, 51], ["infected cells", "CELL_TYPE", 55, 69], ["bystander cells", "CELL_TYPE", 125, 140], ["SARS-CoV", "SPECIES", 20, 28], ["SARS", "PROBLEM", 20, 24], ["CoV", "TEST", 25, 28], ["IFN in infected cells", "PROBLEM", 48, 69], ["broad ISG expression", "PROBLEM", 83, 103], ["SARS", "OBSERVATION", 20, 24], ["infected cells", "OBSERVATION", 55, 69], ["broad", "OBSERVATION_MODIFIER", 83, 88], ["ISG expression", "OBSERVATION", 89, 103], ["infected", "OBSERVATION_MODIFIER", 112, 120], ["bystander cells", "OBSERVATION", 125, 140]]], ["We also observe potent induction of the pro-inflammatory cytokine IL-6 and chemokines, which likely contribute to the inflammatory response in vivo.DiscussionSingle-cell transcriptomics enabled us to elucidate the SARS-CoV-2 transcriptome at single-cell resolution in multiple primary cell types over time.", [["cell", "ANATOMY", 165, 169], ["cell", "ANATOMY", 249, 253], ["cell", "ANATOMY", 285, 289], ["IL-6", "GENE_OR_GENE_PRODUCT", 66, 70], ["DiscussionSingle-cell", "CELL", 148, 169], ["single-cell", "CELL", 242, 253], ["cell", "CELL", 285, 289], ["pro-inflammatory cytokine IL-6", "PROTEIN", 40, 70], ["chemokines", "PROTEIN", 75, 85], ["SARS-CoV-2 transcriptome", "DNA", 214, 238], ["SARS-CoV", "SPECIES", 214, 222], ["the pro-inflammatory cytokine IL", "TREATMENT", 36, 68], ["chemokines", "TREATMENT", 75, 85], ["the inflammatory response in vivo", "PROBLEM", 114, 147], ["the SARS", "PROBLEM", 210, 218], ["CoV", "TEST", 219, 222], ["single-cell resolution", "TREATMENT", 242, 264], ["likely contribute to", "UNCERTAINTY", 93, 113], ["inflammatory", "OBSERVATION", 118, 130], ["multiple", "OBSERVATION_MODIFIER", 268, 276], ["primary cell types", "OBSERVATION", 277, 295]]], ["We developed a novel method to differentiate productively infected cell types by the distribution of the sub-genomic and genomic viral transcripts.", [["cell", "ANATOMY", 67, 71], ["cell", "CELL", 67, 71], ["sub-genomic", "DNA", 105, 116], ["genomic viral transcripts", "RNA", 121, 146], ["a novel method", "PROBLEM", 13, 27], ["productively infected cell types", "PROBLEM", 45, 77], ["the sub-genomic and genomic viral transcripts", "PROBLEM", 101, 146], ["infected cell types", "OBSERVATION", 58, 77], ["sub", "OBSERVATION_MODIFIER", 105, 108], ["viral transcripts", "OBSERVATION", 129, 146]]], ["We also identified polyadenylated viral transcripts remote from the 3\u2019 end of the viral genome, which was unexpected given our sequencing method.", [["3\u2019 end", "CELLULAR_COMPONENT", 68, 74], ["polyadenylated viral transcripts", "RNA", 19, 51], ["3\u2019 end", "DNA", 68, 74], ["viral genome", "DNA", 82, 94], ["polyadenylated viral transcripts", "PROBLEM", 19, 51], ["the viral genome", "PROBLEM", 78, 94], ["polyadenylated", "OBSERVATION", 19, 33], ["viral transcripts", "OBSERVATION", 34, 51], ["viral genome", "OBSERVATION", 82, 94]]], ["Our RT-PCR validation experiments confirm the production of at least two unique, TRS-independent transcripts with poly-A tails that do not appear to result from non-specific oligo-d(T) priming.", [["poly-A tails", "GENE_OR_GENE_PRODUCT", 114, 126], ["TRS", "DNA", 81, 84], ["Our RT-PCR validation experiments", "TEST", 0, 33], ["non-specific oligo-d(T) priming", "TREATMENT", 161, 192]]], ["As the reported recombination rate for coronaviruses is high [23, 24] it is possible these short reads correspond to non-specific polymerase jumping.", [["coronaviruses", "PROBLEM", 39, 52], ["non-specific polymerase jumping", "PROBLEM", 117, 148], ["non-specific", "OBSERVATION_MODIFIER", 117, 129]]], ["However, recent studies have identified TRS-independent chimeric RNAs produced during SARS-CoV-2 infection of Vero cells, a small portion (1.5%) of which are fused in frame [25].", [["Vero cells", "ANATOMY", 110, 120], ["infection", "DISEASE", 97, 106], ["SARS-CoV-2", "ORGANISM", 86, 96], ["Vero cells", "CELL", 110, 120], ["TRS", "DNA", 40, 43], ["chimeric RNAs", "RNA", 56, 69], ["Vero cells", "CELL_LINE", 110, 120], ["SARS-CoV", "SPECIES", 86, 94], ["recent studies", "TEST", 9, 23], ["TRS", "TEST", 40, 43], ["independent chimeric RNAs", "PROBLEM", 44, 69], ["SARS", "PROBLEM", 86, 90], ["CoV", "TEST", 91, 94], ["2 infection of Vero cells", "PROBLEM", 95, 120], ["infection", "OBSERVATION", 97, 106], ["Vero cells", "OBSERVATION", 110, 120], ["small", "OBSERVATION_MODIFIER", 124, 129], ["portion", "OBSERVATION_MODIFIER", 130, 137]]], ["Taken together with our results, this may suggest non-canonical sub-genomic RNAs with coding potential are produced during SARS-CoV-2 infection; however, this would require further validation.", [["infection", "DISEASE", 134, 143], ["SARS-CoV-2", "ORGANISM", 123, 133], ["SARS-CoV-2", "SPECIES", 123, 133], ["non-canonical sub-genomic RNAs", "PROBLEM", 50, 80], ["SARS", "PROBLEM", 123, 127], ["CoV-2 infection", "PROBLEM", 128, 143], ["further validation", "TEST", 173, 191], ["genomic RNAs", "OBSERVATION", 68, 80], ["infection", "OBSERVATION", 134, 143]]], ["HCoV-299E non-structural protein 8 (nsp8) was recently shown to possess template-independent adenyltransferase activity [26].", [["HCoV-299E non-structural protein 8", "GENE_OR_GENE_PRODUCT", 0, 34], ["nsp8", "GENE_OR_GENE_PRODUCT", 36, 40], ["adenyltransferase", "SIMPLE_CHEMICAL", 93, 110], ["HCoV", "PROTEIN", 0, 4], ["299E non-structural protein 8", "PROTEIN", 5, 34], ["nsp8", "PROTEIN", 36, 40], ["adenyltransferase", "PROTEIN", 93, 110], ["HCoV", "TEST", 0, 4], ["non-structural protein", "TEST", 10, 32]]], ["Because poly-A tails play important roles in the stability and translation potential of canonical SARS-CoV-2 sgRNAs, it is interesting to speculate that coronaviruses might rely on the production of non-canonical, poly-adenylated sgRNAs to serve as decoys for cellular deadenylases.", [["cellular", "ANATOMY", 260, 268], ["poly-A", "CHEMICAL", 8, 14], ["poly-A", "GENE_OR_GENE_PRODUCT", 8, 14], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 98, 108], ["coronaviruses", "ORGANISM", 153, 166], ["cellular", "CELL", 260, 268], ["poly-A tails", "PROTEIN", 8, 20], ["SARS-CoV-2 sgRNAs", "DNA", 98, 115], ["sgRNAs", "PROTEIN", 230, 236], ["cellular deadenylases", "PROTEIN", 260, 281], ["canonical SARS", "PROBLEM", 88, 102], ["CoV-2 sgRNAs", "PROBLEM", 103, 115], ["coronaviruses", "PROBLEM", 153, 166], ["non-canonical, poly-adenylated sgRNAs", "TREATMENT", 199, 236], ["cellular deadenylases", "PROBLEM", 260, 281], ["coronaviruses", "OBSERVATION", 153, 166]]], ["This would result in preservation of the poly-A tails of the genomic and subgenomic RNAs.", [["poly-A tails", "PROTEIN", 41, 53], ["genomic and subgenomic RNAs", "RNA", 61, 88], ["the genomic and subgenomic RNAs", "PROBLEM", 57, 88], ["poly", "OBSERVATION", 41, 45], ["subgenomic RNAs", "OBSERVATION", 73, 88]]], ["Indeed, the production of sgRNAs during flaviviral infections is important for resistance to cellular exoribonucleases and innate immune evasion [27, 28].DiscussionIdentification of the cell types infected by SARS-CoV-2 informs pathogenesis.", [["cellular", "ANATOMY", 93, 101], ["cell", "ANATOMY", 186, 190], ["infections", "DISEASE", 51, 61], ["SARS", "DISEASE", 209, 213], ["sgRNAs", "GENE_OR_GENE_PRODUCT", 26, 32], ["cellular", "CELL", 93, 101], ["cell", "CELL", 186, 190], ["SARS-CoV-2", "ORGANISM", 209, 219], ["sgRNAs", "PROTEIN", 26, 32], ["SARS-CoV", "SPECIES", 209, 217], ["sgRNAs during flaviviral infections", "PROBLEM", 26, 61], ["pathogenesis", "PROBLEM", 228, 240], ["sgRNAs", "OBSERVATION", 26, 32]]], ["We find that SARS-CoV-2 infects ciliated cells, basal, club, and BC/club cells.", [["ciliated cells", "ANATOMY", 32, 46], ["basal", "ANATOMY", 48, 53], ["BC/club cells", "ANATOMY", 65, 78], ["SARS", "DISEASE", 13, 17], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 13, 23], ["ciliated cells", "CELL", 32, 46], ["basal", "CELL", 48, 53], ["BC/club cells", "CELL", 65, 78], ["ciliated cells", "CELL_TYPE", 32, 46], ["basal, club, and BC/club cells", "CELL_TYPE", 48, 78], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "TEST", 13, 17], ["CoV", "TEST", 18, 21], ["ciliated cells", "TEST", 32, 46], ["basal, club", "TEST", 48, 59], ["BC/club cells", "PROBLEM", 65, 78], ["ciliated cells", "OBSERVATION", 32, 46], ["basal", "ANATOMY_MODIFIER", 48, 53], ["BC", "ANATOMY", 65, 67], ["club cells", "OBSERVATION", 68, 78]]], ["This may result in aberrant function of these critical cell types.", [["cell", "ANATOMY", 55, 59], ["cell", "CELL", 55, 59], ["aberrant function", "OBSERVATION", 19, 36], ["critical cell types", "OBSERVATION", 46, 65]]], ["Ciliated cells, which are abundant in the respiratory epithelium, propel mucus and associated foreign particles and microbes proximally away from the lower airway.", [["cells", "ANATOMY", 9, 14], ["respiratory epithelium", "ANATOMY", 42, 64], ["mucus", "ANATOMY", 73, 78], ["lower airway", "ANATOMY", 150, 162], ["Ciliated cells", "CELL", 0, 14], ["respiratory epithelium", "TISSUE", 42, 64], ["mucus", "ORGANISM_SUBSTANCE", 73, 78], ["lower airway", "ORGANISM_SUBDIVISION", 150, 162], ["Ciliated cells", "CELL_TYPE", 0, 14], ["Ciliated cells", "PROBLEM", 0, 14], ["the respiratory epithelium", "PROBLEM", 38, 64], ["propel mucus and associated foreign particles", "PROBLEM", 66, 111], ["cells", "OBSERVATION", 9, 14], ["abundant", "OBSERVATION_MODIFIER", 26, 34], ["respiratory epithelium", "ANATOMY", 42, 64], ["mucus", "OBSERVATION", 73, 78], ["foreign particles", "OBSERVATION", 94, 111], ["microbes", "OBSERVATION_MODIFIER", 116, 124], ["proximally", "OBSERVATION_MODIFIER", 125, 135], ["lower", "ANATOMY_MODIFIER", 150, 155], ["airway", "ANATOMY", 156, 162]]], ["Our finding that ciliated cells are the predominant target cell of SARS-CoV-2 infection in the bronchial epithelium has several important implications.", [["ciliated cells", "ANATOMY", 17, 31], ["cell", "ANATOMY", 59, 63], ["bronchial epithelium", "ANATOMY", 95, 115], ["SARS", "DISEASE", 67, 71], ["infection", "DISEASE", 78, 87], ["ciliated cells", "CELL", 17, 31], ["cell", "CELL", 59, 63], ["SARS-CoV-2", "ORGANISM", 67, 77], ["bronchial epithelium", "TISSUE", 95, 115], ["ciliated cells", "CELL_TYPE", 17, 31], ["SARS-CoV-2", "SPECIES", 67, 77], ["ciliated cells", "PROBLEM", 17, 31], ["SARS", "PROBLEM", 67, 71], ["CoV", "TEST", 72, 75], ["2 infection in the bronchial epithelium", "PROBLEM", 76, 115], ["ciliated cells", "OBSERVATION", 17, 31], ["predominant", "OBSERVATION_MODIFIER", 40, 51], ["target cell", "OBSERVATION", 52, 63], ["CoV", "OBSERVATION_MODIFIER", 72, 75], ["infection", "OBSERVATION", 78, 87], ["bronchial", "ANATOMY", 95, 104], ["epithelium", "ANATOMY_MODIFIER", 105, 115], ["several", "OBSERVATION_MODIFIER", 120, 127], ["important", "OBSERVATION_MODIFIER", 128, 137]]], ["First, dysfunction of ciliated cells by infection by SARS-CoV-2 may impair mucociliary clearance and increase the likelihood of secondary infection.", [["ciliated cells", "ANATOMY", 22, 36], ["mucociliary", "ANATOMY", 75, 86], ["infection", "DISEASE", 40, 49], ["SARS", "DISEASE", 53, 57], ["infection", "DISEASE", 138, 147], ["ciliated cells", "CELL", 22, 36], ["SARS-CoV-2", "ORGANISM", 53, 63], ["mucociliary", "ORGAN", 75, 86], ["ciliated cells", "CELL_TYPE", 22, 36], ["SARS-CoV", "SPECIES", 53, 61], ["ciliated cells", "PROBLEM", 22, 36], ["infection", "PROBLEM", 40, 49], ["SARS", "PROBLEM", 53, 57], ["CoV", "TEST", 58, 61], ["mucociliary clearance", "PROBLEM", 75, 96], ["secondary infection", "PROBLEM", 128, 147], ["ciliated cells", "OBSERVATION", 22, 36], ["infection", "OBSERVATION", 40, 49], ["secondary", "OBSERVATION_MODIFIER", 128, 137], ["infection", "OBSERVATION", 138, 147]]], ["Second, asthma, chronic obstructive pulmonary disease, and smoking are associated with both cilia dysfunction and increased severity of COVID-19.", [["pulmonary", "ANATOMY", 36, 45], ["cilia", "ANATOMY", 92, 97], ["asthma", "DISEASE", 8, 14], ["chronic obstructive pulmonary disease", "DISEASE", 16, 53], ["smoking", "CHEMICAL", 59, 66], ["cilia dysfunction", "DISEASE", 92, 109], ["pulmonary", "ORGAN", 36, 45], ["cilia", "MULTI-TISSUE_STRUCTURE", 92, 97], ["asthma", "PROBLEM", 8, 14], ["chronic obstructive pulmonary disease", "PROBLEM", 16, 53], ["both cilia dysfunction", "PROBLEM", 87, 109], ["increased severity of COVID", "PROBLEM", 114, 141], ["asthma", "OBSERVATION", 8, 14], ["chronic", "OBSERVATION_MODIFIER", 16, 23], ["obstructive", "OBSERVATION_MODIFIER", 24, 35], ["pulmonary", "ANATOMY", 36, 45], ["disease", "OBSERVATION", 46, 53], ["cilia dysfunction", "OBSERVATION", 92, 109], ["increased", "OBSERVATION_MODIFIER", 114, 123], ["severity", "OBSERVATION_MODIFIER", 124, 132]]], ["Whether these underlying conditions alter ciliated cells and thus increase their susceptibility to infection remains unclear.", [["ciliated cells", "ANATOMY", 42, 56], ["infection", "DISEASE", 99, 108], ["ciliated cells", "CELL", 42, 56], ["ciliated cells", "CELL_TYPE", 42, 56], ["these underlying conditions alter ciliated cells", "PROBLEM", 8, 56], ["their susceptibility to infection", "PROBLEM", 75, 108], ["ciliated cells", "OBSERVATION", 42, 56], ["infection", "OBSERVATION", 99, 108]]], ["The cell tropism of SARS-CoV-2 in the nasal epithelium and lower airway remain important areas of future investigation which will further enhance our understanding of COVID-19 pathogenesis.DiscussionDisease in COVID-19 patients is characterized by a lag following transmission with symptom onset at day seven and disease severity peaking 14 days post infection [29, 30].", [["cell", "ANATOMY", 4, 8], ["nasal epithelium", "ANATOMY", 38, 54], ["lower airway", "ANATOMY", 59, 71], ["infection", "DISEASE", 351, 360], ["cell", "CELL", 4, 8], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 20, 30], ["nasal epithelium", "TISSUE", 38, 54], ["airway", "MULTI-TISSUE_STRUCTURE", 65, 71], ["COVID-19", "CELL", 167, 175], ["patients", "ORGANISM", 219, 227], ["patients", "SPECIES", 219, 227], ["SARS-CoV", "SPECIES", 20, 28], ["The cell tropism", "TEST", 0, 16], ["SARS", "TEST", 20, 24], ["CoV", "TEST", 25, 28], ["future investigation", "TEST", 98, 118], ["COVID", "TEST", 167, 172], ["disease severity peaking", "PROBLEM", 313, 337], ["infection", "PROBLEM", 351, 360], ["cell tropism", "OBSERVATION", 4, 16], ["nasal epithelium", "ANATOMY", 38, 54], ["lower", "ANATOMY_MODIFIER", 59, 64], ["airway", "ANATOMY", 65, 71]]], ["This is in contrast to seasonal human coronaviruses and implicates an important role for the host immune response in COVID-19 progression.", [["human", "ORGANISM", 32, 37], ["coronaviruses", "ORGANISM", 38, 51], ["COVID-19", "CELL", 117, 125], ["human", "SPECIES", 32, 37], ["human coronaviruses", "SPECIES", 32, 51], ["seasonal human coronaviruses", "PROBLEM", 23, 51], ["COVID", "TEST", 117, 122]]], ["Several recent studies have revealed seemingly contradictory roles regarding SARS-CoV-2 induced innate immunity [31, 32].", [["SARS-CoV-2", "ORGANISM", 77, 87], ["Several recent studies", "TEST", 0, 22], ["SARS", "PROBLEM", 77, 81]]], ["Here, we show that the innate response to SARS-CoV-2 is intact and rapid, as characterized by interferon, chemokine, and IL-6 induction.", [["SARS", "DISEASE", 42, 46], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 42, 52], ["interferon", "GENE_OR_GENE_PRODUCT", 94, 104], ["IL-6", "GENE_OR_GENE_PRODUCT", 121, 125], ["interferon", "PROTEIN", 94, 104], ["chemokine", "PROTEIN", 106, 115], ["IL-6", "PROTEIN", 121, 125], ["SARS-CoV", "SPECIES", 42, 50], ["SARS", "TEST", 42, 46], ["CoV", "TEST", 47, 50], ["interferon", "TREATMENT", 94, 104], ["chemokine", "TREATMENT", 106, 115], ["IL", "TREATMENT", 121, 123], ["intact", "OBSERVATION", 56, 62]]], ["Interestingly, while we do not observe broad depletion of virus-susceptible cell populations, we detect increased expression of cell-death associated genes, which suggests the host anti-viral response is cytotoxic and may contribute to disease pathogenesis.", [["cell", "ANATOMY", 76, 80], ["cell", "ANATOMY", 128, 132], ["cell populations", "CELL", 76, 92], ["cell", "CELL", 128, 132], ["virus-susceptible cell populations", "CELL_LINE", 58, 92], ["cell-death associated genes", "DNA", 128, 155], ["virus", "PROBLEM", 58, 63], ["susceptible cell populations", "PROBLEM", 64, 92], ["cell-death associated genes", "PROBLEM", 128, 155], ["cytotoxic", "PROBLEM", 204, 213], ["disease pathogenesis", "PROBLEM", 236, 256], ["susceptible cell populations", "OBSERVATION", 64, 92], ["increased", "OBSERVATION_MODIFIER", 104, 113], ["cell", "OBSERVATION", 128, 132], ["may contribute to", "UNCERTAINTY", 218, 235]]], ["Consistent with this, IL-6 is a potent pro-inflammatory cytokine and serum IL-6 levels predict respiratory failure [33].", [["serum", "ANATOMY", 69, 74], ["respiratory", "ANATOMY", 95, 106], ["respiratory failure", "DISEASE", 95, 114], ["IL-6", "GENE_OR_GENE_PRODUCT", 22, 26], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["IL-6", "GENE_OR_GENE_PRODUCT", 75, 79], ["IL-6", "PROTEIN", 22, 26], ["pro-inflammatory cytokine", "PROTEIN", 39, 64], ["serum IL-6", "PROTEIN", 69, 79], ["a potent pro-inflammatory cytokine", "TEST", 30, 64], ["serum IL", "TEST", 69, 77], ["respiratory failure", "PROBLEM", 95, 114], ["respiratory failure", "OBSERVATION", 95, 114]]], ["Therapies targeting the IL-6 receptor are currently in clinical trials for the treatment of COVID-19.", [["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 24, 37], ["IL-6 receptor", "PROTEIN", 24, 37], ["Therapies", "TREATMENT", 0, 9], ["the IL-6 receptor", "TREATMENT", 20, 37], ["COVID", "TEST", 92, 97]]], ["This work raises a number of important future directions including whether other airway and endothelial tissues similarly interact with SARS-CoV-2 and how these interactions vary in vitro.Air-liquid interface culture of HBECs ::: MethodsHBECs, from Lonza, were cultured in suspension in PneumaCult-Ex Plus Medium according to manufacturer instructions (StemCell Technologies, Cambridge, MA, USA).", [["airway", "ANATOMY", 81, 87], ["endothelial tissues", "ANATOMY", 92, 111], ["HBECs", "ANATOMY", 220, 225], ["airway", "MULTI-TISSUE_STRUCTURE", 81, 87], ["endothelial tissues", "TISSUE", 92, 111], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 136, 146], ["HBECs", "CELL", 220, 225], ["MethodsHBECs", "CELL", 230, 242], ["HBECs", "CELL_TYPE", 220, 225], ["other airway and endothelial tissues", "PROBLEM", 75, 111], ["Air-liquid interface culture", "TEST", 188, 216], ["MethodsHBECs", "TEST", 230, 242], ["Lonza", "TREATMENT", 249, 254], ["airway", "ANATOMY", 81, 87], ["endothelial tissues", "ANATOMY", 92, 111], ["liquid interface", "OBSERVATION", 192, 208]]], ["To generate air-liquid interface cultures, HBECs were plated on collagen-coated transwell inserts with a 0.4-micron pore size (Costar, Corning, Tewksbury, MA, USA) at 5\u00d7104 cells/ml per filter and inserted into 24 well culture plates.", [["air-liquid interface cultures", "ANATOMY", 12, 41], ["HBECs", "ANATOMY", 43, 48], ["pore", "ANATOMY", 116, 120], ["cells", "ANATOMY", 173, 178], ["HBECs", "CELL", 43, 48], ["collagen", "GENE_OR_GENE_PRODUCT", 64, 72], ["cells", "CELL", 173, 178], ["air-liquid interface cultures", "CELL_LINE", 12, 41], ["HBECs", "CELL_TYPE", 43, 48], ["collagen", "PROTEIN", 64, 72], ["air-liquid interface cultures", "TEST", 12, 41], ["HBECs", "TEST", 43, 48], ["collagen-coated transwell inserts", "TREATMENT", 64, 97], ["a 0.4-micron pore size", "TREATMENT", 103, 125], ["filter", "TREATMENT", 186, 192], ["air-liquid interface", "OBSERVATION", 12, 32]]], ["Cells were maintained for the first 3 days in PneumaCult-Ex Plus Medium, then changed to PneumaCult-ALI Medium (StemCell Technologies) containing the ROCK inhibitor Y-27632 for 4 days.", [["Cells", "ANATOMY", 0, 5], ["ALI", "DISEASE", 100, 103], ["Y-27632", "CHEMICAL", 165, 172], ["Y-27632", "CHEMICAL", 165, 172], ["Cells", "CELL", 0, 5], ["ROCK", "GENE_OR_GENE_PRODUCT", 150, 154], ["Y-27632", "SIMPLE_CHEMICAL", 165, 172], ["ROCK", "PROTEIN", 150, 154], ["Y-27632", "SPECIES", 165, 172], ["Cells", "TEST", 0, 5], ["PneumaCult-Ex Plus Medium", "TREATMENT", 46, 71], ["PneumaCult-ALI Medium (StemCell Technologies", "TREATMENT", 89, 133], ["the ROCK inhibitor Y", "TREATMENT", 146, 166]]], ["Fresh medium, 100 \u03bcl in the apical chamber and 500 \u03bcl in the basal chamber, was provided every day.", [["apical chamber", "ANATOMY", 28, 42], ["medium", "OBSERVATION_MODIFIER", 6, 12], ["apical", "ANATOMY_MODIFIER", 28, 34], ["chamber", "ANATOMY_MODIFIER", 35, 42]]], ["At day 7, medium at the apical chambers were removed, while basal chambers were maintained with 500 \u03bcl of PneumaCult-ALI Medium.", [["apical chambers", "ANATOMY", 24, 39], ["basal chambers", "ANATOMY", 60, 74], ["ALI", "DISEASE", 117, 120], ["apical chambers", "MULTI-TISSUE_STRUCTURE", 24, 39], ["PneumaCult", "TREATMENT", 106, 116], ["apical", "ANATOMY_MODIFIER", 24, 30], ["chambers", "ANATOMY_MODIFIER", 31, 39], ["ALI Medium", "OBSERVATION", 117, 127]]], ["HBECs were maintained at air-liquid interface for 28 days allowing them to differentiate.", [["HBECs", "ANATOMY", 0, 5], ["HBECs", "CELL", 0, 5], ["HBECs", "CELL_TYPE", 0, 5], ["HBECs", "TEST", 0, 5]]], ["Medium in the basal chamber was changed every 2\u20133 days (500 \u03bcl).Viral infection ::: MethodsSARS-CoV-2 isolate USA-WA1/2020 was obtained from BEI reagent repository.", [["Viral infection", "DISEASE", 64, 79], ["USA", "ORGANISM", 110, 113], ["Viral infection", "PROBLEM", 64, 79], ["MethodsSARS", "TEST", 84, 95], ["basal", "ANATOMY_MODIFIER", 14, 19], ["chamber", "ANATOMY_MODIFIER", 20, 27], ["infection", "OBSERVATION", 70, 79]]], ["All infection experiments were performed in a Biosafety Level 3 facility, licensed by the State of Connecticut and Yale University.", [["infection", "DISEASE", 4, 13], ["All infection experiments", "PROBLEM", 0, 25], ["infection", "OBSERVATION", 4, 13]]], ["Immediately prior to infection, the apical side of the HBEC ALI culture was gently rinsed three times with 200 \u03bcl of phosphate buffered saline without divalent cations (PBS\u2212/\u2212).", [["apical", "ANATOMY", 36, 42], ["HBEC", "ANATOMY", 55, 59], ["infection", "DISEASE", 21, 30], ["ALI", "DISEASE", 60, 63], ["phosphate", "CHEMICAL", 117, 126], ["phosphate", "CHEMICAL", 117, 126], ["HBEC", "CELL", 55, 59], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 117, 142], ["divalent cations", "SIMPLE_CHEMICAL", 151, 167], ["HBEC ALI culture", "CELL_LINE", 55, 71], ["infection", "PROBLEM", 21, 30], ["the HBEC ALI culture", "TEST", 51, 71], ["phosphate buffered saline", "TREATMENT", 117, 142], ["divalent cations", "TREATMENT", 151, 167], ["infection", "OBSERVATION", 21, 30], ["apical", "ANATOMY_MODIFIER", 36, 42], ["HBEC ALI", "ANATOMY", 55, 63]]], ["104 plaque forming units (PFU) of SARS-CoV-2 in 100 \u03bcl total volume of PBS was added to the apical compartment.", [["plaque", "ANATOMY", 4, 10], ["apical compartment", "ANATOMY", 92, 110], ["SARS", "DISEASE", 34, 38], ["apical compartment", "MULTI-TISSUE_STRUCTURE", 92, 110], ["SARS-CoV", "SPECIES", 34, 42], ["PFU", "TEST", 26, 29], ["SARS", "TEST", 34, 38], ["CoV", "TEST", 39, 42], ["PBS", "TREATMENT", 71, 74], ["plaque", "OBSERVATION", 4, 10], ["apical", "ANATOMY_MODIFIER", 92, 98], ["compartment", "ANATOMY_MODIFIER", 99, 110]]], ["Cells were incubated at 37\u00b0C and 5% CO2 for 1 hour.", [["Cells", "ANATOMY", 0, 5], ["CO2", "CHEMICAL", 36, 39], ["CO2", "CHEMICAL", 36, 39], ["Cells", "CELL", 0, 5], ["CO2", "SIMPLE_CHEMICAL", 36, 39], ["Cells", "TEST", 0, 5]]], ["Unbound virus was removed and cells were cultured with an air-liquid interface for up to three days.", [["cells", "ANATOMY", 30, 35], ["cells", "CELL", 30, 35], ["Unbound virus", "PROBLEM", 0, 13], ["cells", "TREATMENT", 30, 35], ["an air-liquid interface", "TREATMENT", 55, 78], ["virus", "OBSERVATION", 8, 13]]], ["Infections were staggered by one day and all four samples were processed simultaneously for single-cell RNA sequencing, as described below.Sample preparation for single-cell RNA sequencing ::: MethodsInoculated HBECs were washed with 1X PBS\u2212/\u2212 and trypsinized with TrypLE Express Enzyme (ThermoFisher, Waltham, MA, USA) to generate single-cell suspensions.", [["samples", "ANATOMY", 50, 57], ["HBECs", "ANATOMY", 211, 216], ["cell", "ANATOMY", 339, 343], ["HBECs", "CELL", 211, 216], ["TrypLE", "SIMPLE_CHEMICAL", 265, 271], ["HBECs", "CELL_TYPE", 211, 216], ["Infections", "PROBLEM", 0, 10], ["all four samples", "TEST", 41, 57], ["Sample preparation", "TEST", 139, 157], ["MethodsInoculated HBECs", "TREATMENT", 193, 216], ["1X PBS", "TREATMENT", 234, 240], ["Enzyme", "TEST", 280, 286], ["single-cell suspensions", "TREATMENT", 332, 355]]], ["100\u03bcl of TrypLE was added on the apical chamber, incubated for 10 min at 37\u00b0C in a CO2 incubator, and was gently pipetted up and down to dissociate cells.", [["apical chamber", "ANATOMY", 33, 47], ["cells", "ANATOMY", 148, 153], ["TrypLE", "CHEMICAL", 9, 15], ["TrypLE", "CHEMICAL", 9, 15], ["CO2", "CHEMICAL", 83, 86], ["TrypLE", "SIMPLE_CHEMICAL", 9, 15], ["CO2", "SIMPLE_CHEMICAL", 83, 86], ["cells", "CELL", 148, 153], ["TrypLE", "PROTEIN", 9, 15], ["TrypLE", "TREATMENT", 9, 15], ["a CO2 incubator", "TREATMENT", 81, 96], ["apical", "ANATOMY_MODIFIER", 33, 39], ["chamber", "ANATOMY_MODIFIER", 40, 47]]], ["Harvested cells were transferred in a sterile 1.5 ml tube and neutralized with DMEM containing 10 percent FBS.", [["cells", "ANATOMY", 10, 15], ["FBS", "ANATOMY", 106, 109], ["cells", "CELL", 10, 15], ["tube", "TISSUE", 53, 57], ["FBS", "ORGANISM_SUBSTANCE", 106, 109], ["a sterile 1.5 ml tube", "TREATMENT", 36, 57], ["DMEM", "TREATMENT", 79, 83]]], ["An additional 100 \u03bcl of TrypLE was placed on the apical chamber repeating the same procedure as above for a total of 30 min to maximize collection of cells.", [["cells", "ANATOMY", 150, 155], ["TrypLE", "CHEMICAL", 24, 30], ["TrypLE", "CHEMICAL", 24, 30], ["TrypLE", "SIMPLE_CHEMICAL", 24, 30], ["cells", "CELL", 150, 155], ["TrypLE", "TREATMENT", 24, 30], ["the apical chamber", "TREATMENT", 45, 63], ["the same procedure", "TREATMENT", 74, 92], ["collection of cells", "PROBLEM", 136, 155], ["apical", "ANATOMY_MODIFIER", 49, 55]]], ["Cells were centrifuged at 300 x g for 3 min and resuspended in 100 \u03bcl DMEM with 10 percent FBS.", [["Cells", "ANATOMY", 0, 5], ["FBS", "ANATOMY", 91, 94], ["Cells", "CELL", 0, 5], ["FBS", "ORGANISM_SUBSTANCE", 91, 94], ["Cells", "TEST", 0, 5]]], ["Cell count and viability was determined using trypan blue dye exclusion on a Countess II (ThermoFisher Scientific).", [["Cell", "ANATOMY", 0, 4], ["trypan blue", "CHEMICAL", 46, 57], ["trypan blue", "CHEMICAL", 46, 57], ["Cell", "CELL", 0, 4], ["trypan blue dye", "SIMPLE_CHEMICAL", 46, 61], ["Cell count", "TEST", 0, 10], ["viability", "TEST", 15, 24], ["trypan blue dye", "TREATMENT", 46, 61]]], ["The targeted cell input was 10,000 cells per condition.", [["cell", "ANATOMY", 13, 17], ["cells", "ANATOMY", 35, 40], ["cell", "CELL", 13, 17], ["cells", "CELL", 35, 40]]], ["The Chromium Next GEM (Gel Bead-In Emulsion) Single Cell 3\u2019 Gel beads v3.1 kit (10X Genomics, Pleasanton, CA, USA) was used to create GEMs following manufacturer\u2019s instruction.", [["Chromium", "CHEMICAL", 4, 12], ["GEM", "CHEMICAL", 18, 21], ["Chromium", "CHEMICAL", 4, 12], ["Chromium", "SIMPLE_CHEMICAL", 4, 12], ["The Chromium Next GEM (Gel Bead-In Emulsion", "TREATMENT", 0, 43], ["Single Cell", "TREATMENT", 45, 56]]], ["All samples and reagents were prepared and loaded into the chip and ran in the Chromium Controller for GEM generation and barcoding.", [["samples", "ANATOMY", 4, 11], ["Chromium", "CHEMICAL", 79, 87], ["GEM", "CHEMICAL", 103, 106], ["Chromium", "CHEMICAL", 79, 87], ["All samples", "TEST", 0, 11], ["the Chromium Controller", "TREATMENT", 75, 98], ["GEM generation", "TREATMENT", 103, 117], ["barcoding", "TREATMENT", 122, 131]]], ["GEMs generated were used for cDNA synthesis and library preparation using the Chromium Single Cell 3\u2019 Library Kit v3.1 (10X Genomics) following the manufacturer\u2019s instruction.", [["Chromium", "CHEMICAL", 78, 86], ["Chromium", "CHEMICAL", 78, 86], ["cDNA synthesis", "TREATMENT", 29, 43], ["library preparation", "TREATMENT", 48, 67], ["Library Kit", "TEST", 102, 113]]], ["Generated libraries were sequenced on NovaSeq 6000 system using HiSeq 100 base pair reads and dual indexing.", [["HiSeq 100 base pair reads", "DNA", 64, 89]]], ["Cells were sequenced to an average depth of 31,383 reads per cell.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 61, 65], ["Cells", "CELL", 0, 5], ["cell", "CELL", 61, 65], ["an average depth", "TEST", 24, 40]]], ["The human genome, Ensembl GRCh38.98.gtf, and the SARS-CoV-2 genome, NCBI Genome database accession MT020880.1, were combined and used for alignment.", [["human", "ORGANISM", 4, 9], ["human genome", "DNA", 4, 16], ["Ensembl GRCh38.98", "DNA", 18, 35], ["gtf", "DNA", 36, 39], ["SARS-CoV-2 genome", "DNA", 49, 66], ["NCBI Genome database accession MT020880.1", "DNA", 68, 109], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["SARS-CoV", "SPECIES", 49, 57], ["gtf", "TEST", 36, 39], ["the SARS", "TEST", 45, 53], ["CoV", "TEST", 54, 57], ["human genome", "OBSERVATION", 4, 16]]], ["We ran the standard 10x Genomics cellranger pipeline with a combined human and SARS-CoV-2 genome to obtain count matrices for each of the 4 growth conditions.", [["human", "ORGANISM", 69, 74], ["human and SARS-CoV-2 genome", "DNA", 69, 96], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 69, 74], ["SARS-CoV", "SPECIES", 79, 87], ["a combined human", "TREATMENT", 58, 74], ["CoV-2 genome", "TREATMENT", 84, 96], ["count matrices", "TREATMENT", 107, 121]]], ["Per condition, there were an average of between 10,000 to 15,000 counts per cell or an average of 2,400 to 3,600 unique genes detected per condition.Quantitative RT-PCR of SARS-CoV2 ::: MethodsViral RNA from SARS-CoV-2 infected HBEC cell lysates was extracted using TRIzol (Life Technologies) and purified using Direct-zol RNA MiniPrep Plus according to manufacturer\u2019s instructions (Zymo Research, Irvine, CA, USA).", [["cell", "ANATOMY", 76, 80], ["HBEC cell lysates", "ANATOMY", 228, 245], ["cell", "CELL", 76, 80], ["SARS-CoV-2", "CELL", 208, 218], ["HBEC cell lysates", "CELL", 228, 245], ["SARS-CoV2 ::: MethodsViral RNA", "RNA", 172, 202], ["SARS-CoV", "SPECIES", 208, 216], ["Quantitative RT-PCR", "TEST", 149, 168], ["SARS", "PROBLEM", 172, 176], ["CoV2", "TEST", 177, 181], ["MethodsViral RNA", "PROBLEM", 186, 202], ["SARS", "TEST", 208, 212], ["CoV", "TEST", 213, 216], ["infected HBEC cell lysates", "TREATMENT", 219, 245], ["TRIzol (Life Technologies", "TREATMENT", 266, 291], ["Direct-zol RNA MiniPrep", "TREATMENT", 312, 335], ["HBEC cell", "OBSERVATION", 228, 237]]], ["A two-step cDNA synthesis with 5 \u03bcl RNA, random hexamer, and ImProm-II Reverse Transcriptase (Promega, Madison, WI, USA) was performed.", [["ImProm-II", "GENE_OR_GENE_PRODUCT", 61, 70], ["5 \u03bcl RNA", "RNA", 31, 39], ["A two-step cDNA synthesis", "TREATMENT", 0, 25], ["5 \u03bcl RNA", "TREATMENT", 31, 39], ["random hexamer", "TEST", 41, 55]]], ["The qPCR analysis was performed in duplicate for each of the samples and standard curves generated using SARS-CoV-2 nucleocapsid (N1) specific oligonucleotides from Integrated DNA Technologies (Coralville, IA, USA): Probe: 5\u2019 6FAM ACCCCGCATTACGTTTGGTGGACC-BHQ1 3\u2019; Forward primer: 5\u2019 GACCCCAAAATCAGCGAAAT 3\u2019; Reverse primer: 5\u2019 TCTGGTTACTGCCAGTTGAATCTG 3\u2019.", [["samples", "ANATOMY", 61, 68], ["DNA", "CELLULAR_COMPONENT", 176, 179], ["SARS-CoV-2 nucleocapsid (N1) specific oligonucleotides", "DNA", 105, 159], ["BHQ1 3", "DNA", 256, 262], ["Forward primer", "DNA", 265, 279], ["Reverse primer", "DNA", 309, 323], ["SARS-CoV", "SPECIES", 105, 113], ["The qPCR analysis", "TEST", 0, 17], ["the samples", "TEST", 57, 68], ["standard curves", "TEST", 73, 88], ["SARS", "TEST", 105, 109], ["CoV", "TEST", 110, 113], ["ACCCCGCATTACGTTTGGTGGACC", "TEST", 231, 255], ["GACCCCAAAATCAGCGAAAT", "TEST", 284, 304], ["TCTGGTTACTGCCAGTTGAATCTG", "TEST", 328, 352]]], ["The limit of detection was 10 SARS-CoV-2 genome copies/\u03bcl.", [["detection", "TEST", 13, 22], ["SARS", "TEST", 30, 34], ["CoV", "TEST", 35, 38]]], ["The virus copy numbers were quantified using a control plasmid which contain the complete nucleocapsid gene from SARS-CoV-2.Validation of polyadenylated SARS-CoV-2 transcripts ::: MethodsHuh7.5 cells grown in DMEM containing 10 percent FBS were infected with 104 PFU of SARS-CoV-2 and cell lysates were harvested at 0, 1, 2, and 3 dpi.", [["cells", "ANATOMY", 194, 199], ["FBS", "ANATOMY", 236, 239], ["cell lysates", "ANATOMY", 285, 297], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 113, 123], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 153, 163], ["MethodsHuh7.5 cells", "CELL", 180, 199], ["FBS", "ORGANISM_SUBSTANCE", 236, 239], ["CoV-2", "CELL", 275, 280], ["cell lysates", "CELL", 285, 297], ["control plasmid", "DNA", 47, 62], ["nucleocapsid gene", "DNA", 90, 107], ["polyadenylated SARS-CoV-2 transcripts", "RNA", 138, 175], ["MethodsHuh7.5 cells", "CELL_LINE", 180, 199], ["SARS-CoV", "SPECIES", 113, 121], ["SARS-CoV", "SPECIES", 270, 278], ["The virus copy numbers", "TEST", 0, 22], ["a control plasmid", "TREATMENT", 45, 62], ["CoV", "TEST", 118, 121], ["polyadenylated SARS", "PROBLEM", 138, 157], ["percent FBS", "TEST", 228, 239], ["SARS", "TEST", 270, 274], ["CoV", "TEST", 275, 278], ["cell lysates", "TREATMENT", 285, 297], ["nucleocapsid", "OBSERVATION", 90, 102], ["polyadenylated SARS", "OBSERVATION", 138, 157]]], ["Using 0.3 \u03bcg total RNA extracted from mock or SARSCoV-2-infected Huh7.5 cells at different time points, reverse transcription was performed with oligo-d(T)20 (ThermoFisher) and MarathonRT, a highly processive group II intron-encoded RT.", [["Huh7.5 cells", "ANATOMY", 65, 77], ["SARSCoV-2", "CELL", 46, 55], ["Huh7.5 cells", "CELL", 65, 77], ["Huh7.5 cells", "CELL_LINE", 65, 77], ["\u03bcg total RNA", "TREATMENT", 10, 22], ["SARSCoV", "TEST", 46, 53], ["reverse transcription", "TREATMENT", 104, 125], ["oligo-d(T)", "TREATMENT", 145, 155]]], ["MarathonRT purification and RT reactions were performed as previously described [34].", [["MarathonRT purification", "TREATMENT", 0, 23], ["RT reactions", "PROBLEM", 28, 40]]], ["PCR (NEBNext Ultra II Q5\u00aeMaster Mix, NEB, Ipswich, MA, USA) was performed with a gene-specific forward primer designed 700-nt upstream of the apparent boundary between the SARS-CoV-2 genome body and the putative poly-A tail.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 172, 182], ["poly-A tail", "GENE_OR_GENE_PRODUCT", 212, 223], ["forward primer", "DNA", 95, 109], ["700-nt upstream", "DNA", 119, 134], ["SARS-CoV-2 genome body", "DNA", 172, 194], ["putative poly-A tail", "DNA", 203, 223], ["PCR", "TEST", 0, 3], ["NEBNext Ultra II", "TREATMENT", 5, 21], ["the SARS", "TEST", 168, 176], ["CoV", "TEST", 177, 180], ["tail", "ANATOMY", 219, 223]]], ["Oligo-d(T)20 was used as a reverse primer.", [["Oligo", "CHEMICAL", 0, 5], ["Oligo-d(T)20", "CHEMICAL", 0, 12], ["Oligo-d(T)20", "GENE_OR_GENE_PRODUCT", 0, 12], ["Oligo-d(T)20", "DNA", 0, 12], ["reverse primer", "DNA", 27, 41], ["Oligo-d(T)", "TREATMENT", 0, 10], ["a reverse primer", "TREATMENT", 25, 41]]], ["Touchdown PCR cycling was used to enhance specificity of the PCR reaction.", [["Touchdown PCR cycling", "TEST", 0, 21], ["the PCR reaction", "PROBLEM", 57, 73]]], ["RT-PCR products were resolved on a 1.3% agarose gel with ladder (100 bp DNA Ladder, 1 kb Plus DNA Ladder, Invitrogen).", [["agarose", "SIMPLE_CHEMICAL", 40, 47], ["DNA", "CELLULAR_COMPONENT", 72, 75], ["DNA", "CELLULAR_COMPONENT", 94, 97], ["RT-PCR products", "TREATMENT", 0, 15], ["a 1.3% agarose gel", "TREATMENT", 33, 51], ["ladder (100 bp DNA Ladder", "TREATMENT", 57, 82], ["DNA Ladder", "TREATMENT", 94, 104], ["Invitrogen", "TREATMENT", 106, 116]]], ["Forward PCR oligonucleotides used in this experiment are below, which includes two positive controls.Validation of polyadenylated SARS-CoV-2 transcripts ::: MethodsPrimer Name Position on Genome 5\u2019\u22123\u2019 Sequence:Electron microscopy ::: MethodsThe cells were fixed using 2.5% glutaraldehyde in 0.1M phosphate buffer, osmicated in 1% osmium tetroxide, and dehydrated in increasing ethanol concentrations.", [["cells", "ANATOMY", 245, 250], ["glutaraldehyde", "CHEMICAL", 273, 287], ["0.1M phosphate", "CHEMICAL", 291, 305], ["osmium tetroxide", "CHEMICAL", 330, 346], ["ethanol", "CHEMICAL", 377, 384], ["glutaraldehyde", "CHEMICAL", 273, 287], ["phosphate", "CHEMICAL", 296, 305], ["osmium tetroxide", "CHEMICAL", 330, 346], ["ethanol", "CHEMICAL", 377, 384], ["cells", "CELL", 245, 250], ["glutaraldehyde", "SIMPLE_CHEMICAL", 273, 287], ["0.1M phosphate buffer", "SIMPLE_CHEMICAL", 291, 312], ["osmium tetroxide", "SIMPLE_CHEMICAL", 330, 346], ["ethanol", "SIMPLE_CHEMICAL", 377, 384], ["polyadenylated SARS-CoV-2 transcripts", "RNA", 115, 152], ["Forward PCR oligonucleotides", "TREATMENT", 0, 28], ["polyadenylated SARS", "PROBLEM", 115, 134], ["Methods", "TREATMENT", 234, 241], ["2.5% glutaraldehyde in 0.1M phosphate buffer", "TREATMENT", 268, 312], ["1% osmium tetroxide", "TREATMENT", 327, 346], ["increasing ethanol concentrations", "TREATMENT", 366, 399], ["positive controls", "OBSERVATION", 83, 100], ["polyadenylated SARS", "OBSERVATION", 115, 134], ["increasing", "OBSERVATION_MODIFIER", 366, 376], ["ethanol concentrations", "OBSERVATION", 377, 399]]], ["During dehydration, 1% uranyl acetate was added to the 70% ethanol to enhance ultrastructural membrane contrast.", [["membrane", "ANATOMY", 94, 102], ["dehydration", "DISEASE", 7, 18], ["uranyl acetate", "CHEMICAL", 23, 37], ["ethanol", "CHEMICAL", 59, 66], ["uranyl acetate", "CHEMICAL", 23, 37], ["ethanol", "CHEMICAL", 59, 66], ["uranyl acetate", "SIMPLE_CHEMICAL", 23, 37], ["ethanol", "SIMPLE_CHEMICAL", 59, 66], ["membrane", "CELLULAR_COMPONENT", 94, 102], ["dehydration", "PROBLEM", 7, 18], ["1% uranyl acetate", "TREATMENT", 20, 37], ["ultrastructural membrane contrast", "TEST", 78, 111]]], ["After dehydration the cells were embedded in Durcupan.", [["cells", "ANATOMY", 22, 27], ["dehydration", "DISEASE", 6, 17], ["cells", "CELL", 22, 27], ["dehydration the cells", "PROBLEM", 6, 27], ["Durcupan", "TREATMENT", 45, 53]]], ["70 nm ultrathin sections were cut on a Leica ultramicrotome, collected on Formvar coated single-slot grids, and analyzed with a Tecnai 12 Biotwin electron microscope (FEI).Cell type annotation ::: ScRNA-seq data analysis ::: MethodsWe used the standard scRNA-seq analysis pipeline for clustering [35].", [["sections", "ANATOMY", 16, 24], ["Cell", "ANATOMY", 172, 176], ["Cell", "CELL", 172, 176], ["nm ultrathin sections", "TREATMENT", 3, 24], ["a Leica ultramicrotome", "TREATMENT", 37, 59], ["Formvar coated single-slot grids", "TREATMENT", 74, 106], ["a Tecnai", "TREATMENT", 126, 134], ["MethodsWe", "TREATMENT", 225, 234], ["the standard scRNA", "TREATMENT", 240, 258]]], ["Briefly, to account for transcript dropout inherent to scRNA-seq, we removed genes that were expressed in fewer than 3 cells and removed cells that expressed fewer than 200 genes.", [["3 cells", "ANATOMY", 117, 124], ["cells", "ANATOMY", 137, 142], ["scRNA-seq", "GENE_OR_GENE_PRODUCT", 55, 64], ["cells", "CELL", 119, 124], ["cells", "CELL", 137, 142], ["scRNA-seq", "DNA", 55, 64], ["transcript dropout", "PROBLEM", 24, 42]]], ["Next, we filter out cells with more than 10 percent of mitochondrial genes.", [["cells", "ANATOMY", 20, 25], ["mitochondrial", "ANATOMY", 55, 68], ["cells", "CELL", 20, 25], ["mitochondrial", "CELLULAR_COMPONENT", 55, 68], ["mitochondrial genes", "DNA", 55, 74], ["we filter out cells", "TREATMENT", 6, 25], ["filter", "OBSERVATION", 9, 15], ["mitochondrial genes", "OBSERVATION", 55, 74]]], ["We did not find a correlation between viral copy number and mitochondrial expression.", [["mitochondrial", "ANATOMY", 60, 73], ["mitochondrial", "CELLULAR_COMPONENT", 60, 73], ["mitochondrial expression", "OBSERVATION", 60, 84]]], ["The resulting raw unique molecular identifier (UMI) counts in each cell were normalized to their library size.", [["cell", "ANATOMY", 67, 71], ["cell", "CELL", 67, 71], ["UMI) counts", "TEST", 47, 58], ["library", "OBSERVATION_MODIFIER", 97, 104], ["size", "OBSERVATION_MODIFIER", 105, 109]]], ["Then, normalized counts were square-root transformed, which is similar to a log transform but does not require addition of a pseudo count.", [["a pseudo count", "TEST", 123, 137], ["root transformed", "OBSERVATION", 36, 52]]], ["Data pre-processing was performed in Python (version 3.7.4) using Scanpy (version 1.4.6) [36].Cell type annotation ::: ScRNA-seq data analysis ::: MethodsWe visually observed batch effects between conditions in 2-dimensional cellular embeddings.", [["Cell", "ANATOMY", 94, 98], ["cellular", "ANATOMY", 225, 233], ["Cell", "CELL", 94, 98], ["cellular", "CELL", 225, 233], ["Data pre-processing", "TEST", 0, 19], ["cellular embeddings", "OBSERVATION", 225, 244]]], ["To remove these batch effects for clustering, cell-type annotation, and visualization, we used an approximate batch-balanced kNN graph for manifold learning (BB-kNN batch-effect correction) using Scanpy\u2019s fast approximation implementation [37, 36].", [["cell", "ANATOMY", 46, 50], ["cell", "CELL", 46, 50], ["these batch effects", "TREATMENT", 10, 29], ["visualization", "TEST", 72, 85], ["an approximate batch", "TREATMENT", 95, 115], ["BB-kNN batch", "TREATMENT", 158, 170]]], ["BB-kNN assumes that at least some cell types are shared across batches and that differences between batches for a same cell type are lower than differences between cells of different types within a batch.", [["cell", "ANATOMY", 34, 38], ["cell", "ANATOMY", 119, 123], ["cells", "ANATOMY", 164, 169], ["cell", "CELL", 34, 38], ["cell type", "CELL", 119, 128], ["cells", "CELL", 164, 169], ["BB", "PROTEIN", 0, 2], ["kNN", "PROTEIN", 3, 6], ["some cell types", "PROBLEM", 29, 44], ["a batch", "TREATMENT", 196, 203], ["cell types", "OBSERVATION", 34, 44]]], ["For each cell, the 3-nearest neighboring cells in each condition were identified by Euclidean distance in 100-dimensional Principal Component Analysis (PCA) space.", [["cell", "ANATOMY", 9, 13], ["cells", "ANATOMY", 41, 46], ["cell", "CELL", 9, 13], ["cells", "CELL", 41, 46]]], ["This kNN graph was used as the basis for downstream analysis.Cell type annotation ::: ScRNA-seq data analysis ::: MethodsTo visualize the scRNA-seq data we implemented various non-linear dimension reduction methods and used the BB-kNN batch-corrected connectivity matrix as input for Uniform Manifold Approximation and Projection (UMAP) [38] and Potential of Heat-diffusion for Affinity-based Trajectory Embedding (PHATE) [39].", [["Cell", "ANATOMY", 61, 65], ["Cell", "CELL", 61, 65], ["kNN graph", "DNA", 5, 14], ["scRNA-seq", "DNA", 138, 147], ["This kNN graph", "TEST", 0, 14], ["downstream analysis", "TEST", 41, 60], ["various non-linear dimension reduction methods", "TREATMENT", 168, 214], ["the BB", "TREATMENT", 224, 230], ["kNN batch", "TREATMENT", 231, 240], ["Uniform Manifold Approximation", "TREATMENT", 284, 314], ["Heat-diffusion", "TEST", 359, 373], ["Affinity", "TEST", 378, 386]]], ["UMAP projections were generated using a minimum distance of 0.5.", [["a minimum distance", "TEST", 38, 56]]], ["PHATE projections were generated with a gamma parameter of 1.Cell type annotation ::: ScRNA-seq data analysis ::: MethodsFor cell clustering we used the Louvain community detection method [40] with the BB-kNN graph.", [["Cell", "ANATOMY", 61, 65], ["cell", "ANATOMY", 125, 129], ["Cell", "CELL", 61, 65], ["cell", "CELL", 125, 129], ["PHATE", "PROTEIN", 0, 5], ["BB-kNN graph", "DNA", 202, 214], ["a gamma parameter", "TEST", 38, 55], ["Methods", "TREATMENT", 114, 121], ["the BB", "TEST", 198, 204]]], ["We used high-resolution community detection and merged clusters based on expression of bronchial epithelium cell-type markers in order to isolate some rare cell types, e.g. Tuft cells [41, 42].", [["bronchial epithelium cell", "ANATOMY", 87, 112], ["cell", "ANATOMY", 156, 160], ["Tuft cells", "ANATOMY", 173, 183], ["bronchial epithelium cell-type", "CELL", 87, 117], ["cell", "CELL", 156, 160], ["Tuft cells", "CELL", 173, 183], ["bronchial epithelium cell", "CELL_TYPE", 87, 112], ["Tuft cells", "CELL_LINE", 173, 183], ["bronchial epithelium cell", "PROBLEM", 87, 112], ["some rare cell types", "PROBLEM", 146, 166], ["Tuft cells", "TEST", 173, 183], ["bronchial", "ANATOMY", 87, 96], ["epithelium cell", "OBSERVATION", 97, 112], ["rare cell types", "OBSERVATION", 151, 166]]], ["To annotate the different cell types present in HBECs we analyzed expression of a range of marker genes that were reported in a molecular cell atlas from Travaglini et al. [41].", [["cell", "ANATOMY", 26, 30], ["HBECs", "ANATOMY", 48, 53], ["cell", "ANATOMY", 138, 142], ["cell", "CELL", 26, 30], ["HBECs", "CELL", 48, 53], ["cell", "CELL", 138, 142], ["HBECs", "CELL_TYPE", 48, 53], ["marker genes", "DNA", 91, 103], ["different cell types", "OBSERVATION", 16, 36]]], ["We focused on 8 cell types: (i) Basal cells (KRT5, DAPL1, TP63), (ii) Ciliated cells (FOXJ1, CCDC153, CCDC113, MLF1, LZTFL1), (iii) Club cells (SCGB1A1, KRT15, CYP2F2, LYPD2, CBR2), (iv) BC/club (KRT4, KRT13), (v) Neuroendocrine cells (CHG1, ASCL1), (vi) Tuft cells (POU2F3, AVIL, GNAT3, TRPM5), (vi) Ionocytes (FOXI1, CFTR, ASCL3) and (viii) goblet cells (MUC5AC, MUC5B, GP2, SPDEF).Infection threshold and infection score ::: ScRNA-seq data analysis ::: MethodsCounting a viral transcript in a cell does not mean the cell is infected, as this count can come from virus attached to the surface of the cell, ambient virus in the suspension, or from read misalignment.", [["cell", "ANATOMY", 16, 20], ["Basal cells", "ANATOMY", 32, 43], ["KRT5", "ANATOMY", 45, 49], ["Ciliated cells", "ANATOMY", 70, 84], ["Club cells", "ANATOMY", 132, 142], ["Neuroendocrine cells", "ANATOMY", 214, 234], ["CHG1", "ANATOMY", 236, 240], ["ASCL1", "ANATOMY", 242, 247], ["Tuft cells", "ANATOMY", 255, 265], ["POU2F3", "ANATOMY", 267, 273], ["Ionocytes", "ANATOMY", 301, 310], ["goblet cells", "ANATOMY", 343, 355], ["cell", "ANATOMY", 496, 500], ["cell", "ANATOMY", 519, 523], ["surface", "ANATOMY", 587, 594], ["cell", "ANATOMY", 602, 606], ["infection", "DISEASE", 408, 417], ["cell", "CELL", 16, 20], ["Basal cells", "CELL", 32, 43], ["KRT5", "CELL", 45, 49], ["DAPL1", "GENE_OR_GENE_PRODUCT", 51, 56], ["Ciliated cells", "CELL", 70, 84], ["FOXJ1", "GENE_OR_GENE_PRODUCT", 86, 91], ["CCDC153", "GENE_OR_GENE_PRODUCT", 93, 100], ["CCDC113", "GENE_OR_GENE_PRODUCT", 102, 109], ["MLF1", "GENE_OR_GENE_PRODUCT", 111, 115], ["LZTFL1", "GENE_OR_GENE_PRODUCT", 117, 123], ["Club cells", "CELL", 132, 142], ["SCGB1A1", "GENE_OR_GENE_PRODUCT", 144, 151], ["KRT15", "GENE_OR_GENE_PRODUCT", 153, 158], ["CYP2F2", "GENE_OR_GENE_PRODUCT", 160, 166], ["LYPD2", "GENE_OR_GENE_PRODUCT", 168, 173], ["CBR2", "GENE_OR_GENE_PRODUCT", 175, 179], ["Neuroendocrine cells", "CELL", 214, 234], ["CHG1", "CELL", 236, 240], ["Tuft cells", "CELL", 255, 265], ["POU2F3", "GENE_OR_GENE_PRODUCT", 267, 273], ["AVIL", "GENE_OR_GENE_PRODUCT", 275, 279], ["GNAT3", "GENE_OR_GENE_PRODUCT", 281, 286], ["TRPM5", "GENE_OR_GENE_PRODUCT", 288, 293], ["FOXI1", "GENE_OR_GENE_PRODUCT", 312, 317], ["CFTR", "GENE_OR_GENE_PRODUCT", 319, 323], ["goblet cells", "CELL", 343, 355], ["MUC5AC", "GENE_OR_GENE_PRODUCT", 357, 363], ["MUC5B", "GENE_OR_GENE_PRODUCT", 365, 370], ["GP2", "GENE_OR_GENE_PRODUCT", 372, 375], ["SPDEF", "GENE_OR_GENE_PRODUCT", 377, 382], ["cell", "CELL", 496, 500], ["cell", "CELL", 519, 523], ["surface", "CELLULAR_COMPONENT", 587, 594], ["cell", "CELL", 602, 606], ["Basal cells", "CELL_TYPE", 32, 43], ["KRT5", "CELL_LINE", 45, 49], ["DAPL1", "CELL_LINE", 51, 56], ["TP63", "CELL_LINE", 58, 62], ["Ciliated cells", "CELL_TYPE", 70, 84], ["FOXJ1", "PROTEIN", 86, 91], ["CCDC153", "PROTEIN", 93, 100], ["CCDC113", "PROTEIN", 102, 109], ["MLF1", "PROTEIN", 111, 115], ["LZTFL1", "PROTEIN", 117, 123], ["Club cells", "CELL_TYPE", 132, 142], ["SCGB1A1", "PROTEIN", 144, 151], ["KRT15", "PROTEIN", 153, 158], ["CYP2F2", "PROTEIN", 160, 166], ["LYPD2", "PROTEIN", 168, 173], ["CBR2", "PROTEIN", 175, 179], ["BC", "PROTEIN", 187, 189], ["KRT4", "PROTEIN", 196, 200], ["KRT13", "PROTEIN", 202, 207], ["Neuroendocrine cells", "CELL_TYPE", 214, 234], ["CHG1", "CELL_LINE", 236, 240], ["ASCL1", "CELL_LINE", 242, 247], ["Tuft cells", "CELL_TYPE", 255, 265], ["POU2F3", "PROTEIN", 267, 273], ["AVIL", "PROTEIN", 275, 279], ["GNAT3", "PROTEIN", 281, 286], ["TRPM5", "PROTEIN", 288, 293], ["Ionocytes", "PROTEIN", 301, 310], ["FOXI1", "PROTEIN", 312, 317], ["CFTR", "PROTEIN", 319, 323], ["ASCL3", "PROTEIN", 325, 330], ["goblet cells", "CELL_TYPE", 343, 355], ["MUC5AC", "PROTEIN", 357, 363], ["MUC5B", "PROTEIN", 365, 370], ["GP2", "PROTEIN", 372, 375], ["SPDEF", "PROTEIN", 377, 382], ["viral transcript", "RNA", 474, 490], ["Basal cells", "TEST", 32, 43], ["KRT5", "TEST", 45, 49], ["DAPL1", "TEST", 51, 56], ["TP63", "TEST", 58, 62], ["Ciliated cells", "TEST", 70, 84], ["FOXJ1", "TEST", 86, 91], ["CCDC153", "TEST", 93, 100], ["CCDC113", "TEST", 102, 109], ["MLF1", "TEST", 111, 115], ["LZTFL1", "TEST", 117, 123], ["Club cells", "TEST", 132, 142], ["SCGB1A1", "TEST", 144, 151], ["KRT15", "TEST", 153, 158], ["CYP2F2", "TEST", 160, 166], ["LYPD2", "TEST", 168, 173], ["CBR2", "TEST", 175, 179], ["BC", "TEST", 187, 189], ["club", "TEST", 190, 194], ["KRT4", "TEST", 196, 200], ["KRT13", "TEST", 202, 207], ["Neuroendocrine cells", "TEST", 214, 234], ["CHG1", "TEST", 236, 240], ["ASCL1", "TEST", 242, 247], ["Tuft cells", "TEST", 255, 265], ["POU2F3", "TEST", 267, 273], ["AVIL", "TEST", 275, 279], ["GNAT3", "TEST", 281, 286], ["TRPM5", "TEST", 288, 293], ["Ionocytes", "TEST", 301, 310], ["FOXI1", "TEST", 312, 317], ["CFTR", "TEST", 319, 323], ["ASCL3", "TEST", 325, 330], ["goblet cells", "TEST", 343, 355], ["MUC5AC", "TEST", 357, 363], ["Infection threshold", "PROBLEM", 384, 403], ["a viral transcript", "PROBLEM", 472, 490], ["this count", "TEST", 540, 550], ["virus", "PROBLEM", 565, 570], ["ambient virus", "TREATMENT", 608, 621], ["8 cell", "OBSERVATION_MODIFIER", 14, 20], ["Neuroendocrine cells", "ANATOMY", 214, 234], ["ASCL1", "ANATOMY", 242, 247], ["goblet cells", "OBSERVATION", 343, 355], ["viral transcript", "OBSERVATION", 474, 490], ["infected", "OBSERVATION", 527, 535], ["cell", "ANATOMY", 602, 606], ["ambient virus", "OBSERVATION", 608, 621]]], ["Given the reported shared 3\u2019 poly(A) tail in coronavirus transcripts [43], we were unsure whether we could correctly capture the different ORFs using the 10x Genomics 3\u2019 gene expression library.", [["poly(A) tail", "GENE_OR_GENE_PRODUCT", 29, 41], ["3\u2019 poly(A) tail", "DNA", 26, 41], ["coronavirus transcripts", "RNA", 45, 68], ["ORFs", "DNA", 139, 143], ["10x Genomics 3\u2019 gene expression library", "DNA", 154, 193], ["3\u2019 poly(A) tail in coronavirus transcripts", "TREATMENT", 26, 68]]], ["Therefore, we aligned the viral reads to a genome-wide single \u201dexon,\u201d i.e., a count is given for a read mapped to SARS-CoV-2 ORFs and intergenic regions.", [["SARS", "DISEASE", 114, 118], ["viral reads", "DNA", 26, 37], ["SARS-CoV-2 ORFs", "DNA", 114, 129], ["intergenic regions", "DNA", 134, 152], ["SARS-CoV", "SPECIES", 114, 122], ["a count", "TEST", 76, 83], ["SARS", "TEST", 114, 118], ["CoV", "TEST", 119, 122], ["intergenic regions", "PROBLEM", 134, 152], ["intergenic", "ANATOMY_MODIFIER", 134, 144], ["regions", "ANATOMY_MODIFIER", 145, 152]]], ["These counts were used to infer individual cells\u2019 infectious state.", [["cells", "ANATOMY", 43, 48], ["cells", "CELL", 43, 48], ["These counts", "TEST", 0, 12], ["infectious", "OBSERVATION", 50, 60]]], ["To filter out cells with viral genome transcript counts that may result from viral-cell surface attachment, ambient virus in the droplet suspension, or read misalignment, we considered infected cells to have \u2265 10 viral transcripts counts.", [["cells", "ANATOMY", 14, 19], ["cell surface", "ANATOMY", 83, 95], ["cells", "ANATOMY", 194, 199], ["cells", "CELL", 14, 19], ["cell", "CELL", 83, 87], ["cells", "CELL", 194, 199], ["infected cells", "CELL_TYPE", 185, 199], ["cells", "PROBLEM", 14, 19], ["viral genome transcript counts", "TEST", 25, 55], ["viral-cell surface attachment", "PROBLEM", 77, 106], ["ambient virus", "TREATMENT", 108, 121], ["the droplet suspension", "TREATMENT", 125, 147], ["infected cells", "PROBLEM", 185, 199], ["viral genome", "OBSERVATION", 25, 37], ["infected cells", "OBSERVATION", 185, 199]]], ["This value was determined by a threshold of viral counts in the mock condition.", [["This value", "TEST", 0, 10], ["viral counts", "TEST", 44, 56], ["viral counts", "OBSERVATION", 44, 56]]], ["While the mock condition is not expected to have viral counts, we did observe a small number that we attribute to misalignment.", [["viral counts", "TEST", 49, 61], ["misalignment", "PROBLEM", 114, 126], ["small", "OBSERVATION_MODIFIER", 80, 85], ["misalignment", "OBSERVATION", 114, 126]]], ["We observed only 5 mock cells with full SARS-CoV-2 viral genome transcript counts \u2265 10 transcripts.", [["cells", "ANATOMY", 24, 29], ["cells", "CELL", 24, 29], ["SARS-CoV-2 viral genome transcript", "RNA", 40, 74], ["full SARS", "TEST", 35, 44], ["CoV", "TEST", 45, 48], ["transcript counts", "TEST", 64, 81]]], ["These criteria allowed us to find 144 infected cells at 1 dpi, 1428 cells at 2 dpi and 3173 cells at 3 dpi.Infection threshold and infection score ::: ScRNA-seq data analysis ::: MethodsTo quantify the extent to which an individual cell is transcriptionally similar to an infected cell, we used a previously developed graph signal processing approach called Manifold Enhancement of Latent Dimensions (MELD) [44].", [["cells", "ANATOMY", 47, 52], ["cells", "ANATOMY", 68, 73], ["3173 cells", "ANATOMY", 87, 97], ["cell", "ANATOMY", 232, 236], ["cell", "ANATOMY", 281, 285], ["infection", "DISEASE", 131, 140], ["cells", "CELL", 47, 52], ["cells", "CELL", 68, 73], ["3173 cells", "CELL", 87, 97], ["cell", "CELL", 232, 236], ["cell", "CELL", 281, 285], ["infected cells", "PROBLEM", 38, 52], ["cells", "TEST", 68, 73], ["cells", "TEST", 92, 97], ["Infection threshold", "PROBLEM", 107, 126], ["Methods", "TREATMENT", 179, 186], ["an individual cell", "PROBLEM", 218, 236], ["an infected cell", "PROBLEM", 269, 285], ["Manifold Enhancement of Latent Dimensions (MELD", "TREATMENT", 358, 405], ["infected cell", "OBSERVATION", 272, 285], ["Latent", "OBSERVATION_MODIFIER", 382, 388], ["Dimensions", "OBSERVATION_MODIFIER", 389, 399]]], ["We encoded a raw experimental score for each cell in the dataset such that \u22121 represents a bystander or uninfected cell and +1 represents an infected cell.", [["cell", "ANATOMY", 45, 49], ["cell", "ANATOMY", 115, 119], ["cell", "ANATOMY", 150, 154], ["cell", "CELL", 45, 49], ["cell", "CELL", 115, 119], ["cell", "CELL", 150, 154], ["\u22121", "DNA", 75, 77], ["an infected cell", "PROBLEM", 138, 154], ["uninfected cell", "OBSERVATION", 104, 119], ["infected cell", "OBSERVATION", 141, 154]]], ["Using the kernel from the BB-kNN graph (described above), these raw scores were smoothed in the graph domain, yielding an \u201dinfection score\u201d per cell that represents the extent to which an individual cell is transcriptionally similar to infected cells.", [["cell", "ANATOMY", 144, 148], ["cell", "ANATOMY", 199, 203], ["cells", "ANATOMY", 245, 250], ["infection", "DISEASE", 123, 132], ["cell", "CELL", 144, 148], ["cell", "CELL", 199, 203], ["cells", "CELL", 245, 250], ["BB-kNN graph", "DNA", 26, 38], ["infected cells", "CELL_TYPE", 236, 250], ["the BB-kNN graph", "TEST", 22, 38], ["these raw scores", "TEST", 58, 74], ["an \u201dinfection score", "PROBLEM", 119, 138], ["an individual cell", "PROBLEM", 185, 203], ["infected cells", "PROBLEM", 236, 250], ["infection", "OBSERVATION", 123, 132], ["individual cell", "OBSERVATION", 188, 203], ["infected cells", "OBSERVATION", 236, 250]]], ["For summary statistics, this score was stratified by cell type and condition.Viral genome read coverage analysis ::: ScRNA-seq data analysis ::: MethodsTo visualize the viral read coverage along the viral genome we used the 10X Genomics cellranger barcoded binary alignment map (BAM) files for every sample.", [["cell", "ANATOMY", 53, 57], ["cell", "CELL", 53, 57], ["viral genome", "DNA", 199, 211], ["10X Genomics cellranger barcoded binary alignment map", "DNA", 224, 277], ["BAM", "DNA", 279, 282], ["this score", "TEST", 24, 34], ["Methods", "TREATMENT", 145, 152], ["the viral read coverage", "TREATMENT", 165, 188], ["the viral genome", "TREATMENT", 195, 211], ["the 10X Genomics cellranger", "TREATMENT", 220, 247], ["viral", "OBSERVATION", 169, 174], ["viral genome", "OBSERVATION", 199, 211]]], ["We filtered the BAM files to only retain reads mapping to the viral genome using the bedtools intersect tool.", [["BAM files", "DNA", 16, 25], ["viral genome", "DNA", 62, 74], ["viral genome", "OBSERVATION", 62, 74]]], ["We converted the BAM files into sequence alignment map (SAM) files in order to filter out cells that were removed in our single cell data preprocessing pipeline.", [["cells", "ANATOMY", 90, 95], ["cell", "ANATOMY", 128, 132], ["cells", "CELL", 90, 95], ["cell", "CELL", 128, 132], ["BAM files", "DNA", 17, 26], ["sequence alignment map", "TEST", 32, 54]]], ["The sequencing depth for each base position was calculated using samtools count.", [["samtools count", "TEST", 65, 79]]], ["To characterize read distribution along the viral genome we counted transcripts of 10 different ORFs: ORF1ab, Surface glycoprotein (S), ORF3a, Envelope protein (E), Membrane glycoprotein (M), ORF6, ORF7a, ORF8, Nucleocapsid phosphoprotein (N) and ORF10.Differential Expression Analysis ::: ScRNA-seq data analysis ::: MethodsTo find differentially expressed genes across conditions, we used a combination of three metrics: the Wasserstein or Earth Mover\u2019s distance, an adjusted p-value from a two-sided Mann-Whitney U test with continuity and Benjamini-Hochberg correction, and the binary logarithm of fold change between mean counts.", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 102, 108], ["Surface glycoprotein (S)", "GENE_OR_GENE_PRODUCT", 110, 134], ["ORF3a", "GENE_OR_GENE_PRODUCT", 136, 141], ["Envelope protein (E)", "GENE_OR_GENE_PRODUCT", 143, 163], ["Membrane glycoprotein (M)", "GENE_OR_GENE_PRODUCT", 165, 190], ["ORF6", "GENE_OR_GENE_PRODUCT", 192, 196], ["ORF7a", "GENE_OR_GENE_PRODUCT", 198, 203], ["ORF8", "GENE_OR_GENE_PRODUCT", 205, 209], ["Nucleocapsid phosphoprotein (N)", "GENE_OR_GENE_PRODUCT", 211, 242], ["ORF10", "GENE_OR_GENE_PRODUCT", 247, 252], ["viral genome", "DNA", 44, 56], ["ORFs", "DNA", 96, 100], ["ORF1ab", "DNA", 102, 108], ["Surface glycoprotein", "PROTEIN", 110, 130], ["S", "PROTEIN", 132, 133], ["ORF3a", "PROTEIN", 136, 141], ["Envelope protein", "PROTEIN", 143, 159], ["E", "PROTEIN", 161, 162], ["Membrane glycoprotein", "PROTEIN", 165, 186], ["M", "PROTEIN", 188, 189], ["ORF6", "PROTEIN", 192, 196], ["ORF7a", "PROTEIN", 198, 203], ["ORF8", "PROTEIN", 205, 209], ["Nucleocapsid phosphoprotein", "PROTEIN", 211, 238], ["N", "PROTEIN", 240, 241], ["ORF10", "PROTEIN", 247, 252], ["ORF1ab", "TEST", 102, 108], ["Surface glycoprotein (S)", "TEST", 110, 134], ["ORF3a", "TEST", 136, 141], ["Envelope protein", "TEST", 143, 159], ["Expression Analysis", "TEST", 266, 285], ["Methods", "TREATMENT", 318, 325], ["Benjamini-Hochberg correction", "TREATMENT", 543, 572], ["fold change", "PROBLEM", 602, 613], ["mean counts", "TEST", 622, 633], ["viral genome", "OBSERVATION", 44, 56]]], ["The Earth Mover\u2019s distance, or 1-dimensional Wasserstein distance can be defined as the minimal cost to transform of distribution to another, and was previously used to assess gene expression that significantly differ between conditions [45, 46].", [["minimal", "OBSERVATION_MODIFIER", 88, 95]]], ["We performed several binary comparisons for each timepoint and for pooling 1, 2, and 3 dpi: infected vs. bystander, infected vs. mock cells, and bystander vs. mock cells.", [["cells", "ANATOMY", 134, 139], ["mock cells", "ANATOMY", 159, 169], ["cells", "CELL", 134, 139], ["mock cells", "CELL", 159, 169], ["mock cells", "CELL_LINE", 129, 139], ["mock cells", "CELL_LINE", 159, 169], ["infected", "OBSERVATION", 92, 100], ["infected", "OBSERVATION", 116, 124]]], ["The 30 most differentially expressed genes (up- or downregulated, ranked by Wasserstein distance) in each condition, cell type, and analysis were represented in heatmaps.", [["cell", "ANATOMY", 117, 121], ["cell", "CELL", 117, 121], ["analysis", "TEST", 132, 140], ["cell type", "OBSERVATION", 117, 126]]], ["To identify putative cellular functions changed across conditions, we performed PANTHER-GO [47] statistical over-representation tests for up-regulated genes in each cell type and condition separately, using the default Human PANTHER-GO reference list as a background.Code and Data AvailabilityAll differential gene expression analyses and their associated metrics are publicly available at the Van Dijk Lab GitHub: https://github.com/vandijklab.", [["cellular", "ANATOMY", 21, 29], ["cell", "ANATOMY", 165, 169], ["cellular", "CELL", 21, 29], ["cell", "CELL", 165, 169], ["Human", "ORGANISM", 219, 224], ["Human PANTHER-GO reference list", "DNA", 219, 250], ["Human", "SPECIES", 219, 224], ["representation tests", "TEST", 113, 133], ["cellular functions", "OBSERVATION", 21, 39]]], ["The scRNA-seq data will be made publicly available around two weeks after pre-print submission, to allow time for finalizing the manuscript.", [["scRNA-seq", "DNA", 4, 13], ["The scRNA", "TEST", 0, 9]]]], "PMC7243437": [["The recent COVID-19 pandemic has highlighted these disparities as people of color suffer disparate mortality and face growing inequities in care.", [["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72]]], ["OLIVIA CARTER-POKRAS: In preparation for this discussion, I reached out to other members of the Latino Health Steering Committee from Montgomery County, Maryland, because we are a mix of academics as well as health care providers and others, so I wanted to bring in voices other than just my own.1 At the time of this discussion, we are dealing with the COVID-19 pandemic.IntroductionThere are many factors that can result in lower access and quality of care received by racial and ethnic minorities, in general, and specifically for those with COVID-19 infection.2\u20134 These factors can include not knowing where to go for testing or where to get care, for instance, as well as the ability to pay, transportation to get there, and whether or not the person has a usual health care provider (referral is often required to receive testing).", [["infection", "DISEASE", 554, 563], ["2\u20134", "CHEMICAL", 564, 567], ["COVID-19", "ORGANISM", 545, 553], ["person", "SPECIES", 749, 755], ["the COVID", "TEST", 350, 359], ["pandemic", "PROBLEM", 363, 371], ["COVID-19 infection", "PROBLEM", 545, 563], ["testing", "TEST", 622, 629], ["testing", "TEST", 828, 835], ["infection", "OBSERVATION", 554, 563]]], ["Only about half of foreign-born Latinos in Maryland have health insurance, even though Maryland is ranked second in the nation in median household income.5,6 Health issues are interrelated with other problems such as unemployment and stress.", [["Latinos", "ORGANISM", 32, 39], ["stress", "PROBLEM", 234, 240]]], ["These are long-standing concerns that have only been exacerbated by the coronavirus pandemic.IntroductionOn top of that, we have individuals who are undocumented and afraid to seek care.", [["coronavirus pandemic", "DISEASE", 72, 92], ["coronavirus", "ORGANISM", 72, 83], ["long-standing concerns", "PROBLEM", 10, 32], ["the coronavirus pandemic", "PROBLEM", 68, 92], ["coronavirus", "OBSERVATION", 72, 83]]], ["As we learned after 9/11, many are \u201cfrightened because we don't know what is going to happen (with immigration)\u2026this is an emergency.\u201d7 That fear certainly is coming into play with people who, even if they have the signs and symptoms, even though they are very ill, are refusing to go in for care.", [["people", "ORGANISM", 181, 187], ["people", "SPECIES", 181, 187], ["the signs and symptoms", "PROBLEM", 211, 233]]], ["Many of them were afraid to leave their homes even before all of this happened because of that fear.IntroductionImmigrant workers are a significant share of essential workers these days, from staffing grocery stores to cleaning hospital rooms and transporting food.8 Although 17% of civilians working in 2018 were foreign born, it is a much larger percentage when you look specifically at workers on the front line.IntroductionImmigrant workers are also overrepresented in jobs that are currently shuttered, such as hotels and restaurants, cleaning services, personal services, and hair and nail care.", [["hair", "ANATOMY", 582, 586], ["hair", "MULTI-TISSUE_STRUCTURE", 582, 586], ["nail", "ORGANISM_SUBDIVISION", 591, 595], ["hair and nail care", "TREATMENT", 582, 600], ["nail", "ANATOMY", 591, 595]]], ["Lack of income right now is a big issue and a major disparity during this crisis.IntroductionLanguage is still an issue when trying to figure out where to go for testing; information on testing has mainly been available only in English.9IntroductionAnd finally, inconsistent messaging continues to be a major challenge.", [["a big issue", "PROBLEM", 28, 39], ["this crisis", "PROBLEM", 69, 80], ["testing", "TEST", 162, 169], ["information on testing", "TEST", 171, 193], ["right", "ANATOMY_MODIFIER", 15, 20]]], ["For instance, using Neosporin in the nose to help prevent getting the virus was one piece of misinformation that was spread early on.11IntroductionThese issues existed before COVID-19, such as the lack of insurance and the lack of interpretation and translation of materials, but the pandemic has compounded the problem significantly.IntroductionDR.", [["nose", "ANATOMY", 37, 41], ["Neosporin", "CHEMICAL", 20, 29], ["Neosporin", "SIMPLE_CHEMICAL", 20, 29], ["nose", "ORGAN", 37, 41], ["Neosporin in the nose", "TREATMENT", 20, 41], ["the virus", "PROBLEM", 66, 75], ["COVID", "TEST", 175, 180], ["nose", "ANATOMY", 37, 41]]], ["I actually hope that one silver lining would be that we can learn from these issues and figure out how to handle some of them.", [["silver", "CHEMICAL", 25, 31]]], ["We are seeing that with mental health.IntroductionWe already had many people who did not feel able to talk about their mental health or mental wellness.", [["people", "ORGANISM", 70, 76], ["people", "SPECIES", 70, 76]]], ["And I like the term \u201cmental wellness,\u201d because when I say \u201cmental health,\u201d people often think of that as illness.", [["illness", "DISEASE", 105, 112], ["people", "ORGANISM", 75, 81], ["people", "SPECIES", 75, 81]]], ["I really want us to start thinking about mental health and wellness as our mental life, which includes for all us all the things we manage, our relationships, the stress we manage such as from limited finances and access to food and housing and health care.IntroductionSo those things were already there, and people already did not feel they could always talk about how they were feeling and their emotions and how they were managing stressors and afraid what people would think if they did talk about how they are managing stressors.IntroductionBut now, I think the good thing about this crisis is that people are acknowledging that this is highly stressful and that this is something that is going to make other people very stressed too.", [["people", "ORGANISM", 309, 315], ["people", "ORGANISM", 460, 466], ["people", "ORGANISM", 604, 610], ["people", "ORGANISM", 714, 720], ["people", "SPECIES", 309, 315], ["people", "SPECIES", 460, 466], ["people", "SPECIES", 604, 610], ["people", "SPECIES", 714, 720]]], ["Going forward, I anticipate that we are only going to see increases of this reflection on some of the things in the news and thinking about the number of people who are being impacted by this in different ways, either by family members being ill, being afraid that they are ill and not knowing, not knowing whether they are going to infect their families, and just the trauma of all this is going to be longstanding.IntroductionOne nice thing is this has really propelled us forward in terms of telehealth.", [["trauma", "DISEASE", 369, 375], ["people", "ORGANISM", 154, 160], ["people", "SPECIES", 154, 160]]], ["I am the medical director for a program called North Carolina Maternal Mental Health MATTERS, and that program provides education to frontline providers, such as obstetricians and family practice physicians and pediatricians, to help them support mental health in their patients.IntroductionBut through that, we also had intended to pilot a telehealth assessment that we could do to support primary care providers with psychiatric assessment.", [["psychiatric", "DISEASE", 419, 430], ["patients", "ORGANISM", 270, 278], ["patients", "SPECIES", 270, 278], ["a telehealth assessment", "TEST", 339, 362], ["psychiatric assessment", "TEST", 419, 441]]], ["Owing to new support for telehealth, we have been able to move forward with these telehealth assessments.", [["telehealth", "TREATMENT", 25, 35], ["these telehealth assessments", "TEST", 76, 104]]], ["I certainly have worked with patients who are supposed to be doing our visits through our medical records system but are experiencing access challenges.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37]]], ["Some patients cannot access the Internet, and they do not have the bandwidth to do that kind of visit.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["I have done phone visits with some patients, and I really hope that we can also move that forward as an option when video visits for mental health support are not possible.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["mental health support", "TREATMENT", 133, 154]]], ["But even there, again, a patient may experience inequity, because there are some patients who do not have a reliable phone or a secure private place to talk.", [["patient", "ORGANISM", 25, 32], ["patients", "ORGANISM", 81, 89], ["patient", "SPECIES", 25, 32], ["patients", "SPECIES", 81, 89]]], ["So still some patients are not able to talk as openly about their mental health needs and about stress they are facing if they cannot find privacy.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["For example, this is certainly relevant as we are seeing the increases in intimate partner violence some individuals are facing in their \u201cshelter-in-place\u201d housing situations.IntroductionSo, by moving all these things to telehealth, I think we have to be cognizant that some patients are not going to be able to access those things, and so in some ways, we are taking away barriers from people getting access to mental health care, but I also think we are also highlighting some increased barriers for some individuals.IntroductionDR.", [["patients", "ORGANISM", 275, 283], ["people", "ORGANISM", 387, 393], ["patients", "SPECIES", 275, 283], ["people", "SPECIES", 387, 393], ["increases", "OBSERVATION_MODIFIER", 61, 70]]], ["These are things that the Centers for Medicare & Medicaid Services (CMS) is going to need to change if telehealth will move forward.IntroductionThe impact of the CMS regulations on telehealth for some of the community providers that are not affiliated with large provider networks is even more profound; these are essentially private practices.", [["the CMS regulations", "TREATMENT", 158, 177], ["more profound", "OBSERVATION_MODIFIER", 289, 302]]], ["So now you put them in a position where they do not have the necessary protective equipment to allow patients to come through their doors, they cannot see their patients face to face, and you force them to employ a new telehealth capability that they have to now get up and running.", [["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 161, 169], ["protective equipment", "TREATMENT", 71, 91]]], ["These limitations and loss of patient care revenue have many looking at closure of their practices.", [["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37]]], ["So now an already distressed underserved population becomes even more underserved and facing a real stressful time in terms of trying to get access to health care.IntroductionIn this access to care vacuum, you are seeing people trying to take care of themselves and family members with home remedies.", [["people", "ORGANISM", 221, 227], ["people", "SPECIES", 221, 227], ["home remedies", "TREATMENT", 286, 299]]], ["We have heard about the unfortunate incidents with people using hydroxychloroquine inappropriately.", [["hydroxychloroquine", "CHEMICAL", 64, 82], ["hydroxychloroquine", "CHEMICAL", 64, 82], ["people", "ORGANISM", 51, 57], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 64, 82], ["people", "SPECIES", 51, 57], ["hydroxychloroquine", "TREATMENT", 64, 82]]], ["We have instances of people, because of the misinformation that is being spread, using Neosporin and other things.", [["Neosporin", "CHEMICAL", 87, 96], ["people", "ORGANISM", 21, 27], ["Neosporin", "SIMPLE_CHEMICAL", 87, 96], ["people", "SPECIES", 21, 27], ["Neosporin", "TREATMENT", 87, 96]]], ["I think that people are becoming a little bit more desperate because they are unable to get the care that they feel that they need.IntroductionOn the opposite end of access to care is the issue, when they do wind up getting hospitalized, they then face problems with the distribution of the current health care resources.", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19]]], ["This reflects my concern about potential inequities that may arise when the decision has to be made about who gets a ventilator and who does not.IntroductionWe already know that implicit bias influences health care decision making.", [["a ventilator", "TREATMENT", 115, 127]]], ["How does implicit bias influence a critical resource decision for people who are the most vulnerable?", [["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72]]], ["Will these biases have an untoward influence on not only access to care, but also people's general willingness to seek care?", [["people", "ORGANISM", 82, 88], ["people", "SPECIES", 82, 88]]], ["He is an anesthesiologist, so he is there when patients are being intubated, et cetera.IntroductionAnd he said he watched a provider have a conversation with a family that said, \u201cThis person has a zero percent chance of survival on a vent.\u201d", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["person", "SPECIES", 184, 190], ["intubated", "TREATMENT", 66, 75], ["a vent", "TREATMENT", 232, 238]]], ["So, you know, in essence, he talked the family into a \u201cDo Not Resuscitate\u201d (DNR).", [["DNR", "CHEMICAL", 76, 79]]], ["There was really no medical foundation for that.IntroductionSo you talk about implicit bias, and it sounded a little bit like you were talking about bias on the side of the patients.", [["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181]]], ["You know, we have been looking at and we have been experiencing these tremendous disparities.IntroductionWhat we now know and are seeing is that it is not just the disparity of people dying on the vent, but also what is happening in the system of care where they are not even making it to the vent?", [["people", "ORGANISM", 177, 183], ["people", "SPECIES", 177, 183], ["the vent", "TREATMENT", 193, 201], ["tremendous", "OBSERVATION_MODIFIER", 70, 80], ["disparities", "OBSERVATION", 81, 92]]], ["So some well-meaning provider potentially is steering black and brown and colored and other disparate populations toward DNRs.", [["DNRs", "CELL", 121, 125], ["steering black and brown and colored", "PROBLEM", 45, 81]]], ["When thinking about people's ability to recover when they have comorbid conditions, it is important to bear in mind that those comorbid conditions are often a reflection of social inequities and society.", [["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26], ["comorbid conditions", "PROBLEM", 63, 82], ["those comorbid conditions", "PROBLEM", 121, 146]]], ["And now, providers are having to tell these patients with certain comorbidities that when they need a health care resource, they may be ineligible.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52]]], ["I worry that these biases will potentially lead to greater inequities as this crisis moves forward.", [["these biases", "PROBLEM", 13, 25], ["this crisis", "PROBLEM", 73, 84]]], ["More importantly, some of the policies and processes that are being put in place to deal with resource scarcity caused by the COVID-19 crisis may wind up becoming the new standard that we turn to when making these kinds of decisions, so it is concerning.IntroductionDR.", [["the COVID-19 crisis", "PROBLEM", 122, 141]]], ["CARTER-POKRAS: Differential access and quality of care and implicit bias have been discussed in numerous reports over the past few decades, for example, with the 1985 Task Force Report on Black and Minority Health13 and the Unequal Treatment Report from the Institute of Medicine.14 After taking into account health insurance coverage and other issues, you still see that difference in access to certain treatments when you look at many cardiovascular and other health conditions.IntroductionThe comment that Dr. Mouton just made is absolutely right.", [["cardiovascular", "ANATOMY", 437, 451], ["cardiovascular", "ANATOMICAL_SYSTEM", 437, 451], ["certain treatments", "TREATMENT", 396, 414], ["right", "ANATOMY_MODIFIER", 544, 549]]], ["When it comes down to it during times of really tight constraints like what people are experiencing right now, decisions are indeed being made about who is going to receive care and who is not, and who is going to receive what could be considered lifesaving care and who is not.", [["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82]]], ["Unfortunately, racial and ethnic minorities are more likely to have conditions that put them at greater risk for severe complications.", [["racial and ethnic minorities", "PROBLEM", 15, 43], ["severe complications", "PROBLEM", 113, 133], ["racial", "OBSERVATION_MODIFIER", 15, 21], ["ethnic minorities", "OBSERVATION", 26, 43], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["complications", "OBSERVATION", 120, 133]]], ["Right now, with COVID-19, underlying conditions that could prove to make outcomes worse could include diabetes, cardiovascular disease, hypertension, or asthma.15IntroductionWe already know that racial and ethnic minorities have a disproportionate burden of illness and death.16 The ethicists certainly have their jobs cut out for them.", [["cardiovascular", "ANATOMY", 112, 126], ["diabetes", "DISEASE", 102, 110], ["cardiovascular disease", "DISEASE", 112, 134], ["hypertension", "DISEASE", 136, 148], ["asthma", "DISEASE", 153, 159], ["illness", "DISEASE", 258, 265], ["death", "DISEASE", 270, 275], ["COVID", "TEST", 16, 21], ["underlying conditions", "PROBLEM", 26, 47], ["diabetes", "PROBLEM", 102, 110], ["cardiovascular disease", "PROBLEM", 112, 134], ["hypertension", "PROBLEM", 136, 148], ["asthma", "PROBLEM", 153, 159], ["illness", "PROBLEM", 258, 265], ["death", "PROBLEM", 270, 275], ["hypertension", "OBSERVATION", 136, 148], ["asthma", "OBSERVATION", 153, 159], ["disproportionate", "OBSERVATION_MODIFIER", 231, 247]]], ["As much as people are saying that we understand how stressful this is, I do not know that people always still really do fully understand.", [["people", "ORGANISM", 11, 17], ["people", "ORGANISM", 90, 96], ["people", "SPECIES", 11, 17], ["people", "SPECIES", 90, 96]]], ["I just read an article on a Website about finding a therapist during this time, and it tries to give a number of resources no matter your insurance or need.17 However, our system is still very much biased against those needing mental health support and set up for self-pay.", [["mental health support", "TREATMENT", 227, 248]]], ["I think that as we try to use technology to provide access to health care, without policy guidance and financial support, particularly from CMS, there will be a number of obstacles.", [["financial support", "TREATMENT", 103, 120]]], ["If telehealth is here to stay, which most people say it is, then coupled with the expansion in digital health care monitoring, such as using the Internet of Things in people's homes to support better monitoring, we can start to see an intensification of the inequities for the communities served by these practices.", [["people", "ORGANISM", 42, 48], ["people", "ORGANISM", 167, 173], ["people", "SPECIES", 42, 48], ["people", "SPECIES", 167, 173]]], ["What does that mean for someone who has no Internet and no things?IntroductionSo, you talk about the Internet of Things, but many of our patients who are disadvantaged in terms of access and health care provision also lack those tools and devices.", [["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145]]], ["More and more, health care is going to move in that direction, and unless the funders of health care decide this is of big enough value to distribute to those who no longer can afford it or do not have it, to allow them to reap the benefits of this, we will again create a broader and deeper gap in terms of what people are able to receive and benefit from.IntroductionSo, to me, that is something that, if we would address, would go a long way to bridging that gap.", [["people", "ORGANISM", 313, 319], ["people", "SPECIES", 313, 319]]], ["CARTER-POKRAS: One of the things that has been brought to bear is that people are recognizing now how good or how poor their Internet access is in a way that I do not think they really fully understood previously.IntroductionWe are understanding that in under-resourced communities where children have been expected to continue their schooling at home, they are unable to continue their online studying because they do not have enough bandwidth, even if they do have a computer.18,19 Schools have been making computers available to the children who do not have computers at home, but you have to stand in line within a certain period of time to go pick up the computers, and even then there may not be enough computers.", [["people", "ORGANISM", 71, 77], ["children", "ORGANISM", 288, 296], ["children", "ORGANISM", 536, 544], ["people", "SPECIES", 71, 77], ["children", "SPECIES", 288, 296], ["children", "SPECIES", 536, 544]]], ["And those who do finally get their hands on a computer are not given the online homework that they were supposed to have been given, or their parents cannot help them, whether it is because of language issues or other issues.", [["language issues", "PROBLEM", 193, 208]]], ["So, in addition to universal health care, universal access to the Internet is something that we can put on our wish list.IntroductionOn top of everything else, some people have been asked to vacate their housing.20,21 Can you imagine?", [["people", "ORGANISM", 165, 171], ["people", "SPECIES", 165, 171], ["universal health care", "TREATMENT", 19, 40]]], ["Forget about access to the Internet, right?", [["right", "ANATOMY_MODIFIER", 37, 42]]], ["They do not have a way to pay for their housing because they lost their job, and they have been asked to vacate their housing.IntroductionWe are also seeing an increase in domestic violence22 and calls to mental health lines23 with people experiencing desperation, anxiety attacks, suicidal tendencies, et cetera, because of this.", [["anxiety", "DISEASE", 265, 272], ["suicidal tendencies", "DISEASE", 282, 301], ["people", "ORGANISM", 232, 238], ["people", "SPECIES", 232, 238], ["domestic violence22", "TREATMENT", 172, 191], ["desperation", "PROBLEM", 252, 263], ["anxiety attacks", "PROBLEM", 265, 280], ["suicidal tendencies", "PROBLEM", 282, 301], ["et cetera", "TREATMENT", 303, 312], ["increase", "OBSERVATION_MODIFIER", 160, 168]]], ["It has to be available in other ways that people can access because not everybody has access to the Internet right now.IntroductionDR.", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48], ["right", "ANATOMY_MODIFIER", 109, 114]]], ["FURR-HOLDEN: It is interesting that you mention these points, like the mental health concerns and people being evicted, because again, we are thinking about, what are the policies to support some of these things?", [["people", "ORGANISM", 98, 104], ["people", "SPECIES", 98, 104]]], ["As an example, Michigan has issued a stay on all evictions, so people are not actually allowed to be evicted during this period.", [["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69]]], ["Well, their mortgage is still coming due, so all these pieces are connected.", [["pieces", "OBSERVATION", 55, 61]]], ["What happened in Michigan is then they started adding to the stay of eviction order to prevent people from being evicted, because, of course, housing is so essential, if the whole order is to stay put to stay safe.IntroductionBut then they started to put resources in place for noncommercial owners of homes who are providing housing so that they are also solvent during this time.", [["people", "ORGANISM", 95, 101], ["people", "SPECIES", 95, 101]]], ["KIMMEL: Along those lines, I have talked to some pregnant women who already had housing instability before all this, and they had been saving up to get more stable housing of their own before the baby comes.", [["women", "ORGANISM", 58, 63], ["women", "SPECIES", 58, 63]]], ["Online is now sometimes the only way to access things.IntroductionWe need Internet, better Internet, but we also need better and more case management and services to help people navigate, because the system was always really fractured, but I feel like now it is even more unclear who can help and who cannot.", [["people", "ORGANISM", 171, 177], ["people", "SPECIES", 171, 177], ["fractured", "OBSERVATION", 225, 234]]], ["When we are all allowed to go back to work, there are still going to be these downstream effects of when a person did not find housing at the critical time before the baby came.IntroductionDR.", [["person", "SPECIES", 107, 113]]], ["FURR-HOLDEN: I have what I call a \u201cman-on-the-moon\u201d idea.", [["man", "SPECIES", 35, 38]]], ["What I mean by that is, when they said \u201cman on the moon,\u201d that just seemed like it was purely aspirational and almost impossible to achieve at the time, but despite that, it was well resourced, and it happened.", [["man", "SPECIES", 40, 43]]], ["What do you see as the kind of the man on the moon?", [["man", "ORGANISM", 35, 38], ["man", "SPECIES", 35, 38]]], ["MOUTON: I think because of the COVID-19 crisis, we now have a renewed focus on the need for an adequate public health infrastructure.", [["the COVID-19 crisis", "PROBLEM", 27, 46]]], ["I would like to see us set up a framework of a solid adequately funded public health and preventative care infrastructure that assures a baseline of health care access across all populations and all classes.IntroductionWe couple that with key access provisions for communities across this country, both rural and urban, that gives access both to \u201cbrick and mortar\u201d clinical practices as needed plus access to primary care, either by telehealth or in-person, which assures that these communities are able to maintain an adequate level of health that, in turn, allows the members of the community to enter the workforce, maintain income, and maintain social stability.", [["person", "SPECIES", 450, 456], ["preventative care infrastructure", "TREATMENT", 89, 121]]], ["CARTER-POKRAS: I already talked about my wish for universal health care, but I would also stretch that to not having access to health care be tied to our workplaces because there are so many people who lost their jobs as a direct result of COVID-19, and that also means they lost their health insurance.IntroductionHealth in all policies, also, I think that is really important.24 Health is created by a number of factors that go well beyond the scope of health care and public health activities.", [["people", "ORGANISM", 191, 197], ["people", "SPECIES", 191, 197], ["universal health care", "TREATMENT", 50, 71]]], ["We gave the example about what happens when somebody gets evicted during this pandemic and the need for housing interventions at this time.25IntroductionI also think we need to have better appreciation for essential workers who have previously gone unnoticed.", [["housing interventions", "TREATMENT", 104, 125]]], ["There are so many people who are keeping us going, whether it means our water coming through in our tap, or somebody picking up our garbage, or the people who are stocking the shelves at the grocery store, and hopefully providing them with the benefits that they need going forward.", [["people", "ORGANISM", 18, 24], ["people", "ORGANISM", 148, 154], ["people", "SPECIES", 18, 24], ["people", "SPECIES", 148, 154]]], ["CARTER-POKRAS: And also, protecting our supply chain, especially our food chain, and protecting those who are essential employees, including those who up to this point many people did not even really see them.", [["people", "ORGANISM", 173, 179], ["people", "SPECIES", 173, 179]]], ["I think really trying to get people care in a way that meets their needs and is more individualized and personalized is a priority.", [["people", "ORGANISM", 29, 35], ["people", "SPECIES", 29, 35]]], ["For some people, that is going to mean being able to use the telephone to access care.", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15]]], ["For some people, that is going to mean that their Internet access should be improved.", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15]]], ["Then for some, these improvements still are not going to be the answer, so how can we also have safe places patients can go and use the Internet to do an appointment or that someone comes to them and takes them to a safe place?IntroductionTo have this kind of individualized support will require thinking about how to expand our workforce for mental health support and use our workforce more effectively to ensure patients have time with supports and also those supports have time to personalize their approaches to the resources of each patient.", [["patients", "ORGANISM", 108, 116], ["patients", "ORGANISM", 414, 422], ["patient", "ORGANISM", 538, 545], ["patients", "SPECIES", 108, 116], ["patients", "SPECIES", 414, 422], ["patient", "SPECIES", 538, 545], ["individualized support", "TREATMENT", 260, 282], ["mental health support", "TREATMENT", 343, 364]]], ["This does not necessarily apply only health practitioners but also peer supporters and other community members who can be there to support mental health needs.IntroductionI grew up in a more rural region and now many of the patients I care for are from rural areas.", [["patients", "ORGANISM", 224, 232], ["patients", "SPECIES", 224, 232]]], ["CARTER-POKRAS: Thank you, Dr. Kimmel, for bringing that up, because our previous Surgeon General, Dr. Vivek Murthy, has really felt that loneliness is a crisis, an epidemic in our country.", [["loneliness", "DISEASE", 137, 147], ["a crisis", "PROBLEM", 151, 159]]], ["He is working on trying to get more information out about this crisis.26IntroductionI went through a 7-month training for a certificate in positive psychology and I am also a resilience trainer.", [["this crisis", "PROBLEM", 58, 69], ["a resilience trainer", "TREATMENT", 173, 193]]], ["It seems people are really desperate for finding ways to strengthen resilience skills now more than ever.", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15]]], ["I would be curious to hear your thoughts about how the public health infrastructure was not prepared to meet the demands of the COVID-19 pandemic.", [["the COVID", "TEST", 124, 133]]], ["KIMMEL: I think right now, so much of the focus is understandably on the immediate needs because so many people are getting seriously ill.", [["people", "ORGANISM", 105, 111], ["people", "SPECIES", 105, 111]]], ["With so much immediate need, we are focusing on the immediate needs and realizing the workforce does not have as much plasticity as we need.IntroductionBut then even as COVID-19 cases slow and people are not getting so ill from the coronavirus, we are going to be left with large mental health needs.", [["coronavirus", "DISEASE", 232, 243], ["people", "ORGANISM", 193, 199], ["coronavirus", "ORGANISM", 232, 243], ["people", "SPECIES", 193, 199], ["COVID", "TEST", 169, 174], ["the coronavirus", "PROBLEM", 228, 243]]], ["We need to be building a workforce that can also help communities develop their resilience and help people build resilience.IntroductionPart of managing trauma is helping people realize how their stories are important, and what they have been through is important.", [["trauma", "DISEASE", 153, 159], ["people", "ORGANISM", 100, 106], ["people", "ORGANISM", 171, 177], ["people", "SPECIES", 100, 106], ["people", "SPECIES", 171, 177]]], ["Building that kind of resilience requires time for people to sit down with people and talk, and it is hard to do that in a 15-min visit.", [["people", "ORGANISM", 51, 57], ["people", "ORGANISM", 75, 81], ["people", "SPECIES", 51, 57], ["people", "SPECIES", 75, 81]]], ["How do we have other people who can also fill that role?IntroductionDR.", [["people", "ORGANISM", 21, 27], ["people", "SPECIES", 21, 27]]], ["If we talk about the physician workforce, I think the issue substantially is a maldistribution problem more than an adequate numbers problem.", [["a maldistribution problem", "PROBLEM", 77, 102]]], ["I see economic factors related to where physicians choose to practice as a major driver.IntroductionNow, if we look at the health care workforce at large, I think we still have needs for many health professions in the context of COVID-19, particularly from nursing and respiratory therapy, to meet this acute need.IntroductionBut I even wonder sometimes about that, because when you look at what is happening to the hospitals, due to the COVID-19-related economic forces, many of them are laying off nurses and looking at a future wherein there will be far fewer of these health care workers.IntroductionSo, to me, it begs the question, if we have a true health care workforce shortage, why would economics be the sole driver in the decision to lay off a substantial workforce, because you still would need them to run your enterprise?IntroductionSo, again, I wonder how much of this is driven by a distribution issue, and where people are being deployed, and where they are being located, as opposed to an absolute numbers issue.", [["people", "ORGANISM", 929, 935], ["people", "SPECIES", 929, 935], ["COVID", "TREATMENT", 229, 234], ["respiratory therapy", "TREATMENT", 269, 288]]], ["And it may be both.IntroductionDR.", [["may be", "UNCERTAINTY", 7, 13], ["both", "OBSERVATION_MODIFIER", 14, 18]]], ["How do we build the kind of incentives so we can have people where the needs are versus where the resources are?IntroductionDR.", [["people", "ORGANISM", 54, 60], ["people", "SPECIES", 54, 60]]], ["As you move the economic forces out of the industry and say that we will deploy people where the need is the greatest, and they will be paid substantially the same or with some increased benefit for taking on those assignments, then that would be different.IntroductionNow, I am not saying that a universal one-payer health care system will necessarily do that, but it might.", [["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86]]], ["People may argue about whether or not that is true.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["And without economics being the main motivating factor, figuring out how to distribute the health care workforce in a manner that takes that away, you could have a situation wherein people will choose to work in environments that give them better economic fulfillment.IntroductionDR.", [["people", "ORGANISM", 182, 188], ["people", "SPECIES", 182, 188], ["without", "UNCERTAINTY", 4, 11]]]], "529b8faa755ab03cab50e29ffd423a065efbc608": [["INTRODUCTIONIn early December 2019, cases of pneumonia caused by a new type of coronavirus infection appeared in the city of Wuhan, Hubei Province, China.", [["pneumonia", "DISEASE", 45, 54], ["coronavirus infection", "DISEASE", 79, 100], ["coronavirus", "ORGANISM", 79, 90], ["pneumonia", "PROBLEM", 45, 54], ["coronavirus infection", "PROBLEM", 79, 100], ["pneumonia", "OBSERVATION", 45, 54], ["new", "OBSERVATION_MODIFIER", 67, 70], ["coronavirus", "OBSERVATION_MODIFIER", 79, 90], ["infection", "OBSERVATION", 91, 100]]], ["1 The disease quickly spread to the other parts of China and many other countries on the six continents.", [["The disease", "PROBLEM", 2, 13], ["disease", "OBSERVATION", 6, 13]]], ["The World Health the reverse-transcription polymerase chain reaction (RT-PCR) test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), combined naso-oropharyngeal swabs were taken from the patients who met the criteria laid out in the guidelines.", [["oropharyngeal swabs", "ANATOMY", 163, 182], ["acute respiratory syndrome coronavirus", "DISEASE", 94, 132], ["SARS-CoV-2", "ORGANISM", 136, 146], ["oropharyngeal swabs", "ORGANISM_SUBSTANCE", 163, 182], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["severe acute respiratory syndrome coronavirus", "SPECIES", 87, 132], ["SARS-CoV-2", "SPECIES", 136, 146], ["chain reaction", "TEST", 54, 68], ["RT-PCR) test", "TEST", 70, 82], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 87, 132], ["SARS", "TEST", 136, 140], ["CoV", "TEST", 141, 144], ["combined naso-oropharyngeal swabs", "PROBLEM", 149, 182], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["acute", "OBSERVATION_MODIFIER", 94, 99], ["respiratory syndrome", "OBSERVATION", 100, 120], ["oropharyngeal", "ANATOMY", 163, 176]]], ["The samples were tested in Ankara Public Health Laboratory of the Ministry of Health until April 13, 2020, and later in our hospital laboratory.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11]]], ["Viral analyses and real-time (Q) PCR experiments were applied to sample of the patient.", [["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["Viral analyses", "TEST", 0, 14], ["PCR experiments", "TEST", 33, 48]]], ["The RNA was isolated using vNAT solution (Bioeksen, Istanbul, Turkey).", [["vNAT solution", "TREATMENT", 27, 40]]], ["For all reactions, Rotor-Gene Q (Qiagen, Antwerp, Belgium) instrument and Biospeedy SARS-CoV-2 RT-qPCR kit (Bioeksen) were used.", [["all reactions", "PROBLEM", 4, 17], ["Rotor-Gene Q (Qiagen, Antwerp, Belgium) instrument", "TREATMENT", 19, 69], ["Biospeedy SARS", "TEST", 74, 88], ["CoV", "TEST", 89, 92], ["2 RT-qPCR kit (Bioeksen)", "TREATMENT", 93, 117]]], ["The kit is performed in one step with targeting the RdRp (RNA-dependent RNA polymerase) gene fragment reverse transcription (RT) and rt PCR (QPCR) (RT-QPCR).", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 58, 86], ["RdRp (RNA-dependent RNA polymerase) gene fragment", "DNA", 52, 101], ["the RdRp (RNA-dependent RNA polymerase", "TREATMENT", 48, 86], ["gene fragment reverse transcription", "PROBLEM", 88, 123], ["rt PCR", "TEST", 133, 139], ["QPCR", "TEST", 141, 145]]], ["The data was analyzed using Rotor-Gene Q Software.INTRODUCTIONAt the time of application, complete blood count, serum biochemical test (including renal and liver functions, lactate dehydrogenase [LDH] , and electrolytes), myocardial enzymes, coagulation profile, erythrocyte sedimentation rate, C-reactive protein (CRP), and procalcitonin were studied for these patients.", [["blood", "ANATOMY", 99, 104], ["serum", "ANATOMY", 112, 117], ["renal", "ANATOMY", 146, 151], ["liver", "ANATOMY", 156, 161], ["myocardial", "ANATOMY", 222, 232], ["erythrocyte", "ANATOMY", 263, 274], ["lactate", "CHEMICAL", 173, 180], ["lactate", "CHEMICAL", 173, 180], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["serum", "ORGANISM_SUBSTANCE", 112, 117], ["renal", "ORGAN", 146, 151], ["liver", "ORGAN", 156, 161], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 173, 194], ["LDH", "SIMPLE_CHEMICAL", 196, 199], ["myocardial", "MULTI-TISSUE_STRUCTURE", 222, 232], ["erythrocyte", "CELL", 263, 274], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 295, 313], ["CRP", "GENE_OR_GENE_PRODUCT", 315, 318], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 325, 338], ["patients", "ORGANISM", 362, 370], ["lactate dehydrogenase", "PROTEIN", 173, 194], ["LDH", "PROTEIN", 196, 199], ["myocardial enzymes", "PROTEIN", 222, 240], ["C-reactive protein", "PROTEIN", 295, 313], ["CRP", "PROTEIN", 315, 318], ["procalcitonin", "PROTEIN", 325, 338], ["patients", "SPECIES", 362, 370], ["The data", "TEST", 0, 8], ["complete blood count", "TEST", 90, 110], ["serum biochemical test", "TEST", 112, 134], ["lactate dehydrogenase", "TEST", 173, 194], ["LDH]", "TEST", 196, 200], ["electrolytes", "TEST", 207, 219], ["myocardial enzymes", "TEST", 222, 240], ["coagulation profile", "TEST", 242, 261], ["erythrocyte sedimentation rate", "TEST", 263, 293], ["C", "TEST", 295, 296], ["CRP", "TEST", 315, 318], ["procalcitonin", "TEST", 325, 338], ["renal", "ANATOMY", 146, 151], ["liver", "ANATOMY", 156, 161]]], ["Nasopharyngeal swabs were taken for the influenza test.", [["Nasopharyngeal swabs", "ANATOMY", 0, 20], ["Nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 0, 20], ["Nasopharyngeal swabs", "TEST", 0, 20], ["the influenza test", "TEST", 36, 54]]], ["Blood culture was taken at the fever period from the patients with suspected secondary bacterial infection.", [["Blood", "ANATOMY", 0, 5], ["fever", "DISEASE", 31, 36], ["bacterial infection", "DISEASE", 87, 106], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["Blood culture", "TEST", 0, 13], ["secondary bacterial infection", "PROBLEM", 77, 106], ["secondary", "OBSERVATION_MODIFIER", 77, 86], ["bacterial", "OBSERVATION_MODIFIER", 87, 96], ["infection", "OBSERVATION", 97, 106]]], ["Their chest X-rays were also taken.", [["chest", "ANATOMY", 6, 11], ["Their chest X-rays", "TEST", 0, 18], ["chest", "ANATOMY", 6, 11]]], ["Chest computed tomography (CT) was performed in the patients whose respiratory findings could not be explained by the chest X-ray or in those with poor clinical prognosis.INTRODUCTIONSARS-CoV-2 positive patients were hospitalized and followed up in inpatient clinics during March when the COVID-19 outbreak started in Turkey.", [["respiratory", "ANATOMY", 67, 78], ["patients", "ORGANISM", 52, 60], ["CoV-2", "ORGANISM", 188, 193], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 203, 211], ["Chest computed tomography (CT)", "TEST", 0, 30], ["the chest X-ray", "TEST", 114, 129], ["the COVID", "TEST", 285, 294], ["chest", "ANATOMY", 118, 123]]], ["With the recommendations of the Scientific Committee for COVID-19, some patients were allowed to be isolated at home starting in April.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["COVID", "TEST", 57, 62]]], ["Patients with any of the following conditions were hospitalized: tachypnea (\u2265 70 breaths per minutes for infants aged < 1 year; \u2265 50 breaths per minutes for children aged > 1 year), hypoxia (oxygen saturation < 92%), lack of consciousness, depression, coma, convulsions, dehydration, difficulty feeding, gastrointestinal dysfunction, myocardial injury, elevated liver enzymes, coagulation dysfunction, rhabdomyolysis, and any other manifestations suggesting injuries to vital organs.", [["gastrointestinal", "ANATOMY", 304, 320], ["myocardial", "ANATOMY", 334, 344], ["liver", "ANATOMY", 362, 367], ["organs", "ANATOMY", 476, 482], ["tachypnea", "DISEASE", 65, 74], ["hypoxia", "DISEASE", 182, 189], ["oxygen", "CHEMICAL", 191, 197], ["lack of consciousness", "DISEASE", 217, 238], ["depression", "DISEASE", 240, 250], ["coma", "DISEASE", 252, 256], ["convulsions", "DISEASE", 258, 269], ["dehydration", "DISEASE", 271, 282], ["gastrointestinal dysfunction", "DISEASE", 304, 332], ["myocardial injury", "DISEASE", 334, 351], ["elevated liver enzymes", "DISEASE", 353, 375], ["coagulation dysfunction", "DISEASE", 377, 400], ["rhabdomyolysis", "DISEASE", 402, 416], ["injuries", "DISEASE", 458, 466], ["oxygen", "CHEMICAL", 191, 197], ["Patients", "ORGANISM", 0, 8], ["children", "ORGANISM", 157, 165], ["oxygen", "SIMPLE_CHEMICAL", 191, 197], ["gastrointestinal", "ORGANISM_SUBDIVISION", 304, 320], ["myocardial", "MULTI-TISSUE_STRUCTURE", 334, 344], ["liver", "ORGAN", 362, 367], ["organs", "ORGAN", 476, 482], ["liver enzymes", "PROTEIN", 362, 375], ["Patients", "SPECIES", 0, 8], ["infants", "SPECIES", 105, 112], ["children", "SPECIES", 157, 165], ["tachypnea", "PROBLEM", 65, 74], ["hypoxia", "PROBLEM", 182, 189], ["oxygen saturation", "TEST", 191, 208], ["lack of consciousness", "PROBLEM", 217, 238], ["depression", "PROBLEM", 240, 250], ["coma", "PROBLEM", 252, 256], ["convulsions", "PROBLEM", 258, 269], ["dehydration", "PROBLEM", 271, 282], ["difficulty feeding", "PROBLEM", 284, 302], ["gastrointestinal dysfunction", "PROBLEM", 304, 332], ["myocardial injury", "PROBLEM", 334, 351], ["elevated liver enzymes", "PROBLEM", 353, 375], ["coagulation dysfunction", "PROBLEM", 377, 400], ["rhabdomyolysis", "PROBLEM", 402, 416], ["any other manifestations", "PROBLEM", 422, 446], ["injuries to vital organs", "PROBLEM", 458, 482], ["gastrointestinal", "ANATOMY", 304, 320], ["dysfunction", "OBSERVATION", 321, 332], ["myocardial", "ANATOMY", 334, 344], ["injury", "OBSERVATION", 345, 351], ["liver", "ANATOMY", 362, 367], ["rhabdomyolysis", "OBSERVATION", 402, 416], ["injuries", "OBSERVATION", 458, 466]]], ["From the patients who were followed up at the hospital, RT-PCR swab samples were taken at the 48th hour of hospitalization, which was continued until a negative test result.", [["swab samples", "ANATOMY", 63, 75], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["RT-PCR swab samples", "TEST", 56, 75]]], ["The discharge criteria were the absence of fever for at least 48 hours, a substantial improvement in laboratory tests, the clinical remission of respiratory symptoms, and at least one negative RT-PCR test result for SARS-CoV-2.", [["respiratory", "ANATOMY", 145, 156], ["fever", "DISEASE", 43, 48], ["respiratory symptoms", "DISEASE", 145, 165], ["SARS", "DISEASE", 216, 220], ["SARS-CoV", "SPECIES", 216, 224], ["fever", "PROBLEM", 43, 48], ["laboratory tests", "TEST", 101, 117], ["respiratory symptoms", "PROBLEM", 145, 165], ["PCR test", "TEST", 196, 204], ["SARS", "TEST", 216, 220], ["CoV", "TEST", 221, 224], ["substantial", "OBSERVATION_MODIFIER", 74, 85], ["improvement", "OBSERVATION_MODIFIER", 86, 97]]], ["The outpatients were asked for their complaints via regular phone calls, and they were not retested for SARS-CoV-2 unless additional complaints or findings developed.", [["SARS", "DISEASE", 104, 108], ["outpatients", "ORGANISM", 4, 15], ["outpatients", "SPECIES", 4, 15], ["SARS", "PROBLEM", 104, 108], ["additional complaints", "PROBLEM", 122, 143]]], ["The presence of at least one of each of I and II The presence of at least two of II (for each item, the relation to another item cannot be shown) Presence of two or more people with COVID-19 diagnosis in the same household Infants under 9 months who have a mother diagnosed with COVID-19 COVID-19 = coronavirus disease 2019, RT-PCR = reverse-transcription polymerase chain reaction.INTRODUCTIONThe treatment protocol for the inpatients included general supportive therapy, the monitoring of lung, liver, kidney, and heart functions, an active control of high fever, antibiotherapy, antiviral therapy if necessary (the administration of oseltamivir in the patients who were positive for influenza) and, supplemental oxygen therapy if necessary (oxygen through a nasal cannula at a rate of 2-4 L/min for the patients with saturation < 92% in the absence of oxygen support), systemic corticosteroids, and inhaled corticosteroids.", [["lung", "ANATOMY", 491, 495], ["liver", "ANATOMY", 497, 502], ["kidney", "ANATOMY", 504, 510], ["heart", "ANATOMY", 516, 521], ["nasal", "ANATOMY", 761, 766], ["coronavirus disease", "DISEASE", 299, 318], ["lung, liver, kidney, and heart functions", "DISEASE", 491, 531], ["fever", "DISEASE", 559, 564], ["oseltamivir", "CHEMICAL", 636, 647], ["influenza", "DISEASE", 686, 695], ["oxygen", "CHEMICAL", 715, 721], ["oxygen", "CHEMICAL", 744, 750], ["oxygen", "CHEMICAL", 855, 861], ["oseltamivir", "CHEMICAL", 636, 647], ["oxygen", "CHEMICAL", 715, 721], ["oxygen", "CHEMICAL", 744, 750], ["oxygen", "CHEMICAL", 855, 861], ["people", "ORGANISM", 170, 176], ["lung", "ORGAN", 491, 495], ["liver", "ORGAN", 497, 502], ["kidney", "ORGAN", 504, 510], ["heart", "ORGAN", 516, 521], ["patients", "ORGANISM", 655, 663], ["oxygen", "SIMPLE_CHEMICAL", 715, 721], ["oxygen", "SIMPLE_CHEMICAL", 744, 750], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 761, 774], ["patients", "ORGANISM", 806, 814], ["oxygen", "SIMPLE_CHEMICAL", 855, 861], ["I and II", "PROTEIN", 40, 48], ["people", "SPECIES", 170, 176], ["Infants", "SPECIES", 223, 230], ["patients", "SPECIES", 655, 663], ["patients", "SPECIES", 806, 814], ["COVID", "TEST", 182, 187], ["COVID", "TEST", 279, 284], ["COVID", "TEST", 288, 293], ["coronavirus disease", "PROBLEM", 299, 318], ["RT", "TEST", 325, 327], ["PCR", "TEST", 328, 331], ["transcription polymerase chain reaction", "PROBLEM", 342, 381], ["The treatment protocol", "TREATMENT", 394, 416], ["general supportive therapy", "TREATMENT", 445, 471], ["the monitoring of lung, liver, kidney, and heart functions", "TEST", 473, 531], ["high fever", "PROBLEM", 554, 564], ["antibiotherapy", "TREATMENT", 566, 580], ["antiviral therapy", "TREATMENT", 582, 599], ["oseltamivir", "TREATMENT", 636, 647], ["influenza", "PROBLEM", 686, 695], ["supplemental oxygen therapy", "TREATMENT", 702, 729], ["oxygen", "TREATMENT", 744, 750], ["a nasal cannula", "TREATMENT", 759, 774], ["saturation", "TEST", 820, 830], ["oxygen support", "TREATMENT", 855, 869], ["systemic corticosteroids", "TREATMENT", 872, 896], ["inhaled corticosteroids", "TREATMENT", 902, 925], ["at least", "OBSERVATION_MODIFIER", 16, 24], ["lung", "ANATOMY", 491, 495], ["liver", "ANATOMY", 497, 502], ["kidney", "ANATOMY", 504, 510], ["heart", "ANATOMY", 516, 521], ["active", "OBSERVATION_MODIFIER", 536, 542], ["high", "OBSERVATION_MODIFIER", 554, 558], ["fever", "OBSERVATION", 559, 564]]], ["Ceftriaxone/Cefotaxime was given to the patients with suspected secondary bacterial infection; all others were given azithromycin.", [["Ceftriaxone", "CHEMICAL", 0, 11], ["Cefotaxime", "CHEMICAL", 12, 22], ["bacterial infection", "DISEASE", 74, 93], ["azithromycin", "CHEMICAL", 117, 129], ["Ceftriaxone", "CHEMICAL", 0, 11], ["Cefotaxime", "CHEMICAL", 12, 22], ["azithromycin", "CHEMICAL", 117, 129], ["Ceftriaxone", "SIMPLE_CHEMICAL", 0, 11], ["Cefotaxime", "SIMPLE_CHEMICAL", 12, 22], ["patients", "ORGANISM", 40, 48], ["azithromycin", "SIMPLE_CHEMICAL", 117, 129], ["patients", "SPECIES", 40, 48], ["Ceftriaxone", "TREATMENT", 0, 11], ["Cefotaxime", "TREATMENT", 12, 22], ["secondary bacterial infection", "PROBLEM", 64, 93], ["azithromycin", "TREATMENT", 117, 129], ["secondary", "OBSERVATION_MODIFIER", 64, 73], ["bacterial", "OBSERVATION_MODIFIER", 74, 83], ["infection", "OBSERVATION", 84, 93]]], ["In outpatients, amoxycillin clavulanate and azithromycin treatments were given for secondary bacterial infection susceptibility.Statistical analysisThe data were presented as frequency (number) and percentage (%) for categorical variables and as mean \u00b1 standard deviation or median (interquartile range) for continuous variables, as appropriate. \u03c7 2 test or Fisher's exact tests were used, as appropriate, to compare the qualitative variables.", [["amoxycillin clavulanate", "CHEMICAL", 16, 39], ["azithromycin", "CHEMICAL", 44, 56], ["bacterial infection", "DISEASE", 93, 112], ["amoxycillin clavulanate", "CHEMICAL", 16, 39], ["azithromycin", "CHEMICAL", 44, 56], ["amoxycillin clavulanate", "SIMPLE_CHEMICAL", 16, 39], ["azithromycin", "SIMPLE_CHEMICAL", 44, 56], ["outpatients", "SPECIES", 3, 14], ["amoxycillin clavulanate", "TREATMENT", 16, 39], ["azithromycin treatments", "TREATMENT", 44, 67], ["secondary bacterial infection susceptibility", "PROBLEM", 83, 127], ["Statistical analysis", "TEST", 128, 148], ["percentage", "TEST", 198, 208], ["categorical variables", "TEST", 217, 238], ["median (interquartile range)", "TREATMENT", 275, 303], ["2 test", "TEST", 348, 354], ["Fisher's exact tests", "TEST", 358, 378], ["bacterial", "OBSERVATION_MODIFIER", 93, 102], ["infection", "OBSERVATION", 103, 112]]], ["Two-group comparisons were performed using the Mann Whitney U test for other data.", [["other data", "TEST", 71, 81]]], ["All tests were two-tailed; P values of < 0.05 were considered to indicate statistical significance, applying Bonferroni correction when appropriate.", [["All tests", "TEST", 0, 9], ["P values", "TEST", 27, 35], ["Bonferroni correction", "TREATMENT", 109, 130]]], ["Statistical analyses were performed by using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA).Ethics statementThe present study protocol was reviewed and approved by the Institutional Review Board (IRB) at Uluda\u011f University (IRB No. 2011-KAEK-26/282).", [["Statistical analyses", "TEST", 0, 20], ["SPSS version", "TEST", 45, 57], ["The present study protocol", "TEST", 109, 135], ["KAEK", "TEST", 237, 241]]], ["Informed consent was waived.RESULTSAt the time interval covered by the study, 6,258 visits were made to the pediatric emergency department of our hospital.", [["the study", "TEST", 67, 76]]], ["Naso-oropharyngeal swab samples for RT-PCR were taken from 367 patients (5.8%) suspected of having COVID-19; 79 (21.5%) patients were positive for SARS-CoV-2.", [["oropharyngeal swab samples", "ANATOMY", 5, 31], ["SARS", "DISEASE", 147, 151], ["oropharyngeal swab samples", "ORGANISM_SUBSTANCE", 5, 31], ["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 120, 128], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 147, 157], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 120, 128], ["SARS-CoV", "SPECIES", 147, 155], ["Naso", "TEST", 0, 4], ["oropharyngeal swab samples", "TEST", 5, 31], ["RT-PCR", "TEST", 36, 42], ["COVID", "TEST", 99, 104], ["SARS", "PROBLEM", 147, 151], ["CoV", "TEST", 152, 155], ["oropharyngeal", "ANATOMY", 5, 18]]], ["The swab samples were taken from 22 suspected newborns in the neonatal intensive care unit; four were born to SARS-CoV-2-positive mothers, and 16 were born to mothers suspected of having the virus.", [["swab samples", "ANATOMY", 4, 16], ["SARS", "DISEASE", 110, 114], ["swab samples", "CANCER", 4, 16], ["newborns", "ORGANISM", 46, 54], ["SARS-CoV-2", "ORGANISM", 110, 120], ["mothers", "ORGANISM", 130, 137], ["mothers", "ORGANISM", 159, 166], ["CoV-", "SPECIES", 115, 119], ["SARS-CoV", "SPECIES", 110, 118], ["The swab samples", "TEST", 0, 16], ["SARS", "TEST", 110, 114], ["CoV", "TEST", 115, 118], ["the virus", "PROBLEM", 187, 196]]], ["Two newborns were tested due to having contact history with a SARS-CoV-2-positive parents at home; only these two were positive (9%).", [["SARS", "DISEASE", 62, 66], ["newborns", "ORGANISM", 4, 12], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 62, 72], ["a SARS", "TEST", 60, 66]]], ["Of those who were positive, 44 patients (54%) were hospitalized and followed up in the inpatient clinic.RESULTSThe median age was 9.50 years (3.16-15.08 years) in the study group ( Table 2) .", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]], ["The boys/girls ratio was 1.45 (48/33).", [["boys", "SPECIES", 4, 8], ["girls", "SPECIES", 9, 14], ["The boys/girls ratio", "TEST", 0, 20]]], ["At least one SARS-CoV-2-positive family member was present in 90% of the cases.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 13, 23], ["SARS-CoV-2-positive family member", "PROTEIN", 13, 46], ["SARS", "OBSERVATION", 13, 17]]], ["Four patients had comorbid conditions: two were being followed up for cerebral palsy, one for type-1 diabetes mellitus, and one for asthma.RESULTSThe most frequent symptoms at the time of admission were fever (58%), cough (52%), and fatigue or myalgia (19%).", [["cerebral", "ANATOMY", 70, 78], ["cerebral palsy", "DISEASE", 70, 84], ["type-1 diabetes mellitus", "DISEASE", 94, 118], ["asthma", "DISEASE", 132, 138], ["fever", "DISEASE", 203, 208], ["cough", "DISEASE", 216, 221], ["fatigue", "DISEASE", 233, 240], ["myalgia", "DISEASE", 244, 251], ["patients", "ORGANISM", 5, 13], ["cerebral", "ORGAN", 70, 78], ["patients", "SPECIES", 5, 13], ["comorbid conditions", "PROBLEM", 18, 37], ["cerebral palsy", "PROBLEM", 70, 84], ["type-1 diabetes mellitus", "PROBLEM", 94, 118], ["asthma", "PROBLEM", 132, 138], ["frequent symptoms", "PROBLEM", 155, 172], ["fever", "PROBLEM", 203, 208], ["cough", "PROBLEM", 216, 221], ["fatigue", "PROBLEM", 233, 240], ["myalgia", "PROBLEM", 244, 251], ["cerebral", "ANATOMY", 70, 78], ["palsy", "OBSERVATION", 79, 84], ["diabetes mellitus", "OBSERVATION", 101, 118], ["asthma", "OBSERVATION", 132, 138]]], ["No neurological findings or signs of cardiac, liver, or renal failure were found in the patients.RESULTSA comparison of the inpatients and outpatients for the demographics and the complaints at the time of admission indicated that women gender (P = 0.02) and fever complaints (P < 0.001) were significantly more frequent in hospitalized patients.RESULTSThe laboratory results of the patients were shown in Table 3 .", [["neurological", "ANATOMY", 3, 15], ["cardiac", "ANATOMY", 37, 44], ["liver", "ANATOMY", 46, 51], ["renal", "ANATOMY", 56, 61], ["cardiac, liver, or renal failure", "DISEASE", 37, 69], ["fever", "DISEASE", 259, 264], ["cardiac", "ORGAN", 37, 44], ["liver", "ORGAN", 46, 51], ["renal", "ORGAN", 56, 61], ["patients", "ORGANISM", 88, 96], ["outpatients", "ORGANISM", 139, 150], ["women", "ORGANISM", 231, 236], ["patients", "ORGANISM", 337, 345], ["patients", "ORGANISM", 383, 391], ["patients", "SPECIES", 88, 96], ["women", "SPECIES", 231, 236], ["patients", "SPECIES", 337, 345], ["patients", "SPECIES", 383, 391], ["neurological findings", "PROBLEM", 3, 24], ["cardiac, liver", "PROBLEM", 37, 51], ["renal failure", "PROBLEM", 56, 69], ["fever complaints", "PROBLEM", 259, 275], ["cardiac", "ANATOMY", 37, 44], ["liver", "ANATOMY", 46, 51], ["renal", "ANATOMY", 56, 61], ["failure", "OBSERVATION", 62, 69]]], ["Abnormal results were decreased lymphocytes (2.5%, n = 2), leucopenia (5%, n = 4), and increased LDH (17.2%, n = 14), CRP (16%, n = 13), procalcitonin (3.7%, n = 3), and D-dimer (12.3%, n = 10).", [["lymphocytes", "ANATOMY", 32, 43], ["leucopenia", "DISEASE", 59, 69], ["lymphocytes", "CELL", 32, 43], ["LDH", "GENE_OR_GENE_PRODUCT", 97, 100], ["CRP", "GENE_OR_GENE_PRODUCT", 118, 121], ["D-dimer", "SIMPLE_CHEMICAL", 170, 177], ["lymphocytes", "CELL_TYPE", 32, 43], ["LDH", "PROTEIN", 97, 100], ["CRP", "PROTEIN", 118, 121], ["procalcitonin", "PROTEIN", 137, 150], ["Abnormal results", "PROBLEM", 0, 16], ["lymphocytes", "TEST", 32, 43], ["leucopenia", "TEST", 59, 69], ["increased LDH", "PROBLEM", 87, 100], ["n", "TEST", 109, 110], ["CRP", "TEST", 118, 121], ["n", "TEST", 128, 129], ["procalcitonin", "TEST", 137, 150], ["n", "TEST", 158, 159], ["D-dimer", "TEST", 170, 177], ["decreased", "OBSERVATION_MODIFIER", 22, 31], ["leucopenia", "OBSERVATION", 59, 69], ["increased", "OBSERVATION_MODIFIER", 87, 96], ["LDH", "ANATOMY", 97, 100]]], ["The inpatients had significantly higher levels of D-dimer than the outpatients (P = 0.03).RESULTSIn radiology, chest X-rays were normal in 30 patients (37%) while 51 patients (63%) had potentially pathological findings ( Table 4) .", [["inpatients", "ORGANISM", 4, 14], ["D-dimer", "GENE_OR_GENE_PRODUCT", 50, 57], ["patients", "ORGANISM", 142, 150], ["patients", "ORGANISM", 166, 174], ["D-dimer", "PROTEIN", 50, 57], ["patients", "SPECIES", 142, 150], ["patients", "SPECIES", 166, 174], ["chest X-rays", "TEST", 111, 123], ["chest", "ANATOMY", 111, 116]]], ["30 (59%) who underwent chest CT was from 51 patients with abnormal findings, and 3 (10%) patients with consolidation and 3 (10%) with ground-glass opacities ( Fig. 1 ).RESULTSThere were two newborn patients (3%) with positive test results during the study period; one was 11 days old, the other was 8 days old.", [["chest", "ANATOMY", 23, 28], ["patients", "ORGANISM", 44, 52], ["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 198, 206], ["chest CT", "TEST", 23, 31], ["abnormal findings", "PROBLEM", 58, 75], ["consolidation", "PROBLEM", 103, 116], ["ground-glass opacities", "PROBLEM", 134, 156], ["positive test results", "PROBLEM", 217, 238], ["the study", "TEST", 246, 255], ["chest", "ANATOMY", 23, 28], ["consolidation", "OBSERVATION", 103, 116], ["ground", "OBSERVATION", 134, 140], ["glass opacities", "OBSERVATION", 141, 156]]], ["They were asymptomatic and had no pathological findings in laboratory tests and chest X-rays.", [["pathological findings", "PROBLEM", 34, 55], ["laboratory tests", "TEST", 59, 75], ["chest X-rays", "TEST", 80, 92], ["chest", "ANATOMY", 80, 85]]], ["They were discharged without any additional treatment after nine and eight days of monitoring, respectively.RESULTSAntibiotics were used in 95% of the patients who were hospitalized ( Table 5) .", [["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["any additional treatment", "TREATMENT", 29, 53], ["monitoring", "TEST", 83, 93], ["RESULTSAntibiotics", "TREATMENT", 108, 126]]], ["None of the patients received oseltamivir treatment since none had a positive influenza test.", [["oseltamivir", "CHEMICAL", 30, 41], ["oseltamivir", "CHEMICAL", 30, 41], ["patients", "ORGANISM", 12, 20], ["oseltamivir", "SIMPLE_CHEMICAL", 30, 41], ["patients", "SPECIES", 12, 20], ["oseltamivir treatment", "TREATMENT", 30, 51], ["a positive influenza test", "PROBLEM", 67, 92]]], ["One patient (2%) received oxygen through a nasal cannula, one patient (2%) received inhaled corticosteroids, and two patients (5%) with bronchiolitis did not respond adequately to inhalation therapy received low dose systemic corticosteroid treatment (prednisolone 1 mg/kg per day for three days) in a negative pressure room.RESULTSSeven patients (16%) were asymptomatic at the time of admission.", [["nasal", "ANATOMY", 43, 48], ["oxygen", "CHEMICAL", 26, 32], ["bronchiolitis", "DISEASE", 136, 149], ["prednisolone", "CHEMICAL", 252, 264], ["oxygen", "CHEMICAL", 26, 32], ["prednisolone", "CHEMICAL", 252, 264], ["patient", "ORGANISM", 4, 11], ["oxygen", "SIMPLE_CHEMICAL", 26, 32], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 43, 56], ["patient", "ORGANISM", 62, 69], ["patients", "ORGANISM", 117, 125], ["prednisolone", "SIMPLE_CHEMICAL", 252, 264], ["patients", "ORGANISM", 338, 346], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 62, 69], ["patients", "SPECIES", 117, 125], ["patients", "SPECIES", 338, 346], ["oxygen", "TREATMENT", 26, 32], ["a nasal cannula", "TREATMENT", 41, 56], ["inhaled corticosteroids", "TREATMENT", 84, 107], ["bronchiolitis", "PROBLEM", 136, 149], ["inhalation therapy", "TREATMENT", 180, 198], ["low dose systemic corticosteroid treatment", "TREATMENT", 208, 250], ["prednisolone", "TREATMENT", 252, 264], ["asymptomatic", "PROBLEM", 358, 370], ["nasal cannula", "ANATOMY", 43, 56], ["bronchiolitis", "OBSERVATION", 136, 149]]], ["Four (9%) had the symptoms of upper respiratory tract infection, and 33 (75%) had pneumonia findings.", [["upper respiratory tract", "ANATOMY", 30, 53], ["respiratory tract infection", "DISEASE", 36, 63], ["pneumonia", "DISEASE", 82, 91], ["upper", "ORGANISM_SUBDIVISION", 30, 35], ["respiratory tract", "ORGANISM_SUBDIVISION", 36, 53], ["the symptoms", "PROBLEM", 14, 26], ["upper respiratory tract infection", "PROBLEM", 30, 63], ["pneumonia findings", "PROBLEM", 82, 100], ["upper", "ANATOMY_MODIFIER", 30, 35], ["respiratory tract", "ANATOMY", 36, 53], ["infection", "OBSERVATION", 54, 63], ["pneumonia", "OBSERVATION", 82, 91]]], ["None of the patients needed intensive care except for the newborns.", [["patients", "ORGANISM", 12, 20], ["newborns", "ORGANISM", 58, 66], ["patients", "SPECIES", 12, 20], ["intensive care", "TREATMENT", 28, 42]]], ["The median time to turn SARS-CoV-2 negative in the RT-PCR test was 5 (3) (4) (5) (6) (7) (8) (9) (10) Eighty-one Children in the COVID-19 Pandemic of samples taken to get negative SARS-CoV-2 RT-PCR results was 3 (2-4).", [["samples", "ANATOMY", 150, 157], ["SARS", "DISEASE", 180, 184], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 24, 34], ["Children", "ORGANISM", 113, 121], ["samples", "CANCER", 150, 157], ["Children", "SPECIES", 113, 121], ["SARS", "TEST", 24, 28], ["CoV", "TEST", 29, 32], ["the RT-PCR test", "TEST", 47, 62], ["the COVID", "TEST", 125, 134], ["SARS", "TEST", 180, 184], ["CoV", "TEST", 185, 188], ["PCR", "TEST", 194, 197]]], ["The median length of hospital stay was 5 (4-10) days.", [["median", "OBSERVATION_MODIFIER", 4, 10], ["length", "OBSERVATION_MODIFIER", 11, 17]]], ["The time to turn SARS-CoV-2 negative in RT-PCR test and the length of hospital stay were significantly longer for those aged five years or younger compared to the others (P = 0.037, P = 0.01).", [["SARS", "TEST", 17, 21], ["CoV", "TEST", 22, 25], ["PCR test", "TEST", 43, 51], ["P", "TEST", 171, 172], ["P", "TEST", 182, 183]]], ["Eighty-one Children in the COVID-19 PandemicDISCUSSIONIn this study, we have reported the data for 81 children diagnosed with COVID-19 at a single center since the beginning of the outbreak in Turkey, the country with the eighth highest number of confirmed COVID-19 cases in the world, in order to contribute to the limited knowledge base about pediatric COVID-19 cases.", [["Children", "ORGANISM", 11, 19], ["children", "ORGANISM", 102, 110], ["Children", "SPECIES", 11, 19], ["children", "SPECIES", 102, 110], ["this study", "TEST", 57, 67], ["pediatric COVID", "TEST", 345, 360]]], ["All of the children in the study, including those with comorbid conditions, had recovered; they had no sequelae until the submission of this report.", [["children", "ORGANISM", 11, 19], ["children", "SPECIES", 11, 19], ["the study", "TEST", 23, 32]]], ["SARS-CoV-2 is a highly contagious pathogen that commonly causes pneumonia in infected patients.", [["SARS", "DISEASE", 0, 4], ["pneumonia", "DISEASE", 64, 73], ["SARS-CoV-2", "ORGANISM", 0, 10], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["SARS-CoV-2", "SPECIES", 0, 10], ["a highly contagious pathogen", "PROBLEM", 14, 42], ["pneumonia", "PROBLEM", 64, 73], ["pneumonia", "OBSERVATION", 64, 73], ["infected", "OBSERVATION_MODIFIER", 77, 85]]], ["10 In Turkey, the COVID-19 outbreak started later than in most other countries affected by the pandemic.", [["the COVID", "TEST", 14, 23]]], ["However, the outbreak exhibited a rapid growth, reaching a total of 148,000 cases on May 18 (in 68 days).", [["a rapid growth", "PROBLEM", 32, 46], ["rapid", "OBSERVATION_MODIFIER", 34, 39], ["growth", "OBSERVATION_MODIFIER", 40, 46]]], ["Although the number of cases was high, the number of recorded deaths stayed relatively low compared to most other countries where the SARS-CoV-2 infection has been widespread (4,096 deaths, 2.7% death rate).", [["deaths", "DISEASE", 62, 68], ["SARS", "DISEASE", 134, 138], ["infection", "DISEASE", 145, 154], ["deaths", "DISEASE", 182, 188], ["death", "DISEASE", 195, 200], ["SARS-CoV-2", "ORGANISM", 134, 144], ["SARS-CoV-2", "SPECIES", 134, 144], ["the SARS", "TEST", 130, 138], ["CoV-2 infection", "PROBLEM", 139, 154], ["death rate", "TEST", 195, 205], ["high", "OBSERVATION_MODIFIER", 33, 37], ["infection", "OBSERVATION", 145, 154], ["widespread", "OBSERVATION_MODIFIER", 164, 174]]], ["4DISCUSSIONCompared to adults, COVID-19 is more distinctive and milder in children in terms of its clinical symptoms and outcomes.", [["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82], ["COVID", "TEST", 31, 36], ["its clinical symptoms", "PROBLEM", 95, 116], ["more distinctive", "OBSERVATION_MODIFIER", 43, 59], ["milder", "OBSERVATION_MODIFIER", 64, 70]]], ["10 One speculation was that, unlike adults, children are less likely to have an excessive immune response and cytokine storm.", [["children", "ORGANISM", 44, 52], ["cytokine", "PROTEIN", 110, 118], ["children", "SPECIES", 44, 52], ["an excessive immune response", "PROBLEM", 77, 105], ["cytokine storm", "OBSERVATION", 110, 124]]], ["11 The angiotensin-converting enzyme 2 (ACE2) proteins, which are highly expressed in alveolar type 2 cells, are fewer and immature in children compared to those in adults.", [["alveolar type 2 cells", "ANATOMY", 86, 107], ["angiotensin", "CHEMICAL", 7, 18], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 7, 38], ["ACE2", "GENE_OR_GENE_PRODUCT", 40, 44], ["alveolar type 2 cells", "CELL", 86, 107], ["children", "ORGANISM", 135, 143], ["angiotensin-converting enzyme 2 (ACE2) proteins", "PROTEIN", 7, 54], ["alveolar type 2 cells", "CELL_TYPE", 86, 107], ["children", "SPECIES", 135, 143], ["The angiotensin-converting enzyme", "TEST", 3, 36], ["ACE2) proteins", "TEST", 40, 54], ["alveolar type 2 cells", "OBSERVATION", 86, 107], ["fewer", "OBSERVATION_MODIFIER", 113, 118], ["immature", "OBSERVATION_MODIFIER", 123, 131]]], ["13 Besides, children are often exposed to other viral or bacterial infections in daycare and school settings.", [["viral or bacterial infections", "DISEASE", 48, 77], ["children", "ORGANISM", 12, 20], ["children", "SPECIES", 12, 20], ["bacterial infections", "PROBLEM", 57, 77], ["bacterial", "OBSERVATION_MODIFIER", 57, 66], ["infections", "OBSERVATION", 67, 77]]], ["It has been assumed that a previous exposure to milder respiratory pathogens could train the host immune system to defend against coronavirus.", [["coronavirus", "DISEASE", 130, 141], ["immune system", "ANATOMICAL_SYSTEM", 98, 111], ["coronavirus", "ORGANISM", 130, 141], ["milder respiratory pathogens", "PROBLEM", 48, 76], ["coronavirus", "PROBLEM", 130, 141]]], ["14 In accordance with the literature, none of our patients needed intensive care except for two patients in the neonatal group, and all of our patients were discharged in good conditions.", [["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 96, 104], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 143, 151], ["intensive care", "TREATMENT", 66, 80]]], ["Fever was the most common symptom in our patients.", [["Fever", "DISEASE", 0, 5], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["Fever", "PROBLEM", 0, 5], ["most common", "OBSERVATION_MODIFIER", 14, 25]]], ["While cough and pharyngitis were more frequent in some studies, fever was more common in other studies.", [["cough", "DISEASE", 6, 11], ["pharyngitis", "DISEASE", 16, 27], ["fever", "DISEASE", 64, 69], ["cough", "PROBLEM", 6, 11], ["pharyngitis", "PROBLEM", 16, 27], ["some studies", "TEST", 50, 62], ["fever", "PROBLEM", 64, 69], ["other studies", "TEST", 89, 102], ["pharyngitis", "OBSERVATION", 16, 27]]], ["12,15, 16 Approximately 10% of the infected children may initially show gastrointestinal symptoms such as diarrhea, abdominal pain, and vomiting, making it difficult to distinguish COVID-19 from other common childhood diseases.", [["gastrointestinal", "ANATOMY", 72, 88], ["abdominal", "ANATOMY", 116, 125], ["gastrointestinal symptoms", "DISEASE", 72, 97], ["diarrhea", "DISEASE", 106, 114], ["abdominal pain", "DISEASE", 116, 130], ["vomiting", "DISEASE", 136, 144], ["children", "ORGANISM", 44, 52], ["gastrointestinal", "ORGAN", 72, 88], ["abdominal", "ORGANISM_SUBDIVISION", 116, 125], ["children", "SPECIES", 44, 52], ["gastrointestinal symptoms", "PROBLEM", 72, 97], ["diarrhea", "PROBLEM", 106, 114], ["abdominal pain", "PROBLEM", 116, 130], ["vomiting", "PROBLEM", 136, 144], ["COVID", "TEST", 181, 186], ["other common childhood diseases", "PROBLEM", 195, 226], ["infected", "OBSERVATION", 35, 43], ["diarrhea", "OBSERVATION", 106, 114], ["abdominal", "ANATOMY", 116, 125], ["pain", "OBSERVATION", 126, 130], ["diseases", "OBSERVATION", 218, 226]]], ["15, 16 In our study, gastrointestinal symptoms were less frequent (4%).", [["gastrointestinal", "ANATOMY", 21, 37], ["gastrointestinal symptoms", "DISEASE", 21, 46], ["gastrointestinal", "ORGAN", 21, 37], ["our study", "TEST", 10, 19], ["gastrointestinal symptoms", "PROBLEM", 21, 46], ["gastrointestinal", "ANATOMY", 21, 37]]], ["No neurological finding or sign of cardiac, liver, or renal failure was observed in our patients.DISCUSSIONThe laboratory findings of the pediatric patients with COVID-19 are non-specific.", [["neurological", "ANATOMY", 3, 15], ["cardiac", "ANATOMY", 35, 42], ["liver", "ANATOMY", 44, 49], ["renal", "ANATOMY", 54, 59], ["cardiac, liver, or renal failure", "DISEASE", 35, 67], ["COVID-19", "CHEMICAL", 162, 170], ["cardiac", "ORGAN", 35, 42], ["liver", "ORGAN", 44, 49], ["renal", "ORGAN", 54, 59], ["patients", "ORGANISM", 88, 96], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 148, 156], ["neurological finding", "PROBLEM", 3, 23], ["cardiac, liver", "PROBLEM", 35, 49], ["renal failure", "PROBLEM", 54, 67], ["COVID", "TEST", 162, 167], ["cardiac", "ANATOMY", 35, 42], ["liver", "ANATOMY", 44, 49], ["renal", "ANATOMY", 54, 59], ["failure", "OBSERVATION", 60, 67], ["non-specific", "OBSERVATION_MODIFIER", 175, 187]]], ["Lymphopenia is one of the most common hematological abnormalities.", [["hematological", "ANATOMY", 38, 51], ["Lymphopenia", "DISEASE", 0, 11], ["Lymphopenia", "PROBLEM", 0, 11], ["the most common hematological abnormalities", "PROBLEM", 22, 65], ["one of the most common", "OBSERVATION_MODIFIER", 15, 37], ["abnormalities", "OBSERVATION", 52, 65]]], ["10 In adult patients, a marked or progressive decrease in peripheral blood absolute lymphocyte count (ALC) was observed in the acute phase of COVID-19.", [["peripheral blood", "ANATOMY", 58, 74], ["lymphocyte", "ANATOMY", 84, 94], ["COVID-19", "CHEMICAL", 142, 150], ["patients", "ORGANISM", 12, 20], ["peripheral", "ORGANISM_SUBSTANCE", 58, 68], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["lymphocyte", "CELL", 84, 94], ["patients", "SPECIES", 12, 20], ["a marked or progressive decrease in peripheral blood absolute lymphocyte count", "PROBLEM", 22, 100], ["COVID", "TEST", 142, 147], ["marked", "OBSERVATION_MODIFIER", 24, 30], ["progressive", "OBSERVATION_MODIFIER", 34, 45], ["decrease", "OBSERVATION_MODIFIER", 46, 54], ["peripheral", "ANATOMY_MODIFIER", 58, 68], ["blood", "ANATOMY", 69, 74], ["absolute lymphocyte count", "OBSERVATION", 75, 100], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["phase", "OBSERVATION_MODIFIER", 133, 138]]], ["17 However, the ALC is within the normal range in most pediatric COVID-19 patients.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["the ALC", "TEST", 12, 19], ["normal range", "OBSERVATION_MODIFIER", 34, 46]]], ["15, 16 Other abnormal laboratory results include increased liver, muscle, and cardiac enzymes, LDH, CRP, procalcitonin, and D-dimer.", [["liver", "ANATOMY", 59, 64], ["muscle", "ANATOMY", 66, 72], ["cardiac", "ANATOMY", 78, 85], ["liver", "ORGAN", 59, 64], ["muscle", "ORGAN", 66, 72], ["cardiac", "ORGAN", 78, 85], ["LDH", "GENE_OR_GENE_PRODUCT", 95, 98], ["CRP", "GENE_OR_GENE_PRODUCT", 100, 103], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 105, 118], ["D-dimer", "SIMPLE_CHEMICAL", 124, 131], ["cardiac enzymes", "PROTEIN", 78, 93], ["LDH", "PROTEIN", 95, 98], ["CRP", "PROTEIN", 100, 103], ["procalcitonin", "PROTEIN", 105, 118], ["D-dimer", "PROTEIN", 124, 131], ["increased liver, muscle", "PROBLEM", 49, 72], ["cardiac enzymes", "TEST", 78, 93], ["LDH", "TEST", 95, 98], ["CRP", "TEST", 100, 103], ["procalcitonin", "TEST", 105, 118], ["increased", "OBSERVATION", 49, 58], ["liver", "ANATOMY", 59, 64], ["muscle", "ANATOMY", 66, 72], ["cardiac", "ANATOMY", 78, 85]]], ["16, 18 Similar to the pulmonary involvement due to previous coronavirus infections, typical radiological findings in COVID-19 patients were consolidation, which indicated parenchymal destruction, and ground-glass appearance.", [["pulmonary", "ANATOMY", 22, 31], ["parenchymal", "ANATOMY", 171, 182], ["coronavirus infections", "DISEASE", 60, 82], ["parenchymal destruction", "DISEASE", 171, 194], ["pulmonary", "ORGAN", 22, 31], ["coronavirus", "ORGANISM", 60, 71], ["patients", "ORGANISM", 126, 134], ["parenchymal", "TISSUE", 171, 182], ["patients", "SPECIES", 126, 134], ["the pulmonary involvement", "PROBLEM", 18, 43], ["previous coronavirus infections", "PROBLEM", 51, 82], ["COVID", "TEST", 117, 122], ["consolidation", "PROBLEM", 140, 153], ["parenchymal destruction", "PROBLEM", 171, 194], ["ground-glass appearance", "PROBLEM", 200, 223], ["pulmonary", "ANATOMY", 22, 31], ["coronavirus", "OBSERVATION_MODIFIER", 60, 71], ["infections", "OBSERVATION", 72, 82], ["consolidation", "OBSERVATION", 140, 153], ["parenchymal", "ANATOMY_MODIFIER", 171, 182], ["destruction", "OBSERVATION", 183, 194], ["ground-glass appearance", "OBSERVATION", 200, 223]]], ["While these involvements have mostly been observed in the adult population with low immunity, they are also found in pediatric patients.", [["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["low immunity", "OBSERVATION_MODIFIER", 80, 92]]], ["These findings have typically peripheral, bilateral, and multifocal distribution, prominently in the lower lobe.", [["lower lobe", "ANATOMY", 101, 111], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 101, 111], ["typically peripheral, bilateral, and multifocal distribution", "PROBLEM", 20, 80], ["typically", "OBSERVATION_MODIFIER", 20, 29], ["peripheral", "OBSERVATION_MODIFIER", 30, 40], ["bilateral", "ANATOMY_MODIFIER", 42, 51], ["multifocal", "OBSERVATION_MODIFIER", 57, 67], ["distribution", "OBSERVATION_MODIFIER", 68, 80], ["prominently", "OBSERVATION_MODIFIER", 82, 93], ["lower lobe", "ANATOMY", 101, 111]]], ["19 In our study, pulmonary consolidation was found in three patients (10%), and ground-glass opacity was found in three patients (10%) among those 30 patients who had chest CT.", [["pulmonary", "ANATOMY", 17, 26], ["pulmonary consolidation", "DISEASE", 17, 40], ["pulmonary", "ORGAN", 17, 26], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 150, 158], ["our study", "TEST", 6, 15], ["pulmonary consolidation", "PROBLEM", 17, 40], ["ground-glass opacity", "PROBLEM", 80, 100], ["chest CT", "TEST", 167, 175], ["pulmonary", "ANATOMY", 17, 26], ["consolidation", "OBSERVATION", 27, 40], ["ground", "OBSERVATION_MODIFIER", 80, 86], ["glass opacity", "OBSERVATION", 87, 100], ["chest", "ANATOMY", 167, 172]]], ["These findings support the previous data that pulmonary involvement was mild in children with COVID-19.DISCUSSIONYoung children are more represented in the pediatric population infected with SARS-CoV-2.", [["pulmonary", "ANATOMY", 46, 55], ["pulmonary involvement", "DISEASE", 46, 67], ["SARS", "DISEASE", 191, 195], ["pulmonary", "ORGAN", 46, 55], ["children", "ORGANISM", 80, 88], ["children", "ORGANISM", 119, 127], ["SARS-CoV-2", "ORGANISM", 191, 201], ["children", "SPECIES", 80, 88], ["children", "SPECIES", 119, 127], ["SARS-CoV", "SPECIES", 191, 199], ["pulmonary involvement", "PROBLEM", 46, 67], ["COVID", "TEST", 94, 99], ["pulmonary", "ANATOMY", 46, 55], ["mild", "OBSERVATION_MODIFIER", 72, 76]]], ["Of the patients treated in Wuhan Children's Hospital, 18% were infants under one-year-old.", [["patients", "ORGANISM", 7, 15], ["infants", "ORGANISM", 63, 70], ["patients", "SPECIES", 7, 15], ["Children", "SPECIES", 33, 41], ["infants", "SPECIES", 63, 70]]], ["In another large-scale study, the frequency of serious and critical disease was 10.6% in those under the age of 1, 7.3% in those between 1-5 years old, 4.2% in those between 6-10 years old, and 7.1% in those between 11-17 years old.", [["scale study", "TEST", 17, 28], ["serious and critical disease", "PROBLEM", 47, 75], ["large", "OBSERVATION_MODIFIER", 11, 16], ["serious", "OBSERVATION_MODIFIER", 47, 54], ["critical", "OBSERVATION_MODIFIER", 59, 67], ["disease", "OBSERVATION", 68, 75]]], ["16 Eighty-one Children in the COVID-19 Pandemic two patients who were newborns.", [["Children", "ORGANISM", 14, 22], ["patients", "ORGANISM", 52, 60], ["newborns", "ORGANISM", 70, 78], ["Children", "SPECIES", 14, 22], ["patients", "SPECIES", 52, 60]]], ["Although the patients did not experience any complications, the time to reach negative RT-PCR results for SARS-CoV-2 and the length of hospital stay were found to be longer in those under the age of 5 compared to older patients.DISCUSSIONMany pregnant women were also infected in the outbreak in Wuhan, but only a small portion (9%) of babies born to these mothers were positive for SARS-CoV-2 through vertical transmission.", [["SARS", "DISEASE", 106, 110], ["SARS", "DISEASE", 383, 387], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 219, 227], ["women", "ORGANISM", 252, 257], ["babies", "ORGANISM", 336, 342], ["mothers", "ORGANISM", 357, 364], ["SARS-CoV-2", "ORGANISM", 383, 393], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 219, 227], ["women", "SPECIES", 252, 257], ["SARS-CoV", "SPECIES", 106, 114], ["SARS-CoV", "SPECIES", 383, 391], ["any complications", "PROBLEM", 41, 58], ["SARS", "TEST", 106, 110], ["CoV", "TEST", 111, 114], ["SARS", "PROBLEM", 383, 387], ["CoV", "TEST", 388, 391]]], ["No prenatal transmission was observed in the three newborns born to infected mothers in our study.", [["newborns", "ORGANISM", 51, 59], ["mothers", "ORGANISM", 77, 84], ["prenatal transmission", "PROBLEM", 3, 24], ["our study", "TEST", 88, 97]]], ["Perinatal infection can contribute to adverse events in newborns such as fetal distress, preterm labor, and newborn respiratory distress.", [["fetal", "ANATOMY", 73, 78], ["respiratory", "ANATOMY", 116, 127], ["Perinatal infection", "DISEASE", 0, 19], ["fetal distress", "DISEASE", 73, 87], ["preterm labor", "DISEASE", 89, 102], ["respiratory distress", "DISEASE", 116, 136], ["newborns", "ORGANISM", 56, 64], ["fetal", "ORGANISM_SUBDIVISION", 73, 78], ["Perinatal infection", "PROBLEM", 0, 19], ["adverse events in newborns", "PROBLEM", 38, 64], ["fetal distress", "PROBLEM", 73, 87], ["preterm labor", "PROBLEM", 89, 102], ["newborn respiratory distress", "PROBLEM", 108, 136], ["infection", "OBSERVATION", 10, 19], ["respiratory distress", "OBSERVATION", 116, 136]]], ["21 Both newborns who were followed throughout the study period were asymptomatic, and no pathological feature was found in laboratory tests or chest radiographs.", [["chest", "ANATOMY", 143, 148], ["newborns", "ORGANISM", 8, 16], ["asymptomatic", "PROBLEM", 68, 80], ["pathological feature", "PROBLEM", 89, 109], ["laboratory tests", "TEST", 123, 139], ["chest radiographs", "TEST", 143, 160], ["chest", "ANATOMY", 143, 148]]], ["They were discharged after monitoring without any additional treatment.DISCUSSIONThe publications that describe the management of pediatric patients with COVID-19 have mostly referred to supportive therapy, including oxygen therapy and the antibiotics for bacterial superinfections.", [["oxygen", "CHEMICAL", 217, 223], ["bacterial superinfections", "DISEASE", 256, 281], ["oxygen", "CHEMICAL", 217, 223], ["patients", "ORGANISM", 140, 148], ["oxygen", "SIMPLE_CHEMICAL", 217, 223], ["patients", "SPECIES", 140, 148], ["any additional treatment", "TREATMENT", 46, 70], ["COVID", "TREATMENT", 154, 159], ["supportive therapy", "TREATMENT", 187, 205], ["oxygen therapy", "TREATMENT", 217, 231], ["the antibiotics", "TREATMENT", 236, 251], ["bacterial superinfections", "PROBLEM", 256, 281], ["superinfections", "OBSERVATION", 266, 281]]], ["10, 18 However, some studies have proposed various antiviral treatments when needed.", [["some studies", "TEST", 16, 28], ["various antiviral treatments", "TREATMENT", 43, 71], ["antiviral treatments", "OBSERVATION", 51, 71]]], ["Among these, antiviral drugs such as ribavirin, lopinavir, and ritonavir were recommended based on the experience in severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome.", [["ribavirin", "CHEMICAL", 37, 46], ["lopinavir", "CHEMICAL", 48, 57], ["ritonavir", "CHEMICAL", 63, 72], ["acute respiratory syndrome", "DISEASE", 124, 150], ["SARS", "DISEASE", 152, 156], ["Middle East respiratory syndrome", "DISEASE", 166, 198], ["ribavirin", "CHEMICAL", 37, 46], ["lopinavir", "CHEMICAL", 48, 57], ["ritonavir", "CHEMICAL", 63, 72], ["ribavirin", "SIMPLE_CHEMICAL", 37, 46], ["lopinavir", "SIMPLE_CHEMICAL", 48, 57], ["ritonavir", "SIMPLE_CHEMICAL", 63, 72], ["antiviral drugs", "TREATMENT", 13, 28], ["ribavirin", "TREATMENT", 37, 46], ["lopinavir", "TREATMENT", 48, 57], ["ritonavir", "TREATMENT", 63, 72], ["severe acute respiratory syndrome", "PROBLEM", 117, 150], ["SARS", "PROBLEM", 152, 156], ["the Middle East respiratory syndrome", "PROBLEM", 162, 198], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["acute", "OBSERVATION_MODIFIER", 124, 129], ["respiratory syndrome", "OBSERVATION", 130, 150], ["Middle", "ANATOMY_MODIFIER", 166, 172], ["respiratory syndrome", "OBSERVATION", 178, 198]]], ["22 Some studies are suggesting that hydroxychloroquine and azithromycin treatments reduced the SARS-CoV-2 viral load.", [["hydroxychloroquine", "CHEMICAL", 36, 54], ["azithromycin", "CHEMICAL", 59, 71], ["hydroxychloroquine", "CHEMICAL", 36, 54], ["azithromycin", "CHEMICAL", 59, 71], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 36, 54], ["azithromycin", "SIMPLE_CHEMICAL", 59, 71], ["CoV-2", "ORGANISM", 100, 105], ["Some studies", "TEST", 3, 15], ["hydroxychloroquine", "TREATMENT", 36, 54], ["azithromycin treatments", "TREATMENT", 59, 82], ["the SARS", "TEST", 91, 99], ["CoV", "TEST", 100, 103]]], ["10, 23 Animal studies and early clinical experience with the use of remdesivir in adults are promising, and extensive randomized controlled studies are underway to assess the effectiveness of this treatment.", [["remdesivir", "CHEMICAL", 68, 78], ["remdesivir", "CHEMICAL", 68, 78], ["remdesivir", "SIMPLE_CHEMICAL", 68, 78], ["adults", "ORGANISM", 82, 88], ["Animal studies", "TEST", 7, 21], ["remdesivir", "TREATMENT", 68, 78], ["extensive randomized controlled studies", "TEST", 108, 147], ["this treatment", "TREATMENT", 192, 206]]], ["24 The role of corticosteroids has not been proven yet; while current international consensus and WHO are against the use of corticosteroids, the Chinese guidelines recommend a shortterm treatment with low to medium dose corticosteroids in COVID-19.", [["corticosteroids", "CHEMICAL", 15, 30], ["corticosteroids", "CHEMICAL", 15, 30], ["corticosteroids", "CHEMICAL", 125, 140], ["corticosteroids", "CHEMICAL", 221, 236], ["corticosteroids", "SIMPLE_CHEMICAL", 15, 30], ["corticosteroids", "TREATMENT", 15, 30], ["corticosteroids", "TREATMENT", 125, 140], ["a shortterm treatment", "TREATMENT", 175, 196], ["low to medium dose corticosteroids", "TREATMENT", 202, 236]]], ["25, 26 Other therapeutics recommended for treatment are umifenovir (an antiviral drug available in Russia and China) and intravenous immunoglobulins, interferons, and the administration of plasma isolated from the patients who had previously recovered from COVID-19.", [["intravenous", "ANATOMY", 121, 132], ["plasma", "ANATOMY", 189, 195], ["umifenovir", "CHEMICAL", 56, 66], ["umifenovir", "CHEMICAL", 56, 66], ["umifenovir", "SIMPLE_CHEMICAL", 56, 66], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 121, 132], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 133, 148], ["plasma", "ORGANISM_SUBSTANCE", 189, 195], ["patients", "ORGANISM", 214, 222], ["interferons", "PROTEIN", 150, 161], ["patients", "SPECIES", 214, 222], ["treatment", "TREATMENT", 42, 51], ["umifenovir", "TREATMENT", 56, 66], ["an antiviral drug", "TREATMENT", 68, 85], ["intravenous immunoglobulins", "TREATMENT", 121, 148], ["interferons", "TREATMENT", 150, 161], ["plasma", "TREATMENT", 189, 195], ["COVID", "TEST", 257, 262]]], ["27,28 However, there is still a need for more evidence to recommend these therapies.DISCUSSIONThere are some limitations to the current study, which presented the observational data from a single-center with a limited sample size.", [["these therapies", "TREATMENT", 68, 83], ["the current study", "TEST", 124, 141], ["size", "OBSERVATION_MODIFIER", 225, 229]]], ["In addition, no data was available about when the outpatients were cleared of the infection since they did not provide swab samples for the follow-up test.", [["swab samples", "ANATOMY", 119, 131], ["infection", "DISEASE", 82, 91], ["outpatients", "ORGANISM", 50, 61], ["outpatients", "SPECIES", 50, 61], ["the infection", "PROBLEM", 78, 91], ["swab samples", "TEST", 119, 131], ["the follow-up test", "TEST", 136, 154], ["infection", "OBSERVATION", 82, 91]]], ["Despite these limitations, this study is significant as one of the first reports on the features of confirmed pediatric COVID-19 cases in Turkey.", [["COVID", "DISEASE", 120, 125], ["this study", "TEST", 27, 37], ["pediatric COVID", "TEST", 110, 125]]], ["The study presents valuable data about pediatric cases since COVID-19 is a novel disease about which data are scarce, particularly in the pediatric population.", [["The study", "TEST", 0, 9], ["COVID", "TEST", 61, 66], ["a novel disease", "PROBLEM", 73, 88], ["scarce", "OBSERVATION_MODIFIER", 110, 116]]], ["Data from more extensive multicenter studies are required to improve the diagnosis, follow-up, and treatment approaches.DISCUSSIONIn summary, this study has indicated that the main clinical features of COVID-19 in children are fever, dry cough, and mild pneumonia.", [["COVID-19", "CHEMICAL", 202, 210], ["fever", "DISEASE", 227, 232], ["dry cough", "DISEASE", 234, 243], ["pneumonia", "DISEASE", 254, 263], ["children", "ORGANISM", 214, 222], ["children", "SPECIES", 214, 222], ["extensive multicenter studies", "TEST", 15, 44], ["treatment approaches", "TREATMENT", 99, 119], ["this study", "TEST", 142, 152], ["COVID", "TEST", 202, 207], ["fever", "PROBLEM", 227, 232], ["dry cough", "PROBLEM", 234, 243], ["mild pneumonia", "PROBLEM", 249, 263], ["fever", "OBSERVATION", 227, 232], ["dry", "OBSERVATION_MODIFIER", 234, 237], ["cough", "OBSERVATION", 238, 243], ["mild", "OBSERVATION_MODIFIER", 249, 253], ["pneumonia", "OBSERVATION", 254, 263]]], ["Most often, the pediatric patients have been infected with SARS-CoV-2 through close contact with their family members.", [["SARS", "DISEASE", 59, 63], ["patients", "ORGANISM", 26, 34], ["SARS-CoV-2", "ORGANISM", 59, 69], ["patients", "SPECIES", 26, 34], ["SARS-CoV", "SPECIES", 59, 67]]], ["Pediatric COVID-19 cases have improved without any additional treatment protocols to the standard pneumonia treatments for the other known viral infections, even in hospitalized patients.", [["pneumonia", "DISEASE", 98, 107], ["viral infections", "DISEASE", 139, 155], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["Pediatric COVID", "TEST", 0, 15], ["any additional treatment protocols", "TREATMENT", 47, 81], ["the standard pneumonia treatments", "TREATMENT", 85, 118], ["the other known viral infections", "PROBLEM", 123, 155], ["pneumonia", "OBSERVATION", 98, 107], ["viral", "OBSERVATION_MODIFIER", 139, 144], ["infections", "OBSERVATION", 145, 155]]], ["Moreover, they had no sequelae until the submission of this report.", [["sequelae", "PROBLEM", 22, 30]]], ["Therefore, the diagnostic, clinical, and even therapeutic applications in children can be more conservative than those in adults.", [["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82]]], ["It might be more appropriate to consider chest CT screening, hospitalization, and the treatment options rather than supportive treatment in selected pediatric COVID-19 cases only.", [["chest", "ANATOMY", 41, 46], ["chest", "ORGANISM_SUBDIVISION", 41, 46], ["chest CT screening", "TEST", 41, 59], ["the treatment options", "TREATMENT", 82, 103], ["supportive treatment", "TREATMENT", 116, 136], ["chest", "ANATOMY", 41, 46]]]]}